Dipeptidyl peptidase 1 inhibitors and uses thereof

Abstract

Provided herein are compounds of Formula (A'), (A), (I), (I-A), (I-B), (I-C), (I-D), (I-E), (I-F), (I-G), (II), (II-A), (II-B), II-D-1), (II-D-2), (II-D-3), (II-D-4), (II-D-4'), (II-D-4''), (II-C), (II-D), (II-E), (II-F), (II-G), (II-H), (III), (B), (B-I), or (B-I), or Tables A-D, or pharmaceutically acceptable salts or deuterated forms thereof as defined herein. Also provided herein are pharmaceutical compositions comprising the compound and methods of using the compound, e.g., in the treatment of a disease that is treatable by administration of a DPP1 inhibitor.

Description

Attorney Docket No.: INMD-216 / 01WO 315953-4442DIPEPTIDYL PEPTIDASE 1 INHIBITORS AND USES THEREOFCROSS-REFERENCE TO RELATED APPLICATIO S

[0001] This application claims priority to International Patent Application No. PCT / CN2024 / 139665, filed on December 16, 2024, the content of which is hereby incorporated by reference in its entirety for all purposes.BACKGROUND

[0002] Dipeptidyl peptidase 1 (DPP1; EC 3.4.14.1), also known as cathepsin C, is a lysosomal cysteine protease belonging to the papain family having a molecular weight of 200 kDa. DPP1 was first discovered by Gutman and Fruton in 1948 (J Biol Chem, 174, 851-858); however, the cDNA of the human enzyme was first described in 1995 (Paris et al. 1995, FEBS Lett, 369, 326-330). DPP1 is the only member of the papain family that is functional as a tetramer, consisting of four identical subunits. Each subunit is composed of an N-terminal fragment, a heavy chain and a light chain (Dolenc et al. 1995, J Biol Chem, 270, 21626-21631).

[0003] DPP1 is constitutively expressed in many tissues with highest levels in lung, kidney, liver and spleen DPP1 catalyzes the removal of dipeptides from the N-terminal end of polypeptide substrates with broad specificity. Recent data suggest that besides being an important enzyme in lysosomal protein degradation, DPP1 also functions as a key enzyme in the activation of granule serine proteases in cytotoxic T-lymphocytes and natural killer cells (granzymes A and B), mast cells (chymase and tryptase) and neutrophils (cathepsin G, neutrophil elastase and proteinase-3).

[0004] Mast cells are found in many tissues but are present in greater numbers along the epithelial linings of the body, such as the skin, respiratory tract and gastrointestinal tract. In humans, two types of mast cells have been identified. The T-type, which expresses only tryptase, and the MC-type, which expresses both tryptase and chymase. In humans, the T-type mast cells are located primarily in alveolar tissue and intestinal mucosa while the TC-type cells predominate in skin and conjunctiva. Tryptase and chymase appear to be important mediators of allergic diseases, being involved in processes of inflammation, bronchoconstriction and mucus secretion.

[0005] Neutrophils play a critical role in host defense against invading pathogens. Neutrophils are produced in the bone marrow and are fully mature when released into the circulation to take up their role as the first line of cellular defense. Pro-inflammatory mediators and chemotactic attractants activate neutrophils and draw7them to the site of infection, where they act to engulfAttorney Docket No.: INM D-216 / 01 WO 315953-4442bacteria by phagocytosis, assaulting them with an arsenal of anti-bacterial compounds that use both oxidative and non-oxidative methods of attack. The powerful serine protease, neutrophil elastase, is one of those anti-bacterial compounds that are clearly involved in destroying bacteria. Neutrophil elastase is released into the phagolysome surrounding the microorganism, which it proceeds to destroy. Neutrophil elastase is able to attack the outer membrane protein, OmpA, in gram-negative bacteria, helping to directly kill the pathogen by degrading its membrane, as well as enabling other anti-bacteri l compounds to gain access to the pathogen. In addition, neutrophil elastase may help process other antibacterial compounds, converting them from inactive pro-peptides into their active states, such as for cathelicidin.

[0006] Yet neutrophil elastase can also cause problems for its host. It is one of the most destructive enzymes in the body, with the capability of degrading extracellular matrix proteins (including collagens, proteoglycan, fibronectin, platelet receptors, complement receptor, thrombomodulin, lung surfactant and cadherins) and key plasma proteins (including coagulation and complement factors, immunoglobulin, several proteases and protease inhibitors). Under physiological conditions, endogenous protease inhibitors, such as al-antitrypsin, tightly regulate the activity of neutrophil elastase. However, at inflammatory sites, neutrophil elastase is able to evade regulation, and once unregulated it can induce the release of pro-inflammatory cytokines, such as interleukin-6 and interleukin-8, leading to acute lung injury'. It can even impair host defense against infection by degrading phagocyte surface receptors and opsonins. Its negative role has been reported in a number of diseases characterized by tissue destruction and inflammation.

[0007] As such, there is a need in the art to provide novel DPP1 inhibitors in order to treat the aforementioned diseases, and others associated with DPP1 and neutrophil elastase.SUMMARY

[0008] In embodiments, the present disclosure provides a compound of Formula (A'), (A), (I), (I- A), (I-B), (I-C), (I-D), (I-E), (I-F), (I-G), (II), (II -A), (II-B), (II-C), (II-D), (II-D-1), (II-D-2), (II-D-3), (II-D-4), (II-D-4'), (II-D-4"), (II-E), (II-F), (II-G), (II-H), (III), (B), (B-I), or (B-II), as defined herein.

[0009] In embodiments, the present disclosure provides a compound of Formula (A)Attorney Docket No.: INMD-216 / 01WO 315953-4442

[0010] or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, wherein:

[0011] ring A is a carbocyclyl, aryl, heterocyclyl, or heteroaryl ring;

[0013] R2is a carbocycle, aryl, heterocycle, or heteroaryl ring, wherein each R2is optionally substituted with 1, 2, 3, or 4 R6;

[0014] R3is H; or R3together with one of R” can form a tricyclic, tetracyclic, or pentacyclic ring optionally containing 1, 2, or 3 heteroatoms selected from N, S, or O, wherein the tricyclic, tetracyclic, or pentacyclic ring is optionally substituted with 1, 2, 3, or 4 R-;

[0015] each R4is independently halogen, -Ci-C’6 alkyl, -Ci-Ce haloalkyl, -S(Ci-C6 alkyl), - SO(Ci-Cc alkyl), -SO2(Ci-C6alkyl), or -CN;

[0016] R5and Rfaare each independently halogen, -OH, oxo, -CN, -Ci-Cs alkyl, -Ci-C’6 alkyl- OH, -(C1-C6 alkylene)-O-(Ci-C6 alkyl), -(Ci-C6 alkylene)-O-(Ci-C6 alkyl)-OH, -(Ci-Ce alkylene)-O-(Ci-C6 alkyl ene)-O-(Ci-Ce alkyl), -(Ci-CN alkylene)-O-(Ci-C6 alkylene)-O-(Ci- C6alkyl)-OH, -Ci-Cio haloalkyl, -Ci-Cio haloalkyl-OH, -NR7R8, -Ci-C6alkyl-NR7R8, -S(Ci- Ce alkyl), -SO(Ci-C6alkyl), -SO2(Ci-Co alkyl), -SO2NR7R8, -(Ci-C6alkylene)-carbocycle, - (Ci-Ce alkylene)-heterocycle, carbocycle, or heterocycle, wherein each carbocycle and heterocycle is optionally substituted by 1 or 2 R11;

[0017] each R7and R8is independently H or -Ci-Ce alkyl; or R7and R8together with the nitrogen atom to which they are attached form a heterocyclyl;

[0018] R9andR9aare each independently deuterium, halogen, cyano, hydroxyl, -NH2, -NH(Ci- C6alkyl), -N(CI-C6alkyl)2, -COOH, -Ci-C<5alkyl, -C2-C6alkenyl, -C2-C6alkynyl, -Ci-C6Attorney Docket No.: INMD-216 / 01 WO 315953-4442haloalkyl, -C2-C6 haloalkenyl, -C2-C6 haloalkynyl, -C1-C6alkyl-OH, -CONH2, -SH, - -S(=O)NH2, -S(O)2NH2, -OC1-C6 alkyl, -OC1-C6 haloalkyl, -S(Ci-Ce alkyl), -SO(Ci-C6alkyl), -SCh(Ci-C6 alkyl), -SO2NR7R8, -S(=NH)(O)(C1-C6alkyl), -(Ci-Ce alkylene)-carbocyclyl, or - (C 1 -C 6 alkyl ene)-heteroaryl;

[0019] R’°is H or -Ci-C6alkyl;

[0020] each R11is independently halogen, -OH, oxo, -CN, -Ci-Ce alkyl, -Ci-Ce alkyl-OH, -Ci- C10 haloalkyl, -C1-C10 haloalkyl-OH, -OCi-Ce alkyl, -NR7R8, -Ci-Cs alkyl-NR7R8, -S(Ci-C6alkyl), -SO(Ci-Ce alkyl), -SO / Ci-Cg alkyl), -SO2NR7R8, -(C1-C6 alkylene)-carbocycle, -(Ci- Ce alkylene)-heterocycle, carbocycle, or heterocycle;

[0021] m is 0, 1, 2, or 3; and

[0022] n is 0, 1, 2, or 3;

[0023] wherein when Rlis

[0024] wherein when R1is

[0025] provided that the compound is not(S)-A7-(l-cyano-2-(4-(3-methyl-2-oxo-2,3- dihydrobenzo[d]oxazol-5-yl)phenyl)ethyl)-3-(difluoromethyl)azetidine-3 -carboxamide, (S)-jV-(l-cyano-2-(2-fluoro-4-(3-methyl-2-oxo-2,3-dihydrobenzo[d]oxazol-5-yl)phenyl)ethyl)-3-raethoxy zetidine-3-carboxamide, (1)-A7-(l-cyano-2-(2-fluoro-4-(3-methyl-2-oxo-2,3- dihydrobenzo[d]oxazol-5-yl)phenyl)ethyl)-3-methoxy-l-methylazetidine-3-carboxamide, (5)-JV-(l-cyano-2-(2-fluoro-4-(r-(oxetan-3-yl)-3H-spiro[isobenzofuran-l,4'-piperidin]-6-yl)pheny 1 )ethy l)-3 -(difluoromethyl)azeti di ne-3 -carboxamide, or (5)- / V-( 1 -cyano-2-(2-fluoro-Attorney Docket No.: INMD-216 / 01WO 315953-44424-(r-(oxetan-3-yl)-3H-spiro[isobenzofuran-l,4'-piperidin]-6-yl)phenyl)ethyl)-3-(difluoromethyl)-l-methylazetidine-3-carboxamide, or a stereoisomer thereof.

[0026] In embodiments, the present disclosure provides a compound of Formula (B)R15VR

[0027] or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, wherein:[002S] ring A is a carbocyclyL aryl, heterocyclyl, or heteroaryl ring;

[0029] R2is a carbocycle, aryl, heterocycle, or heteroaryl ring, wherein each R2is optionally substituted with 1, 2, 3, or 4 R6;

[0030] R3is H, or R3together with one of Rbcan form a tricyclic, tetracyclic, or pentacyclic ring optionally containing 1, 2, or 3 heteroatoms selected from N, S, or O, wherein the tricyclic, tetracyclic, or pentacyclic ring is optionally substituted with 1, 2, 3, or 4 R5;

[0031] each R4is independently halogen, -Ci-Cs alkyl, -Ci-Ce haloalkyl, -SfCi-Co alkyl), -SO(Ci-Ce alkyl), -SO2(Ci-C6alkyl), or -CN;

[0032] R5and Rbare each independently halogen, -OH, oxo, -CN, -Ci-Ce alkyl, -Ci-Co alkyl-OH, -(Ci-Ce alkylene)-O-(Ci-C’6 alkyl), -(Ci-Ce alkylene)-O-(Ci-Ce alkyl)-OH, -(Ci-Ce alkylene)-O-(Ci-C6 alkylene)-O-(Ci-C6 alkyl), -(Ci-C6 alkyl ene)-O-(Ci-C6 alkylene)-O-(Ci- Ce alkyl)-OH, -Ci-Cio haloalkyl, -Ci-Cio haloalkyl-OH, -NR7R8, -Ci-Ce alkyl-NR7R8, -S(Ci- C6alkyl), -SO(Ci-Cs alkyl), -SO2(CI-CG alkyl), -SO2NR7R8, -(Ci-Co alkylene)-carbocycle, - (Ci-Cb alkylene)-heterocycle, carbocycle, or heterocycle, wherein each carbocycle and heterocycle is optionally substituted by 1 or 2 Rn;

[0033] R / and R8are each independently H or -Ci-Ce alkyl; or R7and R8together with the nitrogen atom to which they are attached form a heterocyclyl;

[0034] each R11is independently halogen, -OH, oxo, -CN, -Ci-Ce alkyl, -Ci-Ce alkyl-OH, -Ci-Cw haloalkyl, -Ci-Cio haloalkyl-OH, -OCi-C6alkyl, -NR7R8, -Ci-Ce alkyl-NR7R8, -S(Ci-Ce alkyl), -SO(CJ-C6 alkyl), -SO2(Ci-C6alkyl), -SO2NR7R8, -(Ci-C6alkylene)-carbocycle, -(Ci- C& alkylene)-heterocycle, carbocycle, or heterocycle;Attorney Docket No.: INMD-216 / 01WO 315953-4442

[0035] R14is optionally substituted -C1-C.30 alkyl, optionally substituted -C2-C30 alkenyl, or optionally substituted C2-C30 alkynyl;

[0036] R1’ and R16are each independently H or -C1-C6 alkyl; or R1?and R16together with the nitrogen atom to which they are attached form a heterocyclyl; and

[0037] m is 0, 1, 2, or 3.

[0038] In embodiments, the present disclosure provides a compound selected from Compounds A1-A112, or a pharmaceutically acceptable salt, a stereoisomer, a racemic form thereof, or a deuterated form thereof.

[0039] In embodiments, the present disclosure provides a compound selected from Compounds Bl -Bl 64, or a pharmaceutically acceptable salt, a stereoisomer, a racemic form thereof or a deuterated form thereof.

[0040] In embodiments, the present disclosure provides a compound selected from Compounds 1-71 (which includes 21A, 21B, 22A, 22B, 23 A, 23B, 24A, 24B, 24C, 25A, 25B, 25C, 25D, 27 A, 27B, 27C, 28A, 29 A, 29B, 29C, 29D, 38A, 38C, 39E, 39F, 39G, 41 A, 41 B, 42A, and 42B), or a pharmaceutically acceptable salt, a stereoisomer, a racemic form thereof, or a deuterated form thereof.

[0041] In embodiments, the present disclosure provides a compound selected from Compounds Pl-Pl 1, or a pharmaceutically acceptable salt, a stereoisomer, a racemic form thereof, or a deuterated form thereof.

[0042] In embodiments, the present disclosure provides a pharmaceutical composition comprising a compound disclosed herein (e.g., a compound of Formula (A'), (A), (I), (I-A), (I-B), (I-C), (1-D), (1-E), (I-F), (1-G), (11), (11- A), (11-B), (11-C), (11-D), (11-D-l), (ll-D-2), (11-D- 3), (II-D-4), (II-D-4'), (II-D-4"), (II-E), (II-F), (II-G), (II-H), (III), (B), (B-I), or ( B-II), or Tables A-D, or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof), and a pharm ceutically acceptable adjuvant, diluent or carrier.

[0043] In embodiments, the present disclosure provides a method for treating an obstructive disease of the airway in a patient in need thereof comprising administering to the patient an effective amount of a compound disclosed herein (e.g., a compound of Formula (A'), (A), (I), (I-A), (I-B), (I-C), (I-D), (II-D-1), (II-D-2), (II-D-3), (II-D-4), (II-D-4'), (II-D-4"), (I-E), (I-F), (I-G), (II), (II- A), (H-B), (Il-C), (II-D), (II-E), ( II-F), (II-G), (II-H), (III), (B), (B-I), or (B-II), or Tables A-D, or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof) or a pharmaceutical composition comprising the compound disclosed herein.

[0044] In embodiments, the present disclosure provides a method for treating cystic fibrosis in a patient in need thereof, comprising administering to the patient an effective amount of aAttorney Docket No.: INMD-216 / 01WO 315953-4442compound disclosed herein (e.g., a compound of Formula (A'), (A), (I), (LA), (LB), (LC), (I-D), (LE), (I-F), (LG), (II), (ILA), (ILB), (ILC), (II-D), (II-D-1), (ILD-2), (II-D-3), (ILD-4), (ILD-4), (ll-D-4"), (ILE), (ILF), (ILG), (11-H), (111), (B), (B-l), or (B-ll), or Tables A-D, or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof) or a pharmaceutical composition comprising the compound disclosed herein.

[0045] In embodiments, the present disclosure provides a method for treating bronchiectasis in a patient in need thereof, comprising administering to the patient an effective amount of a compound disclosed herein (e.g., a compound of Formula (A'), (A), (I), (I-A), (LB), (LC), (I- D), (I-E), (LF), (LG), (II), (ILA), (II-B), (ILC), (II-D), (ILD-1), (ILD-2), (II-D-3), (ILD-4), (ILD-4'), (ILD-4"), (ILE), (ILF), (ILG), (ILH), (III), (B), (B-I), or (B-II), or Tables A-D, or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof) or a pharmaceutical composition comprising the compound disclosed herein.

[0046] In embodiments, the present disclosure provides a method for treating chronic rhinosinusitis in a patient in need thereof, comprising administering to the patient an effective amount of a compound disclosed herein (e.g., a compound of Formula (A'), (A), (I), (LA), (L B), (LC), (LD), (LE), (LF), (LG), (II), (ILA), (II-B), (ILC), (II-D), (ILD-1), (ILD-2), (II-D-3), (ILD-4), (ILD-4'), (ILD-4"), (ILE), (ILF), (ILG), (ILH), (III), (B), (B-I), or (B-II), or Tables A-D, or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof) or a pharmaceutical composition comprising the compound disclosed herein.

[0047] In embodiments, the present disclosure provides a method for treating hidradenitis suppurativa in a patient in need thereof, comprising administering to the patient an effective amount of a compound disclosed herein (e.g., a compound of Formula (A'), (A), (I), (LA), (1-B), (LC), (LD), (LE), (LF), (LG), (II), (ILA), (ILB), (ILC), (II-D), (ILD-1), (ILD-2), (ILD- 3), (ILD-4), (ILD-4'), (ILD-4"), (ILE), (ILF), (ILG), (ILH), (III), (B), (B-I), or (B-II), or Tables A-D, or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof) or a pharmaceutical composition comprising the compound disclosed herein.

[0048] In embodiments, the present disclosure provides a method for treating cancer in a patient in need thereof, comprising administering to the patient an effective amount of a compound disclosed herein (e.g., a compound of Formula (A'), (A), (I), (LA), (LB), (LC), (I- D), (LE), (LF), (LG), (II), (ILA), (ILB), (ILC), (ILD), (II-D-1), (ILD-2), (ILD-3), (ILD-4), (ILD-4), (ILD-4"), (ILE), (ILF), (ILG), (ILH), (III), (B), (B-I), or (B-II), or Tables A-D, or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof) or a pharmaceutical composition comprising the compound disclosed herein.Attorney Docket No.: INMD-216 / 01WO 315953-4442

[0049] In embodiments, the present disclosure provides a method for treating lupus nephritis in a patient in need thereof, comprising administering to the patient an effective amount of a compound disclosed herein (e.g., a compound of Formula (A'), (A), (1), (1-A), (1-B), (1-C), (1-D), (I-E), (I-F), (I-G), (II), (II- A), (II-B), (II-C), (II-D), (II-D-1), (II-D-2), (II-D-3), (II-D-4), (II-D-4'), (II-D-4"), (II-E), (II-F), (II-G), (II-H), (III), (B), (B-I), or (B-II), or Tables A-D, or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof) or a pharmaceutical composition comprising the compound disclosed herein.

[0050] In embodiments, the present disclosure provides a method for treating arthritis in a patient in need thereof, comprising administering to the patient an effective amount of a compound disclosed herein (e.g., a compound of Formula (A'), (A), (I), (I-A), (I-B), (I-C), (I-D), (I-E), (I-F), (I-G), (II), (II- ), (II-B), (II-C), (II-D), (II-D-1), (II-D-2), (II-D-3), (II-D-4), (II-D-4'), (II-D-4"), (II-E), (II-F), (II-G), (II-H), (III ), (B), (B-I), or (B-II), or Tables A-D, or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof) or a pharmaceutical composition comprising the compound disclosed herein.

[0051] In embodiments, the present disclosure provides a method for treating inflammatory bowel disease in a patient in need thereof, comprising administering to the patient an effective amount of a compound disclosed herein (e.g, a compound of Formula (A'), (A), (I), (I-A), (I-B), (I-C), (I-D), (I-E), (I-F), (I-G), (II), (II- A), (II-B), (II-C), (II-D), (II-D-1), (II-D-2), (II-D-3), (II-D-4), (II-D-4'), (II-D-4"), (II-E), (II-F), (II-G), (II-H), (III), (B), (B-I), or (B-II), or Tables A-D, or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof) or a pharmaceutical composition comprising the compound disclosed herein.

[0052] In embodiments, the present disclosure provides a method for treating an anti¬ neutrophil cytoplasmic antibody associated vasculitis in a patient in need thereof, comprising administering to the patient an effective amount of a compound disclosed herein (e.g., a compound of Formula (A), (A), (I), (I-A), (I-B), (I-C), (I-D), (II-D-1), (II-D-2), (II-D-3), (II-D-4), (II-D-4), (II-D-4"), (I-E), (I-F), (I-G), (II), (II-A), (II-B), (II-C), (II-D), (II-E), (II-F), (II- G), (II-H), (I II), (B), (B-I), or (B-II), or Tables A-D, or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof) or a pharmaceutical composition comprising the compound disclosed herein.

[0053] In embodiments, the present disclosure provides a method for treating a disease in a patient in need thereof, comprising administering to the patient an effective amount of a compound disclosed herein (e.g., a compound of Formula (A), ( A), (I ), (I-A ), (I-B), (I-C), (I- D), (I-E), (I-F), (I-G), (II), (II-A), (II-B), (II-C), (II-D), (II-D-1), (II-D-2), (II-D-3), (II-D-4), (II-D-4'), (II-D-4"), (II-E), (II-F), (II-G), (II-H), (III), (B), (B-I), or (B-II), or Tables A-D, or aAttorney Docket No.: INMD-216 / 01WO 315953-4442pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof) or a pharmaceutical composition comprising the compound disclosed herein, wherein the disease is giant cell arteritis, polyarteritis nodosa, anti-GBM disease (Goodpasture’s), systemic scleroderma, diabetic nephropathy, diabetic neuropathy, diabetic retinopathy, diabetic ulcers, Duchenne muscular dystrophy, bronchiolitis obliterans, atopic dermatitis, pyoderma gangrenosum, sweet’s syndrome, dermatomyositis / polymyositis, neutrophilic dermatoses, thrombosis, bronchopulmonary dysplasia, amyotrophic lateral sclerosis, sickle cell anemia, psoriasis, or a ventilator-induced lung injury.

[0054] In embodiments, the present disclosure provides a method for treating heart failure in a patient in need thereof, comprising administering to the patient an effective amount of a compound disclosed herein (e.g., a compound of Formula (A'), (A), (I), (I-A), (LB), (LC), (I-D), (LE), (I-F), (LG), (II), (ILA), (ILB), (II-C), (ILD), (ILD-1), (ILD-2), (II-D-3), (II-D-4), (ILD-4'), (II-D-4”), (II-E), (ILF), (ILG), (II-H), (III), (B), (B-I), or (B-II), or Tables A-D, or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof) or a pharmaceutical composition comprising the compound disclosed herein.

[0055] In embodiments, the present disclosure provides a method for treating ischemia / reperfusion (IR) injury in a patient in need thereof, comprising administering to the patient an effective amount of a compound disclosed herein (e.g., a compound of Formula (A'), (A), (I), (LA), (LB), (LC), (LD), (LE), (LF), (LG), (II), (ILA), (ILB), (II-C), (ILD), (ILD-1), (ILD-2), (II-D-3), (II-D-4), (ILD-4'), (II-D-4”), (II-E), (ILF), (ILG), (II-H), (III), (B), (B-I), or (B-II), or Tables A-D, or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof) or a pharmaceutical composition comprising the compound disclosed herein.

[0056] In embodiments, the present disclosure provides a method for treating liver injury in a patient in need thereof, comprising administering to the patient an effective amount of a compound disclosed herein (e.g., a compound of Formula (A'), (A), (I), (LA), (LB), (LC), (I-D), (LE), (LF), (LG), (II), (ILA), (ILB), (II-C), (ILD), (ILD-1), (ILD-2), (ILD-3), (ILD-4), (ILD-4'), (ILD-4"), (II-E), (ILF), (ILG), (II-H), (III), (B), (B-I), or (B-II), or Tables A-D, or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof) or a pharmaceutical composition comprising the compound disclosed herein.DETAILED DESCRIPTION

[0057] Throughout this disclosure, various patents, patent applications and publications are referenced. The disclosures of these patents, patent applications and publications in their entireties are incorporated into this disclosure by reference for all purposes in order to moreAttorney Docket No.: INMD-216 / 01WO 315953-4442fully describe the state of the art as known to those skilled therein as of the date of this disclosure. This disclosure will govern in the instance that there is any inconsistency between the patents, patent applications and publications cited and this disclosure.

[0058] Definitions

[0059] Listed below are definitions of various terms used in the specification and claims to describe the present disclosure.

[0060] Unless defined otherwise, all technical and scientific terms used in this disclosure have the same meanings as commonly understood by one of ordinary' skill in the art to which this disclosure belongs.

[0061] The term “about” when immediately preceding a numerical value means a range encompassing said numerical value plus or minus an acceptable amount of variati on in the art (e.g., plus or minus 10% of that value). For example, “about 50” can mean 45 to 55, “about 25,000” can mean 22,500 to 27,500, etc., unless the context of the disclosure indicates otherwise, or is inconsistent with such an interpretation. For example in a list of numerical values such as “about 49, about 50, about 55,.. “about 50” means a range extending to less than half the interval(s) between the preceding and subsequent values, e.g., more than 49.5 to less than 50.5. Furthermore, the phrases “less than about” a value or “greater than about” a value should be understood in view of the definition of the term “about” provided herein. Similarly, the term “about” when preceding a series of numerical values or a range of values (e.g., “about 10, 20, 30” or “about 10-30”) refers, respectively to all values in the series, or the endpoints of the range.

[0062] The terms below, as used herein, have the following meanings, unless indicated otherwise:

[0063] “Cyano” refers to the -CN radical.

[0064] “Hydroxy” or “hydroxyl” refers to the -OH radical.

[0065] “Oxo” refers to the =0 substituent.

[0066] “Alkyl” or “alkyl group” refers to a fully saturated, straight or branched hydrocarbon chain radical having from one to twelve carbon atoms, and which is attached to the rest of the molecule by a single bond. Alkyls comprising any number of carbon atoms from 1 to 12 are included. An alkyl comprising up to 12 carbon atoms is a C1-C12 alkyl, an alkyl comprising up to 10 carbon atoms is a CJ-CIO alkyl, an alkyl comprising up to 6 carbon atoms is a Ci-Cs alkyl and an alkyl comprising up to 5 carbon atoms is a C1-C5 alkyl. i C1-C5 alkyl includes Cs alkyls, C4 alkyls, C3 alkyls, C2 alkyls and Ci alkyl (i.e., methyl). A Ci-Ce alkyl includes all moieties described above for C1-C5 alkyls but also includes Ce alkyls. A C1-C10 alkyl includes allAttorney Docket No.: INMD-216 / 01WO 315953-4442moieties described above for C1-C5 alkyls and C1-C6 alkyls, but also includes C7, C8, C9 and C10 alkyls. Similarly, a C1-C12 alkyl includes all the foregoing moieties, but also includes C11 and C12 alkyls. Non-limiting examples of C1-C12 alkyl include methyl, ethyl, n-propyl, i-propyl, sec-propyl, n-butyl, i-butyl, sec-butyl, t-butyl, n-pentyl, t-amyl, n-hexyl, n-heptyl, n-octyl, n- nonyl, n-decyl, n-undecyl, and n-dodecyl. Unless stated otherwise specifically in the specification, an alkyl group can be optionally substituted

[0067] “Alkylene” or “alkylene chain” refers to a fully saturated, straight or branched divalent hydrocarbon chain radical, and having from one to twelve carbon atoms. Non-limiting examples of C1-C12 alkylene include methylene, ethylene, propylene, n-butylene, ethenylene, propenylene, n-butenylene, propynylene, n-butynylene, and the like. The alkylene chain is attached to the rest of the molecule through a single bond and to the radical group through a single bond. The points of attachment of the alkylene chain to the rest of the molecule and to the radical group can be through one carbon or any two carbons within the chain. Unless stated otherwise specifically in the specification, an alkylene chain can be optionally substituted

[0068] “Alkenyl” or “alkenyl group” refers to a straight or branched hydrocarbon chain radical having from two to twelve carbon atoms, and having one or more carbon-carbon double bonds. Each alkenyl group is attached to the rest of the molecule by a single bond Alkenyl group comprising any number of carbon atoms from 2 to 12 are included. An alkenyl group comprising up to 12 carbon atoms is a C2-C12 alkenyl, an alkenyl comprising up to 10 carbon atoms is a C2-C10 alkenyl, an alkenyl group comprising up to 6 carbon atoms is a C2-C6 alkenyl and an alkenyl comprising up to 5 carbon atoms is a C2-C5 alkenyl. A C2-C5 alkenyl includes C5 alkenyls, C4 alkenyls, C3 alkenyls, and C2 alkenyls. A C2-C6 alkenyl includes all moieties described above for C2-C5 alkenyls but also includes C6 alkenyls. A C2-C10 alkenyl includes all moieties described above for C2-C5 alkenyls and C2-C6 alkenyls, but also includes C7, C8, C9 and C10 alkenyls. Similarly, a C2-C12 alkenyl includes all the foregoing moieties, but also includes C11 and C12 alkenyls. Non-limiting examples of C2-C12 alkenyl include ethenyl (vinyl), 1 -propenyl, 2-propenyl (allyl), iso-propenyl, 2-m ethyl- 1 -propenyl, I-butenyl, 2-butenyl, 3-butenyl, 1-pentenyl, 2-pentenyl, 3-pentenyl, 4-pentenyl, 1-hexenyl, 2-hexenyl, 3-hexenyl, 4-hexenyl, 5-hexenyl, 1 -heptenyl, 2-heptenyl, 3-heptenyl, 4-heptenyl, 5-heptenyl, 6-heptenyl, 1- octenyl, 2-octenyl, 3-octenyl, 4-octenyl, 5-octenyl, 6-octenyl, 7-octenyl, 1-nonenyl, 2-nonenyl, 3-nonenyl, 4-nonenyl, 5-nonenyl, 6-nonenyl, 7-nonenyl, 8-nonenyl, 1-decenyl, 2-decenyl, 3- decenyl, 4-decenyl, 5-decenyl, 6-decenyl, 7-decenyl, 8-decenyl, 9-decenyl, 1-undecenyl, 2- undecenyl, 3-undecenyl, 4-undecenyl, 5-undecenyl, 6-undecenyl, 7-undecenyl, 8-undecenyl, 9-undecenyl, 10-undecenyl, 1 -dodecenyl, 2-dodecenyl, 3-dodecenyl, 4-dodecenyl, 5-Attorney Docket No.: INMD-216 / 01WO 315953-4442dodecenyl, 6-dodecenyl, 7-dodecenyl, 8-dodecenyl, 9-dodecenyl, 10-dodecenyl, and 11-dodecenyl. Unless stated otherwise specifically in the specification, an alkenyl group can be optionally substituted.

[0069] “Alkenylene” or “alkenylene chain” refers to a straight or branched divalent hydrocarbon chain radical, having from two to twelve carbon atoms, and having one or more carbon-carbon double bonds Non-limiting examples of C2-C12 alkenylene include ethene, propene, butene, and the like. The alkenylene chain is attached to the rest of the molecule through a single bond and to the radical group through a single bond. The points of attachment of the alkenylene chain to the rest of the molecule and to the radical group can be through one carbon or any two carbons within the chain. Unless stated otherwise specifically in the specification, an alkenylene chain can be optionally substituted.

[0070] “Alkynyl” or “alkynyl group” refers to a straight or branched hydrocarbon chain radical having from two to twelve carbon atoms, and having one or more carbon-carbon triple bonds. Each alkynyl group is attached to the rest of the molecule by a single bond. Alkynyl group comprising any number of carbon atoms from 2 to 12 are included. An alkynyl group comprising up to 12 carbon atoms is a C2-C12 alkynyl, an alkynyl comprising up to 10 carbon atoms is a C2-C10 alkynyl, an alkynyl group comprising up to 6 carbon atoms is a C2-C6 alkynyl and an alkynyl comprising up to 5 carbon atoms is a C2-C5 alkynyl. A C2-C5 alkynyl includes C5 alkynyls, C4 alkynyls, C3 alkynyls, and C2 alkynyls. A C2-C6 alkynyl includes all moieties described above for C2-C5 alkynyls but also includes C6 alkynyls. A C2-C10 alkynyl includes all moieties described above for C2-C5 alkynyls and C2-C6 alkynyls, but also includes C7, Cs, C9 and C10 alkynyls. Similarly, a C2-C12 alkynyl includes all the foregoing moieties, but also includes C11 and C12 alkynyls. Non-limiting examples of C2-C12 alkenyl include ethynyl, propynyl, butynyl, pentynyl and the like. Unless stated otherwise specifically in the specification, an alkynyl group can be optionally substituted.

[0071] “Alkynylene” or “alkynylene chain” refers to a straight or branched divalent hydrocarbon chain radical, having from two to twelve carbon atoms, and having one or more carbon-carbon triple bonds Non-limiting examples of C2-C12 alkynylene include ethynylene, propargylene and the like. The alkynylene chain is attached to the rest of the molecule through a single bond and to the radical group through a single bond. The points of attachment of the alkynylene chain to the rest of the molecule and to the radical group can be through one carbon or any two carbons within the chain. Unless stated otherwise specifically in the specification, an alkynylene chain can be optionally substituted.Attorney Docket No.: INMD-216 / 01WO 315953-4442

[0072] “Alkoxy” refers to a radical of the formula -ORa where Ra is an alkyl, alkenyl or alkynyl radical as defined above containing one to twelve carbon atoms Unless stated otherwise specifically in the specification, an alkoxy group can be optionally substituted.

[0073] “Alkylamino” refers to a radical of the formula -NHRa or -NRaRa where each Ra is, independently, an alkyl, alkenyl or alkynyl radical as defined above containing one to twelve carbon atoms. Unless stated otherwise specifically in the specification, an alkylamino group can be optionally substituted.

[0074] “Aryl” refers to a hydrocarbon ring system radical comprising hydrogen, 6 to 18 carbon ring atoms and at least one aromatic ring. For purposes of this disclosure, the aryl radical can be a monocyclic, bicyclic, tricyclic or tetracyclic ring system, which can include fused, bridged, or spiro ring systems. Aryl radicals include, but are not limited to, aryl radicals derived from aceanthrylene, acenaphthylene, acephenanthrylene, anthracene, azulene, benzene, chrysene, fluoranthene, fluorene, as-indacene, s-indacene, indane, indene, naphthalene, phenalene, phenanthrene, pleiadene, pyrene, and triphenylene. In embodiments where “L” is aryl, the aryl radical is a diradical. Unless stated otherwise specifically in the specification, the term “aryl” is meant to include aryl radicals that are optionally substituted

[0075] “Aralkyl” or “arylalkyl” refers to a radical of the formula -Rb-Rc where Rb is an alkylene group as defined above and Rc is one or more aryl radicals as defined above, for example, benzyl, diphenylmethyl and the like. Unless stated otherwise specifically in the specification, an aralkyl group can be optionally substituted

[0076] “Carbocyclyl,” “carbocyclic ring” or “carbocycle” refers to a rings structure, wherein the atoms which form the ring are each carbon. Carbocyclic rings can comprise from 3 to 20 carbon atoms in the ring. Carbocyclic rings include cycloalkyl, cycloalkenyl and cycloalkynyl as defined herein. Unless stated otherwise specifically in the specification, a carbocyclyl group can be optionally substituted.

[0077] “Cycloalkyl” refers to a stable non-aromatic monocyclic or polycyclic fully saturated hydrocarbon radical consisting solely of carbon and hydrogen atoms, which can include fused, bridged, or spiro ring systems, having from three to twenty carbon atoms, e.g., having from three to ten carbon atoms, and which is attached to the rest of the molecule by a single bond. Monocyclic cycloalkyl radicals include, for example, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, and cyclooctyl. Polycyclic cycloalkyl radicals include, for example, adamantyl, norbornyl, decalinyl, 7,7-dimethyl-bicyclo[2.2.1]heptanyl, and the like. Unless otherwise stated specifically in the specification, a cycloalkyl group can be optionally substituted.Attorney Docket No.: INMD-216 / 01WO 315953-4442

[0078] “Cycloalkenyl” refers to a stable non-aromatic monocyclic or polycyclic hydrocarbon radical consisting solely of carbon and hydrogen atoms, having one or more carbon-carbon double bonds, which can include fused, bridged, or spiro ring systems, having from three to twenty carbon atoms, e.g., having from three to ten carbon atoms, and which is attached to the rest of the molecule by a single bond. Monocyclic cycloalkenyl radicals include, for example, cyclopentenyl, cyclohexenyl, cycloheptenyl, cycloctenyl, and the like. Polycyclic cycloalkenyl radicals include, for example, bicyclo[2.2.1]hept-2-enyl and the like. Unless otherwise stated specifically in the specification, a cycloalkenyl group can be optionally substituted.

[0079] “Cycloalkynyl” refers to a stable non-aromatic monocyclic or polycyclic hydrocarbon radical consisting solely of carbon and hydrogen atoms, having one or more carbon-carbon triple bonds, which can include fused, bridged, or spiro ring systems, having from three to twenty carbon atoms, e.g., having from three to ten carbon atoms, and which is attached to the rest of the molecule by a single bond. Monocyclic cycloalkynyl radicals include, for example, cycloheptynyl, cyclooctvnyl, and the like. Unless otherwise stated specifically in the specification, a cycloalkynyl group can be optionally substituted.

[0080] “Cycloalky lalkyl” refers to a radical of the formula -Rb-Ra where Rb is an alkylene, alkenylene, or alkynylene group as defined above and Rd is a cycloalkyl, cycloalkenyl, cycloalkynyl radical as defined above. Unless stated otherwise specifically in the specification, a cycloalkylalkyl group can be optionally substituted.

[0081] “Haloalkyl” refers to an alkyl radical, as defined above, that is substituted by one or more halo radicals, as defined above, e.g., trifluoromethyl, difluoromethyl, trichloromethyl, 2,2,2-trifluoroethyl, 1,2-difluoroethyl, 3-bromo-2-fluoropropyl, 1,2-dibromoethyl, and the like. Unless stated otherwise specifically in the specification, a haloalkyl group can be optionally substituted.

[0082] “Haloalkenyl” refers to an alkenyl radical, as defined above, that is substituted by one or more halo radicals, as defined above, e.g., 1 -fluoropropenyl, 1,1-difluorobutenyl, and the like. Unless stated otherwise specifically in the specification, a haloalkenyl group can be optionally substituted.

[0083] “Haloalkynyl” refers to an alkynyl radical, as defined above, that is substituted by one or more halo radicals, as defined above, e.g., 1-fluoropropynyl, 1-fluorobutynyl, and the like. Unless stated otherwise specifically in the specification, a haloalkynyl group can be optionally substituted.

[0084] “Heterocyclyl” “heterocyclic ring” or “heterocycle” refers to a stable 3- to 20-membered non-aromatic, saturated or partially unsaturated ring radical which consists ofAttorney Docket No.: INMD-216 / 01WO 315953-4442two to twelve carbon ring atoms and from one to six heteroatoms as ring atoms selected from nitrogen, oxygen or sulfur, at least one non-aromatic, saturated or partially unsaturated ring containing at least one heteroatom as a ring atom. Unless stated otherwise specifically in the specification, the heterocyclyl radical can be a monocyclic, bicyclic, tricyclic or tetracyclic ring system, which can include fused, bridged, or spiro ring systems, and the nitrogen, carbon or sulfur atoms in the heterocyclyl radical can be optionally oxidized; the nitrogen atom can be optionally quaternized; and the heterocyclyl radical can be partially or fully saturated. Examples of such heterocyclyl radicals include, but are not limited to, dioxolanyl, thienyl[l,3]dithianyl, decahydroisoquinolyl, imidazolinyl, imidazolidinyl, i sothiazolidinyl, isoxazolidinyl, morpholinyl, octahydroindolyl, octahydroisoindolyl, 2-oxopiperazinyl, 2-oxopiperidinyl, 2-oxopyrrolidinyl, oxazolidinyl, piperidinyl, piperazinyl, 4-piperidonyl, pyrrolidinyl, pyrazolidinyl, quinuclidinyl, thiazolidinyl, tetrahydrofuryl, trithianyl, tetrahydropyranyl, thiomorpholinyl, thiamorpholinyl, 1-oxo-thiomorpholinyl, and 1,1 -di oxo-tln omorpholinyl. In embodiments where “L” is heterocyclyl, the heterocyclyl radical is a diradical. Unless stated otherwise specifically in the specification, a heterocyclyl group can be optionally substituted.

[0085] “Heterocyclylalkyl” refers to a radical of the formula -Rb-Re where Rb is an alkylene group as defined above and Re is a heterocyclyl radical as defined above. Unless stated otherwise specifically in the specification, a heterocycloalkyl group can be optionally substituted.

[0086] “N-heterocyclyl” refers to a heterocyclyl radical as defined above containing at least one nitrogen and where the point of attachment of the heterocyclyl radical to the rest of the molecule is through a nitrogen atom in the heterocyclyl radical. Unless stated otherwise specifically in the specification, a N-heterocyclyl group can be optionally substituted.

[0087] “Heteroaryl” refers to a 5- to 20-membered ring system radical comprising one to thirteen carbon ring atoms, one to six heteroatoms as ring atoms selected from nitrogen, oxygen and sulfur, and at least one aromatic ring containing at least one heteroatom as a ring atom. For purposes of this disclosure, the heteroaryl radical can be a monocyclic, bicyclic, tricyclic or tetracyclic ring system, which can include fused, bridged, or spiro ring systems; and the nitrogen, carbon or sulfur atoms in the heteroaryl radical can be optionally oxidized; the nitrogen atom can be optionally quaternized. Examples include, but are not limited to, azepinyl, acridinyl, benzimidazolyl, benzothiazolyl, benzindolyl, benzodioxolyl, benzofuranyl, benzooxazolyl, benzothiazolyl, benzothiadiazolyl, benzo[b][l,4]dioxepinyl, 1,4-benzodioxanyl, benzonaphthofuranyl, benzoxazolyl, benzodioxolyl, benzodioxinyl,Attorney Docket No.: INMD-216 / 01WO 315953-4442benzopyranyl, benzopyranonyl, benzofuranyl, benzofuranonyl, benzothienyl (benzothiophene), benzotriazolyl, benzo[4,6]imidazo[l,2-a]pyridinyl, carbazolyl, cinnolinyl, di benzofuranyl, dibenzothiophene, furanyl, furanonyl, isothiazolyl, imidazolyl, indazolyl, indolyl, indazolyl, isoindolyl, indolinyl, isoindolinyl, isoquinolyl, indolizinyl, isoxazolyl, naphthyridinyl, oxadi azolyl, 2-oxoazepinyl, oxazolyl, oxiranyl, 1-oxidopyridinyl, 1-oxidopyrimidinyl, 1 -oxidopyrazinyl, 1-oxidopyridazinyl, 1 -phenyl- 1 H-pyrrolyl, phenazinyl, phenothiazinyl, phenoxazinyl, phthalazinyl, pteridinyl, purinyl, pyrrolyl, pyrazolyl, pyridinyl, pyrazinyl, pyrimidinyl, pyridazinyl, quinazolinyl, quinoxalinyl, quinolinyl, quinuclidinyl, isoquinolinyl, tetrahydroquinolinyl, thiazolyl, thiadiazolyl, triazolyl, tetrazolyl, triazinyl, and thiophene (i.e. thienyl). In embodiments where “L” is heteroaryl, the heteroaryl radical is a diradical. Unless stated otherwise specifically in the specification, a heteroaryl group can be optionally substituted.

[0088] “N-heteroaryl” refers to a heteroaryl radical as defined above containing at least one nitrogen and where the point of attachment of the heteroaryl radical to the rest of the molecule is through a nitrogen atom in the heteroaryl radical. Unless stated otherwise specifically in the specification, an N-heteroaryl group can be optionally substituted.

[0089] “Heteroarylalkyl” refers to a radical of the formula -Rb-Rf where Rb is an alkylene chain as defined above and Rr is a heteroaryl radical as defined above. Unless stated otherwise specifically in the specification, a heteroaryl alkyl group can be optionally substituted.

[0090] “Thioalkyl” refers to a radical of the formula -SRa where Rais an alkyl, alkenyl, or alkynyl radical as defined above containing one to twelve carbon atoms. Unless stated otherwise specifically in the specification, a thioalkyl group can be optionally substituted.

[0091] The term “substituted” used herein means any of the above groups (i.e., alkyl, alkylene, alkenyl, alkenylene, alkynyl, alkynylene, alkoxy, alkylamino, thioalkyl, aryl, aralkyl, carbocyclyl, cycloalkyl, cycloalkenyl, cycloalkynyl, cycloalkyl alkyl, haloalkyl, heterocyclyl, N-heterocyclyl, heterocyclylalkyl, heteroaryl, N-heteroaryl and / or heteroarylalkyl) wherein at least one hydrogen atom is replaced by a bond to a non-hydrogen atoms such as, but not limited to: a halogen atom such as F, Cl, Br, and I; an oxygen atom in groups such as hydroxyl groups, alkoxy groups, and ester groups, a sulfur atom in groups such as thiol groups, thioalkyl groups, sulfone groups, sulfonyl groups, and sulfoxide groups; a nitrogen atom in groups such as amines, amides, alkylamines, dialkylamines, arylamines, alkylarylamines, diarylamines, N- oxides, imides, and enamines, a silicon atom in groups such as trialkylsilyl groups, dialkylarylsilyl groups, alkyldiaryl silyl groups, and triaryl silyl groups; and other heteroatoms in various other groups.Attorney Docket No.: INMD-216 / 01WO 315953-4442

[0092] “Substituted” also means any of the above groups in which one or more hydrogen atoms are replaced by a higher-order bond (e.g., a double- or triple-bond) to a heteroatom such as oxygen in oxo, carbonyl, carboxyl, and ester groups; and nitrogen in groups such as imines, oximes, hydrazones, and nitriles. For example, “substituted” includes any of the above groups in which one or more hydrogen atoms are replaced with -NRgRh, -NRgC(=O)Rh, -NRgC(=O)NRgRh, -NRgC(=O)ORh, -NRgSO2Rh, -OC(=O)NRgRh, -ORg, -SRg, -SORg, -SO2Rg, -OSO2Rg, -SO2ORg, =NSO2Rg, and -SO2NRgRh. “Substituted also means any of the above groups in which one or more hydrogen atoms are replaced with -C(=O)Rg, -C(=O)ORg, -C(=O)NRgRh, -CH2SO2Rg, -CH2SO2NRgRh In the foregoing, Rgand Rh are the same or different and independently hydrogen, alkyl, alkenyl, alkynyl, alkoxy, alkylamino, thioalkyl, aryl, aralkyl, cycloalkyl, cycloalkenyl, cycloalkynyl, cycloalkylalkyl, haloalkyl, haloalkenyl, haloalkynyl, heterocyclyl, N-heterocyclyl, heterocyclylalkyl, heteroaryl, N-heteroaryl and / or heteroaryl alkyl. “Substituted” further includes any of the above groups in which one or more hydrogen atoms are replaced by a bond to an amino, cyano, hydroxyl, imino, nitro, oxo, thioxo, halo, alkyl, alkenyl, alkynyl, alkoxy, alkylamino, thioalkyl, aryl, aralkyl, cycloalkyl, cycloalkenyl, cycloalkynyl, cycloalkylalkyl, haloalkyl, haloalkenyl, haloalkynyl, heterocyclyl, N-heterocyclyl, heterocyclylalkyl, heteroaryl, N-heteroaryl and / or heteroaryl alkyl group. In addition, each of the foregoing substituents can also be optionally substituted with one or more of the above substituents.

[0093] As used herein, the symbol “1 ” or “ ’ ” (hereinafter can be referred to as “a point of attachment bond”) denotes a bond that is a point of attachment between two chemical entities, one of which is depicted as being attached to the point of attachment bond and the other of which is not depicted as being attached to the point of attachment bond. For example,XYH™ XY— - 1“ ■ ” or “ ' ” indicates that the chemical entity “XY” is bonded to another chemical entity via the point of attachment bond. Furthermore, the specific point of attachment to the non-depicted chemical entity can be specified by inference.

[0094] In this specification, unless stated otherwise, the term “pharmaceutically acceptable” is used to characterize a moiety (e.g., a salt, dosage form, or excipient) as being appropriate for use in accordance with sound medical judgment. In general, a pharmaceutically acceptable moiety has one or more benefits that outweigh any deleterious effect that the moiety may have. Deleterious effects may include, for example, excessive toxicity, irritation, allergic response, and other problems and complications.Attorney Docket No.: INMD-216 / 01WO 315953-4442

[0095] The term “pharmaceutically acceptable salt” includes both acid and base addition salts. Pharmaceutically acceptable salts include those obtained by reacting the active compound functioning as a base, with an inorganic or organic acid to form a salt, for example, salts of hydrochloric acid, sulfuric acid, phosphoric acid, methanesulfonic acid, camphorsulfonic acid, oxalic acid, maleic acid, succinic acid, citric acid, formic acid, hydrobromic acid, benzoic acid, tartaric acid, fumaric acid, salicylic acid, mandelic acid, carbonic acid, etc. Those skilled in the art will further recognize that acid addition salts may be prepared by reaction of the compounds with the appropriate inorganic or organic acid via any of a number of known methods.

[0096] The compounds of the disclosure, or their pharmaceutically acceptable salts can contain one or more asymmetric centers and can thus give rise to enantiomers, diastereomers, and other stereoisomeric forms that can be defined, in terms of absolute stereochemistry, as ( / )- or (S)- or, as (D)- or (L)- for amino acids. The present disclosure is meant to include all such possible isomers, as well as their racemic and optically pure forms whether or not they are specifically depicted herein. Optically active (+) and (-), (R)~ and (5)-, or (D)- and ( L)- isomers can be prepared using chiral synthons or chiral reagents, or resolved using conventional techniques, for example, chromatography and fractional crystallization. Conventional techniques for the preparation, isolation of individual enantiomers include chiral synthesis from a suitable optically pure precursor or resolution of the racemate (or the racemate of a salt or derivative) using, for example, chiral high pressure liquid chromatography (HPLC). When the compounds described herein contain olefinic double bonds or other centers of geometric asymmetry, and unless specified otherwise, it is intended that the compounds include both E and Z geometric isomers. Likewise, all tautomeric forms are also intended to be included.

[0097] A “stereoisomer” refers to a compound made up of the same atoms bonded by the same bonds but having different three-dimensional structures, which are not interchangeable. The present disclosure contemplates various stereoisomers and mixtures thereof and includes “enantiomers”, which refers to two stereoisomers whose molecules are nonsuperimposable mirror images of one another.

[0098] The term “treating” as used herein with regard to a patient, refers to an approach for obtaining beneficial or desired results including but not limited to a therapeutic benefit and / or a prophylactic benefit. Therapeutic benefit refers to any therapeutically relevant improvement in or effect on one or more diseases, conditions, or symptoms under treatment. The term “treating” in one embodiment, includes: (1) preventing or delaying the appearance of clinical symptoms of the state, disorder or condition developing in the patient that may be afflicted with or predisposed to the state, disorder or condition but does not yet experience or displayAttorney Docket No.: INMD-216 / 01WO 315953-4442clinical or subclinical symptoms of the state, disorder or condition; (2) inhibiting the state, disorder or condition (e.g,, arresting, reducing or delaying the development of the disease, or a relapse thereof in case of maintenance treatment, of at least one clinical or subclinical symptom thereof); (3) relieving the condition (for example, by causing regression, or reducing the severity of the state, disorder or condition or at least one of its clinical or subclinical symptoms).

[0099] An “effective amount” means the amount compound or pharmaceutical formulation, that when administered to a patient for treating a state, disorder or condition is sufficient to effect such treatment.

[0100] The term “therapeutically effective” applied to dose or amount refers to that quantity of a compound or pharmaceutical formulation that is sufficient to result in a desired clinical benefit after administration to a patient in need thereof. A “therapeutically effective amount”, in some embodiments, is a dose or amount of a compound or pharm ceutical formulation that is sufficient to result in prophylaxis after administration to a patient in need thereof.

[0101] The terms “subject,” “individual,” and “patient” are used interchangeably herein to refer to a vertebrate, such as a mammal. The mammal may be, for example, a mouse, a rat, a rabbit, a cat, a dog, a pig, a sheep, a horse, a non-human primate (e.g., cynomolgus monkey, chimpanzee), or a human.

[0102] Compounds

[0103] In one aspect of the present disclosure, a DPP1 inhibitor is provided, and the DPP1 inhibitor is a compound of Formula (A'), (A), (I), (I -A), (I-B), (I-C), (I-D), (I-E), (I-F), (I-G), (II), (11-A), (11-B), (11-C), (11-D), (1I-D-1), (ll-D-2), (ll-D-3), (ll-D-4), (ll-D-4'), (ll-D-4”), (11- E), (II-F), (II-G), (II-H), (III), (B), (B-I), or (B-1I), or Tables A-D, or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof.

[0104] In embodiments, the present disclosure provides a compound of Formula (A'):R3R2(R4)m(A'),

[0105] or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, wherein:

[0106] ring A is a carbocyclyl, aryl, heterocyclyl, or heteroaryl ring;Attorney Docket No.: INMD-216 / 01WO 315953-4442

[0107] R1is h10

[0108] R2is a carbocycle, aryl, heterocycle, or heteroaryl ring, wherein each R2is optionally substituted with 1, 2, 3, or 4 R6;

[0109] R3is H; or R3together with one of R6can form a tricyclic, tetracyclic, or pentacyclic ring optionally containing 1, 2, or 3 heteroatoms selected from N, S, or O, wherein the tricyclic, tetracyclic, or pentacyclic ring is optionally substituted with 1, 2, 3, or 4 R5;

[0110] each R4is independently halogen, -Ci-Cs alkyl, -Ci-Ce haloalkyl, -S(Ci-C6 alkyl), - SO(C]-C6 alkyl), -SO2(Ci-C6alkyl), or -CN;

[0111] R5and R6are each independently halogen, -OH, oxo, -CN, -Ci-Ce alkyl, -Ci-Ce alkyl-OH, -(Ci-C6 alkylene)-O-(Ci-C6 alkyl), -(Ci-Ce alkylene)-O-(Ci-C6 alkyl)-OH, -(C1-C6 alkylene)-O-(Ci-Ce alkylene)-O-(Ci-Ce alkyl), -(Ci-Cs alkylene)-O-(Ci-C6 alkyl ene)-O-(Ci-C6alkyl)-OH, -Ci-Cio haloalkyl, -Ci-Cio haloalkyl-OH, -NR7R8, -Ci-C6alkyl-NR7Rs, -S(Ci- C6 alkyl), -SO(Ci-Cs alkyl), -SO2(Ci-C6 alkyl), -SOiNR'R8, -(Ci-Ce. alkylene)-carbocycle, -(Ci-Ce alkylene)-heterocycle, carbocycle, or heterocycle, wherein each carbocycle and heterocycle is optionally substituted by 1 or 2 R11;

[0112] each R7and R8is independently H or -Ci-Ce alkyl; or R7and R8together with the nitrogen atom to which they are attached form a heterocyclyl;

[0113] R9and R9aare each independently deuterium, halogen, cyano, hydroxyl, -NH2, -NH(Ci-Cc alkyl), -N(CI-C6 alkyl)2, -COOH, -Ci-Cr, alkyl, -C2-Cr, alkenyl, -C2-C6alkynyl, -C1-C6haloalkyl, -C2-C6 haloalkenyl, -C2-C’6 haloalkynyl, -Ci-Ce alkyl-OH, -CONH2, -SH, -Attorney Docket No.: INMD-216 / 01WO 315953-4442S(=O)NH2, -S(O)2NH2, -0C1-C6 alkyl, -OCi-C6haloalkyl, -S(Ci-C6alkyl), -SO(Ci-C6alkyl), -SO2(Ci-C6alkyl), -SO2NR7R8, -S(-NH)(O)(CI-C6alkyl), -(Ci-Ce alkylene)-carbocyclyl, or- (Ci-C6alkylene)-heteroaryl,

[0114] R9bis independently halogen, cyano, -NH2, -NH(C1-C6alkyl), -N(CI-C6 alkyl)2, - COOH, -C1-C6 alkyl, -C2-C6 alkenyl, -C2-C6 alkynyl, -Ci-Ce haloalkyl, -C2-C6 haloalkenyl, - C2-C6 haloalkynyl, -Ct-C6alkyl-OH, -CONH2, -SH, -S(=O)NH2, -S(O)2NH2, -OCi-Ce haloalkyl, -S(Ci-C6alkyl), -SO(Ci-C6alkyl), -SO2(Ci-C6 alkyl), -SO2NR7R8, -S(=NH)(O)(Ci- Ce alkyl), -(C1-C6 alkylene)-carbocyclyl, or-(Ci-C6 alkylene)-heteroaryl;

[0115] R10is H or -Ci-C6alkyl;

[0116] each R11is independently halogen, -OH, oxo, -CN, -Ci-Ce alkyl, -Ci-Ce alkyl-OH, -Ct- C10 haloalkyl, -C1-C10 haloalkyl-OH, -OCi-Ce alkyl, -NR7R8, -C1-C6alkyl-NR7R8, -S(Ci-C6alkyl), -SO(Ci-C6alkyl), -SO2(Ci-C6alkyl), -SO2NR7R8, -(Ci-C6alkylene)-carbocycle, -(Ci- Cs alkylene)-heterocycle, carbocycle, or heterocycle;

[0117] m is 0, 1, 2, or 3; and[01 IS] n is O, 1, 2, or 3;

[0119] provided that the compound is not a compound disclosed in WO2024 / 026433, WO2024 / 148308, WO2024 / 173556, WO2024 / 192416 and / or W02024 / 008680

[0120] In the compounds of For ula (A') or a pharmaceutically acceptable salt, a stereoisomer,R-N-VR” or a deuterated form thereof, when R is* and R is H, R is not'

[0121] In the compounds of Formula (A') or a pharmaceutically acceptable salt, a stereoisomer,RI° R9a, vs or a deuterated form thereof, when R isz, Rzis notu

[0122] In the compounds of Formula (A') or a pharmaceutically acceptable salt, a stereoisomer, the compound is notAttorney Docket No.: INMD-216 / 01WO 315953-4442(5)-A -(1 -cy an o-2-(4-(3 - ethyl -2-oxo-2, 3 - dihydrobenzo[d]oxazol-5-yl)phenyl)ethyl)-3-(ditluoromethyl)azetidine-3 -carboxamide, (A)- A’-(l-cyano-2-(2-fluoro-4-(3-methyl-2-oxo-2,3-dihydrobenzo[d]oxazol-5-yl)phenyl)ethyl)-3- methoxyazetidine-3-carboxamide, (A)-A-(l-cyano-2-(2-fluoro-4-(3-methyl-2-oxo-2,3- dihydrobenzo[d]oxazol-5-yl)phenyl)ethyl)-3-methoxy-l-methylazetidine-3-carboxamide, (A)- N-( 1 -cyano-2-(2-fluoro-4-(1'-(oxetan-3 -yl)-3 H-spi ro[i sobenzofuran- 1,4'-piperidin]-6-yl)phenyl)ethyI)-3-(difluoromethyl)azetidine-3-carboxamide, or (A)-A-(l-cyano-2-(2-fluoro-4-(r-(oxetan-3-yl)-3H-spiro[isobenzofuran-l,4'-piperidin]-6-yl)phenyl)ethyl)-3- (difhioromethyl)-l-methylazetidine-3 -carboxamide, or a stereoisomer thereof.

[0123] In embodiments of the compounds of Formula (A') or a pharmaceutically acceptableHO xH3X JX (T n (TNo salt, a stereoisomer, or a deuterated form thereof, R1isHN,z,HN,zAttorney Docket No.: INMD-216 / 01WO 315953-4442

[0124] In embodiments, the present disclosure provides a compound of Formula (A):YAi(R4)m(A),

[0125] or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, wherein:

[0126] ring A is a carbocyclyl, aryl, heterocyclyl, or heteroaryl ring;Attorney Docket No.: INMD-216 / 01WO 315953-4442

[0128] R2is a carbocycle, aryl, heterocycle, or heteroaryl ring, wherein each R2is optionally substituted with 1, 2, 3, or 4 R9;

[0129] R3is H; or R3together with one of R6can form a tricyclic, tetracyclic, or pentacyclic ring optionally containing 1, 2, or 3 heteroatoms selected from N, S, or O, wherein the tricyclic, tetracyclic, or pentacyclic ring is optionally substituted with 1, 2, 3, or 4 R5;

[0130] each R4is independently halogen, -Ci-Ce alkyl, -Ci-Ce haloalkyl, -S(Ci-Ce alkyl), - SO(Ci-Ce alkyl), -SO2(Ci-Ce alkyl), or -CN;

[0131] R3and R6are each independently halogen, -OH, oxo, -CN, -Ci-Ce alkyl, -Ci-Ce alkyl-OH, -(Ci-Cs alkylene)-O-(Ci-Ce alkyl), -(Ci-Ce alkylene)-O-(Ci-Ce alkyl)-OH, -(Ci-Ce alkylene)-O-(Ci-C6 alkylene)-O-(Ci-C6 alkyl), -(Ci-Ce alkylene)-O-(Ci-Ce alkylene)-O-(Ct-C6 alkyl)-OH, -Ci-Cio haloalkyl, -Ci-Cio haloalkyl-OH, -NR7R8, -Ci-C6alkyl-NR7R8, -S(Ci-Ce alkyl), -SO(Ci-Ce alkyl), -SO2(Ci-Ce alkyl), -SO2NR7R8, -(Ci-Ce alkylene)-carbocycle, -(Ci-Ce alkylene)-heterocycle, carbocycle, or heterocycle, wherein each carbocycle and heterocycle is optionally substituted by 1 or 2 R”;

[0132] each R7and R8is independently H or -Ci-Ce alkyl; or R7and R8together with the nitrogen atom to which they are atached form a heterocyclyl;

[0133] R9and R9aare each independently deuterium, halogen, cyano, hydroxyl, -NHz, -NH(CJ-Ce alkyl), -N(Ci-Ce alkyl)2, -COOH, -Ci-Ce alkyl, -C2-Ce alkenyl, -C2-Ce alkynyl, -Ci-Ce haloalkyl, -Cz-Cc, haloalkenyl, -Cz-Ce haloalkynyl, -Cj-Ce alkyl-OH, -CONHz, -SH, - S(=O)NH2, -S(O)2NH2, -OC1-C6 alkyl, -OCi-C6haloalkyl, -S(Ci-C6alkyl), -SO(Ci-C6alkyl), -SO2(Ci-C6 alkyl), -SO2NR7R8, -S(=NH)(O)(C1-C6alkyl), -(Ci-Ce alkylene)-carbocyclyl, or ---(C 1 -C 6 alky lene)-heteroaryl;

[0134] R’° is H or -Ci-C6alkyl;

[0135] each R11is independently halogen, -OH, oxo, -CN, -Ci-Ce alkyl, -Ci-Ce alkyl-OH, -Ci-C10 haloalkyl, -C1-C10 haloalkyl-OH, -OCi-Ce alkyl, -NR7R8, -C1-C6 alkyl-NR7R8, -S(Ci-C6alkyl), -SO(Ci-Ce alkyl), -SO2(Ci-Ce alkyl), -SO2NR7R8, -(C1-C6 alkylene)-carbocycle, -(C1-C6 alkylene)-heterocycle, carbocycle, or heterocycle;

[0136] m is 0, 1, 2, or 3; and

[0137] n is 0, 1, 2, or 3;R10R9a

[0138] wherein when Rlis and R’ is H, R2is not'; andAttorney Docket No.: INMD-216 / 01WO 315953-4442dihydrobenzo[d]oxazol-5-yl)phenyl)ethyl)-3-(difluoromethyl)azetidine-3 -carboxamide, (S)-A'-(l-cyano-2-(2-fluoro-4-(3-methyl-2-oxo-2,3-dihydrobenzo[d]oxazol-5-yl)phenyI)ethyl)-3-methoxyazetidine-3 -carboxamide, (5)-A-(l-cyano-2-(2-fluoro-4-(3-methyl-2-oxo-2,3- dihydrobenzo[d]oxazol-5-yl)phenyl)ethyl)-3-methoxy-l-methylazetidine-3-carboxamide, (S)~. V-(l-cyano-2-(2-fluoro-4-(r-(oxetan-3-yl)-3H-spiro[isobenzofuran-l,4'-piperidin]-6-yl)phenyl)ethyl)-3-(difluoromethyl)azetidine-3-carboxamide, or (5')-A7-(l-cyano-2-(2-fluoro-4-(r-(oxetan-3-yl)-3H-spiro[isobenzofuran-l,4'-piperidin]-6-yl)phenyl)ethyl)-3- (difluoromethyl)-l-methylazetidine-3-carboxamide, or a stereoisomer thereof.

[0141] In embodiments of the compounds of Formula (A') or (A) or a pharmaceuticallycompounds of Formula (A') or (A) or a pharmaceutically acceptable salt, a stereoisomer, or aAttorney Docket No.: INMD-216 / 01WO 315953-4442deuterated form thereof, R1embodiments,R1is R9and R9aare each independently deuterium, halogen, hydroxyl, -Ci -Co alkyl, -C2-C6 alkenyl, -C2-C6 alkynyl, -Ci-Cg haloalkyl, -C2-C6 haloalkenyl, -C2-C6 haloalkynyl, -OCi-Ce alkyl, or - OCi-Cg haloalkyl. In embodiments, R9and R9aare each independently halogen, hydroxyl, -Ci-Ce alkyl, -C2-C6 alkenyl, -C2-C6 alkynyl, -Ci-Ce haloalkyl, -C2-C0 haloalkenyl, -C2-C6 haloalkynyl, -OCi-Ce alkyl, or -OCi-Ce haloalkyl. In embodiments, R9and R9aare each independently halogen, hydroxyl, -Ci-Ca alkyl, -C1-C3 haloalkyl, -OC1-C3 alkyl, or -OC1-C3 haloalkyl. In embodiments, R9and R9aare each independently halogen, hydroxyl, methoxy, ethoxy, fluoromethyl, or difluoromethyl. In embodiments, R,ois H or methyl. In embodiments, n is 0 or 1, In embodiments, n is O. In embodiments of the compounds of Formula (A') or (A) or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, R1isAttorney Docket No.: INMD-216 / 01WO 315953-4442

[0142] In embodiments of the compounds of Formula (A') or (A) or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, R1is

[0143] In embodiments, the present disclosure provides a compound of Formula (I ):Attorney Docket No.: INMD-216 / 01WO 315953-4442(R4)m

[0144] or a pharmaceutically acceptable salt a stereoisomer, or a deuterated form thereof, wherein:

[0145] ring A is a carbocycle, aryl, heterocycle, or heteroaryl ring;

[0146] R2is a carbocycle, aryl, heterocycle, or heteroaryl ring, wherein each R2is optionally substituted with 1, 2, 3, or 4 R6;

[0147] R3is H; or R3together with one of R6can form a tricyclic, tetracyclic, or pentacyclic ring optionally containing 1, 2, or 3 heteroatoms selected from N, S, or O, wherein the tricyclic, tetracyclic, or pentacyclic ring is optionally substituted with 1, 2, 3, or 4 R5;

[0148] each R4is independently halogen, -Ci-Ce alkyl, -Ci-Ce haloalkyl, -S(Ci-C6 alkyl), - SO(C1-C6alkyl), -SO2(Ci-C6 alkyl), or -CN;

[0149] R5and R6are each independently halogen, -OH, oxo, -CN, -Ci-Ce alkyl, -C1-C6alkyl-OH, -(CJ-C6 alkylene)-O-(Ci-C6 alkyl), -(Ci-Ce alkylene)-O-(Ci-C6 alkyl)-OH, -(C1-C6 alkylene)-O-(Ci-Cs alkylene)-O-(Ci-Ce alkyl), -(Ci-Cs alkylene)-O-(Ci-Ce alkylene)-O-(Ci-Ce alkyl)-OH, -Ci-Cio haloalkyl, -Ci-Cio haloalkyl-OH, -NR7R8, -Ci-Ce alkyl-NR7R8, -S(Ci-C6alkyl), -SO(Ci-C6 alkyl), -SO2(Ci-C6 alkyl), -SO2NR7R8, -(Ci-C6alkylene)-carbocycle, - (Ci-Ce alkylene)-heterocycle, carbocycle, or heterocycle, wherein each carbocycle and heterocycle is optionally substituted by 1 or 2 R”;

[0150] R' and R8are each independently H or -Ci-C6alkyl; or R7and R8together with the nitrogen atom to which they are attached form a heterocyclyl;

[0151] R9and R9aare each independently deuterium, halogen, cyano, hydroxyl, -NH2, -NH(Ci-C6 alkyl), -N(CI-C6 alkyl)2, -COOH, -Ci-Cs alkyl, -C2-C6 alkenyl, -C2-C6 alkynyl, -Ci-Cs haloalkyl, -C2-Ce haloalkenyl, -C2-Cb haloalkynyl, -Ci-Ce alkyl-OH, -CONH2, -SH, -S(=O)NH2, -S(O)2NH2, -OC1-C6 alkyl, -OC1-C6 haloalkyl, -S(Ci-C6 alkyl), -SO(Ci-Ce alkyl), -SO2(CJ-C6alkyl), -SO2NR7R8, -S(=NH)(O)(C1-C6alkyl), -(C1-C6 alkylene)-carbocyclyl, or -(C1-C6 alkylene)-heteroaryl;

[0152] R10is H or -Ci-C6alkyl;

[0153] each R11is independently halogen, -OH, oxo, -CN, -Ci-Ce alkyl, -Ci-Ce alkyl-OH, -Ci-Cw haloalkyl, -Ci-Cio haloalkyl-OH, -OC1-C6 alkyl, -NR7R8, -Ci-C6alkyl-NR7R8, -S(Ci-C6Attorney Docket No.: INMD-216 / 01WO 315953-4442alkyl), -SO(C1-C6 alkyl), -SO2(C1-C6 alkyl), -SO2NR7R8, -(C1-C6 alkylene)-carbocycle, -(C1- C6 alkylene)-heterocycle, carbocycle, or heterocycle,

[0154] m is 0, 1, 2, or 3; and

[0155] n is 0, 1, 2, or 3;

[0156] wherein when R3is H, R2is not

[0157] wherein R2is not; and

[0158] wherein the compound is not: (iS)-A-(l-cyano-2-(4-(3-methyl-2-oxo-2,3- dihydrobenzo[d]oxazol-5-yl)phenyl)ethyl)-3-(difluoromethyl)azetidine-3 -carboxamide, (5)- A-(l-cyano-2-(2-fluoro-4-(3-methyl-2-oxo-2,3-dihydrobenzo[d]oxazol-5-yl)phenyl)ethyl)-3-methoxy zetidine-3-carboxamide, (S)-A-(l-cyano-2-(2-fluoro-4-(3-methyl-2-oxo-2,3- dihydrobenzo[d]oxazol-5-yl)phenyl)ethyl)-3-methoxy-l-methylazetidine-3-carboxamide, (5)- 7 -(l-cyano-2-(2-fluoro-4-(r-(oxetan-3-yl)-3H-spiro[isobenzofuran-l,4'-piperidin]-6-yl)phenyl)ethy!)-3-(difluoromethyl)azetidine-3-carboxamide, or (S)- / V-(l-cyano-2-(2-fluoro- 4-(r-(oxetan-3-yl)-3H-spiro[isobenzofuran-l,4'-piperidin]-6-yl)phenyl)ethyl)-3- (di fl uorom ethyl )- 1 -methylazeti dine-3 -carboxam i de

[0159] In embodiments of the compounds of Formula (A'), (A), or (I), or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, R2is a bicyclic ring, wherein at least one ring is aromatic, and wherein2is optionally substituted with 1, 2, 3, or 4 Rb.

[0160] In embodiments of the compounds of Formula (A'), (A), or (I), or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, R2is a fused bicyclic ring, optionally substituted with 1, 2, 3, or 4 R6.

[0161] In embodiments of the compounds of Formula (A'), (A), or (I), or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, R2is a 5,5-, 5,6-, 6,5-, or 6,6-fused bicyclic ring, optionally substituted with 1, 2, 3, or 4 R6,

[0162] In embodiments of the compounds of Formula (A'), (A), or (I), or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof:Attorney Docket No.: INMD-216 / 01WO 315953-4442

[0164] each Xlais independently -NR6a-, -O-, -CR!2R13-, -C(O)-, -S-, -S(O) - or -S(O)2-;

[0165] each R6is independently halogen, -OH, oxo, -CN, -CI-CG alkyl, -CI-CG alkyl-OH, -(CI-CG alkylene)-O-(C]-C6 alkyl), -(C1-C6alkylene)-O-(Ci-C6alkyl)-OH, -(C1-C6alkylene)-O-(Cj-CG alkylene)-O-(Cj-Cc alkyl), -(C1-C6alkylene)-O-(Ci-CG alkylene)-O-(Ci-CG alkyl)-OH, -CJ- C10 haloalkyl, -C1-C10 haloalkyl-OH, -NR7R8, -CI-CG alkyl-NR7R8, -S(Ci-C6alkyl), -SO(Ci-CG alkyl), -SO2(Ci-C6alkyl), -SO2NR7Rs, -(C1-C6alkylene)-carbocycle, -(CI-CG alkylene)-heterocycle, carbocycle, or heterocycle, wherein each carbocycle and heterocycle is optionally substituted by 1 or2 Rn;

[0166] each R6ais independently H, -CI-CG alkyl, -CI-CG alkyl-OH, -C1-C10 haloalkyl, -C1-C10 haloalkyl-OH, -CJ-CG alkyl-NR7R8, -(CI-CG alkylene)-O-(Ci-C6 alkyl), -(Ci-Ce alkylene)-O-(Ci-Ce alkyl)-OH, -(Ci-C6alkylene)-O-(Ci-C6 alkyl)-COOH, -(Ci-C6alkylene)-O-(Ci-C6 alkylene)-O-(Ci-C6 alkyl), -(CI-CG alkylene)-O-(Ci-C6 alkylene)-NR7Rs, -(CI-CG alkylene)-O-(CI-CG alkylene)-C(O)NR7R8, -(Ci-C6alkylene)-O-(Ci-C6alkylene)-NR7C(O)-(Ci-C6alkyl), --(C1-C6 alkylene)-O-(C1-C6 alkylene)-C(O)NR7-(C1-C6 alkylene)-O-(C1-C6 alkyl), -(CI-CG alkylene)-O-(Ci-C6 alkylene)-NR7C(O)-(Ci-CG alkylene)-O-(Ci-C6 alkyl), -(C1-C6alkylene)-O-(CI-CG alkylene)-C(O)NR7-(Ci-C6 alkylene)-O-(Ci-C6 alkylene)-NR7-aryl, -(CI-CG alkylene)-O-(Ci-C6 alkyd ene)-NR7C(O)-(Ci-C6 alkylene)-O-(Ci-C6 alkylene)-NR'-aryl, -(C1-C6alkylene)-NR7Rs, -(CI-CG alkylene)-NR7-(Ci-C6 alky1)-OH, -(Ci-Ce alkylene)-NR7-(Ci-C6 alkyl)-O-(Ci-C6 alkyl), -(C1-C6alkylene)-NR7-(Ci-C6 alkylene)-NR7R8, -(C1-C6alkylene)-heterocycle, or -(CI-CG alkyl ene)-heteroaryl;

[0167] R7and Rsare each independently H or -CI-CG alkyl, or R7and R8together with the nitrogen atom to which they are attached form a heterocyclyl;

[0168] each R11is independently halogen, -OH, oxo, -CN, -CI-CG alkyl, -CI-CG alkyl-OH, -Ci-C10 haloalkyl, -C1-C10 haloalkyl-OH, -OCI-CG alkyl, -NR7R8, -Ci-C6alkyl-NR7R8, -S(C1-C6 alkyl), -SO(Ci-C6alkyl), -SO2(Ci-C6 alkyl), -SO2NR7R8, -(C1-C6alkylene)-carbocycle, -(CI- CG alkylene)-heterocycle, carbocycle, or heterocycle;

[0169] R12and R13are each independently selected from H, deuterium, halogen, or -CI-CG alkyl: and

[0170] p is O, 1, 2, or 3.

[0171] In embodiments of the compounds of Formula (A'), (A), or (I), or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, R2is a tricyclic ring, wherein at least one ring is aromatic, and wherein R2is optionally substituted with 1, 2, 3, or 4 Rb.Attorney Docket No.: INMD-216 / 01WO 315953-4442In embodiments of the compounds of Formula (A'), (A), or (I), or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, R2is a tricyclic ring containing at least one phenyl ring and wherein R2is optionally substituted with 1, 2, 3, or 4 R6.

[0172] In embodiments of the compounds of Formula (A'), (A), or (I), or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, R together with one of R6can form a tricyclic, tetracyclic, or pentacyclic ring optionally containing 1, 2, or 3 heteroatoms selected from N, S, or O, wherein the tricyclic, tetracyclic, or pentacyclic ring is optionally substituted with 1, 2, 3, or 4 R5.

[0173] In embodiments, the present disclosure provides a compound of Formula (1-A):(R> (LA),

[0174] or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof wherein:

[0175] ring A is a carbocycle, and, heterocycle, or heteroaryl ring;

[0177] each X,ais independently -NR6a-, -O-, -CR,2R13-, -C(O)-, -S-. -S(O) - or -S(O)2-;

[0178] R3is H; or R3together with one of R6can form a tricyclic, tetracyclic, or pentacyclic ring optionally containing 1, 2, or 3 heteroatoms selected from N, S, or O, wherein the tricyclic, tetracyclic, or pentacyclic ring is optionally substituted with 1, 2, 3, or 4 R5;

[0179] each R4is independently halogen, -Ci-Ce alkyl, -Ci-Ce haloalkyl, -S(Ci-Ce alkyl), - SO(C1-C6 alkyl), -SO2(Ci-C6alkyl), or -CN;

[0180] R3and R6are each independently halogen, -OH, oxo, -CN, -Ci-Ce alkyl, -Ci-Ce alkyl -OH, -(CJ-C6alkylene)-O-(Ci-C6 alkyl), -(Ci-C6alkylene)-O-(Ci-C6alkyl)-OH, -(Ci-C6alkylene)-O-(Ci-C6 alkylene)-O-(Ci-Ce alkyl), -(Ci-Cs alkylene)-O-(Ci-C6 alkylene)-O-(Ci-Ce alkyl)-OH, -Ci-Cto haloalkyl, -Ci-Cio haloalkyl-OH, -NR7R8, -Ci-C6alkyl-NR7R8, -S(Ci-Ce alkyl), -SO(Ci-C6 alkyl), -SO2(Ci-C6 alkyl), -SO2NR7R8, -(Ci-Ce. alkylene)-carbocycle, -(Ci-Ce alkylenel-heterocycle, carbocycle, or heterocycle, wherein each carbocycle and heterocycle is optionally substituted by 1 or 2 R11;Attorney Docket No.: INMD-216 / 01WO 315953-4442

[0181] each R6ais independently H, -Ci-Ce alkyl, -C1-C6 alkyl-OH, -C1-C10 haloalkyl, -Ci-Cio haloalkyl-OH, -Ci-C6alkyl-NR7R8, -(Ci-Ce alkylene)-O-(Ci-C6 alkyl), -(Ci-C6alkylene)-O-(Ci-C6alkyl)-OH, -(Ci-C6alkylene)-O-(Ci-C6alkyl)-COOH, -(C1-C6 alkylene)-O-(Ci-C6alkylene)-O-(Ci-Co alkyl), -(C1-C6alkylene)-O-(Cj-C6 alkylene)-NR7R8, -(Ci-C alkylene)-O-(C1-C6 alkylene)-C(O)NR7R8, -(Ci-C6alkylene)-O-(Ci-C6alkylene)-NR7C(O)-(Ci-C6 alkyl), - (C1-C6 alkylene)-O-(Ci-C6a1kylene)-C(O)NR7-(Ci-C6alkylene)-O-(Cj-C6alkyl), -(Ci-C6alkylene)-O-(Ci-Cs alkylene)-NR7C(O)-(Ci-C6 alkylene)-O-(Ci-C6 alkyl), -(Ci-Ce alkylene)-O-(CJ-C6 alkylene)-C(O)NR7-(Ci-C6 alkylene)-O-(Ci-C6 alkylene)-NR7-aryl, -(C1-C6 alkylene)-O-(Ci-C6 alkylene)-NR7C(O)-(Ci-Ce alkylene)-O-(Ci-Ce alkylene)-NR'-aryl, -(Ci- Ce alkylene)-NR7R8, -(Ci-C6alkylene)-NR7-(Ci-Ce alkyl)-OH, -(Ci-Ce alkylene)-NR7-(Ci-C6alkyl)-O-(Ci-C6alkyl), -(Ci-Ce alkylene)-NR7-(Ci-Ce alkylene)-NR7R8, -(Ci-Ce alkylene)-heterocycle, or -(Ci-C6 alkylene)-heteroaryl;

[0182] R7and R8are each independently H or -Ci-Ce alkyl; or R7and R8together with the nitrogen atom to which they are attached form a heterocyclyl;

[0183] R9and R9aare each independently deuterium, halogen, cyano, hydroxyl, -NH2, -NH(Ci-C6alkyl), -N(Ci-C6alkyl)2, -COOH, -Ci-C6alkyl, -C2-C6 alkenyl, -C2-C6 alkynyl, -Ci-C6haloalkyl, -C2-C0 haloalkenyl, -C2-C6 haloalkynyl, -Ci-Cc alkyl-OH, -CONH2, -SH, - -S(=O)NH2, -S(O)2NH2, -OC1-C6 alkyl, -OCi-Ce haloalkyl, -S(Ci-Ce alkyl), -SO(Ci-CSalkyl), -SO2(CJ-C6 alkyl), -SO2NR7R8, -S(=NH)(O)(Ci-C6 alkyl), -(Ci-Ce alkylene)-carbocyclyl, or- (Ci-Cs alkylene)-heteroaryl,

[0184] R10is H or -Ci-C6alkyl;

[0185] each R11is independently halogen, -OH, oxo, -CN, -C1-C6 alkyl, -Ci-Ce alkyl-OH, -CJ- C10 haloalkyl, -C1-C10 haloalkyl-OH, -OCi-C6alkyl, -NR7R8, -Ci-C6alkyl-NR7R8, -S(Ci-C6alkyl), -SO(CJ-C6 alkyl), -SO2(Ci-C6 alkyl), -SO2NR7R8, -(Cj-Ce alkylene)-carbocycle, -(Ci- Ce alkylene)-heterocycle, carbocycle, or heterocycle;

[0186] R12and R13are each independently selected from H, deuterium, halogen, or -Ci-Cc, alkyl;

[0187] m is 0, 1, 2, or 3;

[0188] n is 0, 1, 2, or 3; and

[0189] p is O, 1, 2, or 3;N

[0190] wherein when R3is H, R2is notAttorney Docket No.: INMD-216 / 01WO 315953-4442

[0191] wherein R2is not

[0192] wherein the compound is not: (<. S)-A-(l-cyano-2-(4-(3-methyl-2-oxo-2,3- dihydrobenzo[d]oxazol-5-yl)phenyl)ethyl)-3-(difluoromethyl)azetidine-3-carboxamide, (5)- yV-(l-cyano-2-(2-fluoro-4-(3-methyl-2-oxo-2,3-dihydrobenzo[d]oxazol-5-yl)phenyl)ethyl)-3-methoxyazetidine-3-carboxamide, (S)-A-(l-cyano-2-(2-fluoro-4-(3-methyl-2-oxo-2,3-dihydrobenzo[d]oxazol-5-yl)phenyl)ethyl)-3-methoxy-l-methylazetidine-3-carboxamide, (S)- A-(l-cyano-2-(2-fluoro-4-(r-(oxetan-3-yl)-3H-spiro[isobenzofuran-l,4'-piperidin]-6-yl)phenyl)ethyl)-3-(difluoromethyl)azetidine-3-carboxamide, or (1S’)-Ar-(l-cyano-2-(2-fluoro-4-(r-(oxetan-3-yl)-3H-spiro[isobenzofuran-l,4'-piperidin]-6-yl)phenyl)ethyl)-3-(difluoroniethyl)-l-methylazetidine-3-carboxamide.

[0193] In embodiments of the compounds of Formula (A'), (A), (I), or (I-A), or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, A is aryl. Inembodiments, A is phenylene. In embodiments, A isKor

[0194] In embodiments of the compounds of Formula (A'), (A), (1), or (I-A), or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof5is H.

[0195] In embodiments of the compounds of Formula (A'), (A), (I), or (I-A), or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, each R4is independently halogen, -C1-C3 alkyl, or -CN. In embodiments, R4is halogen.

[0196] In embodiments of the compounds of Formula (A'), (A), (I), or (I-A), or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, m is 0 or 1.

[0197] In embodiments, the present disclosure provides a compound of Formula (1-B):

[0198] or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof wherein:Attorney Docket No.: INMD-216 / 01WO 315953-4442

[0200] each X,ais independently -NR6a~, -O-, -CRI2R13-, -C(O)-, -S-, -S(O) - or -S(O)2-;

[0201] each R4is independently halogen, -Ci-Cs alkyl, -CI-CG haloalkyl, -S(CI-CG alkyl), - SO(C1-C6alkyl), -SO2(Ci-C6 alkyl), or -CN;

[0202] each R6is independently halogen, -OH, oxo, -CN, -CI-CG alkyl, -CI-CG alkyl-OH, -(CI- CG alkylene)-O-(Ci-C6 alkyl), -(CI-CG alkylene)-O-(Ci-Ce alkyl)-OH, -(Ci-Ce alkylene)-O-(Ci- CG alkylene)-O-(Cj-C6 alkyl), -(CI-CG alkylene)-O-(Ci-Cb alkylene)-O-(Ci-Cb alkyl)-OH, -Ci- Cio haloalkyl, -Ci-Cio haloalkyl-OH, -NR7R8, -Ci-C6alkyl-NR7R8, -S(CI-CG alkyl), -SO(CJ- CG alkyl), -SO2(Ci-C6 alkyl), -SO2NR7R8, -(Ci-Ce alkylene)-carbocycle, -(CI-CG alkylene)-heterocycle, carbocycle, or heterocycle, wherein each carbocycle and heterocycle is optionally substituted by 1 or 2 R11;

[0203] each R6ais independently H, -CI-CG alkyl, -CI-CG alkyl-OH, -Ci-Cio haloalkyl, -Ci-Cio haloalkyl-OH, -CI-CG alkyl-NR7R8, -(CI-CG alkylene)-O-(Ci-C6 alkyl), -(CI-CG alkylene)-O- (CI-CG alkyl)-OH, -(CI-CG alkylene)-O-(Ci-C6 alkyl)-COOH, -(CI-CG alkylene)-O-(Ci-Ce alkylene)-O-(Ci-C6 alkyl), -(CI-CG alkylene)-O-(Ci-CG alkylene)-NR7R8, -(CI-CG alkylene)-O- (Ci-Ce alkylene)-C(0)NR7R8, -(CI-CG alkylene)-O-(Ci-C6 alkylene)-NR7C(O)-(Ci-C6 alkyl), - (Ci-Cb alkylene)-O-(Ci-C6alkylene)-C(O)NR7-(Ci-C6alkylene)-O-(Ci-Cb alkyl), -(CI-CG alkylene)-O-(Ci-C6 alkylene)-NR7C(O)-(Ci-C6 alkylene)-O-(Ci-Cb alkyl), -(CI-CG alkylene)- O-(CI-CG alkylene)-C(O)NR7-(Ci-C6 alkylene)-O-(Ct-C6 alkylene)-NR7-aryl, -(CI-CG alkylene)-O-(Ci-Cs alkylene)-NR'C(O)-(Ci-C6 alkylene)-O-(Ci-C6 alkylene)-NR''-aryl, -(Ci- CG alkylene)-NR7R8, -(Ci-Cs alkylene)-NR7-(Cj-C6 alkyl)-OH, -(Ci-Cs alkylene)-NR7-(Ci-C6 alkyl)-O-(Ci-Ce alkyl), -(Ci-Cs al ylene)-NR '-(Ci-Ce alkylene)-NR7R8, -(Ci-Cb alkylene)-heterocycle, or -(Ci-Cc, alkylene)-heteroaryl;

[0204] R7and R8are each independently H or -Ci-Ce alkyl; or R7and R8together with the nitrogen atom to which they are attached form a heterocyclyl;

[0205] R9and R9aare each independently deuterium, halogen, cyano, hydroxyl, -NH2, -NH(Ci- CG alkyl), -N(Ci-C<5 alkyl)?, -COOH, -CI-CG alkyl, -C2-C alkenyl, -CS-CG alkynyl, -Ci-Ce haloalkyl, -C2-Ce haloalkenyl, -C2-Ce haloalkynyl, -CI-CG alkyl-OH, -CONH2, -SH, - -S(=O)NH2, -S(O)2NH2, -OCI-CG alkyl, -OCi-Ce haloalkyl, -S(Ci-Cs alkyl), -SO(Ci-Ce alkyl), -SO2(Ci-C6 alkyl), -SO2NR7R8, -S(=NH)(O)(CI-CG alkyl), -(CI-CG alkylene)-carbocyclyl, or- ( C 1 -C 6 alkyl ene)-heteroa ry 1;Attorney Docket No.: INMD-216 / 01WO 315953-4442

[0206] R10is H or -Ci-C6alkyl;

[0207] each R11is independently halogen, -OH, oxo, -CN, -Ci-Co alkyl, -Ci-Cc. alkyl-OH, -Ci-Cio haloalkyl, -Ci-Cio haloalkyl-OH, -OCi-C6alkyl, -NR7R8, -C1-C6 alkyl-NR7R8, -S(Ci-C6alkyl), -SO(Ci-C6 alkyl), -SO2(Ci-C6alkyl), --SO2NR7R8, -(C1-C6alkylene)-carbocycle, -(CJ- Ce alkylene j-heterocycle, carbocycle, or heterocycle;

[0208] R12and R13are each independently selected from H, deuterium, halogen, or -Ci-Cs alkyl;

[0209] m is 0, 1, 2, or 3;

[0210] n is 0, 1, 2, or 3; and

[0211] p is O, 1, 2, or 3;

[0212] wherein the compound is not: (5)- / V-(l-cyano-2-(4-(3-methyl-2-oxo-2,3-dihydrobenzo[d]oxazol-5-yl)phenyl)ethyl)-3-(difluoromethyl)azetidine-3 -carboxamide, (, S)-Ar-(l-cyano-2-(2-fluoro-4-(3-methyl-2-oxo-2,3-dihydrobenzo[d]oxazol-5-yl)phenyl)ethyl)-3-methoxyazetidine-3-carboxamide, or ( )- / V-(l-cyano-2-(2-fluoro-4-(3-methyl-2-oxo-2,3-dihydrobenzo[d]oxazol-5-yl)phenyl)ethyl)-3-methoxy-l-methylazetidine-3-carboxamide

[0213] In embodiments of the compounds of Formula (A'), (A), (I), (1-A), or (I-B) or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, wherein R2isIn embodiments, each R6ais independently H, -Ci-Ce alkyl, -C1-C10 haloalkyl, -Ci-Cg alkyl- NR7R8, -(C1-C6 alkylene)-O-(Ci-C6 alkyl)-OFI, -(C1-C0 alkylene)-O-(Ci-Ce alkylene)-O-(Ci- Ce alkyl), -(Ci-Ce alkylene)-O-(Ci-C6 alkylene)-NR7R8, -(CJ-C6 alkylene)-NR7-(Ct-C6 alkyl)- OH, -(Ci-Ce alkylene)-NR7-(Ci-C6 alkyl)-O-(Ci-C6 alkyl), -(Ci-Cs alkylene)-heterocycle, or -(Ci-Cr, alkylene)-heteroaryl. In embodiments, each R6ais independently H, -C1-C3 alkyl, -Ci-C3alkyl-NR7R8, -(C1-C3 alkylene)-NR7-(Ci-C3alkyl)-O-(Ci-C3alkyl), or -(C1-C3 alkylene)-heterocycle. In some embodiments, p is 0.

[0214] In embodiments of the compounds of Formula (A'), (A), (I), (I-A), or (I-B) or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, wherein R2isAttorney Docket No.: INMD-216 / 01WO 315953-4442

[0215] In embodiments of the compounds of Formula (I-B) or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, whereinZ x1aXs. X1aX^W,---X1aH 2 (l I ) ll I X=° f 1

[0216] R2is(F^P^6a.(rS)pk?(R6)P k6dQr(R6)Pk.

[0217] each Xlais independently -NR63-, -O-, -CR12R13-, -C(O)-, -S-, -S(O) - or -S(O) -;

[0218] each R4is independently halogen, -C1-C6 alkyl, -Ci-Ce haloalkyl, -S(Ci-C6 alkyl), - SO(C1-C6alkyl), -SO2(Ci-C6alkyl), or -CN,

[0219] each R6is independently halogen, -OH, oxo, -CN, -Ci-Ce alkyl, -Ci-Ce alkyl-OH, -(Ci- Ce alkylene)-O-(Ci-C alkyl), -(Ci-Cs alkylene)-O-(Ci-G> alkyl)-OH, -(Ci-Ce alkylene)-O-(Ci-Ce alkylene)-O-(Ci-Cb alkyl), -(Ci-Cs alkylene)-O-(Ci-C’6 alkylene)-O-(Ci-C alkyl)-OH, -Ci-Cio haloalkyl, -CI-CJO haloalkyl-OH, -NR7R8, -Ci-C6alkyl-NR7R8, -S(Ci-C6alkyl), -SO(CJ- Ce alkyl), -SO2(Ci-Ce alkyl), -SO2NR7R8, -(Ci-Ce alkylene)-carbocycle, -(Ci-Cs alkylene)-heterocycle, carbocycle, or heterocycle, wherein each carbocycle and heterocycle is optionally substituted by 1 or 2 R11;

[0220] each R6ais independently H, -Ci-C, alkyl, -Ci-Ce alkyl-OH, -Ci-Cio haloalkyl, -Ci-Cio haloalkyl-OH, -Ci-Ce alkyl-NR7R8, -(Ci-Cs alkylene)-O-(Ci-C6 alkyl), -(Ci-Ce alkylene)-O- (Ci-C6alkyl)-OH, -(Ci-C6alkylene)-O-(Ci-C6 alkyl)-COOH, -(Ci-C6alkylene)-O-(Ci-C6 alkylene)-O-(Ci-Cfi alkyl), -(CI-CG alkylene)-O-(Ci-C6 alkylene)-NR7R8, -(Ci-Cs alkylene)-O-(Ci-Ce alkylene)-C(O)NR / R8, -(Ci-Ce alkylene )-O-(Ci-C6 alkylene)-NR7C(O)-(Ci-C6 alkyl), - (CI-CG alkylene)-O-(Ci-C6 alkylene)-C(O)NR7-(Ci-C6 alkylene)-O-(Ci-C6 alkyl), -(Ci-Cs alkylene)-O-(Ci-Ce alkylene)-NR7C(O)-(Ci-C6 alkylene)-O-(Ci-C6 alkyl), -(Ci-Cb alkylene)-O-(Ci-Ce alkylene)-C(O)NR7-(Ci-C6 alkylene)-O-(Ci-C6 alkylene)-NR7-aryl, -(Ci-Ce alkylene)-O-(Ci-C6 alkylene)-NR7C(O)-(Ci-Cb alkylene)-O-(Ci-C6 alkylene)-NR7-aryl, -(Ci-Attorney Docket No.: INMD-216 / 01WO 315953-4442Co alkylene)-NR7R8, -(CI-CG alkylene)-NR7-(Ci-Cb alkyl)-OH, -(CI-CG alkylene)-NR7-(Ci-C6 alkyl)-0-(Ci-C6 alkyl), -(CI-CG alkylene)-NR7-(Ci-C6 a1kylene)-NR7R8, -(CI-CG alkylene)-heterocycle, or -(CI-CG alkylene)-heteroaryl;

[0221] R7and R8are each independently H or -CI-CG alkyl; or R7and R8together with the nitrogen atom to which they are attached form a heterocyclyl;

[0222] R9is each independently halogen, cyano, hydroxyl, -NH2, -NH(CI-CG alkyl), -N(CI-CG alkyl)2, -COOH, -Ci-Ce alkyl, -C2-C6alkenyl, -C2-C6 alkynyl, -Ci-Ce haloalkyl, -C2-C6 haloalkenyl, -C2-C6haloalkynyl, -CI-CG alkyl-OH, -CONH2, -SH, -S(=O)NH2, -S(O)2NH2, - OCi-Cs alkyl, -OCI-CG haloalkyl, -S(Ci-Cs alkyl), -SO(Ci-C6alkyl), -SO2(CI-CG alkyl), - SO2NR7R8, -S(=NH)(O)(CJ-CG alkyl), -(CI-CG alkylene)-carbocyclyl, or -(CI-CG alkylene)-heteroaryl;

[0223] R9ais hydroxyl;

[0224] R10is H or -Ci-C6alkyl;

[0225] each R” is independently halogen, -OH, oxo, -CN, -CI-CG alkyl, -CI-CG alkyl-OH, -Ci- C10 haloalkyl, -C1-C10 haloalkyl-OH, -OCi-C6alkyl, -NR7R8, -CI-CG alkyl-NR7R8, -S(CI-CG alkyl), -SO(Ci-C6alkyl), -SO2(CI-CG alkyl), -SO2NR7R8, -(C1-C6alkylene)-carbocycle, -(CI- CG alkylene)-heterocycle, carbocycle, or heterocycle;

[0226] R12and R13are each independently selected from H, deuterium, halogen, or -Ci-Ce alkyl;

[0227] m is 0, 1, 2, or 3;

[0228] n is O, 1, 2, or 3; and

[0229] p is 0, 1, 2, or 3.

[0230] In embodiments of the compounds of Formula (1-B) or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, whereinAttorney Docket No.: INMD-216 / 01WO 315953-4442

[0232] each R4is independently halogen, -Ci-Cc, alkyl, -Ci-Ce haloalkyl, -S(Ct-C6 alkyl), - SO(Ci-C6 alkyl), -SO2(Ci-C6 alkyl), or -CN;

[0233] R9is each independently halogen, cyano, hydroxyl, -NHz, -NH(Ci-Ce alkyl), -N(CI-C6 alkyl)2, -COOH, -Ci-C6alkyl, -C2-C6alkenyl, -C2-C6 alkynyl, -Ci-C6haloalkyl, -C2-C6 haloalkenyl, -C2-C6 haloalkynyl, -Ci-Ce alkyl-OH, -CONH2, -SH, -S(=O)NH2, -S(O)2NH2, - OC1-C alkyl, -OCj-Ce haloalkyl, -S(Ct-C6alkyl), -SO(CJ-C6alkyl), -SO2(Ct-C6alkyl), - SO2NH2, -SO2NH(CI-C6alkyl), -SO2N(CI-C6 alkyl)2, -SO2NR7R8, or -S(=NH)(O)(CI-C6alkyl);

[0234] R9ais hydroxyl;

[0235] R10is H or -Ci-C6alkyl;

[0236] m is 0, I, 2, or 3; and

[0237] n is 0, 1, 2, or 3.

[0238] In embodiments of the compounds of Formula (I-B) or a pharmaceutically acceptable □ 10salt, a stereoisomer, or a deuterated form thereof, whereinzis '

[0239] In embodiments, the present disclosure provides a compound of Formula (I-C):

[0240] or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof wherein:

[0241] ring B is 5-8 membered ring optionally containing 1, 2, or 3 heteroatoms selected from N, S, or O;

[0242] ring C is monocyclic, bicyclic, or tricyclic ring containing at least one aromatic ring;

[0243] each R4is independently halogen, -Ci-CN alkyl, -Ci-Ce haloalkyl, -S(Ci-Co alkyl), -SO(Ct-Ce alkyl), -SO2(Ci-C6 alkyl), or -CN;

[0244] R5and Rbare each independently halogen, -OH, oxo, -CN, -C1-C6 alkyl, -Ci-Ce alkyl- OH, -(C1-C6 alkylene)-O-(Ci-C’6 alkyl), -(Ci-Ce alkylene)-O-(Ci-C6 alkyl)-OH, -(Ci-Ce alkylene)-O-(Ci-Cs alkylene)-O-(Ci-C6 alkyl), -(Ci-Ce alkyl ene)-O-(Ci-C6 alkylene)-O-(Ci- Ce alkyl )-OH, -C1-C10 haloalkyl, -C1-C10 haloalkyl-OH, -NR7R8, -Ci-Ce alkyl-NR7R8, -S(Ci-Ce alkyl), -SO(Ci-C6alkyl), -SO2(Ci-C6 alkyl), -SO2NR7R8, -(Ci-Co alkylene)-carbocycle, -Attorney Docket No.: INMD-216 / 01WO 315953-4442(Ci-Cfi alkyl ene)-heterocycle, carbocycle, or heterocycle, wherein each carbocycle and heterocycle is optionally substituted by 1 or 2 R";

[0245] R7and Rsare each independently H or -C1-C6 alkyl; or R7and R8together with the nitrogen atom to which they are attached form a heterocyclyl;

[0246] R9and R9aare each independently halogen, cyano, hydroxyl, -NH2, -NH(Ci-Ce alkyl), -N(CI-C6lky!).’ -COOH, -Cj-Ce alkyl, -C2-C6 alkenyl, -C2-C6 alkynyl, -Ci-Ce haloalkyl, -C2-Ce haloalkenyl, -C2-C6 haloalkynyl, -Ci-Ce alkyl-OH, -CONH2, -SH, -S(=O)NH2, -S(O)2NH2, -OC1-C6 alkyl, -OC1-C6 haloalkyl, -S(Ci-C6alkyl), -SO(Ci-C6alkyl), -SO2(Ci-C6 alkyl), - SO? NR7R8, -S(=NH)(O)(C1-C6alkyl), -(Ci-Ce alkylene)-carbocyclyl, or -(Ci-Cs alkylene)-heteroaryl;

[0247] R10is H or -Ci-C6alkyl,

[0248] each R11is independently halogen, -OH, oxo, -CN, -Ci-C6alkyl, -Ci-Ce alkyl-OH, -Ci-C10 haloalkyl, -Ci-Cio haloalkyl-OH, -OCi-Co alkyl, -NR7R8, -Ci-C6alkyl-NR7R8, -S(Ci-C6 alkyl), -SO(Ci-C6 alkyl), -SO2(Ci-C6 alkyl), -SO2NR7R8, -(Ci-Ce alkylene)-carbocycle, -(Ci- C<> alkylene)-heterocycle, carbocycle, or heterocycle;

[0249] m is 0, 1, 2, or 3;

[0250] n is 0, 1, 2, or 3;

[0251] p is 0, I, 2, or 3; and

[0252] q is 0, I, 2, or 3.

[0253] In embodiments of the compounds of Formula (I-C) or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, ring C is phenyl

[0254] In embodiments of the compounds of Formula (1-C) or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, the multicyclic ring containing ring B and; Xlais -NR6a-, -O-, -CR12R13-, -C(O)-, -S-, -S(O) - or -S(O)2-; and R12and R” are each independently selected from H, deuterium, halogen, or C1-6 alkyl. In embodiments, Xlais -NH-, -NCH3-, -O-, or -CH2-. In embodiments, each R6is independentlyAttorney Docket No.: INMD-216 / 01WO 315953-4442halogen, -OH, -CN -C1-C3 alkyl, -C1-C3 haloalkyl, -S(Ci-C3alkyl), -SO(Ci-C3alkyl), -SO2(Ci-C3 alkyl), -SO2N(CI-C3alkyl), -SO2NR7R8, or 4-6 membered heterocycle. In embodiments, each R6is halogen, -CN, or 4-membered heterocycle. In embodiments, each R6isindependently halogen, -CN,In embodiments, each R6is independentlyF, -CN,. In embodiments, each R4is independently halogen, -C1-C3 alkyl, or -CN. In embodiments, R4is halogen. In embodiments, R4is F.

[0255] In embodiments of the compounds of Formula (I-C) or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, the multicyclic ring containing ring B andor 1 and p is 0, 1, or 2. In embodiments, each R6is independently halogen, -OH, -CN -C1-C3 alkyl, -C1-C3 haloalkyl, -S(Ci-C3alkyl), -SO(Ci-C3alkyl), -SO2(Ci-C3alkyl), -SO2N(Ci-C3alkyl), -SO2NR7R8, or 4-6 membered heterocycle. In embodiments, each R6is halogen, -CN,or 4-membered heterocycle. In embodiments, each R6is independently halogen, -CN,' r-O r-j r-0 or'. In embodiments, each R6is independently F, -CN, ', or' In embodiments, each R4is independently halogen, -C1-C3 alkyl, or -CN. In embodiments, R4is halogen. In embodiments, R4is F.Attorney Docket No.: INMD-216 / 01WO 315953-4442

[0256] In embodiments of the compounds of Formula (I-C) or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof,

[0257] In embodiments of the compounds of Formula (1-C) or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, q is 0 or 1. In embodiments, q is 0.

[0258] In embodiments of the compounds of Formula (I-C) or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, the multicyclic ring containing ring B and

[0259] In embodiments of the compounds of Formula (I-C) or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, ring C is a bicyclic ring forming a tetracyclic ring. In embodiments, ring C is a bicyclic ring wherein one ring is a phenyl ring. In embodiments, ring C is a fused bicyclic ring.

[0260] In embodiments of the compounds of Formula (I-C) or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, the multicyclic ring containing ring B andheterocyclic ring containing I, 2, or 3 heteroatoms selected from N, S, or O, In embodiments, each R6is independently halogen, -OH, -CN -C1-C3 alkyl, -C1-C3 haloalkyl, -S(Ci-C3 alkyl), - SO(Ci~C3alkyl), -SO2(Ci-C3alkyl), -SO2N(CI-C3alkyl), -SO2NR7R8, or 4-6 membered heterocycle. In embodiments, each R6is independently halogen, -C1-C3 alkyl, -CN, or 4-Attorney Docket No.: INMD-216 / 01WO 315953-4442membered heterocycle. In embodiments, each R6is independently halogen, -C1-C3 alkyl, -CN, / -> r-o', or. In embodiments, each R4is independently halogen, -C1-C3 alkyl, or -CN. In embodiments, each R4is halogen. In embodiments, each R4is F. In embodiments, m is 0 or 1. In embodiments, m is I.

[0261] In embodiments of the compounds of Formula (I-C) or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, the multicyclic ring containing ring B andhalogen, -C1-C3 alkyl, or -CN. In embodiments, each R4is halogen. In embodiments, each R4is F. In embodiments, m is 0 or 1 In embodiments, m is 1.

[0262] In embodiments of the compounds of Formula (I-C) or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, the multicyclic ring containing ring B andO

[0263] In embodiments of the compounds of Formula (I-C) or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, ring C is a tricyclic ring forming a pentacyclic ring. In embodiments, ring C is a tricyclic ring wherein one ring is a phenyl ring.

[0264] In embodiments of the compounds of Formula (I-C) or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, the multicyclic ring containing ring B andAttorney Docket No.: INMD-216 / 01WO 315953-4442bicyclic ring wherein at least one ring is a heterocyclic ring containing 1, 2, or 3 heteroatoms selected from N, S, or O. in embodiments, ring D is a spiro bicyclic ring. In embodiments, each R6is independently halogen, -OH, -CN -C1-C3 alkyl, -C1-C3 haloalkyl, -S(Ci-C3 alkyl), - SO(Ci-C alkyl), -SO2(Ci-C3 alkyl), -SO2N(CI-C3 alkyl), -SO2NR'R8, or 4-6 membered heterocycle. In embodiments, each R6is independently halogen or -C1-C3 alkyl. In embodiments, each R6is independently methyl. In embodiments, p is 0 or 1. In embodiments, each R4is independently halogen, -C1-C3 alkyl, or -CN. In embodiments, each R4is halogen. In embodiments, each R4is F. In embodiments, m is 0 or 1. In embodiments, m is 1.

[0265] In embodiments of the compounds of Formula (I-C) or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, the multicyclic ring containing ring B andhalogen, -C1-C3 alkyl, or -CN. In embodiments, each R4is halogen. In embodiments, each R4is F. In embodiments, m is 0 or 1. In embodiments, m is 1.Attorney Docket No.: INMD-216 / 01WO 315953-4442

[0266] In embodiments of the compounds of Formula (I-C) or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, the multicyclic ring containing ring B and

[0267] In embodiments, the present disclosure provides a compound of Formula (I-D):(RV (i-D),

[0268] or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof wherein:

[0269] ring A is a carbocycle, aryl, heterocycle, or heteroaryl ring;Attorney Docket No.: INMD-216 / 01WO 315953-4442R5R5

[0271] R3is H; or R3together with one of R6can form a tricyclic, tetracyclic, or pentacyclic ring optionally containing 1, 2, or 3 heteroatoms selected from N, S, or O, wherein the tricyclic, tetracyclic, or pentacyclic ring is optionally substituted with 1, 2, 3, or 4 R5;

[0272] each R4is independently halogen, -Ci-Ce alkyl, -Ci-Ce haloalkyl, -S(Ci-Ce alkyl), - SO(C1-C6alkyl), -SO2(Ci-C6 alkyl), or -CN;

[0273] each R' is independently hydrogen, halogen, -OH, -CN, -Ci-Ce alkyl, -Ci-Ce alkyl -OH, -O-(Ci-Ce alkyl), -(Ci-Ce alkylene)-O-(Ci-Ce alkyl), -(Ci-Ce alkylene)-O-(Ci-Cb alkyl)-OH, -(Ci-Cb alkylene)-O-(Ci-C6 alkylene)-O-(Ci-C6 alkyl), -(Ci-Ce alkylene)-O-(Ci-C6 alkylene)-O-(Ci-Cs alkyl)-OH, -Ci-Cio haloalkyl, -Ci-Cio haloalkyl-OH, -NR7R8, -CONR7R8, -Ci-C6alkyl-NR7R8, -S(Ci-C6alkyl), -SO(Ci-C6alkyl), -SO2(Ci-C6alkyl), -SO2NR7R8, -(Ci-Ce. alkylene)-carbocycle, -(Ci-Ce alkylene)-heterocycle, carbocycle, or heterocycle, wherein each carbocycle and heterocycle is optionally substituted by 1 or 2 R1’;

[0274] each R6is independently halogen, -OH, oxo, -CN, -Ci-Ce alkyl, -Ci-Ce alkyl-OH, -O-(Ci-C’6 alkyl), -(Ci-Ce alkylene)-O-(Ci-C6 alkyl), -(Ci-Ce alkylene)-O-(Ci-C6 alkyl)- OH, -(Ci-Ce alkylene)-O-(Ci-C6 alkylene)-O-(Ci-Co alkyl), -(Ci-Ce alkylene)-O-(Ci-Co alkylene)-O-(Ci-C6 alkyl)-OH, -Ci-Cio haloalkyl, -Ci-Cio haloalkyl-OH, -NR7R8, -Ci-Ce alkyl-NR7R8, -SF5, -S(Ci-C6 alkyl), -SO(Ci-C6alkyl), -SO2(Ci-C6alkyl), -SO2NR7R8, -(Ci-Ce alkylene)-carbocycle, -(Ci-Ce alkylene)-heterocycle, carbocycle, or heterocycle, wherein each carbocycle and heterocycle is optionally substituted by 1 or 2 Rn;

[0275] R7and R8are each independently H or -Ci-Ce alkyl; or R7and R8together with the nitrogen atom to which they are attached form a heterocyclyl;

[0276] R9and R9aare each independently halogen, cyano, hydroxyl, -NH2, -NH(Ci-Ce alkyl), -N(Ci-Ce alkyl)2, -COOH, -Ci-Cs alkyl, -C2-C6 alkenyl, -C2-C6alkynyl, -Ci-Ce haloalkyl, -C2- Ce haloalkenyl, -C2-C6haloalkynyl, -Ci-C6alkyl-OH, -CONH2, -SH, -S(=O)NH2, -S(O)2NH2, -OCi-Cb alkyl, -OCi-Ce haloalkyl, -S(Ci-Ce alkyl), -SO(Ci-Ce alkyl), -SO2(Ci-C6 alkyl), -Attorney Docket No.: INMD-216 / 01WO 315953-4442SO2NR7R8, -S(=NH)(O)(CJ-C6 alkyl), -(Ci-Ce alkylene)-carbocyclyl, or -(Ct-Ce alkylene)- heteroaryl;

[0277] R10is H or -Ci-C6alkyl;

[0278] each R11is independently halogen, -OH, oxo, -CN, -Ci-C6alkyl, -Ci-Ce alkyl-OH, -Ci-Cio haloalkyl, -C1-C10 haloalkyl-OH, -OC1-C6 alkyl, -NR7R8, -Ci-Ce alkyl-NR7R8, -S(Ci-C6 alkyl), -SO(Ci-C6alkyl), -SO2(Ci-C6alkyl), -SO2NR7R8, -(Ci-C6alkylene)-carbocycle, -(Ci- Ce alkylene)-heterocycle, carbocycle, or heterocycle;

[0279] Z1is CH2, NR5, S, S(O), or S(O)2;

[0280] g is 0, 1, 2, or 3;

[0281] m is 0, 1, 2, or 3;

[0282] n is 0, 1, 2, or 3; and

[0283] p is 0, 1, 2, or 3.

[0284] In embodiments of the compounds of Formula (I-D) or a pharmaceutically acceptableis independently halogen, -OH, -Ci-Ce alkyl, -O-(Ci-C6 alkyl), -C1-C10 haloalkyl, -NR7R8, - S(Ci-Ce alkyl), -SO(Ci-Ce alkyl), -SO2(Ci-C6 alkyl), carbocycle, or heterocycle, wherein each carbocycle and heterocycle is optionally substituted by 1 or 2 Rn. In embodiments, each R6is independently halogen, -C1-C3 alkyl, -C1-C3 haloalkyl, or a 5- or 6-membered heterocycle, wherein each heterocycle is optionally substituted by 1 or 2 R11. In embodiments, each R6is independently halogen, -C1-C3 alkyl or 6-membered heterocycle, wherein each heterocycle is optionally substituted by 1 or 2 R11In embodiments, R11is independently halogen, -OH, -Ci-Attorney Docket No.: INMD-216 / 01WO 315953-4442Ce alkyl, -NR7R8, -S(Ci-C6 alkyl), -SO(Ci-C6alkyl), or -SO2(Ci-Ce alkyl). In embodiments, Rnis independently halogen, -OH, or -C1-C3 alkyl. In embodiments, Rnis methyl.

[0285] In embodiments of the compounds of Formula (I-D) or a pharmaceutically acceptable. In embodiments, each R6is independently halogen, -OH, -Ci-Cs alkyl, -O-(CJ- Cs alkyl), -C1-C10 haloalkyl, -NR7R8, -S(Ci-Cs alkyl), -SO(Ci-Cs alkyl), -SO2(Ci-C6alkyl), carbocycle, or heterocycle, wherein each carbocycle and heterocycle is optionally substituted by 1 or 2 R11. In embodiments, each R6is independently halogen, -C1-C3 alkyl, -C1-C3 haloalkyl, or a 5- or 6-membered heterocycle, wherein each heterocycle is optionally substituted by 1 or 2 R11. In embodiments, each R6is independently halogen, -C1-C3 alkyl or 6-membered heterocycle, wherein each heterocycle is optionally substituted by 1 or 2 R11. In embodiments, R11is independently halogen, -OH, -Ci-Ce alkyl, -NR7R8, -S(Ci-Ce alkyl), - SO(Ci-Ce alkyl), or -SO2(Ci-C6 alkyl). In embodiments, R11is independently halogen, -OH, or -C1-C3 alkyl. In embodiments, R11is methyl.

[0286] In embodiments of the compounds of Formula (I-D) or a pharmaceutically acceptablesalt, a stereoisomer, or a deuterated form thereof, R2isAttorney Docket No.: INMD-216 / 01WO 315953-4442

[0287] In embodiments of the compounds of Formula (I-D) or a pharmaceutically acceptablesalt, a stereoisomer, or a deuterated form thereof, R2is

[0288] In embodiments of the compounds of Formula (I-D) or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, ring A is arylene or heteroarylene ring; each R4is independently halogen, -Ci-Ce alkyl, or -Ci-Cs haloalkyl; and m is 0 or 1. In embodiments,Attorney Docket No.: INMD-216 / 01WO 315953-4442

[0289] In embodiments, the present disclosure provides a compound of Formula (I-E):4.)m(I-E),

[0290] or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof wherein:

[0291] ring A is a carbocycle, aryl, heterocycle, or heteroaryl ring;Attorney Docket No.: INMD-216 / 01WO 315953-4442, wherein each R2is optionally substituted with 1 or 2

[0293] each R4is independently halogen, -Ci-C’s alkyl, -Ci-Ce. haloalkyl, -S(Ci-C6 alkyl), - SO(Ci-Ce alkyl), -SO2(Ci-C6alkyl), or -CN;

[0294] each R' is independently hydrogen, halogen, -OH, -CN, -Ci-Ce alkyl, -Ci-Ce alkyl-OH, -O-(CJ-C6 alkyl), -(Ci-Ce alkylene)-O-(Ci-C6 alkyl), -(Ci-Ce alkylene)-O-(Ci-C6 alkyl)-OH, -(Ci-Ce alkylene)-O-(Ci-C6 alkylene)-O-(Ci-Ce alkyl), -(Ci-C6alkylene)-O-(Ci-C6alkylene)-O-(Ci-C6alkyl)-OH, -Ci-Cio haloalkyl, -Ci-Cio haloalkyl-OH, -NR7R8, -CONR7R8, -Ci-C6alkyl-NR7R8, -SF5, -S(Ci-C6alkyl), -SO(Ci-C6alkyl), -SO2(Ci-C6alkyl), -SO2NR7R8, -(Ci-C6alkylene)-carbocycle, -(Ci-Ce alkylene)-heterocycle, carbocycle, or heterocycle, wherein each carbocycle and heterocycle is optionally substituted by 1 or 2 R11,

[0295] each R6is independently halogen, -OH, oxo, -CN, -Ci-Ce alkyl, -Ci-Ce alkyl- OH, -O-(Ci-C6 alkyl), -(Ci-Ce alkylene)-O-(Ci-C6 alkyl), -(Ci-C6alkylene)-O-(Ci-C6alkyl)-OH, -(Ci-Ce alkylene)-O-(Ci-C6 alkylene)-O-(Ci-C6 alkyl), -(Ci-Ce alkylene)-O-(Ci-C6 alkylene)-O-(Ci-C6alkyl)-OH, -Ci-Cio haloalkyl, -Ci-Cio haloalkyl-OH, -NR7R8, -Ci-C6alkyl-NR7R8, -SF5, -S(Ci-C6alkyl), -SO(Ci-Cc alkyl), -SO2(Ci-Cc alkyl), -SO2NR7R8, -(Ci-C6alkylene)-carbocycle, -(Ci-Ce alkylene)-heterocycle, carbocycle, or heterocycle, wherein each carbocycle and heterocycle is optionally substituted by 1 or 2 R11;

[0296] R7and R8are each independently H or -Ci-C6alkyl; or R7and R8together with the nitrogen atom to which they are attached form a heterocyclyl;

[0297] R9and R9aare each independently halogen, cyano, hydroxyl, -NH2, -NH(Ci-C6alkyl), -N(Ci-C6alkyl)2, -COOH, -Ci-Ce alkyl, -C2-C6alkenyl, -C2-C6alkynyl, -Ci-Ce haloalkyl, -C2-Ce haloalkenyl, -C2-Ce haloalkynyl, -Ci-C6alkyl-OH, -CONH2, -SH, -S(=O)NH2, -S(O)2NH2, -OC1-C6 alkyl, -OCi-C6haloalkyl, -S(Ci-C6alkyl), -SO(Ci-C6alkyl), -SO2(Ci-C6alkyl), -SO2NR7R8, -S(=NH)(O)(Ci-C6alkyl), -(C1-C6alkylene)-carbocyclyl, or -(Ci-C6alkylene)-heteroaryl;

[0298] R10is H or -Ci-C6alkyl;

[0299] each R11is independently halogen, -OH, oxo, -CN, -Ci-C6alkyl, -Ci-Ce alkyl-OH, -Ci-Cio haloalkyl, -Ci-Cio haloalkyl-OH, -OCi-C6alkyl, -NR7R8, -Ci-C6alkyl-NR7R8, -S(Ci-C6alkyl), -SO(Ci-C6alkyl), -SO2(Ci-C6 alkyl), -SO2NR7R8, -(Ci-Ce alkylene)-carbocycle, -(Ci-Ce alkylene)-heterocycle, carbocycle, or heterocycle;Attorney Docket No.: INMD-216 / 01WO 315953-4442

[0300] m is 0, 1, 2, or 3;

[0301] n is 0, 1, 2, or 3, and

[0302] p is 0, 1, 2, or 3.

[0303] In embodiments of the compounds of Formula (I-E) or a pharmaceutically acceptableis optionally substituted with 1 or 2 R6.

[0304] In embodiments of the compounds of Formula (I-E) or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, each R3is independently hydrogen, -Ci-Ce alkyl, -(C1-C6 alkylene)-carbocycle, -(Ci-Ce alkylene)-heterocycle, carbocycle, or heterocycle. In embodiments, each R3is independently hydrogen, -C1-C3 alkyl, or 3- to 6-membered heterocycle. In embodiments, each R3is independently hydrogen, -C1-C3 alkyl, or 4-membered heterocycle. In embodiments, each R5is independently hydrogen, methyl, or oxetanyl.

[0305] In embodiments of the compounds of Formula (I-E) or a pharmaceutically acceptableAttorney Docket No.: INMD-216 / 01WO 315953-4442

[0306] In embodiments of the compounds of Formula (I-E) or a pharmaceutically acceptable

[0307] In embodiments of the compounds of Formula (I-E) or a pharmaceutically acceptablesalt, a stereoisomer, or a deuterated form thereof,R2is

[0308] In embodiments of the compounds of Formula (I-E), or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, A is aryl. In embodiments, A. is phenylene.In embodiments, Ais

[0309] In embodiments of the compounds of Formula (I-E), or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, R3is H.Attorney Docket No.: INMD-216 / 01WO 315953-4442

[0310] In embodiments of the compounds of Formula (I-E), or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, each R4is independently halogen, -C1-C3 alkyl, or -CN. In embodiments, R4is halogen.

[0311] In embodiments of the compounds of Formula (I-E), or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, m is 0 or 1.

[0312] In embodiments, the present di sclosure provides a compound of Formula (I-F):

[0313] or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof wherein:

[0314] each R4is independently halogen, -Ci-Ce alkyl, -Ci-Ce haloalkyl, -S(Ci-Ce alkyl), - SO(C1-C6alkyl), -SO2(C1-C6alkyl), or -CN;

[0315] R6is -NR7R8, -C1-C6 alkyl-NR7R8, -S(Ci-C6alkyl), -SO(Ci-C6alkyl), -SO2(Ci-C6alkyl), -SO2NR7R8, -(C1-C6 alkylene)-carbocycle, -(C1-C6 alkylene)-heterocycle, carbocycle, or heterocycle, wherein each carbocycle and heterocycle is optionally substituted by 1 or 2 R11;

[0316] R7and R8are each is independently H or -Ci-Ce alkyl; or R7and R8together with the nitrogen atom to which they are attached form a heterocyclyl;

[0317] R9and R9aare each independently halogen, cyano, hydroxyl, -NH2, -NH(C1-C6alkyl), -N(C1-C6alkyl)2, -COOH, -Ci-Ce alkyl, -C2-C6alkenyl, -C2-C6 alkynyl, -C1-C6haloalkyl, -C2-C6haloalkenyl, -C2-C6 haloalkynyl, -Ci-Ce alkyl-OH, -CONH2, -SH, -S(=O)NH2, -S(O)2NH2, -OCi-Ce alkyl, -OCi-Cs haloalkyl, -S(Ci-Ce alkyl), -SO(Ci-Cfi alkyl), -SO2(Ci-C6 alkyl), - SO2NR7R8, -S(=NH)(O)(C1-C6alkyl), -(Ci-Ce alkylene)-carbocyclyl, or -(Ci-Ce alkylene)-heteroaryl;

[0318] R10is H or -C1-C6alkyl;

[0319] each R11is independently halogen, -OH, oxo, -CN, -Ci-Ce alkyl, -Ci-C6alkyl-OH, -Ci- C10 haloalkyl, -C1-C10 haloalkyl-OH, -OCi-Cs alkyl, -NR7R8, -C1-C6 alkyl-NR7R8, -S(Ci-C6alkyl), -SO(Ci-C6 alkyl), -SO2(C1-C6alkyl), -SO2NR7R8, -(C1-C6alkylene)-carbocycle, -(C1-C6alkylene)-heterocycle, carbocycle, or heterocycle;

[0320] m is 0, 1, 2, or 3; and

[0321] n is 0, 1, 2, or 3.Attorney Docket No.: INMD-216 / 01WO 315953-4442

[0322] In embodiments of the compounds of Formula (I-F), or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, R6is at the para position.

[0323] In embodiments of the compounds of Formula (I-F), or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, R6is --SO2NR7R8or -(C1-C6alkylene)- heterocycle, wherein the heterocycle is optionally substituted by 1 or 2 Rn. In embodiments, R6is -SO2NR7R8or -(C1-C3 alkylene)-(6-membered heterocycle), wherein the heterocycle is optionally substituted by 1 or 2 R11; R7and R8together with the nitrogen atom to which they are attached form a 3- to 6-membered heterocyclyl; and each R11is independently halogen or-C1-C3 alkyl. In embodiments,R6is

[0324] In embodiments, the present disclosure provides a compound of Formula (I-G):(I-G),

[0325] or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof wherein:

[0326] ring A is a fused bicyclic heteroaryl ring;Attorney Docket No.: INMD-216 / 01WO 315953-4442

[0328] each Xlais independently -NR6a-, -O-, -CR12R13-, -C(O)-, -S-, -S(O) - or -S(O)2-,

[0329] each Z1is independently -CH2-, -NR3-, -S-, -S(O) -, or -S(O)2-;

[0330] R3is H;

[0331] each R4is independently halogen, -Ci-Cs alkyl, -Ci-Ce haloalkyl, -S(Ci-Ce alkyl), - SO(C1-C6alkyl), -SO2(Ct-C6 alkyl), or -CN;

[0332] each R3is independently hydrogen, -OH, -CN, -Ci-Ce alkyl, -Ci-Ce. alkyl-OH, -O-(Ci-C6 alkyl), -(C1-C6 alkylene)-O-(Ci-C6 alkyl), -(Ci-Ce alkylene)-O-(Ci-C6 alkyl)-OH, -(C1-C6 alkylene)-O-(Ci-Co alkylene)-O-(Ci-Co alkyl), -(C1-C6alkylene)-O-(C1-C6alkylene)-O-(C1-C6alkyl)-OH, -C1-C10 haloalkyl, -C1-C10 haloalkyl-OH, -NR7R8, -CONR7R8, -Ci-C’6 alkyl- NR7R8, -SF5, -S(CJ-C6alkyl), -SO(Ci-C6alkyl), -SO2(C1-C6alkyl), -SO2NR7R8, -(C1-C6alkylene)-carbocycle, -(Ci-Ce alkylene)-heterocycle, carbocycle, or heterocycle, wherein each carbocycle and heterocycle is optionally substituted by 1 or 2 Rn;

[0333] each R6is independently halogen, -OH, oxo, -CN, -Ci-Ce alkyl, -C1-C6alkyl-OH, -0-(CJ-C6 alkyl), -(C1-C6 alkylene)-O-(Ci-C6 alkyl), -(Ct-Co alkylene)-O-(Ci-C6 alkyl)-OH, -(Ci-Ce alkylene)-O-(Ci-C6 alkylene)-O-(Ci-Ce alkyl), -(Ci-Co alkylene)-O-(Ci-Ce alkylene)-O-(Ci-C6 alkyl)-OH, -C1-C10 haloalkyl, -C1-C10 haloalkyl-OH, -NR7R8, -Ci-Ce alkyl-NR7R8, -SF5, -S(C1-C6alkyl), -SO(Ci-C6alkyl), -SO2(Ci-C6alkyl), -SO2NR7R8, -(Ci-Ce alkylene)-carbocycle, -(C1-C6alkylene)-heterocycle, carbocycle, or heterocycle, wherein each carbocycle and heterocycle is optionally substituted by 1 or 2 R11;

[0334] each R6ais independently H, -C1-C6 alkyl, -Ci-Ce alkyl-OH, -C1-C10 haloalkyl, -C1-C10 haloalkyl-OH, -Ci-Ce alkyl-NR7R8, -(C1-C6alkylene)-O-(C1-C6alkyl), -(Ci-Ce alkylene)-O-(Ci-Cb alkyl)-OH, -(C1-C6alkylene)-O-(C1-C6alkyl)-COOH, -(Ci-Ce alkylene)-O-(Ci-C6 alkylene)-O-(Ci-C6 alkyl), -(Ci-Ce alkylene)-O-(Ci-C6 alkylene)-NR7R8, -(Ci-Ce alkylene)-O-(Ci-Ce alkylene)-C(O)NR / R8, -(Ci-Ce alkylene)-O-(Ci-C6 alkylene)-NR7C(O)-(Ci-C6 alkyl), -(C1-C6alkylene)-O-(C1-C6alkylene)-C(O)NR7-(C1-C6alkylene)-O-(C1-C6alkyl), -(C1-C6alkylene)-O-(C1-C6alkylene)-NR7C(O)-(C1-C6alkylene)-O-(C1-C6alkyl), -(Ci-Ce alkylene)-Attorney Docket No.: INMD-216 / 01WO 315953-44420-(Ci-C6 alkylene)-C(O)NR7-(Ci-C6 alkylene)-0-(Ci-C6 alkylene)-NR7-aryl, -(Ci-Ce alkylene)--O-(C1-C6alkylene)-NR7C(O)-(C1-C6alkylene)-O-(C1-C6alkylene)-NR7-aryl, -(C1-C6alkylene)-NR7R8, -(Ci-Cs alkylene)-NR7-(Ci-C6 alkyl)-OH, -(Ci-Ce alkylene)-NR7-(Ci-C6 alkyl)-O-(Ci-C6alkyl), -(C1-C6alkylene)-NR7-(C1-C6alkylene)-NR7R8, -(Ci-C6alkylene)- heterocycle, or -(Ci-Ce alkylene)-heteroaryl;

[0335] R7and R8are each independently H or -Ci-Ce alkyl; or R7and R8together with the nitrogen atom to which they are attached form a heterocyclyl;

[0336] R9and R9aare each independently halogen, cyano, hydroxyl, -NH2, -NH(C1-C6alkyl), -N(Ci-Ce alkyl)2, -COOH, -Ci-C6alkyl, -C2-C6 alkenyl, -C2-C6 alkynyl, -Ci-C6haloalkyl, -C2-Ce haloalkenyl, -C2-C6 haloalkynyl, -Ci-C6alkyl-OH, -CONH2, -SH, -S(=O)NH2, -S(O)2NH2, -OC1-C6 alkyl, -OCi-Ce haloalkyl, -S(Ci-C6alkyl), -SO(Ci-C6alkyl), -SO2(Ci-C6 alkyl), -SO2NR7R8, -S(=NH)(O)(C1-C6alkyl), -(Ci-Ce alkylene)-carbocyclyl, or -(Ci-Cs alkylene)-heteroaryl,

[0337] R’° is H or -C1-C6 alkyl;

[0338] each R11is independently halogen, -OH, oxo, -CN, -Ci-Ce alkyl, -Ci-Ce alkyl-OH, -Ci-C10 haloalkyl, -C1-C10 haloalkyl-OH, -OCi-Ce alkyl, -NR7R8, -C1-C6alkyl-NR7R8, -S(Ci-C6alkyl), -SO(Ci-C6alkyl), -SO2(Ci-C6 alkyl), -SO2NR7R8, -(C1-C6alkylene)-carbocycle, -(C1-C6alkylene)-heterocycle, carbocycle, or heterocycle;

[0339] R12and R13are each independently selected from H, deuterium, halogen, or -Ci-Ce alkyl;

[0340] g is O, 1, 2, or 3;

[0341] m is 0, 1, 2, or 3;

[0342] n is 0, 1, 2, or 3; and

[0343] p is 0, 1, 2, or 3.

[0344] In embodiments of the compounds of Formula (I-G) or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, A is a 5,6-fused heteroaryl, 6,5-fused heteroaryl, or 6,6-fused heteroaryl. In embodiments, ring A contains one or two heteroatoms selected from N, S, or O

[0345] In embodiments of the compounds of Formula (I-G) or a pharmaceutically acceptablesalt, a stereoisomer, or a deuterated form thereof, ringA is (Ror (Rwherein each X is independently selected from O, S, NH or N(Ct-6 alkyl)Attorney Docket No.: INMD-216 / 01WO 315953-4442

[0346] In embodiments of the compounds of Formula (I-G) or a pharmaceutically acceptablesalt, a stereoisomer, or a deuterated form thereof, ring Ais, (R )m,In embodiments, R4is halogen. In embodiments, R4is F.

[0347] In embodiments of the compounds of Formula (I-G) or a pharmaceutically acceptableconnectivity to R2.Attorney Docket No.: INMD-216 / 01WO 315953-4442

[0348] In embodiments of the compounds of Formula (I-G) or a pharmaceutically acceptableRais independently H, -Ci-Ce alkyl, -C1-C10 haloalkyl, -Ci-Ce alkyl-NR7R8, -(Ci-Ce alkylene)- O-(Ci-Ce alkyl)-OH, -(Ci-Ce alkylene)-O-(Ci-C6 alkylene)-O-(Ci-C6 alkyl), -(Ci-Ce alkylene)-O-(Ci-Ce alkylene)-NR7R8, -(C1-C6alkylene)-NR7-(C1-C6alkyl)-OH, -(C1-C6alkylene)-NR7-(C1-C6alkyl)-O-(C1-C6alkyl), -(Ci-Ce alkylene)-heterocycle, or -(Ci-Ce alkylene)-heteroaryl. In embodiments, each R6ais independently H, -C1-C3alkyl, -C1-C3alkyl-NR7R8, -(C1-C3 alkylene)-NR7-(Ci-C3 alkylene)-O-(Ci-C3 alkyl), or -(C1-C3 alkylene)-heterocycle. In embodiments, each R6is independently halogen, -OH, -C1-C6alkyl, -O-(Ci-C6 alkyl), -C1-C10 haloalkyl, -NR7R8, -S(Ci-Ce alkyl), -SO(Ci-C6 alkyl), or -SO2(Ci-C6 alkyl). In embodiments, R6is halogen or -Ci-Ce alkyl. In embodiments, R’ is halogen or -Ci-Cs alkyl.

[0349] In embodiments of the compounds of Formula (I-G) or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, each R6is independently halogen, -OH, -CN, -Ci-Cs alkyl, -Ci-Ce alkyl-OH, -O-(Ci-Cs alkyl), -C1-C10 haloalkyl, -C1-C10 haloalkyl-OH, -NR7R8, -C1-C6alkyl-NR7R8, -SF5, -S(Ci-C6alkyl), -SO(C1-C6alkyl), -SO2(C!-C6 alkyl), - SO2NR7R8, -(Ci-Ce alkylene)-carbocycle, -(C1-C6alkylene)-heterocycle, carbocycle, or heterocycle, wherein each carbocycle and heterocycle is optionally substituted by 1 or 2 R11. In some embodiments, R6is -SO2NH2, -SO2NH(CI-C6 alkyl), or -SO2N(Ci-C6 alkyl)2. In embodiments, each R6is independently halogen, -C1-C6 alkyl, or heterocycle, wherein each heterocycle is optionally substituted by 1 or 2 R11. In embodiments, each R6is independently halogen, -Ci-Ce alkyl, or 6-membered heterocycle, wherein each heterocycle is optionally substituted by 1 or 2 R11In embodiments, each R6is independently halogen, -Ci-Ce alkyl, or 6-membered heterocycle containing 1 or 2 heteroatoms selected from N, S, or O, wherein each heterocycle is optionally substituted by 1 or 2 R11. In embodiments, each R6is independentlyAttorney Docket No.: INMD-216 / 01WO 315953-4442halogen, -Ci-Cs alkyl, or heteroc cle, wherein the heterocycle isIn embodiments, each R1 1is independently halogen, -OH, oxo, -CN, -Ci-Ce alkyl, -Ci-Ce alkyl - OH, -C1-C10 haloalkyl, -C1-C10 haloalkyl-OH, -OCi-Cb alkyl, -NR7R8, -Ci-Ce alkyl-NR7R8, - S(Ci-C6 alkyl), -SO(Ci-C6 alkyl), -SO2(Ci-Ce alkyl), or -SO2NR7R8In some embodiments, R11is -SO2NH2, -SO2NH(C1-C6alkyl), or -SO2N(CI-C6 alkyl)2. In embodiments, each R11is independently halogen or-Ci-Cs alkyl. In embodiments, R11is methyl.

[0350] In embodiments of the compounds of Formula (I-G) or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, R6ais H, -C1-C3alkyl, -C1-C3alkyl-NR7R8, -(C1-C3 alkylene)-NR7-(Ci-C.3 alkylene)-O-(Ci-C3 alkyl), or -(C1-C3 alkylene)-heterocycle; and R7and R8are each independently H or -C1-C6alkyl. In embodiments, R6ais H, methyl, ethyl, -C1-C3alkyl-NH2, -(C1-C3alkylene)-N(CH3)-(C1-C3alkyl)-O-(C1-C3alkyl), or -(C1-C3 alkylene)-heterocycle, wherein the heterocycle is 6-membered heterocycle. In embodiments, R6ais H, methyl, ethyl, -C1-C3 alkyl-NH2, -(C1-C3 alkylene)-N(CH3)-(Ci-C3 alkyl)-O-(Ci-C3 alkyl), or -(C1-C3 alkylene)-heterocycle, wherein the heterocycle is 6-membered heterocycle containing 1 or 2 heteroatoms selected from N, S, or O In embodiments, R6ais H, methyl, ethyl, -C1-C3 alkyl-NH2, -(C1-C3 alkylene)-N(CH3)-(Ci-C3 alkyl)-O-(Ci-C3 alkyl), or -(C1-C3AN-'Z"^alkylene)-heterocycle, wherein the heterocycle is.

[0351] In embodiments of the compounds of Formula (I-G) or a pharmaceutically acceptable x(f)p9X. / cA k N / / salt, a stereoisomer, or a deuterated form thereof,R2is In embodiments, R2isAttorney Docket No.: INMD-216 / 01WO 315953-4442. In embodiments, each R6is independently halogen, -OH, -Ci-Ce alkyl, -O-(Ci- C6 alkyl), -Ci-Cio haloalkyl, -NR7R8, -S(Ci-C6alkyl), -SO(Ci-C6alkyl), -SO2(Ci-C6alkyl), carbocycle, or heterocycle, wherein each carbocycle and heterocycle is optionally substituted by 1 or 2 R11. In embodiments, each R6is independently halogen, -C1-C3 alkyl, -C1-C3 haloalkyl, or a 5- or 6-membered heterocycle, wherein each heterocycle is optionally substituted by 1 or 2 R11. In embodiments, each R6is independently halogen, -C1-C3 alkyl or 6-membered heterocycle, wherein each heterocycle is optionally substituted by 1 or 2 R11. In embodiments, R11is independently halogen, -OH, -Ci-Ce alkyl, -NR7R8, -S(Ci-C6 alkyl), - SO(Ci-Ce alkyl), or -SO2(Ci-Ce alkyl). In embodiments, R11is independently halogen, -OH, or -C1-C3 alkyl. In embodiments, R11is methyl. In embodiments, each R6is independently halogen, -OH, -Ci-Cs alkyl, -O-(Ci-C6alkyl), -C1-C10 haloalkyl, -NR7R8, -S(Ci-Ce alkyl), - SO(Ci-C6 alkyl), or -SO2(Ci-C6 alkyl). In embodiments, R6is halogen or -C1-C6 alkyl. In embodiments, R5is halogen or -C1-C6 alkyl.

[0352] In embodiments of the compounds of Formula (I-G) or a pharmaceutically acceptablesalt, a stereoisomer, or a deuterated form thereof, R2isAttorney Docket No.: INMD-216 / 01WO 315953-4442

[0353] In embodiments of the compounds of Formula (A'), (A), (I), (I-A), (I-B), (I-C), (I-D), (I-E), (I-F), or (I-G), or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof R9and R9aare each independently halogen, hydroxyl, -Ci-Ce alkyl, -C -C6 alkenyl, - C2-C6 alkynyl, -Ci-Ce haloalkyl, -C2-C6 haloalkenyl, -C2-C6 haloalkynyl, -OCi-Cs alkyl, or - OC1-C6 haloalkyl. In embodiments, R9and Raare each independently halogen, hydroxyl, -Ci- C3 alkyl, -C1-C3 haloalkyl, -OCi-Cs alkyl, or -OC1-C3 haloalkyl. In embodiments, R9and R9aare each independently halogen, hydroxyl, methoxy, ethoxy, fluoromethyl, or difluoromethyl.

[0354] In embodiments of the compounds of Formula (A'), (A), (I), (I-A), (I-B), (I-C), (I-D), (I-E), (I-F), or (I-G), or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, R9ais halogen, hydroxyl, -NH2, -NH(C1-C6alkyl), -N(CI-C6 alkyl)2, -Ct-Ce alkyl, -Ci- Cfi haloalkyl, -C1-C6 alkyl-OH, -OC1-C6 alkyl, -OCi-C<5 haloalkyl, -S(Ci-Cfi alkyl), -SO(Ci-Cs alkyl), or -SO2(Ci-C<5 alkyl). In embodiments, Rais halogen, hydroxyl, -Ci-Ce alkyl, -Ci-Cs haloalkyl, -OCi-Ce alkyl, or -OCi-Ce haloalkyl. In embodiments, R9ais halogen, hydroxyl, - C1-C3 alkyl, -C1-C3 haloalkyl, -OC1-C3 alkyl, or -OC1-C3 haloalkyl. In embodiments, R9ais halogen, hydroxyl, methoxy, ethoxy, fluoromethyl, or difluoromethyl.

[0355] In embodiments of the compounds of Formula (A'), (A), (I), (I-A), (I-B), (I-C), (1-D), (I-E), (I-F), or (I-G), or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof n is 0.

[0356] In embodiments of the compounds of Formula (A'), (A), (I), (I-A), (I-B), (I-C), (1-D), (I-E), (I-F), or (I-G), or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, R10is H or methyl.

[0357] In embodiments, the present disclosure provides a compound of Formula (II):Attorney Docket No.: INMD-216 / 01WO 315953-4442

[0358] or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof wherein:

[0359] ring A is a carbocycle, aryl, heterocycle, or heteroaryl ring;

[0361] R2is a carbocycle, aryl, heterocycle, or heteroaryl ring, wherein each R2is optionally substituted with 1, 2, 3, or 4 R6;

[0362] R3is H; or R3together with one of R6can form a tricyclic, tetracyclic, or pentacyclic ring optionally containing 1, 2, or 3 heteroatoms selected from N, S, or O, wherein the tricyclic, tetracyclic, or pentacyclic ring is optionally substituted with 1, 2, 3, or 4 R5;

[0363] each R4is independently halogen, -Ci-Ce alkyl, -Ci-Cb haloalkyl, -S(Ci-C6 alkyl), - SO(Ci-C6alkyl), -SO2(Ci-C6 alkyl), or -CN;

[0364] R? and R6are each independently halogen, -OH, oxo, -CN, -Ci-Ce alkyl, -Ci-Ce alkyl-OH, -(Ci-Ce al ylene)-O-(Ci-C6 alkyl), -(Ci-Ce alkylene)-O-(Ci-C6 alkyl)-OH, -(Ci-Ce alkylene)-O-(Ci-C alkylene)-O-(Ci-C alkyl), -(Ci-Ce alkylene)-O-(Ci-Ce alkylene)-O-(Cj-Ce alkyl)-OH, -Ci-Cio haloalkyl, -Ci-Cw haloalkyl-OH, -NR7R8, -Ci-Ce alkyl-NR7R8, -S(Ci- Ce alkyl), -SO(Ci-Ce alkyl), -SO2(Ci-Ce alkyl), -SO2NR7R8, -(Ci-Ce alkylene)-carbocycle, - (Ci-Ce alkylenej-heterocycle, carbocycle, or heterocycle, wherein each carbocycle and heterocycle is optionally substituted by 1 or 2 R11;

[0365] R7and R8are each independently H or -Ci-Ce alkyl; or R7and R8together with the nitrogen atom to which they are attached form a heterocyclyl;

[0366] R9is halogen, cyano, hydroxyl, -NH2, -NH(Ci-Ce alkyl), -N(Ci-Ce alkyl)2, -COOH, -Ci-Ce alkyl, -C2-C6 alkenyl, -C2-C6 alkynyl, -Ci-Ce haloalkyl, -C2-Ce haloalkenyl, -C2-C6 haloalkynyl, -Ci-Ce alkyl-OH, -CONH2, -SH, -S(=O)NH2, -S(O)2NH2, -OCj-Ce alkyl, -OCi- Ce haloalkyl, -S(Ci-C6alkyl), -SO(Ci-Ce alkyl), -SO2(Ci-Ce alkyl), -SO2NR7R8, - S(=NH)(O)(Ci-Ce alkyl), -(Ci-Ce alkylene)-carbocyclyl, or-(Ci-Ce alkylene)-heteroaryl;Attorney Docket No.: INMD-216 / 01WO 315953-4442

[0367] each R11is independently halogen, -OH, oxo, -CN, -Ci-Ce alkyl, -CI-CG alkyl-OH, -Ci- C10 haloalkyl, -C1-C10 haloalkyl-OH, -OCi-Ce alkyl, -NR7R8, -Ci-C6alkyl-NR7R8, -S(Ci-C6alkyl), -SO(Ci-C6alkyl), -SO2(Ci-C6 alkyl), -SO2NR7R8, -(Ci-C6alkylene)-carbocycle, -(CJ- CG alkylene)-heterocyde, carbocycle, or heterocycle;

[0368] R10is H or -Ci-C6alkyl;

[0369] m is 0, 1, 2, or 3; and

[0370] n is 0, 1, 2, or 3;

[0371] provided that the compound is notHor

[0372] In embodiments of the compounds of Formula (A'), (A), or (II), or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, R2is a bicyclic ring, wherein at least one ring is aromatic, and wherein R2is optionally substituted with 1, 2, 3, or 4 Rb.

[0373] In embodiments of the compounds of Formula (A'), (A), or (II), or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, R2is a fused bicyclic ring, optionally substituted with 1, 2, 3, or 4 R6.

[0374] In embodiments of the compounds of Formula (A'), (A), or (II), or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, R2is a 5,5-, 5,6-, 6,5-, or 6,6-fused bicyclic ring, optionally substituted with 1, 2, 3, or 4 R6.

[0375] In embodiments of the compounds of Formula (A'), (A), or (II), or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof:

[0377] each Xlais independently -NR6a-, -O-, -CR12R13-, -C(O)-, -S-, -S(O) - or -S(O)2-;Attorney Docket No.: INMD-216 / 01WO 315953-4442

[0378] each R6is independently halogen, -OH, oxo, -CN, -Ci-Ce alkyl, -Ci-C& alkyl-OH, -(Ci- C6 alkylene)-O-(Ci-C6 alkyl), -(Ci-C& alkylene)-O-(Ci-C6 alkyl)-OH, -(Ci-Ce alkylene)-O-(Ci-Ce alkylene)-O-(Cj-C6 alkyl), -(Ci-Cs alkylene)-O-(Ci-C6 alkylene)-O-(Ci-C6 alkyl)-OH, -Ci-Cio haloalkyl, -Ci-Cio haloalkyl-OH, -NR7R8, -Ci-C6alkyl-NR7R8, -S(Ci-Ce alkyl), -SO(CJ-Ce. alkyl), -SO2(Ci-C6 alkyl), -SO2NR7R8, -(Ci-Ce alkylene)-carbocycle, -(Ci-Ce alkylene)-heterocycle, carbocycle, or heterocycle, wherein each carbocycle and heterocycle is optionally substituted by 1 or 2 R11;

[0379] each R6ais independently H, -Ci-Cs alkyl, -Ci-Ce alkyl-OH, -Ci-Cio haloalkyl, -Ci-Cio haloalkyl-OH, -Ci-C6alkyl-NR7R8, -(Ci-Ce alkylene)-O-(Ci-C6alkyl), -(Ci-C6alkylene)-O- (Ci-C6alkyl)-OH, -(Ci-C6alkylene)-O-(Ci-C6 alkyl)-COOH, -(Ci-Co alkylene)-O-(Ci-C6alkylene)-O-(Ci-C6 alkyl), -(Ci-Co alkylene)-O-(Ci-C6 alkylene)-NR7R8, -(Ci-Ce alkylene)-O-(Ci-Ce alkylene)-C(O)NR7R8, -(Ci-Ce alkylene)-O-(Ci-C6 alkylene)-NR7C(O)-(Ci-C6 alkyl), -(Ci-Ce alkylene)-O-(Ci-C6 alkylene)-C(O)NR7-(Ci-Ce alkylene)-O-(Ci-C6 alkyl), -(Ci-Cs alkylene)-O-(Ci-C6 alkylene)-NR7C(O)-(Ci-Ce alkylene)-O-(Ci-C’6 alkyl), -(Ci-Ce alkylene)-O-(Ci-C6 alkylene)-C(O)NR7-(Ci-C6 alkylene)-O-(Ci-C6 alkylene)-NR7-aryl, -(Ci-CGalkylene)-O-(Ci-Cs alkylene)-NR7C(O)-(Ci-C6 alkylene)-O-(Ci-C6alkylene)-NR7-aryl, -(Ci-C6 alkylene)-NR7R8, -(Ci-CGalkylene)-NR7-(Ci-C6 alkyl)-OH, -(Ci-Ce alkylene)-NR7-(Ci-C6 alkyl)-O-(Ci-C6 alkyl), -(Ci-C6alkyl ene)-NR7-(Ci-Ce alkylene)-NR7R8, -(Ci-C6alkylene)-heterocycle, or -(Ci-Ce alkylene)-heteroaryl;

[0380] R7and R8are each independently H or -Ci-Ce alkyl; or R7and R8together with the nitrogen atom to which they are attached form a heterocyclyl;

[0381] each R11is independently halogen, -OH, oxo, -CN, -Ci-Cs alkyl, -Ci-Ce alkyl-OH, -Ci-Cio haloalkyl, -Ci-Cio haloalkyl-OH, -OCi-C6alkyl, -NR7R8, -Ci-C6alkyl-NR7R8, -S(Ci-C6alkyl), -SO(CJ-C6 alkyl), -SO2(Ci-C6 alkyl), -SO2NR7R8, -(Cj-Ce alkylene)-carbocycle, -(Ci- Ce alkylene)-heterocycle, carbocycle, or heterocycle;

[0382] R12and R13are each independently selected from H, deuterium, halogen, or -Ci-Cr, alkyl; and

[0383] p is O, 1, 2, or 3.

[0384] In embodiments of the compounds of Formula (A'), (A), or (II), or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, R2is a tricyclic ring, wherein at least one ring is aromatic, and wherein R2is optionally substituted with 1, 2, 3, or 4 R6.In embodiments of the compounds of Formula (A'), (A), or (II), or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, R2is a tricyclic ring containing at least one phenyl ring and wherein R2is optionally substituted with 1, 2, 3, or 4 R6.Attorney Docket No.: INMD-216 / 01WO 315953-4442

[0385] In embodiments of the compounds of Formula (A'), (A), or (II), or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, R3together with one of R6can form a tricyclic, tetracyclic, or pentacyclic ring optionally containing 1, 2, or 3 heteroatoms selected from N, S, or O, wherein the tricyclic, tetracyclic, or pentacyclic ring is optionally substituted with 1, 2, 3, or 4 R5

[0386] In embodiments, the present disclosure provides a compound of Formula (IT- A):R’ N AIR=IA1(R4)m(ILA),

[0387] or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof wherein:

[0388] ring A is a carbocycle, aryl, heterocycle, or heteroaryl ring;

[0391] each X,ais independently -NR63-, -O-, -CR12R13-, -C(O)-, -S-, -S(O) - or -S(O)2-,

[0392] R3is H; or R3together with one of R6can form a tricyclic, tetracyclic, or pentacyclic ring optionally containing 1, 2, or 3 heteroatoms selected from N, S, or O, wherein the tricyclic, tetracyclic, or pentacyclic ring is optionally substituted with 1, 2, 3, or 4 R5;

[0393] each R4is independently halogen, -Ci-Cs alkyl, -Ci-Cs haloalkyl, -S(Ci-C6 alkyl), - SO(C1-C6 alkyl), -SO2(Ci-C6 alkyl), or -CN;

[0394] R5and Rbare each independently halogen, -OH, oxo, -CN, -Ci-C6 alkyl, -Ci-Ce alkyl-OH, -(Ci-Ce alkylene)-O-(Ci-C'6 alkyl), -(Ci-Ce alkylene)-O-(Ci-C6 alkyl)-OH, -(Ci-Ck alkylene)-O-(Ci-C6 alkylene)-O-(Ci-C6 alkyl), -(Ci-Cs alkyl ene)-O-(Ci-C6 alkylene)-O-(Ci- C6 alkyl)-OH, -Ci-Cio haloalkyl, -Ci-Cio haloalkyl-OH, -NR7R8, -Ci-Ce alkyl-NR7R8, -S(Ci-C& alkyl), -SO(Ci-Cs alkyl), -SO2(Ct-C6 alkyl), -SO2NR7R8, -(Ci-Ce alkylene)-carbocycle, -(Ci-Cb alkylene)-heterocycle, carbocycle, or heterocycle, wherein each carbocycle and heterocycle is optionally substituted by 1 or 2 R”;Attorney Docket No.: INMD-216 / 01WO 315953-4442

[0395] each R6ais independently H, -Ci-Ce alkyl, -C1-C6 alkyl-OH, -C1-C10 haloalkyl, -Ci-Cio haloalkyl-OH, -Ci-C6alkyl-NR7R8, -(Ci-Ce alkylene)-O-(Ci-C6 alkyl), -(Ci-C6alkylene)-O-(Ci-C6alkyl)-OH, -(Ci-C6alkylene)-O-(Ci-C6alkyl)-COOH, -(C1-C6 alkylene)-O-(Ci-C6alkylene)-O-(Ci-Co alkyl), -(C1-C6alkylene)-O-(Cj-C6 alkylene)-NR7R8, -(Ci-C alkylene)-O-(C1-C6 alkylene)-C(O)NR7R8, -(Ci-C6alkylene)-O-(Ci-C6alkylene)-NR7C(O)-(Ci-C6 alkyl), - (C1-C6 a]kylene)-O-(Ci-C6 a1kylene)-C(O)NR7-(Ci-C6alkylene)-O-(Cj-C6alkyl), -(Ci-C6alkylene)-O-(Ci-Cs alkylene)-NR7C(O)-(Ci-C6 alkylene)-O-(Ci-C6 alkyl), -(Ci-Ce alkylene)-O-(CJ-C6 alkylene)-C(O)NR7-(Ci-C6 alkylene)-O-(Ci-C6 alkylene)-NR7-aryl, -(C1-C6 alkylene)-O-(Ci-C6 alkylene)-NR7C(O)-(Ci-Ce alkylene)-O-(Ci-Ce alkylene)-NR'-aryl, -(Ci- Ce alkylene)-NR7R8, -(Ci-C6alkylene)-NR7-(Ci-Ce alkyl)-OH, -(Ci-Ce alkylene)-NR7-(Ci-C6alkyl)-O-(Ci-C6alkyl), -(Ci-Ce alkylene)-NR7-(Ci-Ce alkylene)-NR7R8, -(Ci-Ce alkylene)-heterocycle, or -(Ci-C6 alkylene)-heteroaryl;

[0396] R7and R8are each independently H or -Ci-Ce alkyl; or R7and R8together with the nitrogen atom to which they are attached form a heterocyclyl;

[0397] R9is halogen, cyano, hydroxyl, -NH2, -NH(Ci-Ce alkyl), -N(Ci-Ce alkyl)2, -COOH, - Ci-Ce alkyl, -C2-C6 alkenyl, -C2-C6 alkynyl, -Ci-Ce haloalkyl, -C2-C6 haloalkenyl, -C2-C6 haloalkynyl, -Ci-C6alkyl-OH, -CONH2, -SH, -S(=O)NH2, -S(O)2NH, -OC]-C6alkyl, -OCJ-Ce haloalkyl, -S(Ci-C6alkyl), -SO(Ci-Ce alkyl), -SO2(Ci-C6 alkyl), -SO2NR7R8, -S(=NH)(O)(C1-C6alkyl), -(CJ-C6 alkylene)-carbocyclyl, or -(Ci-Ce alkylene)-heteroaryl;

[0398] R10is H or -Ci-C6alkyl,

[0399] each R11is independently halogen, -OH, oxo, -CN, -C1-C6 alkyl, -Ci-Ce alkyl-OH, -Ci-C10 haloalkyl, -Ci-Cio haloalkyl-OH, -OCi-C6alkyl, -NR7R8, -Ci-C6alkyl-NR7R8, -S(Ci-C6alkyl), -SO(Ci-C6alkyl), -SO2(Ci-C6alkyl), -SO2NR7R8, -(Ci-Ce alkylene)-carbocycle, -(Ci- Ce alkylene)-heterocycle, carbocycle, or heterocycle,

[0400] R12and R13are each independently selected from H, deuterium, halogen, or -Ci-Cg alkyl;

[0401] m is 0, 1, 2, or 3;

[0402] n is 0, 1, 2, or 3; and

[0403] p is 0, 1, 2, or 3;

[0404] provided that the compound is notMorAttorney Docket No.: INMD-216 / 01WO 315953-4442

[0405] In embodiments of the compounds of Formula (A'), (A), (II), or (II-A), or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, A is aryl. Inembodiments, A is phenylene. In embodiments, A isor

[0406] In embodiments of the compounds of Formula (A'), (A), (II), or ( II-A), or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, R3is H.

[0407] In embodiments of the compounds of Formula (A'), (A), (II), or (II-A), or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, each R4is independently halogen, -C1-C.3 alkyl, or -CN. In embodiments, R4is halogen.

[0408] In embodiments of the compounds of Formula (A'), (A), (II), or ( II-A), or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, m is 0 or 1.

[0409] In embodiments, the present disclosure provides a compound of Formula (II-B).

[0410] or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof wherein:

[0411] R' is

[0412] R2is

[0413] each Xlais independently -NRba-, -O-, -CR!2R13-, -C(O)-, -S-, -S(O) - or -S(O)2-;Attorney Docket No.: INMD-216 / 01WO 315953-4442

[0414] each R4is independently halogen, -Ci-Cc, alkyl, -Ci-Ce haloalkyl, -S(Ct-C6 alkyl), - SO(C1-C6alkyl), -SO2(Ci-C6alkyl), or -CN;

[0415] each R6is independently halogen, -OH, oxo, -CN, -Cj-Ce alkyl, -Ci-Ce alkyl-OH, -(CJ-C( alkylene)-O-(Ci-C6 alkyl), -(Ci-Cr, alkylene)-O-(Ci-C6 alkyl)-OH, -(CI-CG alkylene)-O-(Ci- Ce alkylene)-O-(Ci-C6 alkyl), -(Ci-C6alkylene)-O-(Ci-C6 alkylene)-O-(Ci-C6alkyl)-OH, -Ci- Cio haloalkyl, -Ci-Cio haloalkyl-OH, -NR7R8, -Ci-Ca alkyl-NR7R8, -S(Ct-C6alkyl), -SO(Ci- Ce alkyl), -SO2(Ci-C6 alkyl), -SO2NR7R8, -(Ci-Ce alkylene)-carbocycle, -(Ci-Ce alkylene)-heterocycle, carbocycle, or heterocycle, wherein each carbocycle and heterocycle is optionally substituted by 1 or2 Rn;

[0416] each R6ais independently H, -Ci-Cs alkyl, -Ci-Ce alkyl-OH, -Ci-Cio haloalkyl, -Ci-Cio haloalkyl-OH, -Ci-Ce alkyl-NR7R8, -(Ci-Ce alkylene)-O-(Ci-C6 alkyl), -(Ci-C6alkylene)-O-(Ci-C6alkyl)-OH, -(Ci-Cs alkylene)-O-(Ci-C6 alkyl)-COOH, -(Ci-C6alkylene)-O-(Ci-C6alkylene)-O-(Ci-Cd alkyl), -(Ci-Cs alkylene)-O-(Ci-C6 alkylene)-NR7R8, -(Ci-Ce alkylene)-O-(Ci-C6alkylene)-C(O)NR7R8, -(Ci-C6 alkylene)-O-(Ci-C6 alkylene)-NR7C(O)-(Ci-C6 alkyl), - (Ci-Cs alkylene)-O-(Ci-Ce alkylene)-C(O)NR7-(Ci-C6 alkylene)-O-(Cj-Ce alkyl), -(CI-CG alkylene)-O-(Ci-C6 alkylene)-NR7C(O)-(Ci-C6 alkylene)-O-(Ci-C6alkyl), -(Ci-Ce alkylene)-O-(Ci-C6 alkylene)-C(O)NR7-(Ci-Cfi alkylene)-O-(Ci-Cf> alkylene)-NR'-aryl, -(Ci-Cs alkylene)-O-(Ci-Co alkylene)-NR7C(O)-(Ci-Ce alkylene)-O-(Ci-C6 alkylene -NR'-aryl, -(Ci-Ce alkylene)-NR7R8, -(Ci-C6alkylene)-NR7-(Ci-C6alkyl)-OH, -(Ci-C6alkylene)-NR7-(Ci-C6alkyl)-O-(Ci-Ce alkyl), -(Ci-Ce alkylene)-NR7-(Ci-Ce alkylene)-NR7R8, -(Ci-Ce alkylene)-heterocycle, or -(Ci-Ce alkylene)-heteroaryl;

[0417] R7and R8are each independently H or -Ci-Ce alkyl; or R7and R8together with the nitrogen atom to which they are attached form a heterocyclyl;

[0418] R9is halogen, cyano, hydroxyl, -NH2, -NH(Ci-C6 alkyl), -N(Ci-C6 alkyl)2, -COOH, -Ci-Ce alkyl, -Ci-C alkenyl, -C2-C6 alkynyl, -C1-C0 haloalkyl, -C2-C6 haloalkenyl, -C2-C6 haloalkynyl, -Ci-C6alkyl-OH, -CONH2, -SH, -S(=O)NH2, -S(O)2NH2, -OC]-C6alkyl, -OCi-Ce haloalkyl, -S(Ci-C6alkyl), -SO(Ci-Ce alkyl), -SO2(Ci-C6 alkyl), -SO2NR7R8, -S(=NH)(O)(Ci-C6 alkyl), -(C1-C6 alkylene)-carbocyclyl, or -(Ci-Ce alkylene)-heteroaryl;

[0419] R10is H or -Ci-C6alkyl;

[0420] each R11is independently halogen, -OH, oxo, -CN, -Ci-Ce alkyl, -Ci-Ce alkyl-OH, -Ci-C10 haloalkyl, -C1-C10 haloalkyl-OH, -OC1-C alkyl, -NR7R8, -Ci-C6alkyl-NR7R8, -S(Ci-C6alkyl), -SO(Ci-C6 alkyl), -SO2(Ci-C6alkyl), -SO2NR7R8, -(Ci-C6alkylene)-carbocycle, -(Ci- Ce alkylene [-heterocycle, carbocycle, or heterocycle;Attorney Docket No.: INMD-216 / 01WO 315953-4442

[0421] R12and R13are each independently selected from H, deuterium, halogen, or -Ci-Ce alkyl;

[0422] m is 0, 1, 2, or 3;

[0423] n is 0, 1, 2, or 3; and

[0424] p is 0, 1, 2, or 3;

[0425] provided that the compound is notHor

[0426] In embodiments of the compounds of Formula (II-B) or a pharmaceutically acceptablesalt, a stereoisomer, or a deuterated form thereof, Rlis and R9is halogen, cyano, hydroxyl, -NH2, -NH(C1-C6alkyl), -N(Ci-Ce alkyl)2, -COOH, -Ci-Ce alkyl, -C2-Ce alkenyl, -C2-C6 alkynyl, -C1-C6 haloalkyl, -C2-C6 haloalkenyl, -C2-C6 haloalkynyl, -Ci-Ce alkyl-OH, -CONH2, -SH, -S(=O)NH2, -S(O)2NH2, -OCi-Ce alkyl, -OCi-Ce haloalkyl, -S(Ci- C6alkyl), -SO(Ci-C6 alkyl), -SO2(Ci-C6 alkyl), -SO2NH2, -SO2NH(CI-C6alkyl), -SO2N(CI-C6 alkyl)2, -S(=NH)(O)(C1-C6alkyl), -(Ct-Ce alkylene)-carbocyclyl or -(Ci-Ce alkylene)- heteroaryl; R10is H or -Ci-Ce alkyl; n is 0, 1, or 2. In some embodiments, R9is -SO2NR7R8In a further embodiment, n is 0. In a further embodiment, R10is H. In yet a further embodiment,o f A o f AR1is NH jn afurtherembodiment,R1is,anj R2 JS NOTH<-N>C=OO / \. In even a further embodiment, R1is, and the carbon centerAttorney Docket No.: INMD-216 / 01WO 315953-4442marked by * has an R or S configuration. In a further embodiment, R1is and the carbon center marked by * has an S configuration.

[0427] In embodiments of the compounds of Formula (11-B) or a pharmaceutically acceptable f vyo \RA Rfesalt, a stereoisomer, or a deuterated form thereof, Rzisv'p; and p is 0 or I; R6is halogen, -OH, -CN, -CI-CA alkyl, -Ci-Ce alkyl-OH, -(Ci-Ce alkylene)-O-(Cj-C6 alkyl), -(Ci-Cs alkylene)-O-(Ci-Co alkyl)-OH; and Rbais H, -Ci-Cs alkyl, -C1-C10 haloalkyl, -Ci-Ce alkyl-NR7R8, -(C1-C6 alkylene)-O-(Ci-C'6 alkyl)-OH, -(Ci-C6alkylene)-O-(Ci-C6alkylene)-O-(Ci-C6alkyl), -(Ci-Ce alkylene)-O-(Ci-C6alkylene)-NR7R8, -(Ci-C6alkylene)-NR7-(Ci-C6alkyl)- OH, -(Ci-Ce alkylene)-NR7-(Ci-Ce alkyl )-O-(Ci-Ce alkyl), -(Ci-Ce alkylene)-heterocycle, or - (Ci-Ce alkylene)-heteroaryl. In a further embodiment, p is 0. In a further embodiment, R6ais H, -C1-C3 alkyl, -C1-C3 alkyl-NR7R8, -(C1-C3 alkylene)-NR7-(Ci-C3alkyl)-O-(Ci-C3alkyl), or -(C1-C3 alkylene)-heterocycle. In yet a further embodiment, Rbais -C1-C3 alkyl. In even a further embodiment, R6ais methyl, even a further embodiment, R6ais ethyl. In yet even a furtherembodiment,R is

[0428] In embodiments of the compounds of Formula (II-B) or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, m is 0 1, or 2, and each R4is independently halogen, -Ci-Cc, alkyl, or -C1-C0 haloalkyl. In a further embodiment, m is 1, and R4is halogen.In a further embodiment, R4is F. In yet a further embodiment, ring A is, wherein the asterisk (*) represents the point of attachment to R2. In yet a further embodiment,

[0429] In embodiments of the compounds of Formula (A'), (A), (II), (II- A), or (II-B) or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, wherein R2isAttorney Docket No.: INMD-216 / 01WO 315953-4442In embodiments, each R6ais independently H, -Ci-Ce alkyl, -C1-C10 haloalkyl, -Ci-Ce alkyl-NR7R8, -(CI-CS alkylene)-O-(Ci-C6 alkyl)-OH, -(Ci-C6alkylene)-O-(Ci-C6alkylene)-O-(Ci- Ce. alkyl), -(Ci-Cs alkylene)-O-(Ci-C6 alkylene)-NR'Rs, -(Ci-Ce alkylene)-NR7-(Ci-C6 alkyl)-OH, -(Ci-Ce alkylene)-NR7-(Ci-C6 alkyl)-O-(C;-C6 alkyl), -(Ci-Ce alkylene)-heterocycle, or - (Ci-Ce alkylene)-heteroaryl In embodiments, each R6ais independently H, -C1-C3 alkyl, -Ci-C3 alkyl-NR7Rs, -(C1-C3 alkylene)-NR7-(Cj-C3 alkyl)-O-(Ci-C3 alkyl), or -(C1-C3 alkylene)-heterocycle. In some embodiments, p is 0.

[0430] In embodiments of the compounds of Formula (I I-B) or a pharmaceutically acceptable Osalt, a stereoisomer, or a deuterated form thereof, R2is; and p is 0 or 1. In embodiments, R6aisH, -C1-C6 alkyl, -Ci-Ciohaloalkyl, -Ci-Ce alkyl-NR7Rs, -(Ci-Ce alkylene)- O-(CJ-C6alkyl)-OH, -(Ci-C6alkylene)-O-(Ci-C6alkylene)-O-(Ci-C6alkyl), -(Ci-C6alkylene)- O-(Ci-Ce alkyl ene)-NR7Rs, -(Ci-Ce alkylene)-NR7-(Ci-C6 alkyl)-OH, -(Ci-Ce alkylene)- N7- (Ci-Cs alkyl)-0-(Ci-Co alkyl), -(Ci-Ce alkylene)-heterocycle, or -(Ci-Ce alkylene)-heteroaryl. In embodiments, R6ais H, -C1-C3 alkyl, -C1-C3 alkyl-NR7R8, -(C1-C3 alkylene)-NR7-(Ci-C3 alkyl)-O-(Ci-C3 alkyl), or -(C1-C3 alkylene)-heterocycle. In embodiments, R6ais -C1-C3 alkyl. In embodiments, R6ais methyl. In embodiments, R6ais ethyl. In some embodiments, p is 0,

[0431] In embodiments of the compounds of Formula (A'), (A), (11), (11-A), or (Il-B) or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, wherein R2isAttorney Docket No.: INMD-216 / 01WO 315953-4442

[0432] In embodiments of the compounds of Formula (A'), (A), (II), (II-A), or (II-B) or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, R2is

[0433] In embodiments, the present disclosure provides a compound of Formula (II-C):

[0434] or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof wherein:

[0435] ring B is 5-8 membered ring optionally containing 1, 2, or 3 heteroatoms selected from N, S, or O;

[0436] ring C is monocyclic, bicyclic, or tricyclic ring containing at least one aromatic ring;[043S] each R4is independently halogen, -Ci-Ce alkyl, -Ci-Ce haloalkyl, -S(Ct-C6 alkyl), - SO(Ci-Cfi alkyl), -SO2.(Ci-C6 alkyl), or -CN;

[0439] R5and R6are each independently halogen, -OH, oxo, -CN, -Ci-Ce alkyl, -Ci-Ce alkyl- OH, -(Ci-Ce alkylene)-O-(Ci-C6 alkyl), -(Ci-Ce alkylene)-O-(Ci-C6 alkyl)-OH, -(Ci-Cs alkylene)-O-(Ci-C6 alkylene)-O-(Ci-C6 alkyl), -(Ci-Cc, alkylene)-O-(Ci-C6 alkylene)-O-(Ci-Ce alkyl)-OH, -Ci-Cio haloalkyl, -Ci-Cio haloalkyl-OH, -NR7R8, -Ci-Co alkyl -NR7R8, -S(Ci-Ce alkyl), -SO(Ci-C6 alkyl), -SCh(Ci-C6 alkyl), -SO2NR7R8, -(Ci-Ce alkylene)-carbocycle, - (Ci-Co alkylene)-heterocycle, carbocycle, or heterocycle, wherein each carbocycle and heterocycle is optionally substituted by 1 or 2 R”;

[0440] R7and R8are each independently H or -Ci-Ce alkyl; or R7and R8together with the nitrogen atom to which they are attached form a heterocyclyl;

[0441] R9is halogen, cyano, hydroxyl, -NH2, -NH(Ci-Cs alkyl), -N(CI-C6 alkyl)2, -COOH, - C1-C6 alkyl, -C2-C6 alkenyl,alkynyl, -Ci-Ce haloalkyl, -C2-C6 haloalkenyL -C2-C6 haloalkynyl, -Ci-C6alkyl-OH, -CONH2, -SH, -S(=O)NH2, -S(O)2NH2, -OCi-Ce alkyl, -OCi-Attorney Docket No.: INMD-216 / 01WO 315953-4442c6haloalkyl, -S(Ct-C6alkyl), -SO(Ci-C6 alkyl), -SO2(Ci-C,5alkyl), -SO2NR7R8, - S(:=NH)(0)(CI-C6 alkyl), -(Ci-Ce alkylene)-carbocyclyl, or -(Ci-Ce alkylene)-heteroaryl;

[0442] R10is H or -Ci-C6alkyl;

[0443] each R11is independently halogen, -OH, oxo, -CN, -Ci-C6alkyl, -Ci-Ce alkyl-OH, -Ci-Cio haloalkyl, -C1-C10 haloalkyl-OH, -OC1-C6 alkyl, -NR7R8, -Ci-Ce alkyl-NR7R8, -S(Ci-C6 alkyl), -SO(Ci-C6alkyl), -SO2(Ci-C6alkyl), -SO2NR7R8, -(Ci-C6alkylene)-carbocycle, -(Ci- Ce alkylene)-heterocycle, carbocycle, or heterocycle;

[0444] m is 0, 1, 2, or 3;

[0445] n is 0, 1, 2, or 3;

[0446] p is 0, 1, 2, or 3; and

[0447] q is 0, 1, 2, or 3.

[0448] In embodiments of the compounds of Formula (II-C) or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, ring C is phenyl.

[0449] In embodiments of the compounds of Formula (II-C) or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, the multicyclic ring containing ring B andX1x5 (R )q ring C is!4)m x1a(R^q Aand R13are each independently selected from H, deuterium, halogen, or C1-6 alkyl In embodiments, Xlais -NH-, -NCH3-, -O-, or -CH2-. In embodiments, each R6is independently halogen, -OH, -CN -C1-C3 alkyl, -C1-C3 haloalkyl, -S(Ci-C3alkyl), -SO(Ci-C3alkyl), -SO2(Ci-C3alkyl), -SO2N(Ci-C3alkyl), -SO2NR7R8, or 4-6 membered heterocycle. In embodiments, each R6is halogen, -CN, or 4-membered heterocycle. In embodiments, each R6isindependently halogen, -CN,. In embodiments, each R6is independentlyAttorney Docket No.: INMD-216 / 01WO 315953-4442In embodiments, each R4is independently halogen, -C1-C3 alkyl or -CN. In embodiments, R4is halogen. In embodiments, R4is F.

[0450] In embodiments of the compounds of Formula (II-C) or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, the multicyclic ring containing ring B andor 1 and p is 0, 1, or 2. In embodiments, each R6is independently halogen, -OH, -CN -C1-C3 alkyl, -C1-C3 haloalkyl, -S(Ci-C3alkyl), -SO(Ci-C3alkyl), -SO2(Ci-C3alkyl), -SO2N(Ci-C3alkyl), -SO2NR7R8, or 4-6 membered heterocycle. In embodiments, each R6is halogen, -CN,or 4-membered heterocycle. In embodiments, each R6is independently halogen, -CN,' / ^° a r° or '. In embodiments, each R6is independently F, -CN,', or '. In embodiments, each R4is independently halogen, -Ci-C3alkyl, or -CN. In embodiments, R4is halogen. In embodiments, R4is F.

[0451] In embodiments of the compounds of Formula (II-C) or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof,

[0452] In embodiments of the compounds of Formula (II-C) or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, q is 0 or 1. In embodiments, q is 0.

[0453] In embodiments of the compounds of Formula (II-C) or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, the multicyclic ring containing ring B andAttorney Docket No.: INMD-216 / 01WO 315953-4442

[0454] In embodiments of the compounds of Formula (II-C) or a pharmaceutically acceptable salt a stereoisomer, or a deuterated form thereof, ring C is a bicyclic ring forming a tetracyclic ring. In embodiments, ring C is a bicyclic ring wherein one ring is a phenyl ring. In embodiments, ring C is a fused bicyclic ring.

[0455] In embodiments of the compounds of Formula (II-C) or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, the multicyclic ring containing ring B andheterocyclic ring containing 1, 2, or 3 heteroatoms selected from N, S, or O. In embodiments, each R° is independently halogen, -OU, -CN -C1-C3 alkyl, -C1-C3 haloalkyl, -S(Ci-C3 alkyl), - SO(Ci-C3 alkyl), -SO2(Ci-Cs alkyl), -SO2N(CI-C'3 alkyl), -SO2NR7R8, or 4-6 membered heterocycle. In embodiments, each R6is independently halogen, -C1-C3 alkyl, -CN, or 4- membered heterocycle. In embodiments, each R6is independently halogen, -C1-C3 alkyl, -CN, r? r°', or ''. In embodiments, each R4is independently halogen, -C1-C3 alkyl, or -CN In embodiments, each R4is halogen. In embodiments, each R4is F. In embodiments, m is 0 or 1. In embodiments, m is 1.Attorney Docket No.: INMD-216 / 01WO 315953-4442

[0456] In embodiments of the compounds of Formula (II-C) or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, the multicyclic ring containing ring B andhalogen, -C1-C alkyl, or -CN. In embodiments, each R4is halogen. In embodiments, each R4is F. In embodiments, m is 0 or 1 In embodiments, m is 1.

[0457] In embodiments of the compounds of Formula (II-C) or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, the multicyclic ring containing ring B and

[0458] In embodiments of the compounds of Formula (II-C) or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, ring C is a tricyclic ring forming a pentacyclic ring. In embodiments, ring C is a tricyclic ring wherein one ring is a phenyl ring.

[0459] In embodiments of the compounds of formula (II-C) or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, the multicyclic ring containing ring B andAttorney Docket No.: INMD-216 / 01WO 315953-4442and ring D is a 7-12 membered bicyclic ring wherein at least one ring is a heterocyclic ring containing 1, 2, or 3 heteroatoms selected from N, S, or O In embodiments, ring D is a spiro bicyclic ring. In embodiments, each R6is independently halogen, -OH, -CN -C1-C3 alkyl, -C1-C3 haloalkyl, -S(Ci-C3 alkyl), - SO(Ct-C3 alkyl), -SOzfCi-C? alkyl), -SO2N(CI-C3 alkyl), -SO2NR7Rs, or 4-6 membered heterocycle. In embodiments, each R6is independently halogen or -C1-C3 alkyl. In embodiments, each R6is independently methyl In embodiments, p is 0 or 1 In embodiments, each R4is independently halogen, -C1-C.3 alkyl, or -CN. In embodiments, each R4is halogen. In embodiments, each R4is F. In embodiments, m is 0 or 1. In embodiments, m is 1.

[0460] In embodiments of the compounds of Formula (II-C) or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, the multi cyclic ring containing ring B andhalogen, -C1-C3 alkyl, or -CN. In embodiments, each R4is halogen. In embodiments, each R4is F. In embodiments, m is 0 or 1. In embodiments, m is 1.

[0461] In embodiments of the compounds of Formula (II-C) or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, the multi cyclic ring containing ring B andAttorney Docket No.: INMD-216 / 01WO 315953-4442

[0463] or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof wherein:

[0464] ring A is a carbocycle, aryl, heterocycle, or heteroaryl ring;R5Attorney Docket No.: INMD-216 / 01WO 315953-4442

[0467] R3is H; or R together with one of R6can form a tricyclic, tetracyclic, or pentacyclic ring optionally containing 1, 2, or 3 heteroatoms selected from N, S, or O, wherein the tricyclic, tetracyclic, or pentacyclic ring is optionally substituted with 1, 2, 3, or 4 R5;

[0468] each R4is independently halogen, -Ci-G, alkyl, -Ci-Co haloalkyl, -S(Ci-Cfi alkyl), - SO(C1-C6alkyl), -SO2(Ci-C6alkyl), or -CN;

[0469] each R5is independently hydrogen, halogen, -OH, -CN, -Ci-Ce alkyl, -Ci-Ce alkyl- OH, -O-(Ci-C6alkyl), -(Ci-Ce alkylene)-O-(Ci-C6alkyl), -(Ci-C6alkylene)-O-(Ci-C6 alkyl)- OH, -(Ci-Cb alkylene)-O-(Ci-C6 alkylene)-O-(Ci-C6 alkyl), -(Ci-Cs alkylene)-O-(Ci-C6 alkylene)-O-(Ci-C6alkyl)-OH, -Ci-Cio haloalkyl, -Ci-Cio haloalkyl-OH, - R7R8, -CONR7R8, -Ci-C6alkyl-NR7R8, -SF5, -S(Ci-C6alkyl), -SO(Ci-C6alkyl), -SO2(Ci-C6 alkyl), -SO2NR7R8, -(Ci-Ce alkylene)-carbocycle, -(Ci-Co alkylene)-heterocycle, carbocycle, or heterocycle, wherein each carbocycle and heterocycle is optionally substituted by 1 or 2 R1’;

[0470] each R6is independently halogen, -OH, oxo, -CN, -Ci-Ce alkyl, -Ci-Ce alkyl-OH, -O-(Ci-C’6 alkyl), -(Ci-Ce alkylene)-O-(Ci-C6 alkyl), -(Ci-Ce alkylene)-O-(Ci-C6 alkyl)- OH, -(Ci-Ce alkylene)-O-(Ci-C6 alkylene)-O-(Ci-Co alkyl), -(Ci-Ce alkylene)-O-(Ci-Co alkylene)-O-(Ci-C6 alkyl)-OH, -Ci-Cio haloalkyl, -Ci-Cio haloalkyl-OH, -NR7R8, -Ci-C6alkyl-NR7R8, -SF5, -S(Ci-C6alkyl), -SO(Ci-C6alkyl), -SO2(Ci-C6alkyl), -SO2NR7R8, -(Ci-C6alkylene)-carbocycle, -(Ci-Ce alkylene)-heterocycle, carbocycle, or heterocycle, wherein each carbocycle and heterocycle is optionally substituted by 1 or 2 Rn;

[0471] R7and R8are each independently H or -Ci-Ce alkyl; or R7and R8together with the nitrogen atom to which they are attached form a heterocyclyl;

[0472] R9is halogen, cyano, hydroxyl, -NH2, -NH(Ci-Cs alkyl), -N(Ci-Ce alkyl)2, -COOH, - Ci-C6alkyl, -C2-Ce alkenyl, -Ci-C alkynyl, -Ci-Cs haloalkyl, -C2-Ce haloalkenyl, -C2-C6 haloalkynyl, -Ci-C6alkyl-OH, -CONH2, -SH, -S(=O)NH2, -S(O)2NH2, -OCi-Ce alkyl, -OCt- C6haloalkyl, -S(Ci-C6alkyl), -SO(Ci-Ce alkyl), -SO2(Ci-C6alkyl), -SO2NR7R8, -S(=NH)(O)(Ci-Ce alkyl), -(Ci-Ce alkylene)-carbocyclyl, or -(Ci-Ce alkylene)-heteroaryl;

[0473] R10is H or -Ci-Cs alkyl;

[0474] each R! lis independently halogen, -OH, oxo, -CN, -Ci-Ce alkyl, -C1-C6 alkyl-OH, -Ci-C10 haloalkyl, -C1-C10 haloalkyl-OH, -OCi-C6alkyl, -NR7R8, -Ci-C6alkyl-NR7R8, -S(CI-CG alkyl), -SO(Ci-C6 alkyl), -SO2(Ci-C6 alkyl), -SO2NR7R8, -(C1-C6 alkylene)-carbocycle, -(Ci- Ce alkylene)-heterocycle, carbocycle, or heterocycle;

[0475] Z1is CH2, NR5, S, S(O), or S(O)2;

[0476] gis O, 1, 2, or 3;

[0477] m is 0, 1, 2, or 3;Attorney Docket No.: INMD-216 / 01WO 315953-4442

[0478] n is 0, 1, 2, or 3; and

[0479] p is 0, 1, 2, or 3.

[0480] In some embodiments of the compounds of Formula (11-D), or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, ring A is an aryl or heteroaryl ring. In further embodiments, ring A is monocyclic aryl or heteroaryl ring. In further embodiments,... " Vring A is phenylene or thiozolene In yet a further embodiment, ring A is (R )mtn is 0 1, or 2, and each R4is independently halogen, -Ci-Ce alkyl, or -Ci-Co haloalkyl. In even a further embodiment, m is 1, and R4is halogen. In a further embodiment, R'1is F. In yet even afurther embodiment, ring A is(m is 0). In yet even a further embodiment, ring Ais, wherein the asterisk (*) represents the point of attachment to R2.

[0481] Tn some embodiments of the compounds of Formul (TI-D), or a pharmaceuticallyacceptable salt, a stereoi somer, or a deuterated form thereof, R1is cyano, hydroxyl, -NH2, -NH(C1-C6alkyl), -N(CI-C6 alkyl)2, -COOH, -Ci-Cs alkyl, -C2-C6 alkenyl, -C2-C6 alkynyl, -Ci-Ce haloalkyl, -C2-C6 haloalkenyl, -C2-C6 haloalkynyl, -Ci-Ce alkyl-OH, -CONH2, -SH, -S(=O)NH2, -S(O)2NH2, -OCi-Ce alkyl, -OCi-Ce haloalkyl, -S(Ci- C6alkyl), -SO(Ci-C6alkyl), -SO2(Ci-C6 alkyl), -SO2NH2, -SO2NH(C>-C6 alkyl), -SO2N(CI-C alkyl)2, -S(::::NH)(O)(CI-C6 alkyl), -(Ci-Ce alkylene)-carbocyclyl, or -(Ci-Ce alkylene)- heteroaryl, R10is H or -Ci-Ce alkyl; n is 0, 1, or 2. In some embodiments, R9is -SO2NR7Rs. In a further embodiment, n is 0. In a further embodiment, R10is H. In yet a further embodiment,H_NO' V A / . In even a further embodiment, R’ is 'z, and the carbon centerAttorney Docket No.: INMD-216 / 01WO 315953-4442marked by * has an R or S configuration. In a further embodiment, R1is and the carbon center marked by * has an S configuration. In yet even a further embodiment, R1is, and the carbon center marked by * has an S configuration, and the carbon H-N Oz'\ center marked by ** has an R or S configuration. In a further embodiment,R1is, and the carbon center marked by * has an S configuration, and the carbon center marked by ** has an S configuration.

[0482] In some embodiments of the compounds of Formula (II-D), or a pharmaceuticallyacceptable salt, a stereoisomer, or a deuterated form thereof, R2isand R?is hydrogen, -C1-C0 alkyl, -Ci-Ce alkyl-OH, -(Ci-Ce alkylene)-O-(Ci-C6 alkyl), -(Ci-Cs alkylene)-O-(Ci-C6 alkyl)-OH, -(Ci-Ce alkylene)-O-(Ci-C6 alkylene)-O-(Ci-Cs alkyl), -(Ci-Ce alkylene)-O-(Ci-C6 alkylene)-O-(Ci-Ce alkyl)-OH, -(Ci-Ce alkylene)-heterocycle, carbocycle, or heterocycle, wherein each carbocycle and heterocycle is optionally substituted by 1 or 2 R11, each R11is independently halogen, -OH, or -C1-C3 alkyl; each p is independently 0, 1, or 2; each R6is independently halogen, -OH, oxo, -Ci-Ce alkyl, -O-(Ci-Ce alkyl), -C1-C10 haloalkyl, -NR7R8, -S(Ci-C6 alkyl), -SO(Ci-C& alkyl), - SO2(Ci-C6alkyl), carbocycle, or heterocycle, wherein each carbocycle and heterocycle is optionally substituted by 1 or 2 R1 ], each Ruis independently halogen, -OH, or -C1-C3 alkyl.In a further embodiment, R2is (R)p, p is 1 or 2, each R6is independently -CI-CGalkyl. In yet a further embodiment, R2isr<^rw (R6)p, p]or2, and each R6isAttorney Docket No.: INMD-216 / 01WO 315953-4442independently -Ct-Ce alkyl. In yet an even further embodiment, p is 1 or 2, and each R° is methyl or ethyl. In a further embodiment, p is 2 and R6is methyl. In even a further embodiment,R5R2is. In a further embodiment, R2is )p, p is 0, 1 or 2, each Rbisindependently halogen, -OH, oxo, -C1-C6 alkyl, and R3is hydrogen or -Ci-Cc, alkyl. In yet a R5'■ ('R ) ffurther embodiment,R‘ is,p, each R is oxo, and R- is hydrogen or -Ci-Ce alkyl. In yet an even further embodiment, R3is methyl or ethyl. In even a further embodiment, R2is I S (R5)PN. In a further embodiment, R2isH, P is 0, 1 or 2, and each R6is (R6)P N''N hf independently -Ci-Cs alkyl. In yet a further embodiment, R2isH, p is 0 or 1, and N''N R6is -Ci-Cs alkyl. In even a further embodiment, R2is k6, and R6is -Ci-Ce alkyl. In a further embodiment, Rbis methyl or ethyl. In yet even a further embodiment, R2is

[0483] In embodiments, the compound of Formula (II-D) has a structure of Formula (II-D-1)R10(II-D-1),[0484J or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, wherein:Attorney Docket No.: INMD-216 / 01WO 315953-4442

[0485] ring A is arylene or heteroarylene;

[0486] each R4is independently halogen, -C1-C6 alkyl, or -Ci-Cs haloalkyl; and

[0487] m is 0 or 1; and

[0488] R2, R3, each R5, each R'\ R7, R8, R9, R10, each R11, Z1, g, n, and p are according to those defined in Formula (II-D).

[0489] In embodiments, the compound ofFormul (II-D) or (TT-D-1) has a structure of Formula (II-D-2)HN(R4)m(II-D-2),

[0490] or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, wherein:

[0491] ring A is phenylene or thiozolene;

[0492] each R4is independently halogen, -Ci-Co alkyl, or -Ci-Cs haloalkyl, and

[0493] in is 0 or 1; and

[0494] R2, R3, each R3, each R6, R7, R8, each R11, Z1, g, and p are defined previously according to Formula (II-D).

[0495] In embodiments, the compound ofFormula (II-D), (II-D-1), or (II-D-2) has a structure ofFormula (II-D-3)H NN

[0496] or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, wherein:

[0497] each R4is independently halogen, -Ci-G, alkyl, or -Ci-Cs haloalkyl; and

[0498] m is 0 or 1; and

[0499] R2, each R5, each R6, R', R8, each Ru, Zl, g, and p are defined previously according to Formula (II-D).Attorney Docket No.: INMD-216 / 01WO 315953-4442

[0500] In embodiments, the compound of Formula (II-D), (II-D-1), (II-D-2), or (II-D-3) has a structure of Formula (II-D-4)H NR2

[0501] or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, wherein:

[0502] each R'1is independently halogen, -Ci-C<5 alkyl, or -Ci-Cs haloalkyl; and

[0503] m is 0 or I; and

[0504] R2, each R5, each R°, R', R8, each R11, Z1, g, and p are defined previously according to Formula (II-D).

[0505] In embodiments, the compound of Formula (II-D), (II-D-1), (II-D-2), (II-D-3), or (II- D-4) has a structure of Formula (II-D-4')HN(II-D-4'),

[0506] or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, wherein:

[0507] each R4is independently halogen, -Ci-Cs alkyl, or -Ci-Cs haloalkyl; and

[0508] m is 0 or 1; and

[0509] R2, each R5, each R6, Rz, R8, each R11, Z1, g, and p are defined previously according to Formula (II-D).

[0510] In embodiments, the compound of Formula (II-D), (II-D-1), (II-D-2), (II-D-3), (II-D- 4), or (II-D-4') has a structure of Formula (II-D-4'')HN^,|7s,

[0511] or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, wherein:Attorney Docket No.: INMD-216 / 01WO 315953-4442

[0512] each R4is independently halogen, -Ci-Cf, alkyl, or -C1-C6haloalkyl; and

[0513] m is 0 or 1; and

[0514] R2, each R3, each R6, R7, R8, each R11, Z1, g, and p are defined previously according to Formula (II-D).

[0515] In embodiments of the compounds of Formula (II-D-3), (II-D-4), (II-D-4'), or (II-D-4"), or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof,

[0516] In embodiments of the compounds of Formula (II-D), (II-D-1), (II-D-2), (II-D-3), (II- D-4), (II-D-4'), or (II-D-4'') or a pharmaceutically acceptable salt, a stereoisomer, or a(R6)Pr r " N'H. In embodiments, p is 0, 1, or 2. In embodiments, p is 0. In embodiments, p is 1. In embodiments, eachR6is independently halogen, -OH, oxo, -Ci-Ce alkyl, -O-(Ci-Ce alkyl), -Ct-Cio haloalkyl, -NR7R8, -S(Ci-C6 alkyl), -SO(Ci-C6 alkyl), -SO2(Ci-Ce alkyl), carbocycle, or heterocycle, wherein each carbocycle and heterocycle is optionally substituted by 1 or 2 R11. In embodiments, each R6is independently halogen, oxo, -C1-C3 alkyl, -C1-C3 haloalkyl, or a 5-or 6-membered heterocycle, wherein each heterocycle is optionally substituted by 1 or 2 R11. In embodiments, each R6is independently halogen, oxo, -C1-C3 alkyl or 6-membered heterocycle, wherein each heterocycle is optionally substituted by 1 or 2 R11. In embodiments, R11is independently halogen, -OH, -Ci-Cs alkyl, -NR7R8, -S(Ci-Ce alkyl), -SO(Ci-Ce alkyl),Attorney Docket No.: INMD-216 / 01WO 315953-4442or -SChfCi-Cfi alkyl). In embodiments, R11is independently halogen, -OH, or -C1-C3 alkyl. In embodiments, Rnis methyl.

[0517] In embodiments of the compounds of Formula (11-D) or a pharmaceutically acceptable(R6)PI ir " N'H. In embodiments, each R6is independently halogen, -OH, -Ci-Cs alkyl, -O-(C] -Cs alkyl), -C1-C10 haloalkyl, -NR7R8, -S(Ci-Cs alkyd), -SO(Ci-Ce alkyl), -SO2(Ci-C6 alkyl), carbocycle, or heterocycle, wherein each carbocycle and heterocycle is optionally substituted by 1 or 2 R11. In embodiments, each R6is independently halogen, -C1-C3 alkyl, -C1-C3 haloalkyl, or a 5- or 6-membered heterocycle, wherein each heterocycle is optionally substituted by 1 or 2 R11. In embodiments, each R6is independently halogen, -C1-C3 alkyl or 6-membered heterocycle, wherein each heterocycle is optionally substituted by 1 or 2 R11. In embodiments, R11is independently halogen, -OH, -Ci-Ce alkyl, -NR7R8, -S(Ci-Ce alkyl), - SO(Ci-Ce alkyl), or -SO2(Ci-Ce alkyl). In embodiments, R11is independently halogen, -OH, or -C1-C3 alkyl. In embodiments, R11is methyl.

[0518] In embodiments of the compounds of Formula (II-D), (II-D-1), (II-D-2), (II-D-3), (II-D-4), (II-D-4'), or (II-D-4'') or a pharmaceutically acceptable salt, a stereoisomer, or aAttorney Docket No.: INMD-216 / 01WO 315953-4442

[0519] In embodiments of the compounds of Formula (I I-D) or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, R2is

[0520] In embodiments of the compounds of Formula (II-D), (II-D-1), (II-D-2), (II-D-3), (II- D-4), (II-D-4'), or (II-D-4") or a pharm ceutically acceptable salt, a stereoisomer, or a

[0521] In embodiments, the present disclosure provides a compound of Formula (II-E):Attorney Docket No.: INMD-216 / 01WO 315953-4442

[0522] or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof wherein:

[0523] ring A is a carbocycle, aryl, heterocycle, or heteroaryl ring;

[0526] each R4is independently halogen, -Ci-C’s alkyl, -Ci-Ce haloalkyl, -S(Ci-C6 alkyl), - SO(Ci-Ce alkyl), -SO2(Ci-C6 alkyl), or -CN;

[0527] each E is independently hydrogen, halogen, -OH, -CN, -Ci-CN alkyl, -Ci-Ce alkyl-OH, -0-(CJ-C6 alkyl), -(Ci-Ce alkylene)-O-(Ci-C6 alkyl), -(Ci-Ce alkylene)-O-(Ci-C6 alkyl)-OH, -(Ci-Ce alkylene)-O-(Ci-C6 alkylene)-O-(Ci-Ce alkyl), -(Ci-CN alkylene)-O-(Ci-CeAttorney Docket No.: INMD-216 / 01WO 315953-4442alkylene)-O-(Ci-C6alkyl)-OH, -C1-C10 haloalkyl, -C1-C10 haloalkyl-OH, -NR7R8, -CONR7R8, -Ci-Ce alkyl-NR7R8, -SF5, -S(Ci-C6alkyl), -SO(Ci-C6alkyl), -SO2(Ci-C6 alkyl), -SO2NR7R8, -(Ci-Ce alkylene)-carbocycle, -(Ci-Ce alkylene)-heterocycle, carbocycle, or heterocycle, wherein each carbocycle and heterocycle is optionally substituted by 1 or 2 R11;

[0528] each R6is independently halogen, -OH, oxo, -CN, -Ci-Ck alkyl, -Ci-Ck alkyl- OH, -O-(CJ-C6alkyl), -(Ci-Cs alkylene)-O-(Ci-C6alkyl), -(Ci-Ce alkylene)-O-(Ci-C6alkyl)- OH, -(Ci-Cb alkylene)-O-(Ci-C6 alkylene)-O-(Ci-C6 alkyl), -(Ci-Co alkylene)-O-(Ci-C6 alkylene)-O-(Ci-C6 alkyl)-OH, -Ci-Cio haloalkyl, -Ci-Cio haloalkyl-OH, -NR7R8, -Ci-Ce alkyl-NR7R8, -SF5, -S(Ci-Ce alkyl), -SO(Ci-C6alkyl), -SO2(Ci-C6alkyl), -SO2NR7R8, -(Ci-Ce alkylene)-carbocycle, -(Ci-Ce alkylene)-heterocycle, carbocycle, or heterocycle, wherein each carbocycle and heterocycle is optionally substituted by 1 or 2 Rn;

[0529] R' and R8are each independently H or -Ci-Ce alkyl; or R7and R8together with the nitrogen atom to which they are attached form a heterocyclyl;

[0530] R9is halogen, cyano, hydroxyl, -NH2, -NH(C1-C6alkyl), -N(Ci-C6 alkyl)2, -COOH, -Ci-C6alkyl, -C2-C6alkenyl, -C2-C6alkynyl, -Ct-C6haloalkyl, -C2-Ce haloalkenyl, -C2-C haloalkynyl, -Ci-C6alkyl-OH, -CONH2, -SH, -S(==O)NH2, -S(O)2NH2, -OCi-Ce alkyl, -OCi-C6haloalkyl, -S(Ci-C6alkyl), -SO(Ci-C6alkyl), -SO2(Ci-C6alkyl), -SO2NR7R8, - S(:;;:NH)(0)(CI-C6 alkyl), -(Ci-Ce alkylene)-carbocyclyl, or -(Ci-Ce. alkylene)-heteroaryl;

[0531] R10is H or -Ci-Ce alkyl;

[0532] each R11is independently halogen, -OH, oxo, -CN, -Ci-Ce alkyl, -Ci-Ce alkyl-OH, -Ci-Cio haloalkyl, -Ci-Cio haloalkyl-OH, -OCi-Ce alkyl, -NR7R8, -Ci-Ce alkyl-NR7R8, -S(Ci-C6alkyl), -SO(Ci-Ce alkyl), -SO2(Ci-Ce alkyl), -SO2NR7R8, -(Ci-Ce alkylene)-carbocycle, -(Cj- Ce alkylene)-heterocycle, carbocycle, or heterocycle;

[0533] m is 0, 1, 2, or 3;

[0534] n is 0, 1, 2, or 3; and

[0535] p is 0, 1, 2, or 3.

[0536] In embodiments of the compounds of Formula (U-E) or a pharmaceutically acceptable NR5T v=oC. 65 k NR5salt, a stereoisomer, or a deuterated form thereof, R2is NRAttorney Docket No.: INMD-216 / 01WO 315953-4442is optionally substituted with 1 or 2 R6.

[0537] In embodiments of the compounds of Formula (II-E) or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, each R5is independently hydrogen, -Ci-Ce alkyl, -(Ci-Cb alkylene)-carbocycle, -(Ci-Ce alkyl ene)-heterocycle, carbocycle, or heterocycle. In embodiments, each R5is independently hydrogen, -Ci-Ca alkyl, or 3- to 6-membered heterocycle. In embodiments, each R5is independently hydrogen, -C1-C3 alkyl, or 4-membered heterocycle. In embodiments, each R5is independently hydrogen, methyl, or oxetanyl. In r-oembodiments, R' is H, methyl or '

[0538] In embodiments of the compounds of Formula (11-E) or a pharmaceutically acceptableAttorney Docket No.: INMD-216 / 01WO 315953-4442

[0539] In embodiments of the compounds of Formula (II -E), or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, A is aryl, In embodiments, A is phenylene.In embodiments,A is or

[0540] In embodiments of the compounds of Formula (II -E), or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, R3is H.

[0541] In embodiments of the compounds of Formula (II -E), or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, each R is independently halogen, -C1-C3 alkyl, or -CN. In embodiments, R4is halogen.

[0542] In embodiments of the compounds of Formula (II -E), or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, m is 0 or 1

[0543] In embodiments, the present disclosure provides a compound of Formula (II-F):

[0544] or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof wherein:Attorney Docket No.: INMD-216 / 01WO 315953-4442

[0546] each R4is independently halogen, -Ci-Cc, alkyl, -Ci-Ce haloalkyl, -S(Ct-C6 alkyl), - SO(Ci-C6 alkyl), -SO2(Ci-C6 alkyl), or -CN;

[0547] R6is -NR7R8, -Ci-C6alkyl-NR" R8, -S(Ci-C6alkyl), -SO(Ci-C6 alkyl), -SO2(Ci-C6 alkyl), -SO2NR7R8, -(Ci-Co alkylene)-carbocycle, -(Ci-Ce alkylene)-heterocycle, carbocycle, or heterocycle, wherein each carbocycle and heterocycle is optionally substituted by 1 or 2 R11;

[0548] R7and R8are each independently H or -Ci-Ce alkyl; or R7and R8together with the nitrogen atom to which they are attached form a heterocyclvl;

[0549] R9is halogen, cyano, hydroxyl, -NH2, -NH(Ci-Cs alkyl), -N(Ci-Ce alkyl)2, -COOH, - Ci-Ce alkyl, -C2-C6 alkenyl, -C2-C6 alkynyl, -Ci-Cs haloalkyl, -C2-Ce haloalkenyl, -C2-Ce haloalkynyl, -CJ-C6alkyl-OH, -CONH2, -SH, -S(=O)NH2, -S(O)2NH2, -OCi-Ce alkyl, -OCi-C6 haloalkyl, -S(Ci-C6 alkyl), -SO(Ci-Ce alkyl), -SO2(Ci-C6 alkyl), -SO2NR7R8, -S(=NH)(O)(C1-C6alkyl), -(Ci-Ce alkylene)-carbocyclyl, or (Ci-Cg alkylene)-heteroaryl;

[0550] R10is H or -Ci-C6alkyl;

[0551] each R” is independently halogen, -OH, oxo, -CN, -Ci-Ce alkyl, -Ci-Ce alkyl-OH, -Ci- C10 haloalkyl, -C1-C10 haloalkyl-OH, -OCi-C6alkyl, -NR7R8, -Ci-Cs alkyl-NR7R8, -S(CI-CG alkyl), -SO(Ci-Ce alkyl), -SO2(Ci-C6 alkyl), -SO2NR7R8, -(Ci-Ce alkylene)-carbocycle, -(Ci-C6 alkylene)-heterocycle, carbocycle, or heterocycle;

[0552] m is 0, 1, 2, or 3; and

[0553] n is 0, I, 2, or 3.

[0554] In embodiments of the compounds of Formula (II-F), or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, R6is at the para position.

[0555] In embodiments of the compounds of Formula (Il-F), or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, R6is -SO2NR7R8or -(Ci-Ce alkylene)-heterocycle, wherein the heterocycle is optionally substituted by 1 or 2 R11. In embodiments, R6is -SO2NR7R8or -(C1-C3 alkylene)-(6-membered heterocycle), wherein the heterocycle is optionally substituted by 1 or 2 R”; R7and R8together with the nitrogen atom to which they are attached form a 3- to 6-membered heterocyclyl; and each Rnis independently halogen or, In embodiments, R6is

[0556] In embodiments, the present disclosure provides a compound of Formula (1I-G):Attorney Docket No.: INMD-216 / 01 WO 315953-4442

[0557] or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof wherein:

[0558] ring A is a fused bicyclic heteroaryl ring;

[0561] each Xlais independently -NR6a-, -O-, -CR12R13-, -C(O)-, -S-, -S(O) - or -S(O)i-;Attorney Docket No.: INMD-216 / 01WO 315953-4442

[0562] each Z1is independently -CH2-, -NR3-, -S-, -S(O) or -S(O)2-;

[0563] R3is H;

[0564] each R4is independently halogen, -C1-C6 alkyl, -Ci-Ce haloalkyl, -S(Ci-C6 alkyl), - SO(Ci-Cc alkyl), -SO2(Ci-C6 alkyl), or -CN;

[0565] each R5is independently hydrogen, -OH, -CN, -C1-C6 alkyl, -Ci-Ce alkyl-OH, -O-(Ci- C6alkyl), -(Ci-C6alkylene)-O-(Ci-C6 alkyl), -(Ci-C6alkylene)-O-(Ci-C6 alkyl)-OH, -(Ci-C6alkylene)-O-(Ci-Cs alkylene)-O-(Ci-Ce alkyl), -(Ci-Cb alkylene)-O-(Ci-C6 alkylene)-O-(Ci- Ce alkyl)-OH, -Ci-Cio haloalkyl, -C1-C10 haloalkyl-OH, -NR7R8, -CONR7R8, -C1-C6 alkyl-NR7R8, -SF5, -S(CI-C6alkyl), -SO(Ci-C6alkyl), -SO2(Ci-C6 alkyl), -SO2NR7R8, -(Ci-Ce alkylene)-carbocycle, -(Ci-Ce alkylene)-heterocycle, carbocycle, or heterocycle, wherein each carbocycle and heterocycle is optionally substituted by 1 or 2 Rn;

[0566] each R6is independently halogen, -OH, oxo, -CN, -Ci-Ce alkyl, -Ci-Ce alkyl-OH, -O-(C1-C6alkyl), -(Ci-Co alkylene)-O-(C]-C6alkyl), -(Ci-C6alkylene)-O-(Ci-C6alkyl)-OH, -(Ci-Ce alkylene)-O-(Ci-C6 alkylene)-O-(Ci-C6 alkyl), -(Ci-Ce alkvlene)-O-(Ci-C6 alkylene)-O-(Ci-C6 alkyl)-OH, -C1-C10 haloalkyl, -C1-C10 haloalkyl-OH, -NR7R8, -CI-CG alkyl-NR7R8, -SF5, -S(CI-CG alkyl), -SO(Ci-C6alkyl), -SO2(Ci-C6alkyl), -SO2NR7R8, -(C1-C6alkylene)-carbocycle, -(CI-CG alkylene)-heterocycle, carbocycle, or heterocycle, wherein each carbocycle and heterocycle is optionally substituted by 1 or 2 R11;

[0567] each R6ais independently H, -CI-CG alkyl, -CI-CG alkyl-OH, -C1-C10 haloalkyl, -C1-C10 haloalkyl-OH, -CI-CG alkyl-NR7R8, -(CI-CG alkylene)-O-(Ci-Cs alkyl), -(Ci-Ce alkylene)-O-(CI-CG alkyl)-OH, -(CI-CG alkylene)-O-(Ci-C6 alkyl)-COOH, -(CI-CG alkylene)-O-(Ci-C6 alkylene)-O-(Ci-Co alkyl), -(C1-C6alkylene)-O-(Cj-C6 alkylene)-NR7R8, -(CI-CG alkylene)-O-(Ci-Cs alkylene)-C(O)NR7R8, -(Ci-Cs alkylene)-O-(Ci-Cs alkylene)-NR7C(O)-(Ci-C6 alkyl), - (Ci-Cr, alkylene)-O-(Ci-C6 alkylene)-C(O)NR7-(Ci-C6 alkylene)-O-(Cj-C6 alkyl), -(CI-CG alkylene)-O-(Ci-Cs alkylene)-NR'C(O)-(Ci-C6 alkylene)-O-(Ci-C6 alkyl), -(Ci-Cs alkylene)-O-(Ci-C6 alkylene)-C(O)NR7-(Ct-C6 alkylene)-O-(Ci-C6 alkylene)-NR'-aryl, -(Ci-Cc, alkylene)-O-(Ci-C6 alkylene)-NR7C(O)-(Ci-C6 alkylene)-O-(Ci-C6 alkylene)-NR7-aryl, -(Ci-Ce alkylene)-NR7R8, -(Ci-Cc, alkylene)-NR7-(Ci-Ce alkyl)-OH, -(Ci-Cs alkylene)-NR7-(Ci-C6 alkyl)-O-(Ci-C6alkyl), -(Ci-C6alkylene)-NR7-(Ci-C6 alkylene)-NR7R8, -(Ci-Ce alkylene)- heterocycle, or -(C1-C6 alkylene)-heteroaryl;

[0568] R7and R8are each independently H or -Ci-Cc, alkyl; or R7and R8together with the nitrogen atom to which they are attached form a heterocyclyl;

[0569] R9is halogen, cyano, hydroxyl, -NHz, -NH(Ci-C6 alkyl), -N(Ci-C6 alkyl)2, -COOH, - Ci-Ce alkyl, -C2-CG alkenyl, -C2-CG alkynyl, -CI-CG haloalkyl, -C2-C0 haloalkenyl, -C2-C6Attorney Docket No.: INMD-216 / 01WO 315953-4442haloalkynyl, -Ci-C6alkyl-OH, -CONH2, -SH, -S(=O)NH2, -S(O)2NH2, -OCi-Ce alkyl, -OCi-Cb haloalkyl, -S(Ci-Cb alkyl), -SO(Ci-C6 alkyl), -SO2(Ci-C alkyl), -SO2NR R8, -S(=NH)(O)(Ci-C alkyl), -(Ci-Ce alkylene)-carbocyclyl, or-(C]-Ce alkylene)-heteroaryl;

[0570] R10is H or -Ci-Cc alkyl;

[0571] each Rnis independently halogen, -OH, oxo, -CN, -C1-C6 alkyl, -Ci-Ce alkyl-OH, -Ci- C10 haloalkyl, -C1-C10 haloalkyl-OH, -OCi-Cs alkyl, -NR7R8, -Ci-C6alkyl-NR7R8, -S(Ci-Co alkyl), -SO(Ci-C6 alkyl), -SO2(Ci-C6 alkyl), -SO2NR7R8, -(Ci-Ce alkylene)-carbocycle, -(Ci- Cb alkylene)-heterocycle, carbocycle, or heterocycle;

[0572] R12and R13are each independently selected from H, deuterium, halogen, or -Ci-Ce alkyl;

[0573] g is 0, I, 2, or 3;

[0574] m is 0, 1, 2, or 3;

[0575] n is 0, 1, 2, or 3; and

[0576] p is 0, 1, 2, or 3.

[0577] In embodiments of the compounds of Formula (II-G) or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, A is a 5,6-fused heteroaryl, 6,5-fused heteroaryl, or 6,6-fused heteroaryl. In embodiments, ring A contains one or two heteroatoms selected from N, S, or O.

[0578] In embodiments of the compounds of Formula (II-G) or a pharmaceutically acceptableAttorney Docket No.: INMD-216 / 01WO 315953-4442(R )m. In embodiments, m is 1 or 1. In embodiments, R4is halogen or -Ci-Ce alkyl. In embodiments, R4is halogen. In embodiments, R4is F.

[0579] In embodiments of the compounds of Formula (II-G) or a pharmaceutically acceptableconnectivity to R2.

[0580] In embodiments of the compounds of Formula (II-G) or a phar ceutically acceptableR6ais independently H, -Ci-Ce alkyl, -Ci-Cio haloalkyl, -C1-C6alkyl-NR7R8, -(Ci-Ce alkylene)- 0-(CJ-C6 alkyl)-OH, -(Ci-Cs alkylene)-O-(Ci-C6 alkylene)-O-(Ci-C6 alkyl), -(Ci-Ce alkylene)- O-(CJ-C6alkylene)-NR7R8, -(Ci-Cf, alkylene)-NR7-(Ci-C6 alkyl)-OH, -(Ci-C6alkylene)-NR7- (Ci-Cb alkyl)-O-(Ci-C6 alkyl), -(Ci-Ce alkylene)-heterocycle, or -(Ci-Ce alkylene)-heteroaryl. In embodiments, each R6ais independently H, -C1-C3 alkyl, -C1-C3 alkyl-NR7R8, -(C1-C3 alkylene)-NR'-(Ci-C3 alkylene)-O-(Ci-C3 alkyl), or -(C1-C3 alkylene)-heterocycle. InAttorney Docket No.: INMD-216 / 01WO 315953-4442embodiments, each R6is independently halogen, -OH, -Ci-Cc, alkyl, -O-(Ci-Ce alkyl), -Ci-Cio haloalkyl, -NR7R8, -S(Ci-C6 alkyl), -SO(Ci-C6 alkyl), or -SO2(Ci-C6 alkyl). In embodiments, R6is halogen or -C1-C6 alkyl. In embodiments, R3is halogen or -C1-C6 alkyl.In embodiments of the compounds of Formula (II-G) or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, each R6is independently halogen, -OH, -CN, -Ci-C6alkyl, -Ci-C6alkyl-OH, -O-(Ci-Cs alkyl), -Ci-Cio haloalkyl, -Ci-Cio haloalkyl-OH, - NR7R8, -C1-C6 alkyl-NR7R8, -SF5, -S(Ci-C6 alkyl), -S0(Ci-Ce alkyl), -SO2(Ci-C6alkyl), - SO2NR7R8, -(C1-C6 alkylene)-carbocycle, -(Ci-Ce alkylene)-heterocycle, carbocycle, or heterocycle, wherein each carbocycle and heterocycle is optionally substituted by 1 or 2 R11. In some embodiments, R° is -SO2NH2, -SO2NH(CI-C6 alkyl), or -SO2N(CI-C6 alkyl)2. In embodiments, each R6is independently halogen, -Ci-Cs alkyl, or heterocycle, wherein each heterocycle is optionally substituted by 1 or 2 R11. In embodiments, each R6is independently halogen, -C1-C6 alkyl, or 6-membered heterocycle, wherein each heterocycle is optionally substituted by 1 or 2 R11. In embodiments, each R6is independently halogen, -Ci-Ce alkyl, or 6-membered heterocycle containing 1 or 2 heteroatoms selected from N, S, or O, wherein each heterocycle is optionally substituted by 1 or 2 R11. In embodiments, each RbisI NHindependently halogen, -Ci-Gs alkyl, or heterocycle, wherein the heterocycle isorRIn embodiments, each Rnis independently halogen, -OH, oxo, -CN, -Ci-Cs alkyl, -Cj-Ce alkyl-OH, -C1-C10 haloalkyl, -C1-C10 haloalkyl-OH, -OCi-C6alkyl, -NR7R8, - Ci-C6alkyl-NR7R8, -S(Ci-C6alkyl), -SO(Ci-C6alkyl), -S02(Ci-Cs alkyl), or -SO2NR7R8. In some embodiments, RJ Jis -SO2NH2, -SO2NH(CI-C6 alkyl), or -SO2N(CJ-CS alkyl)2. In embodiments, each R11is independently halogen or -C1-C3 alkyl. In embodiments, R11is methyl.

[0581] In embodiments of the compounds of Formula (II-G) or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, R6ais H, -C1-C3 alkyl, -C1-C3 alkyl-NR7R8, -(CJ-C3alkylene)-NR7-(Ci-C3 alkylene)-0-(Cj-C3 alkyl), or -(C1-C3 alkylene)-heterocycle; and R7and R8are each independently H or -C1-C6 alkyl. In embodiments, Rbais H, methyl, ethyl, -C1-C3 alkyl-NH2, -(C1-C3 alkylene)-N(CH3)-(Ci-C3 alkyl)-0-(Ci-C alkyl), or -(C1-C3 alkylene)-heterocycle, wherein the heterocycle is 6-membered heterocycle. In embodiments, R6ais H, methyl, ethyl, -C1-C3 alkyl-NH2, -(C1-C3 alkylene)-N(CH3)-(Ci-C.3 alkyl)-O-(Ci-C3Attorney Docket No.: INMD-216 / 01WO 315953-4442alkyl), or -(C1-C3 alkylene)-heterocycle, wherein the heterocycle is 6-membered heterocycle containing 1 or 2 heteroatoms selected from N, S, or O. In embodiments, R6ais H, methyl, ethyl, -C1-C3 alkyl-N b, -(CJ-CS alkylene)-N(CH3)-(Ci-C3 alkyl)-O-(Ci-C'3 alkyl), or -(C1-C3alkylene)-heterocycle, wherein the heterocycle is

[0582] In embodiments of the compounds of Formula (II-G) or a pharmaceutically acceptablesalt, a stereoisomer, or a deuterated form thereof, R2isR5In embodiments, each R6is independently halogen, -OH, -Ci-Cs alkyl, -O-(Ci- C6alkyl), -C1-C10 haloalkyl, -NR7R8, -S(Ci-C6alkyl), -SO(Ci-C6alkyl), -SO2(Ci-C6 alkyl), carbocycle, or heterocycle, wherein each carbocycle and heterocycle is optionally substituted by 1 or 2 R11. In embodiments, each R6is independently halogen, -C1-C3 alkyl, -C1-C3 haloalkyl, or a 5- or 6-membered heterocycle, wherein each heterocycle is optionally substituted by 1 or 2 R11. In embodiments, each R6is independently halogen, -C1-C3 alkyl or 6-membered heterocycle, wherein each heterocycle is optionally substituted by 1 or 2 R11. In embodiments, Ruis independently halogen, -OH, -Ci-Ce alkyl, -NR7R8, -S(Ci-C6 alkyl), - SO(Ci-C alkyl), or -SO2(Ci-C6 alkyl) In embodiments, R, Jis independently halogen, -OH, or -C1-C3 alkyl. In embodiments, R11is methyl. In embodiments, each R6is independently halogen, -OH, -Ci-Ce alkyl, -O-(Ci-Cs alkyl), -C1-C10 haloalkyl, -NR7R8, -S(Ci-C6 alkyl), - SO(Ci-Ce alkyl), or -SOsfCi-Ce alkyl). In embodiments, R6is halogen or -Ci-Ce alkyl. In embodiments, R’ is halogen or -Ci-Ce alkyl.Attorney Docket No.: INMD-216 / 01WO 315953-4442

[0583] In embodiments of the compounds of Formula (II-G) or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, R2is

[0584] In embodiments, the present disclosure provides a compound of Formula (1I-H):(Il-H),

[0585] or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereofAttorney Docket No.: INMD-216 / 01WO 315953-4442

[0587] R2is

[0588] each R4is independently halogen, -C1-C6 alkyl, -Ci-Ce haloalkyl, -S(Ci-C6 alkyl), - SO(Ci-Ce alkyl), -SO2(Ci-Ce alkyl), or -CN;

[0589] R5is H, -Ci-C6alkyl, -Ci-Cio haloalkyl, or -Ci-Ce alkyl-NR7R8;

[0590] each R6is independently halogen, -OH, -CN, -Ci-Ce alkyl, -C1-C6alkyl-OH, -O-(Ci-Ce alkyl), -Ci-Cio haloalkyl, -Ci-Cio haloalkyl-OH, -NR7R8, -Ci-Ce alkyl-NR7R8, -S(Ci-C6 alkyl), -SO(Ci-C6alkyl), -SO2(Ci-C6alkyl), or -SO2NR7R8;

[0591] R6ais H, -C1-C6 alkyl, -Ci-Cio haloalkyl, or -Ci-C6alkyl-NR7R8;

[0592] R7and R8are each independently H or -Ci-Ce alkyl; or R7and R8together with the nitrogen atom to which they are attached form a heterocyclyl;

[0593] R9is halogen, cyano, hydroxyl, -NH2, -NH / Ci-Cs alkyl), -N(Ci-Ce alkyl)2, -COOH, - Ci-C.6 alkyl, -Ci-Ce haloalkyl, -C1-C6alkyl-OH, -CONH2, -SH, -S(===O)NH2, -S(O)2NEh, -OCi-Ce alkyl, -OC1-C.5 haloalkyl, -S(Ci-Ce alkyl), -SO(Ci-C6 alkyl), -SO2(Ci-C6alkyl), -SO2NR7R8, or -S(=NH)(O)(C1-C6alkyl);

[0594] R10is H or -Ci-C6alkyl,

[0595] m is 0, 1 or 2;

[0596] n is 0 or 1; and

[0597] p is 0, 1, 2, or 3.

[0598] In embodiments of the compounds of Formula (I I -H), or a pharmaceutically acceptableNsalt, a stereoisomer, or a deuterated form thereof,R1is

[0599] In embodiments of the compounds of Formula (II-H), or a pharmaceutically acceptablesalt, a stereoisomer, or a deuterated form thereof, R2isN'Attorney Docket No.: INMD-216 / 01WO 315953-4442

[0600] In embodiments of the compounds of Formula (II-H), or a pharmaceutically acceptablesalt, a stereoisomer, or a deuterated form thereof, R1isand R2isN'

[0601] In embodiments of the compounds of Formula (II-H), or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, each R4is halogen, -Ci-Cs alkyl, or -Ci-Ce haloalkyl. In embodiments, each R4is halogen. In embodiments, R4is F. In embodiments, n is 1 and R4is F In embodiments, m is 0,

[0602] In embodiments of the compounds of Formula (II-H), or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, each R6is independently halogen, -OH, -CN, -Ct-Ce alkyl, -O-(Ci-C6 alkyl), or-Ci-Cio haloalkyl In embodiments, each R is independently -Ci-Co alkyl. In embodiments, each R6is independently -C1-C3 alkyl. In embodiments, each R6is independently methyl.

[0603] In embodiments of the compounds of Formula (II-H), or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, R6ais hydrogen, methyl, ethyl, or propyl.

[0604] In embodiments of the compounds of Formula (A'), (A), (II), (II-A), (II-B), (11-C), (11-D), (II-E), (II-F), (II-G), or (II-H), or a pharm ceutically acceptable salt, a stereoisomer, or a deuterated form thereof, R9is halogen, hydroxyl, -Ci-Cs alkyl, -C2-C6 alkenyl, -C2-C6 alkynyl, -Ci-Cs haloalkyl, -C2-C6 haloalkenyl, -C2-C6 baloalkynyl, -OCi-Cs lkyl, or -OCi-Ce haloalkyl In embodiments, R9is halogen, hydroxyl, -C1-C3 alkyl, -C1-C3 haloalkyl, -OC1-C3 alkyl, or -OC1-C3 haloalkyl. In embodiments, R9is halogen, hydroxyl, methoxy, ethoxy, fluoromethyl, or difluoromethyl.

[0605] In embodiments of the compounds of Formula (A'), (A), (II), (II-A), (II-B), (II-C), (II- D), (II-D-1), (Il-E), (II-F), (II-G), or (II-H), or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, n is 0.

[0606] In embodiments of the compounds of Formula (A'), (A), (II), (II-A), (II-B), (II-C), (II-D), (II-D-1), (II-E), (II-F), (II-G), or (II-H), or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, RiOis II or methyl. In embodiments, R10is H.

[0607] In embodiments of the compounds of Formula ( / A), (A ), (II), (II-A), (II-B), (II-C ), (II- D), (II-E), (II-F), or (II-G), or a pharmaceutically acceptable salt, a stereoisomer, or aAttorney Docket No.: INMD-216 / 01WO 315953-4442

[0608] In embodiments of the compounds of Formula (A'), (A), (I), (I- A), (I-D), (I-E), (II), (II-A), (II-D), (II-D-1), (ILE), or (III), or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, A is aryl or heteroaryl. In embodiments, A is a monocyclic or a bicyclic ring.

[0609] In embodiments of the compounds of Formula (A'), (A), (I), (LA), (I-D), (I-E), (II), (II-A), (ILD), (II-D-1), (ILE), or (III), or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, A is aryl or heteroaryl. In embodiments, A is a monocyclic or bicyclic heteroaryl.

[0610] In embodiments of the compounds of Formula (A'), (A), (I), (LA), (I-D), (I-E), (II), (II-A), (ILD), (II-D-1), (ILE), or (III), or a pharmaceutically acceptable salt, a stereoisomer, or adeuterated form thereof, A is a phenyl ring In embodiments,A is (R)m. in embodiments, m is 1 or 2 and R4is each independently a halogen. In embodiments, A is

[0611] In embodiments of the compounds of Formula (A'), (A), (I), (LA), (I-D), (I-E), (II), (II-A), (ILD), (II-D-1), (ILE), or (III), or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, A is a 5-membered heteroaryl, 6-membered heteroaryl, 5,6-fused heteroaryl, 6,5-fused heteroaryl, or 6,6-fused heteroaryl. In embodiments, ring A contains oneAttorney Docket No.: INMD-216 / 01WO 315953-4442om. In some embodiments, ring A is (R

[0612] In embodiments of the compounds of Formula (A'), (A), (I), (I-A), (I-D), (I-E), (II), (II-A), (II-D), (II-D-1), (II-E), or (III), or a pharmaceutically acceptable salt, a stereoisomer, or a

[0613] In embodiments of the compounds of Formula (A'), (A), (I), (I-A), (I-D), (I-E), (II), (II- A), (II-D), (II-D-1), (II-E), or (III), or a pharmaceutically acceptable salt, a stereoisomer, or aembodiments,Attorney Docket No.: INMD-216 / 01WO 315953-4442, wherein * denotes connectivity to R2. In embodiments,or, wherein * denotes connectivity to R2.

[0614] In embodiments of the compounds of Formula (I-A), (I-B), (II-A), or (II-B), or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, Xiais -NH-, - NCII3-, -O-, or -CH2- In embodiments, Xlais -Nil- or -O-.

[0615] In embodiments of the compounds of Formula (A'), (A), (I), or (II), or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, R2is a monocyclic, bicyclic, or tricyclic ring, wherein R2is optionally substituted with 1, 2, 3, or 4 R6. In one embodiment, R2is a monocyclic carbocycle, monocyclic aryl, monocyclic heterocycle, or monocyclic heteroaryl, wherein R2is optionally substituted with 1, 2, 3, or 4 R6In one embodiment, R2is phenyl, optionally substituted with 1, 2, 3, or 4 R6.

[0616] In embodiments of the compounds of Formula (A'), (A), (I), or (II), or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, R2is aryl, wherein R2is optionally substituted with 1, 2, 3, or 4 R6. In embodiments, R2is phenyl, wherein R2is optionally substituted with 1, 2, 3, or 4 R6.

[0617] In embodiments of the compounds of Formula (A'), (A), (I), or (II), or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, R2is a bicyclic carbocycle, bicyclic aryl, bicyclic heterocycle, or bicyclic heteroaryl, wherein R2is optionally substituted with I, 2, 3, or 4 R6In one embodiment, R2is a fused ring or a spiral ring.

[0618] In embodiments of the compounds of Formula (A'), (A), (I), or (II), or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, R2is tricyclic ring, optionally substituted with I, 2, 3, or 4 R6.

[0619] In embodiments of the compounds of Formula (A'), (A), (I), (I-A), (I-B(I-G), (II), (II-A), (II-B), or (Il-G),or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated formN Nb6a b6ais 0 or 1.

[0620] In embodiments of the compounds of Formula (A'), (A), (I), (I-A), (I-B), (I-G), (II), (II-A), (II-B), or (II-G), or a pharmaceutically acceptable salt, a stereoisomer, or a deuteratedAttorney Docket No.: INMD-216 / 01WO 315953-4442

[0621] In embodiments of the compounds of Formula (A'), (A), (I), (1-A), (I-B), (I-G), (II), (II-A), (II-B), or (II-G), or a pharmaceutically acceptable salt, a stereoisomer, or a deuteratedhSaform thereof,R2is 'p. In embodiments, Xlais -O-.Attorney Docket No.: INMD-216 / 01WO 315953-4442

[0622] In embodiments of the compounds of Formula (A'), (A), (I), (I-A), (I-B), (I-G), (II), (II-A), (II-B), or (II-G), or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof,

[0623] R2is

[0624] Xlais ■()■■ or -CR12R13-;

[0625] R6ais -Ci-C6alkyl, -(Ci-Ce alkyl ene)-O-(Ci-C6alkyl), or -Ci-C6alkyl-NR7R8;

[0626] R7and R8are each independently Ci-6 alkyl, or -(Ci-C6 alkylene)-O-(Ci-C6 alkyl);

[0627] R11and R12are each independently -Ci-Ce alkyl; and

[0628] p is O.

[0629] In embodiments of the compounds of Formula (A'), (A), (I-D), (I-G), (II-D), (II-D-1), (II-D-2), (II-D-3), (II-D-4), ( II-D-4'), (II-D-4"), or (II-G), or a pharmaceutically acceptable salt,Na stereoisomer, or a deuterated form thereof, R2is( )P jnembodiments, R2is. In embodiments, R6is halogen, -OH, -CN, -C1-C6 alkyl, -C1-C10 haloalkyl, - CONH2, carbocycle, or heterocycle, wherein each carbocycle and heterocycle is optionally substituted by 1 or 2 R11. In embodiments, R6is halogen, -Ci-Cs alley!, -C1-C10 haloalkyl, carbocycle, or heterocycle, wherein each carbocycle and heterocycle is optionally substituted by 1 or 2 R11. In embodiments, R6is halogen or -C1-C3 alkyl. In embodiments, R2is

[0630] In embodiments of the compounds of Formula (A'), (A), (I-D), (I-G), (II-D), (II-D-1), (II-D-2), (II-D-3), (II-D-4), (II-D-4'), (II-D-4"), or (II-G), or a pharmaceutically acceptable salt,Attorney Docket No.: INMD-216 / 01WO 315953-4442R5Kla stereoisomer, or a deuterated form thereof,R2is (R6)P embodiments, R5is hydrogen, methyl, or -CONH2. In embodiments, p is 0 or 1. In embodiments, R6is oxo

[0631] In embodiments of the compounds of Formula (A'), (A), (I-D), (I-G), (II-D), (II-D-1), (II-D-2), (II-D-3), (II-D-4), (II-D-4'), (II-D-4”), or (II-G), or a pharmaceutically acceptable salt,

[0632] In embodiments of the compounds of Formula (A'), (A), (I-D), (I-G), (II-D), (II-D-1), (II-D-2), (II-D-3), (II-D-4), (II-D-4'), (II-D-4”), or (II-G), or a pharmaceutically acceptable salt,R5a stereoisomer, or a deuterated form thereof, R isis 1 or 2. In embodiments, R6is each independently halogen, -OH, oxo, -CN, -Ci-Ce alkyl, or -CONH2 In embodiments, R6is each independently -OH or oxo. In embodiments, R6is eachAttorney Docket No.: INMD-216 / 01 WO 315953-4442NN 'S independently -OH. In embodiments, R2is orO

[0633] In embodiments of the compounds of Formula (A'), (A), (1-D), (I-G), (II-D), (II-D-1), (II-D-2), (II-D-3), (II-D-4), (II-D-4'), (II-D-4"), or (II-G), or a pharmaceutically acceptable salt,a stereoisomer, or a deuterated form thereof, R2In embodiments, n is 1 or 2. In embodiments, R6is each independently halogen, -OH, oxo, -CN, -Ci-Cf, alkyl, or -CONH2. In embodiments, RDis each independently -OH, oxo, -methyl, or -CONH2 In embodiments, R6is each independently -OH,H-methyl, or -CONH2 In embodiments, R2isAttorney Docket No.: INMD-216 / 01WO 315953-4442N' H. In embodiments, R" is

[0634] In embodiments of the compounds of Formula (A'), (A), (I-D), (I-G), (II-D), (II-D-1), (II-D-2), (II-D-3), (II-D-4), (II-D-4'), (II-D-4"), or (I I-G), or a pharmaceutically acceptable salt,< R6)PNa stereoisomer, or a deuterated form thereof,R2isH. In embodiments, p is 1 or 2. In embodiments, R6is halogen, -OH, -CN, -Ci-Ce alkyl, -Ci-Cio haloalkyl, -CONH2, carbocycle, or heterocycle, wherein each carbocycle and heterocycle is optionally substituted by 1 or 2 Rn. In embodiments, R6is halogen, -Ci-Ce alkyl, -C1-C10 haloalkyl, carbocycle, or heterocycle, wherein each carbocycle and heterocycle is optionally substituted by 1 or 2 R11. In embodiments, R6is halogen, -C1-C3 alkyl or 6-membered heterocycle optionally substituted by 1 or 2 Rn. In embodiments, R6is halogen, methyl or piperidine optionally substituted by 1 or 2 R11. In embodiments, R11is halogen, -OH, -Ci-Ce alkyl, -NR7R8, -S(Ct-C6 alkyl), -SO(Ci-C alkyl), or -SO2(Ci-Cs alkyl). In embodiments, R11is -C1-C3 alkyl. In embodiments, R11is FNmethyl. In embodiments, R2is. In embodiments, R2is or

[0635] In embodiments of the compounds of Formula (A'), (A), (I-D), (I-G), (II-D), (II-D-1), (II-D-2), (II-D-3), (II-D-4), (II-D-4'), (II-D-4"), or (II-G), or a pharmaceutically acceptable salt,(R51PNa stereoisomer, or a deuterated form thereof,R2isH. In embodiments, R2isAttorney Docket No.: INMD-216 / 01WO 315953-4442'^sxr^Nr rx'n. In embodiments, R6is -Ci-Ce alkyl, -Ci-Cio haloalkyl, carbocycle, or heterocycle, wherein each carbocycle and heterocycle is optionally substituted by 1 or 2 Rn. In embodiments, R6is -C1-C3 alkyl or 6-membered heterocycle optionally substituted by 1 or 2 Rn. In embodiments, R6is methyl or piperidine optionally substituted by I or 2 R11. In embodiments, R11is halogen, -OH, -C1-C6 alkyl, -NR7R8, -S(Ci-C6 alkyl), -SO(Ci-C'6 alkyl), or -SO2(Ci-Ce alkyl). In embodiments, R11is -C1-C3 alkyl. In embodiments, R11is methyl. InL jT -'Nembodiments, R2is

[0636] In embodiments of the compounds of Formula (A'), (A), (I-D), (I-G), (II -D), (II-D-1), (Il-D-2), (Il-D-3), (II-D-4), (II-D-4'), (ILD-4"), or (I I-G), or a pharmaceutically acceptable salt,a stereoisomer, or a deuterated form thereof, R2is. In embodiments, R2isIn embodiments, R6is halogen, -OH, -CN, -Ci-Ce alkyl, -C1-C10 haloalkyl, - CONH2, carbocycle, or heterocycle, wherein each carbocycle and heterocycle is optionally substituted by 1 or 2 R11. In embodiments, R6is halogen, -Ci-Ce alkyl, -C1-C10 haloalkyl, carbocycle, or heterocycle, wherein each carbocycle and heterocycle is optionally substituted by 1 or 2 R11. In embodiments, R6is halogen or -C1-C3 alkyl. In embodiments, R2is

[0637] In embodiments of the compounds of Formula (A'), (A), (I), (LA), (I-B), (I-C), (I-D), (I-E), (I-F), (I-G), (II), (ILA), (ILB), (I I-C), (ILD), (II-D-1), (II-D-2), (ILD-3), (II-D-4), (II-D- 4'), (II-D-4"), (II-E), (ILF), (II-G), or (II-H), or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, each R4is independently halogen, -C1-C3 alkyl, or -CN. In embodiments, at least one R4is a halogen. In embodiments, m is 0 or 1.

[0638] In embodiments of the compounds of Formula (A'), (A), (I), (I-A), (LC), (I-D), (LE), (LG), (II), (ILA), (ILC), (ILD), (ILD-1), (ILD-2), (ILD-3), (ILD-4), (ILD-4'), (II-D-4"), (II-E), or (II-G), or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof,Attorney Docket No.: INMD-216 / 01WO 315953-4442R5is hydrogen, -CI-CG alkyl, or -CONR'R8, wherein R7and R8are each independently hydrogen or Ci-4 alkyl. In embodiments, R5is hydrogen, methyl, or -CONH2.

[0639] In embodiments of the compounds of Formula (A'), (A), (1), (I-A), (LB), (1-C), (1-D), (I-E), (I-G), (II), (ILA), (II-B), (II-C), (II-D), (ILD-1), (ILD-2), (II-D-3), (II-D-4), (ILD-4'), ( II-D-4"), (II-E), or (II-G), or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, each R6is independently halogen, -OH, -CN -C1-C3 alkyl, -C1-C3 haloalkyl, - S(Ci-C3alkyl), -SO(Ci-C3alkyl), -SO2(Ci-C3alkyl), -SO2N(CI-C3alkyl), -SO2NR7R8, or 4-6 membered heterocycle. In some embodiments, R6is independently halogen, -OH, -CN, - 0 0

[0640] embodiments of the compounds of Formula (A1), (A), (I), (I-A), (LB), (II), (ILA), or (II-B), or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, R6ais -C1-C6 alkyl, -CH2CH2OCH2CH3, -CH2CH2OCH2CH2CH3, -CH2CH2OCH2CH2CH2CH3, -CH2CH2OCH2CH2OH, -CH2CH2OCH2CH2OCH3, -CH2CH2N(CH3)2, or \ In embodiments, R5is -Ci-Cs alkyl or -CH2CH2OCH2CH3.

[0641] In embodiments of the compounds of Formula (I-A), (I-B), (1-D), (I-E), (I-F), (I-G), (II-A), (II-B), (II-D), (II-E), (ILF), or (II-G), or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, R12and R13are each independently hydrogen, halogen, or -CJ-C4 alkyl.

[0642] In embodiments of the compounds of Formula (A'), (A), (I), (I-A), (I-B), (I-C), (I-D), (I-E), (I-F), (I-G), (II), (II-A), (II-B), (II-C), (II-D), (II-E), (ILF), (II-G), or (II-H), or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, n is 0 or 1.

[0643] In embodiments, the present disclosure provides a compound of Formula (III):

[0644] or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof wherein:Attorney Docket No.: INMD-216 / 01WO 315953-4442Attorney Docket No.: INMD-216 / 01WO 315953-4442

[0646] R1is

[0647] each R4is independently halogen, -Ci-Cs alkyl, -Ci-Ce haloalkyl, -SfCi-Co alkyl), -SO(Ct-Ce alkyl), -SO2(Ci-C6alkyl), or -CN;

[0648] R6are each independently halogen, -OH, oxo, -CN, -Ci-Ce alkyl, -Ci- alkyl-OH, -(Ci-Cs alkylene)-O-(Ci-Ce alkyl), -(Ci-Ce alkylene)-O-(Ci-Ce alkyl)-OH, -(Ci-Ce alkylene)-O-(Ci-Ce alkylene)-O-(Ci-Ce alkyl), -(Ci-Ce alkylene)-O-(Ci-Ce alkylene)-O-(Ci-Ce alkyl)-OH, -Ci-Cio haloalkyl, -Ci-Cio haloalkyl-OH, -NR7R8, -Ci-Ce alkyl-NR7R8, -S(Ci-Ce alkyl), - SO(Ci-Ce alkyl), -SO2(Ci-Ce alkyl), - -SO2NR7R8, -(Ci-C6alkylene)-carbocycle, -(Ci-C6alkylene)-heterocycle, carbocycle, or heterocycle, wherein each carbocycle and heterocycle is optionally substituted by 1 or 2 R";

[0649] R7and R8are each independently H or -Ci-Ce alkyl; or R' and R8together with the nitrogen atom to which they are attached form a heterocyclyl;

[0650] R9and R9aare each independently halogen, cyano, hydroxyl, -NH2, -NH(Ci-Ce alkyl), -N(Ci-C6 alkyl)2, -COOH, -Ci-Ce alkyl, -Ci-Ce alkenyl, -C2-Ce alkynyl, -Ci-Ce haloalkyl, -C2-C6haloalkenyl, -C2-C6haloalkynyl, -Ci-Ce alkyl-OH, -CONH2, -SH, -S(=O)NH2, -S(O)2NH2, -OC1-C6 alkyl, -OCi-Ce haloalkyl, -S(Ci-Ce alkyl), -SO(Ci-Ce alkyl), -SO2(Ci-Ce alkyl), - SO2NR7R8, -S(=NH)(O)(C1-C6alkyl), -(Ci-Ce alkylene)-carbocyclyl, or -(Ci-Ce alkylene)-heteroaryl;

[0651] R10is H or -Ci-Cs alkyl;

[0652] each R11is independently halogen, -OH, oxo, -CN, -Ci-Cs alkyl, -Ci-Ce. alkyl-OH, -Ci-Cio haloalkyl, -Ci-Cio haloalkyl-OH, -OCi-Ce alkyl, -NR7R8, -Ci-Cs alkyl-NR7R8, -S(Ci-C6alkyl), -SO(Ci-C6 alkyl), -SO2(Ci-C6alkyl), -SO2NR7R8, -(Ci-C6alkylene)-carbocycle, -(Ci- Ce alkylene [-heterocycle, carbocycle, or heterocycle;

[0653] m is 0, 1, 2, or 3; and

[0654] n is O, 1, 2, or 3;

[0655] p is 0, 1, 2, or 3.Attorney Docket No.: INMD-216 / 01WO 315953-4442

[0656] In embodiments of the compounds of Formula (III), or a pharmaceutically acceptablesalt, a stereoisomer, or a deuterated form thereof, R1is

[0657] In embodiments, of the compounds of Formula (III), or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, each R4is independently halogen, -C1-C3 alkyl, or -CN. In embodiments, R4is halogen. In embodiments, R4is F.

[0658] In embodiments, of the compounds of Formula (III), or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, each R6is independently halogen, -OH, -CN -C1-C3 alkyl, -C1-C3 haloalkyl, -S(Ci-C3alkyl), -SO(Ci-C3alkyl), -SO2(Ci-C3 alkyl), - SO2N(CI-C3 alkyl), -SO2NR7Rs, or 4-6 membered heterocycle. In embodiments, each R6is independently halogen, -C1-C3 alkyl, -CN, or 4-membered heterocycle. In embodiments, each r~oR6is independently halogen, -C1-C3 alkyl, -CN,', or '. In embodiments, each R6is independently halogen or -C1-C3 alkyl. In embodiments, each R6is independently methyl.

[0659] In embodiments, of the compounds of Formula (III), or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, m is 0 or 1. In embodiments, m is 1.

[0660] In embodiments, of the compounds of Formula (III), or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, p is 0 or 1.Attorney Docket No.: INMD-216 / 01WO 315953-4442

[0661] In embodiments of the compounds of Formula (III), or a pharmaceutically acceptable

[0662] In embodiments of the compounds of Formula (III), or a pharm ceutically acceptableAttorney Docket No.: INMD-216 / 01WO 315953-4442

[0663] In embodiments of the compounds of Formula (III), or a pharmaceutically acceptablesalt, a stereoisomer, or a deuterated form thereof,Y is

[0664] In embodiments of the compounds of Formula (III), or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, m is 0 or 1 and p is 0, 1, or 2, In embodiments, R4is halogen. In embodiments, R4is F. In embodiments, R6is halogen, -CN, or heterocycle wherein the heterocycle is optionally substituted by 1 or 2 R11. In embodiments, R6is halogen,-CN, oxetane, or pyrrolidine. In embodiments, R? is F, -CN,or, optionally substituted by 1 or2 Ru.

[0665] In embodiments, the present disclosure provides a compound of Formula (B ):Attorney Docket No.: INMD-216 / 01WO 315953-4442R15PR(R4)m

[0666] or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, wherein:

[0667] ring A is a carbocyclyl, aryl, heterocyclyl, or heteroaryl ring;

[0668] R2is a carbocycle, aryl, heterocycle, or heteroaryl ring, wherein each R2is optionally substituted with 1, 2, 3, or 4 R6;

[0669] R3is H; or R together with one of R6can form a tricyclic, tetracyclic, or pentacyclic ring optionally containing 1, 2, or 3 heteroatoms selected from N, S, or O, wherein the tricyclic, tetracyclic, or pentacyclic ring is optionally substituted with 1, 2, 3, or 4 R5,

[0670] each R4is independently halogen, -Ci-Ci, alkyl, -C1-C6 haloalkyl, -S(Ci-Cs alkyl), - SO(C1-C6alkyl), -SO2(Ci-C6alkyl), or -CN;

[0671] R3and R6are each independently halogen, -OH, oxo, -CN, -Ci-Ce alkyl, -C1-C6alkyl-OH, -(Ci-C6alkylene)-O-(Ci-C6 alkyl), -(Ci-Ce alkylene)-O-(Ci-Ce alkyl)-OH, -(Ci-Ce alkylene)-O-(Ci-C6 alkylene)-O-(Ci-C6 alkyl), -(Ci-Ce alkylene)-O-(Ci-C6 alkylene)-O-(Ci-Ce alkyl)-OH, -Ci-Cio haloalkyl, -Ci-Cio haloalkyl-OH, -NR7R8, -Ci-Ce alkyl-NR7R8, -S(Ci-Ce alkyl), -SO(Ci-Ce alkyl), -SOiiCi-Ce alkyl), -SO2NR7R8, -(Ci-Ce alkylene)-carbocycle, - (Ci-Cr, alkylene)-heterocycle, carbocycle, or heterocycle, wherein each carbocycle and heterocycle is optionally substituted by 1 or 2 R11;

[0672] R7and R8are each independently H or -Ci-Ce alkyl; or R7and R8together with the nitrogen atom to which they are attached form a heterocyclyl;

[0673] each R11is independently halogen, -OH, oxo, -CN, -Ci-Ce alkyl, -C1-C6 alkyl-OH, -Ci-Cio haloalkyl, -Ci-Cio haloalkyl-OH, -OCi-Ce alkyl, -NR7R8, -C1-C6alkyl-NR7R8, -S(Ci-Ce alkyl), -SO(Ci-Ce alkyl), -SO2(Ci-Cb alkyl), -SOzNR’R8, -(CI-C6 alkylene)-carbocycle, -(Ci-Ce alkylene)-heterocycle, carbocycle, or heterocycle;

[0674] R’4is optionally substituted -C1-C30 alkyl, optionally substituted -C2-C30 alkenyl, or optionally substituted C2-C30 alkynyl;

[0675] R13and R16are each independently H or -Ci-Ce alkyl; or R15and R16together with the nitrogen atom to which they are attached form a heterocyclyl, andAttorney Docket No.: INMD-216 / 01WO 315953-4442

[0676] m is 0, 1, 2, or 3.

[0677] In embodiments of the compounds of Formula (B), or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, A is and. In embodiments, A is phenylene.i t-. p2In embodiments,A is orr.

[0678] In embodiments of the compounds of Formula (B), or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, R3is H.

[0679] In embodiments of the compounds of Formula (B), or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, each R4is independently halogen, -C1-C3 alkyl, or -CN. In embodiments, R4is halogen.

[0680] In embodiments of the compounds of Formula (B), or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, m is 0 or 1.

[0681] In embodiments, the compound of Formula (B) has a structure of Formula (B-l)

[0682] or a pharmaceutically acceptable salt, a stereoisomer. or a deuterated form thereof, wherein:

[0684] each X!ais independently -NR6a-, -O-, -CR’2R13-, -C(O)-, -S-, -S(O) - or -S(O)2-;

[0685] each R is independently halogen, -Ci-Ce alkyl, -Ci-Ce haloalkyl, -S(Ci-C6 alkyl), - SO(C1-C6alkyl), -SO2(Ci-C6alkyl), or -CN;

[0686] each R!>is independently halogen, -OH, oxo, -CN, -Ci-Ce alkyl, -CJ-C6 alkyl-OH, -(Ct-C6alkyIene)-O-(Ci-C6alkyl), -(Ci-C’6 alkylene)-()-(Ci-C6 alkyl)-()H, -(C1-C6 alkyl ene)-O-(Ci- Ct, alkylene)-O-(Ci-C6 alkyl), -(Ci-Cs alkylene)-O-(Ci-Ce alkylene)-O-(Ci-Ce alkyl)-OH, -Ci-C10 haloalkyl, -C1-C10 haloalkyl-OH, -NR7R8, -Ci-Ce alkyl-NR7R8, -S(Ci-C6alkyl), -SO(Ci-Ce alkyl), -SCh(Ci-C6 alkyl), -SChNR7R8, -(Ci-Cr, alkylene)-carbocycle, -(Ct-Ce alkylene)-Attorney Docket No.: INMD-216 / 01WO 315953-4442heterocycle, carbocycle, or heterocycle, wherein each carbocycle and heterocycle is optionally substituted by 1 or 2 R";

[0687] each R6ais independently H, -CI-CG alkyl, -Ci-Ce alkyl-OH, -Ci-Cio haloalkyl, -CI-CJO haloalkyl-OH, -Ci-Ce alkyl-NR7R8, -(Ci-Cc alkylene)-O-(Ci-C6 alkyl), -(Ci-Cc alkylene)-O- (C1-C6 alkyl)-OH, -(Ci-C6alkylene)-O-(Ci-C6 alkyl)-COOH. -(Ci-C6alkylene)-O-(Ci-C6 alkylene)-O-(Ci-C6alkyl), -(Ci-C6alkylene)-O-(Ci-C6alkylene)-NR7R8, -(Ci-Ce alkylene)-O- (Ci-Ce alkylene)-C(O)NR7R8, -(Ci-C6alkylene)-O-(Ci-C6alkylene)-NR7C(O)-(Ci-C6alkyl), - (Ci-Ce alkylene)-O-(Ci-C6 alkylene)-C(O)NR7-(Ci-C6 alkylene)-O-(Ci-C6 alkyl), -(CI-CG alkylene)-O-(Ci-C6 alkylene)-NR7C(O)-(Ci-Ce alkylene)-O-(Ci-C6 alkyl), -(C1-C0 alkylene)-O-(CI-CG alkylene)-C(O)NR7-(Ci-C6 alkylene)-O-(Ci-Cc alkylene)-NR7-aryl, -(Ci-Ce alkylene)-O-(Ci-C6 alkylene)-NR7C(O)-(Ci-C6 alkylene)-O-(Ci-C6alkylene)-NR7-aryl, -(Ci-C6alkylene)-NR7R8, -(Ci-C6alkylene)-NR7-(Ci-C6alkyl)-OH, -(Ci-C<5 alkylene)-NR7-(Ci-C6alkyl)-O-(Ci-C6alkyl), -(C1-C6 alkylene)-NR7-(Cj-C6alkylene)-NR7R8, -(Ci-C6alkylene)- heterocycle, or -(Ci-Ce alkylene)-heteroaryl;

[0688] R7and R8are each independently H or -Ci-Ce alkyl; or R7and R8together with the nitrogen atom to which they are attached form a heterocyclyl;

[0689] each R11is independently halogen, -OH, oxo, -CN, -CI-CG alkyl, -Ci-Ce alkyl-OH, -CJ-C10 haloalkyl, -C1-C10 haloalkyl-OH, -OCi-C6alkyl, -NR7R8, -Ci-Cs alkyl-NR7R8, -S(Ci-Ce alkyl), -SO(Ci-C6 alkyl), -SO2(Ci-C6alkyl), -SO2NR7Rs, -(CJ-CG alkylenej-carbocycle, -(Ct- CG alkylene)-heterocycle, carbocycle, or heterocycle;

[0690] R12and Rnare each independently selected from H, deuterium, halogen, or -Ci-Ce alkyl;

[0691] R’4is optionally substituted -C1-C30 alkyl, optionally substituted -C2-C30 alkenyl, or optionally substituted C2-C30 alkynyl;

[0692] R13and R16are each independently H or -Ci-Ce alkyl; or R15and R10together with the nitrogen atom to which they are attached form a heterocyclyl;

[0693] m is 0, 1, 2, or 3; and

[0694] p is 0, 1, 2, or 3.

[0695] In embodiments, the compound of Formula (B-I) has a structure of Formula (B-II)Attorney Docket No.: INMD-216 / 01WO 315953-4442(B-II)

[0696] or a pharmaceutically acceptable salt. a stereoisomer, or a deuterated form thereof, wherein:

[0697] each R'1is independently halogen, -CI-CG alkyl, or -Ci-Cs haloalkyl; and

[0698] m is 0 or I.

[0699] In embodiments of the compounds of Formula (B-I) or (B-II), or a pharmaceuticallyacceptable salt, a stereoisomer, or a deuterated form thereof,R2

[0700] In embodiments of the compounds of Formula (B-I) or (B-II), or a pharmaceuticallyacceptable salt, a stereoisomer, or a deuterated form thereof,

[0701] In embodiments of the compounds of Formula (B), (B-I) or (B-II), or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, R2isp is 0 or 1. In embodiments, p is 0. In

[0702] In embodiments of the compounds of Formula (B), (B-I) or (B-II), or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, R,4is optionallyAttorney Docket No.: INMD-216 / 01WO 315953-4442substituted -C1-C20 alkyl, optionally substituted -C2-C20 alkenyl, or optionally substituted C2-C20 alkynyl. In embodiments, R14is optionally substituted -C1-C16 alkyl, optionally substituted -C2-C15 alkyl, optionally substituted -CS-CM alkyl, optionally substituted -C4-C13 alkyl, optionally substituted -C5-C12 alkyl, optionally substituted -CA-CU alkyl, optionally substituted -C7-C10 alkyl, or optionally substituted -C8-C9 alkyl.

[0703] In embodiments of the compounds of Formula (B), (B-I) or (B-TI), or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, R14is optionally substituted -C1-C16 alkyl. In embodiments, R14is -CH3, -CH2CH3, -CH(CH3)2, - C(CH3)3, -(CI b)2CH3, -(CH2)3CH3, -(CH2)4CH3, -(CH2)5CH3, -(CEI2)6CH3, -(CE12)7CH3, -(CH 2 CH.3, -(CH2)9CH3, -(CH2)IOCH3, -(CH2)IJCH3, -(CH2)i2CH3, -(CH2)i3CH3, -(CH2)i4CH3, or -(CH2)i5CH3. In embodiments, R14is -Clh, -CH(CH3)2, C(CH3)3, -(CH2)2CH3, -(CH2)3CH3, -(CH2)4CH3, -(CH2)6CH3, -(CH2)8CH3, -(CH2)IOCH3, -(C H2)I2CH3, or -(CH2)14CH3.

[0704] In embodiments of the compounds of Formula (B), (B-I) or (B-II), or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, R15and R16are each independently -Ci-Ce alkyl. In embodiments, R15and Rlfaare each independently -Ci-Ce alkyl, -C2-C5 alkyl, or -C3-C4 alkyl. In embodiments, Ri3and R16are the same. In embodiment, R15and R16are different. In embodiments, R1?and R16are -CII3.

[0705] In embodiments of the compounds of Formula (A'), (A), (I), (I-A), (I-B), (I-C), (I-D), (I-E), (I-F), (I-G), (II), (II-A), (II-B), (II-C), (II-D), (II-D-1 ), (II-D-2), (II-D-3), (II-D-4), (II-D-4'), (II-D-4"), (II-E), (II-F), (II-G), (II-H), or (III), or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, R4is halogen. In embodiments, R4is F.In embodiments of the compounds of Formula (A'), (A), (I ), ( I-A ), (I-B), (I-C ), (I-D), (I-E), (I-F), (I-G), (II), (II-A), (II-B), (II-C), (II-D), (II-D-1), (II-D-2), (II-D-3), (II-D-4), (II-D-4'), (II-D-4''), (II-E), (II-F), (II-G), (II-H), or (III), or (III), or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, R5, if present, is -SO2NH2, -SO2NH(Ci-C<5 alkyl), -SO2N(CI-C6 alkyl)2or -SO2NR7R8, wherein R7and R8together with the nitrogen atom to which they are attached form a heterocyclyl.

[0706] In embodiments of the compounds of Formula (A'), (A), (I), (I-A), (I-B), (I-C), (I-D), (I-E), (I-F), (I-G), (II), (II-A), (II-B), (II-C), (II-D), (II-D-1), (II-D-2), (II-D-3), (II-D-4), (II-D- 4'), (II-D-4"), (II-E), (II-F), (II-G), (II-H), or (III), or (III), or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, each R6is independently halogen, -OH, -CN, -Ci-C3alkyl, -C1-C3 haloalkyl, -S(Ci-C3alkyl), -SO(Ci-C3alkyl), -SO2(Ci-C3alkyl), - SO2N(Ci-C3alkyl), -SO2NR7R8, or 4-6 membered heterocycle. In embodiments, R6isAttorney Docket No.: INMD-216 / 01WO 315953-4442independently halogen, -C1-C3 alkyl, -OH, -CN, -SO2CH3,. In embodiments, R” is independently halogen or -C1-C3 alkyl.

[0707] In embodiments of the compounds of Formula (A'), (A), (I), (I-A), (I-B), (I-C), (I-D), (I-E), (I-F), (I-G), (II), (II-A), (II-B), (II-C), (II-D), (II-D- 1), (II-D-2), (II-D-3), (II-D-4), (II-D-4'), (II-D-4"), (II-E), (II-F), (II-G), (II-H), or (III), or (III), or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, R6, if present, is -SO2NH2, -SO2NH(CI-C6 alkyl), -SO2N(Ci-Cg alkyl)2 or -SChNRfl ) wherein R'and R8together with the nitrogen atom to which they are attached form a heterocyclyl. In some embodiments, R6is --SO2NR7R8, wherein R7and R8together with the nitrogen atom to which they are attached form a 3- to 6- membered heterocyclyl containing 1 or 2 ring heteroatoms selected from N, O, or S.

[0708] In embodiments of the compounds of Formula (A'), (A), (I), (I-A), (1-B), (I-C), (I-D), (1-E), (1-F), (I-G), (11), (11-A), (11-B), (II-C), (II-D), (Il-D-1), (II-D-2), (ll-D-3), (ll-D-4), (11-D-4'), (II-D-4"), (II-E), (IT-F), (H-G), (II-H), or (III), or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, R7and R8are each independently hydrogen or C1-4 alkyl.

[0709] In embodiments of the compounds of Formula (A1), (A), (I), (I-A), (I-B), (I-C), (I-D), (I-E), (I-F), (I-G), (II), (II-A), (II-B), (II-C), (II-D), (II-E), (II-F), (II-G), (II-H), or (III), or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, R9is halogen, hydroxyl, -Ci-Ce alkyl, -C2-C6 alkenyl, -C2-C6 alkynyl, -Ci-Co haloalkyl,. haloalkenyl, -C2-C6 haloalkynyl, -OCi-Ce. alkyl, or -OCi-Ce haloalkyl. In embodiments, R9is halogen, hydroxyl, -C1-C3 alkyl, -C1-C3 haloalkyl, -OC1-C3 alkyl, or -OC1-C3 haloalkyl. In embodiments, R9is halogen, hydroxyl, methoxy, ethoxy, fluoromethyl, or difluoromethyl.

[0710] In embodiments of the compounds of Formula (A'), (A), (I ), (I-A), (I-B), (I-C), ( I-D), (I-E), (I-F), (I-G), (II), (II-A), (II-B), (II-C), (II-D), (II-E), (II-F), (II-G), (II-H), or (III), or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, R9is -SO2NH2, -SO2NH(CJ-C6 alkyl), -SO2N(CI-C6 alkyl)2 or -SO2NR7R8, wherein R7and R8together with the nitrogen atom to which they are attached form a heterocyclyl.

[0711] In embodiments of the compounds of Formula (A'), (A), (I), (I-A), (I-B), (I-C), (I-D), (I-E), (I-F), (I-G), or (III), or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, R9ais halogen, hydroxyl, -Ci-Ce alkyl, -C2-C6alkenyl, -C2-C6 alkynyl, -Ci-Ce haloalkyl, -C2-C6 haloalkenyl, -C2-C6 haloalkynyl, -OCi-Ce alkyl, or -OCi-Ce haloalkyl. InAttorney Docket No.: INMD-216 / 01WO 315953-4442embodiments, R9ais halogen, hydroxyl, -C1-C3 alkyl, -C1-C3 haloalkyl, -OC1-C3 alkyl, or -OCi-C3 haloalkyl. In embodiments, R9ais halogen, hydroxyl, methoxy, ethoxy, fluoromethyl, or difluoromethyl.

[0712] In embodiments of the compounds of Formula (A'), (A), (I), (LA), (I-B), (LC), (LD), ( LE), (I-F), (I-G), or (III), or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, R9ais -SO2NH2, -SO2NH(Ci-C6 alkyl), -SO2N(CI-C6alkyl)2or -SO2NR7R8, wherein R7and R8together with the nitrogen atom to which they are attached form a heterocyclyl.

[0713] In embodiments of the compounds of Formula (A'), (A), (I), (I-A), (LB), (I-C), (I-D), (LE), (I-F), (I-G), (II), (ILA), (ILB), (ILC), (ILD), (II-E), (ILF), (ILG), (ILH), or (III), or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, R10is H or -Ci-C3 alkyl. In embodiments, R10is H or methyl.In embodiments of the compounds of Formula (A), (I), (LA), (LB), (I-C), (I-D), (LE), (LF), (I-G), (II), (ILA), (ILB), (ILC), (II-D), (II-D-1), (ILD-2), (ILD-3), (ILD-4), (I D-4'), (ILD-4"), (II-E), (ILF), (ILG) (ILH), and / or (III), R1 ], if present, is -SO2NH2, -SO2NH(CI-C6 alkyl), -SO2N(CI-C6 alkyl)2 or -SO2NR7R8, wherein R7nd R8together with the nitrogen atom to which they are attached form a heterocyclyl.

[0714] In embodiments of the compounds of Formula (A'), (A), (I), (LA), (I-B), (I-C), (LD), (ILD-1), (ILD-2), (ILD-3), (ILD-4), (ILD-4'), (ILD-4"), (LE), (LF), (LG), (II), (ILA), (ILB), (ILC), (II-D), (II-E), (ILF), (ILG), (ILH), or (III), m is 0 or 1.

[0715] In embodiments of the compounds of Formula ( / A), (A), (I ), (LA), (LB), (LC), (LD), (LE), (LF), (LG), (II), (ILA), (ILB), (ILC), (11-D), (11-E), (ILF), (ILG), (11-H), or (111), n is 0 or 1. In embodiments, n is 0.

[0716] In embodiments of the compounds of Formula (A'), (A), (I), (LA), (LB), (I-C), (LD), ( E), (I-F), (LG), (II), (ILA), (ILB), (II-C), (II-D), (ILD-1), (ILD-2), (ILD-3), (ILD-4), (ILD-4'), (ILD-4"), (II-E), (ILF), (ILG), (ILH), or (III), p is 0, I, or 2.

[0717] Embodiments provided herein for Formula (A') can be applied for Formula (A), (I), (I-A), (LB), (I-C), (LD), (LE), (LF), (LG), (II), (ILA), (ILB), (ILC), (ILD), (II-D-1), (ILD-2), (ILD-3), (ILD-4), (ILD-4'), (ILD-4"), (II-E), (ILF), (ILG). (ILH), and / or (III), if appropriate under the definitions of Formula (A), (I), (LA), (LB), (LC), (I-D), (LE), (LF), (LG), (II ), (II- A), (ILB), (II-C), (ILD), (ILD-1), (ILD-2), (ILD-3), (ILD-4), (ILD-4'), (ILD-4"), (ILE), (II- F), (ILG), (ILH), and / or (III).

[0718] Embodiments provided herein for Formula (A) can be applied for Formula (I), (LA), (LB), (LC), (LD), (LE), (LF), (LG), (II), (ILA), (ILB), (II-C), (II-D), (II-D-1), (ILD-2), (II-Attorney Docket No.: INMD-216 / 01WO 315953-4442D-3), (II-D-4), (II-D-4'), (II-D-4"), (II-E), (II-F), (II-G), and / or (II-H), if appropriate under the definitions of Formula (I), (I- A), (I-B), (I-C), (I-D), (I-E), (I-F), (I-G), (II), (II-A), (II-B), (II-C), (1I-D), (Il-D-1), (ll-D-2). (Il-D-3), (II-D-4), (ll-D-4'), (ll-D-4"), (11-E), (II-F), (11-G), and / or (II-H).

[0719] Embodiments provided herein for Formula (I) can be applied for Formula (I-A), ( I-B), (I-C), (T-D), (I-E), (I-F), and / or (I-G), if appropriate under the definitions of formula (I), (I-A), (I-B), (I-C), (I-D), (I-E), (I-F), and / or (I-G).

[0720] Embodiments provided herein for Formula (II) can be applied for Formula (II-A), (II-B), (II-C), (II-D), (II-D-1), (II-D-2), (II-D-3), (II-D-4), (II-D-4'), (II-D-4"), (II-E), (II-F), (II- G), and / or (II-H), if appropriate under the definitions of Formula (II-A), (II-B), (II-C), (II-D), (II-D-1), (ll-D-2), (II-D-3), (II-D-4), (II-D-4'), (II-D-4"), (II-E), (II-F), (II-G), and / or (II-H)

[0721] Another embodiment is a product obtainable by any of the processes or examples disclosed herein.

[0722] In embodiments, provided herein is a compound of Formula (A'), (A), (I), (I-A), (I-B), (I-C), (I-D), (I-E), (I-F), (I-G), (II), (II-A), (II-B), (II-C), (II-D), (II-D-1), (II-D-2), (II-D-3), (II-D-4), (II-D-4'), (II-D-4”), (II-E), (II-F), (II-G), (II-H), (III), (B), (B-I), or (B-II), or a stereoisomer thereof, or a pharmaceutically acceptable salt thereof

[0723] In embodiments, provided herein is a pharmaceutically acceptable salt of a compound of Formula (A'), (A), (I), (I-A), (I-B), (I-C), (I-D), (I-E), (I-F), (I-G), (II), (II-A), (II-B), (II-C), (II-D), (II-D-1), (II-D-2), (II-D-3), (II-D-4), (II-D-4'), (II-D-4”), (II-E), (II-F), (II-G), (II-H), (III), (B), (B-I), or (B-II), Further embodiments of the disclosure relate to a deuterated compound of Formula (A'), (A), (1), (I-A), (1-B), (1-C), (1-D), (I-E), (I-F), (I-G), (11), (11- A), (II-B), (II-C), (II-D), (II-D-1), (II-D-2), (II-D-3), (II-D-4), (II-D-4'), (II-D-4"), (II-E), (II-F), (II-G), (II-H), (III), (B), (B-I), or (B-II), or a pharmaceutically acceptable salt thereof.

[0724] In embodiments, provided herein is a compound of Formula (A'), (A), or (I), selected from Compounds Al -Al 00, or a pharmaceutically acceptable salt thereof, a deuterated form thereof, racemic form thereof, or stereoisomer thereof. In embodiments, the compound is Compound A3 or a pharmaceutically acceptable salt thereof, a deuterated form thereof, racemic form thereof, or stereoisomer thereof.

[0725] In embodiments, provided herein is a compound of Formula (A'), (A), or (I), selected from Compounds A1-A112, or a pharmaceutically acceptable salt thereof, a deuterated form thereof, racemic form thereof, or stereoisomer thereof. In embodiments, the compound is Compound A3, A34, A35, A36, or A39, or a pharmaceutically acceptable salt thereof, a deuterated form thereof, racemic form thereof, or stereoisomer thereof.Attorney Docket No.: INMD-216 / 01WO 315953-4442

[0726] In embodiments, provided herein is a compound in Table A, or a pharmaceutically acceptable salt thereof, deuterated form thereof, racemic form thereof, or stereoisomer thereof,

[0727] In embodiments, provided herein is a compound in Table A, or a pharmaceutically acceptable salt thereof, or stereoisomer thereof.

[0728] In embodiments, provided herein is a compound in Table A, or a pharmaceutically acceptable salt thereof.

[0729] In one embodiment, provided herein is a compound set forth in Table A.

[0730] In some embodiments, provided herein is a pharmaceutically acceptable salt of a compound in Table A.o oTable A. Various compounds of the invention AComp. ID StructurehO 1AlHN'%C ^NV'HrA2 o 1 hw OJj J \0 1A3 ] J \—NV‘OHHli IoA4K / O HO H— N 2< L-NKA5Attorney Docket No.: INMD-216 / 01WO 315953-4442Table A. Various compounds of the invention Comp. ID StructureN | | V: O o I IA6.yXrW\ / O H S N C "-0 ) ) “Tl1 ■I H | \=o 0 1A7 [ J] \— N / \CXN''‘X / 'O H1, X<ON f| | ^ Y\ \=O O l|lF\Xy\XN o AS— N / \^N','XXXXx / O H / N'~-Z\ A H— N )<\NA95iXX-0<FII T >o 0 1A10 z\ 1.— N X N''X / 0 H11 \~~0 o 1 1All J J \— N / \<XN''’x / O H1Attorney Docket No.: INMD-216 / 01WO 315953-4442Table A. Various compounds of the invention Comp. ID Structure0 / A KAllA) ¥b" M J o N H oz. ~ A J'A SznzO o III ^AAA13 )A No z:— N¥> T^N'''AA\A \ o ¥ 1., ^4)HHo / \0HH 4 V / K— N >4, NA14^A A ° j A 1L>°A151A16 o!— NAV 'N'1'^OHHr^jr-'0m F 1 A A° A17 O I Ih'Y^Y<^'N A3HhAA18 -o< AAttorney Docket No.: INMD-216 / 01WO 315953-4442Table A. Various compounds of the inventionComp. ID StructureN H T >° A19^OHh'"-O'"' A20 o A z:o z zy U_ \O0O K LL=--Ay 'OH2 LL AAllz = / —X " o-AozFA22cA >FH i / X AA> XN~“ A23I5FA24Attorney Docket No.: INMD-216 / 01WO 315953-4442Table A. Various compounds of the invention Comp. ID StructureF F H L / x >NxX^HA25H O A N X N— A2611H A / —( •'NC>\N”~ A27 ( \LL.....\ / \ _ O LL V n - -ag F. / .LL H'Vv- A28O X Jo" ""F H A Z\^NJ'XN~“ A29XX''N |70\=O I I FA300J \vx\ / " O H1HA3XN A X / \1N—u“Attorney Docket No.: INMD-216 / 01WO 315953-4442Table A. Various compounds of the invention Comp. ID Structurei H i / x A32FxN N— G-AA33F / M\zF HH0■'Ny< / N” A34F |_| HO A35i5°\wF HHOX / \ A35-A5F'-N^XKN'-" A36N\ [| ' jF, N N— A36-A if ' iAttorney Docket No.: INMD-216 / 01WO 315953-4442Table A. Various compounds of the invention Comp. ID StructurebTlA'PA37 o 1r" ' o zV-'S / OHH0T X1’” \ / .\ / \— \A38ZI / T Q—V o o / I ry—0x Z ^ ° Xr z A39 o\) 0 N / / i A40 NA HN... / , _. A\ / \ / ^r? Nz\ iHA41 ”NC>yN- j AAXA’Y'- 'NA AAA42 o 1-NX; uAX / ^O H1\) O NWX 1 A43 / N- -JJ H MfcNj,.... / <, _. AAttorney Docket No.: INMD-216 / 01WO 315953-4442Table A. Various compounds of the inventionAttorney Docket No.: INMD-216 / 01WO 315953-4442Table A. Various compounds of the invention Comp. ID StructureA51OH o N / -L? / / / | A52 rw. <z OHHoo \-- A531( U_ I H ZNH h / x N A54 z z o f / \ W-~N / VzWxN''‘vJ NAQHHOH o N / / / | ASS Hk.y / =^ANZ\ PHHA56IFAA ^yNsiI L / NA57 O 1\Z\)HHAttorney Docket No.: INMD-216 / 01WO 315953-4442Attorney Docket No.: INMD-216 / 01WO 315953-4442Table A. Various compounds of the invention Comp. ID Structure1A65 0 1x / X) H1o bA66 o i o O K\ / O H \ >oOMb 1 1 1 ° A67 o 1R > LL. LL. \\ / O H / / o 1A68 ~-N04H‘"1O 1A69\Z 'O H1rA70 o!\ / O H1Attorney Docket No.: INMD-216 / 01WO 315953-4442Table A. Various compounds of the invention Comp. ID Structureo S'A71 o i i\rA72 o 1“N / xA\CoXN H''‘WMF0 1 1A73 — N v.y \ / O H1 LL \si 1 Wo 1 1 yyVVyC A74v,N / AHH\si f IT y^o A75 0 1 i-N' y VVHHo S' 1 \ V o A76 0 i i”N0^H'' \ 0 r i \ T o A77 o 1 1 yyAVyL - / yVH'4H / Attorney Docket No.: INMD-216 / 01WO 315953-4442Table A. Various compounds of the invention Comp. ID Structuresi | |TAo o 1 IA78 — NXC 'N'*'Hs| \ YA0 1 IA79-NAAN1'’ \_ oNzyA -" / 3YyC^ °'')~ \ A.i Vsi A° A80 o 1 i— NX^N'’- i?H) LL, \ LL._ / Or*JF f T Y A81 o 1 i---NXC 'N1'"\ISA82 o 14HHO 1A83 — N A yA NV- \ / 'OHH10 1: AN A84-t / vA'''x / ^o HAttorney Docket No.: INMD-216 / 01WO 315953-4442Table A. Various compounds of the inventionComp. ID Structurero 1A85\ / 'O HLX o 1^TYOJzz IZY^z-' ° / Tl \nferA86 O l|lX / ^O H w' GO' O XN | HA87 o HI 0X / x) H / ho 1A88 i i neo nN\VA0HH10 1A89 i yY— NYV^N''’NXzOHHA90A91Attorney Docket No.: INMD-216 / 01WO 315953-4442Table A. Various compounds of the invention Comp. ID Structure\. NHA92 z~_O=< 1 F / / WJ ^X d xo — \ \) O ) Z - NHN- / rA93 o o QZ. " -' F T II 'N\) \_> z\— HO N A ~j...A94 ^~d HNi.-Z 0 2^.X / / \ o o LL-OX JxZ1^s °J. OA95\ z? 1A96\) O Nr~~^ / / / / / / FA97A98Attorney Docket No.: INMD-216 / 01WO 315953-4442Table A. Various compounds of the invention Comp. ID StructureX O NA99A O H— N 2<\N / < mA1005I r «^rvAoX-No| T y=| J o z > OFYY lEIZo l|l ^ IC A101 Y --N^V^N^'Y-Xn o \ / A) HX y O u — —1F F O 1A102 LL. X 1— o V N" X?'N'''" X '0 HA ) / A^ON || | >=O D D 0 IHA103 X J i 1! J 'y- ° HFHH0A104FA nXXV 11A105Attorney Docket No.: INMD-216 / 01WO 315953-4442Table A. Various compounds of the inventionComp. ID StructureoNCMA1060HnOH o NftY"-7HNi. <^A107 XjQ1OH o Nr4~<^^—7 HNI.- / o / L IL ' A108NN1 J. o IJ\Z OA109N fYO^O o HI\ / O HAHOOHO Nopj — / / / F i iTAHI\.,,NH1 F / / V-7 / AH 2 N 0 6HAttorney Docket No.: INMD-216 / 01WO 315953-4442

[0731] In embodiments, provided herein is a compound of Formula (A'), (A), or (II) selected from Compounds Bl -Bl 59, or a pharmaceutically acceptable salt thereof, a deuterated form thereof, racemic form thereof, or stereoisomer thereof, in embodiments, the compound is Compound B3, B34, B37, B41, or B44, or a pharmaceutically acceptable salt thereof, a deuterated form thereof, racemic form thereof, or stereoisomer thereof.

[0732] In embodiments, provided herein is a compound of Formula (A'), (A), or (II) selected from Compounds Bl -Bl 64, or a pharmaceutically acceptable salt thereof, a deuterated form thereof, racemic form thereof, or stereoisomer thereof. In embodiments, the compound is Compound B3, B3-A, B3-B, B34, B34-A, B34-B, B37, B41, B41-A, B41-B, B44, B44-A, B44-B, B 162, or B 163, or a pharmaceutically acceptable salt thereof, a deuterated form thereof, racemic form thereof, or stereoisomer thereof.

[0733] In embodiments, provided herein is a compound in Table B, or a pharmaceutically acceptable salt thereof, deuterated form thereof, racemic form thereof, or stereoisomer thereof.

[0734] In embodiments, provided herein is a compound in Table B, or a pharmaceutically acceptable salt thereof, or stereoisomer thereof.

[0735] In embodiments, provided herein is a compound in Table B, or a pharmaceutically acceptable salt thereof

[0736] In one embodiment, provided herein is a compound set forth in Table B,

[0737] In some embodiments, provided herein is a pharmaceutically acceptable salt of a compound in Table BTable B. Various compounds of the inventionComp. ID StructureN H lo 11Bl o.1 Xs. JJrVJ O N II IO 11B2 oV~-\HAttorney Docket No.: INMD-216 / 01WO 315953-4442Table B. Various compounds of the inventionComp. ID StructureHO( Y 1 HN / \B31.QH O NB3-AZI1H / — -NB3-B1b 1 A H V | ° VrO 0 1 IB4 J!.O r' X-"VN'' L y A. < X JHH QB51 / A -0 h JcH T >=o o!B6,.o JIo r >••' " N'1A )H / 'N~^v V-NHAttorney Docket No.: INMD-216 / 01WO 315953-4442Table B. Various compounds of the inventionComp. ID StructureHO( Y 1 HN / \B71OO iz b J [| \zzrO O i B8 ^O==T< XJHHr^5^0•j H I B9 Jy 7 \O-._V°BIO<\ X-NH%F'CZ / M ) V0 fQ H6< V vOy_j7 / — < / N 4 z>\A y_jBllo \ — / V-NH0- / Attorney Docket No.: INMD-216 / 01WO 315953-4442Attorney Docket No.: INMD-216 / 01WO 315953-4442Attorney Docket No.: INMD-216 / 01WO 315953-4442Attorney Docket No.: INMD-216 / 01WO 315953-4442Table B. Various compounds of the inventionComp. ID StructureB24o o z „ AQZ \= B25O °m~”\ ii( ZEE —H ZI N_,H r ¥> 1. N A / 'O B26-vP 11°Fy - <f)ON / vyB27O ) — / FV-NHsAttorney Docket No.: INMD-216 / 01WO 315953-4442Table B. Various compounds of the inventionComp. ID StructureNN F— Z \-0B28 \ L a _0 ) — / V-NH^0TZ) = Z - " H \9i sB29| If T W 9°r on<?’ sB30 0 >--- / FV-NH) HN' / \B31Attorney Docket No.: INMD-216 / 01WO 315953-4442Table B. Various compounds of the inventionComp. ID StructureBV-NHO \ FB32^~ v- y. -JVY, e exx z: 2:B33 CV" " i n:?err 1tO A ZU Vo / =\1 Ji Z 4 \ H B34 W \.., NH / -"Nx / / " OpB34-AB34-BHB35°uiCVAttorney Docket No.: INMD-216 / 01WO 315953-4442Table B. Various compounds of the inventionComp. ID StructureHN 1 1 O HIB36 ji.1 JL JJO " V N'' / V J HH iz \4 z NAY A v / / \HB37 - / > " NH r"N\ V LL \ r-Q } < Z - - H y **O / ""'A< x i o HX / \. AB38 ^■o' >r61 1 F'^yAr-%B39H° A"N\< y i HzAB40 ”o y **■1H0 r~~ 'Ndr / «B41 rd'Y*'AA-N'Attorney Docket No.: INMD-216 / 01WO 315953-4442Table B. Various compounds of the inventionComp. ID StructureH HO' \ 1 N.B41-Az Z 5s'■ " H< V Ha \ 1 NB41-B "■Oxy-"f) <J T II 'N LL / HN— \H ( V > N 1 / \) B42rw i °H O Z^Nx< y i HB43HB44V<NS;iHN\ AHB44-AJF^VT^Attorney Docket No.: INMD-216 / 01WO 315953-4442Table B. Various compounds of the inventionComp. ID StructureH— -NB-44-B> T IHN-_ iE '*'"fH ( / O’ B45Oi Y^ £JAN^J99z- B46nc#o \ — / V-N140— / 9B47Attorney Docket No.: INMD-216 / 01WO 315953-4442Table B. Various compounds of the inventionComp. ID StructureHN-—.N C SB48o \ — / V-N14n\ HN\rXN-xXzAhrNB490 \ — / V-NHs8X-NHcfB50\== / Z^N / 0^8HN 1 H "8 O 11 11 Fxzx A A J B51 o JL. L JIu VJKAttorney Docket No.: INMD-216 / 01WO 315953-4442Table B. Various compounds of the invention Comp. ID StructureB52 / ov f? <T1V>0 Z^-.^,r 1 z z / & Z z,,< X X •XXVx;,z z z-- / ■ / B53N— - / \ / / V _ / N\ CZ / B54 o \ - / V-N'H9Attorney Docket No.: INMD-216 / 01WO 315953-4442Table B. Various compounds of the inventionComp. ID StructureB55 oA Y? <T1V0^-.,r 1 z z / .Y Z Z z,< x -n x ~n •XXVx;,z z z z-- / B56B57 / r^n.. N Y Xj nr r^41 10 1B58 — o K - O < V N'' V. / V J HN / \ H HO r-NA^N— B59JAttorney Docket No.: INMD-216 / 01WO 315953-4442Table B. Various compounds of the inventionComp. ID Structure0 o 1B60 ^0 JI.□ r v NV\ < X )H'--NHO -^-r_ _ 0 Z: T ho!B61 -0 JI. ) Ti0 < V N< A JHZT HO -1 \o 1B62 \ _. JI.1X Z / ° O>O< V N'' \_N / H? o < X JHB63B64Attorney Docket No.: INMD-216 / 01WO 315953-4442Table B. Various compounds of the inventionComp. ID Structure0 F Or x o 1 1B65 ^0 JI.□ r v NV< X )H'--NH0 ho!FB66 -0 JI. \0 < V N< A JHHo 1B67 _. O JIO < V N''< X JHHy —ZX-, NoB68 o \ - / V-NTH0— / Attorney Docket No.: INMD-216 / 01WO 315953-4442Attorney Docket No.: INMD-216 / 01WO 315953-4442Attorney Docket No.: INMD-216 / 01WO 315953-4442Table B. Various compounds of the inventionComp. ID Structure0)= / l— NN F— Z \B75 yj / DAo \ - f o / z "V-NHQ —; ft.;q\ HNo / \ / / / ) LL. )< = oZ = - ZT / V-X-A / \o z1 \ T N F— / B760 \ — / V-NH9B77NHl. A.. 1 k J N.0 IIIB78wvV. NHHAttorney Docket No.: INMD-216 / 01WO 315953-4442Table B. Various compounds of the inventionComp. ID StructureN ifY O 0 HIFyV^ k / Nx B79 o J! J. 1 JC X jHHN f |j t) B80 o HIo< XJHH° rONr- 1 II0 IIIB81.o ji A xXx— NHH NQN_N / \B82O \ — / — NT- IO— {QAttorney Docket No.: INMD-216 / 01WO 315953-4442Table B. Various compounds of the inventionAttorney Docket No.: INMD-216 / 01WO 315953-4442Table B. Various compounds of the inventionComp. ID StructureB86o / ™\B87 k NX^ V__# A.,, NH Ns Ji TX) Z7\A ° / oF{ / ZI==\1 J, Z> —( (\ / ) — \B88HAX-X o= V_ / \.,, NH r'Nxw NZc?— — \z.( — ~„.oC \ / O O N z~i B89 H >-< / F: f" T >0''N-'HN" <H1 JB90^-0r \ / ~-o o NVN_7 HNH ZB91Hj / T || 'Nr o Nn )•■■£ / z^N— / Hhli' ZB92HF I H 'NAttorney Docket No.: INMD-216 / 01WO 315953-4442Table B. Various compounds of the inventionComp. ID Structure°' [ / > - \ H B93 \., NH r"N\. J ■ / / L> Or LL.j - 5xX,o B94 J TkO ZFV^-0 O NYB95 Yix. w / HxJjyxF T r> NVF.;z.:V ¥ i""o o No ( )■■■'{ / ''B96v H"f' QQN H \zz: O B97 °N x / — ° Y L JL / X— NHFy^o O NOB98V Y <n ^ ix^°HN / •" X O NB99Y< Y.. ■ Y=VVX^NAttorney Docket No.: INMD-216 / 01WO 315953-4442Table B. Various compounds of the inventionComp. ID StructureB100sJZ AzZCLL _ \ / \ / \ / N / % / \NHy_) A B1011 / / / N' D z X } d b d \ T] "" ) / --N \F'' \ 1, N 0Bl 02 >r ) T -x— / 5^z: 0j d- "n HN—x.1 1 H N 1 f A LF B103 H Y^' X °’f l AUB104 / --NHF'-vJy.BIOS> — ^NHF'<0^Bl 06As. d---#Attorney Docket No.: INMD-216 / 01WO 315953-4442Table B. Various compounds of the inventionComp. ID StructureNHF'' C0^K<Bl 07jJ T H 'NLL / — -NH^ VoZB108F'-CAA1T J1 / 'Nho 1 1 fv^XI?"0B109 Y j \F- / V N''I )Hz: J— \__-NHN rrn O HIFYV^ V-NX Bl 10FA / z--° V’ K Y Y " V J>i!HV.-NHNHF"\ ( 1 )HBill'-° I ] I F r1kX>Bill1O i 1B113 ^-0 JJ.F't.y N''x )HX_NHAttorney Docket No.: INMD-216 / 01WO 315953-4442Table B. Various compounds of the inventionComp. ID Structure'J r- 1 H ^) B114Vf / \ \ z: —Hi I H "1 o 1Bl 15 / —0K - I )x.._NHHTgh Ck z0 o / = V' ' z1Bl 160K f J \F^ / V N''\ H / ZT ft.X / X— NHLL Y \ m o O HI zx / J - B117 jl >. jl JX— NHNHFi / " \HB118v~o yvBl 19Attorney Docket No.: INMD-216 / 01WO 315953-4442Table B. Various compounds of the inventionComp. ID Structureh0 1Bl 20 z-° K ■Y v 1NH''X--NH LL.1 (1 7 o 1 z pB121 ( T _F- Y N- N'' / oY j H r^ “ \ \ / \ ■ \ho 1 \ O=\B122 z-° K °YsF^y N f o y#_ i )HNHY ' "n o o 2:' F / Bl 23 % ( JXXJ1HN— \ J 1L H N 1 ( / L*F B1240FB125XIJ[Attorney Docket No.: INMD-216 / 01WO 315953-4442Table B. Various compounds of the inventionComp. ID StructureHN— \ 1 H ( V. A A B126o Tz--A6 < / z—\ / \B127 f O Z^ ~ZO o NA ’"£„ / / 0B128 rt Ck 2TA / XV T J |T 'N y AAN' I A A / v c. z TB129N oAA> OB130 o! 1f \ o 1 X< J HHN -J^0 °NO B131HTJ \B132Attorney Docket No.: INMD-216 / 01WO 315953-4442Table B. Various compounds of the inventionComp. ID StructureB133Yz- / (\ \ _ _ / z— / z— T B134 T Z / -O M fTZ O=HKl 1 HH\ J., N. 5TZ O= / =zB1351 vV Ck z'V I " ^ z Z \ z— z I I\B136 LLBl 37r-oHB138V jXX^v HKf r~° 1 H HB139J FXX^N1Attorney Docket No.: INMD-216 / 01WO 315953-4442Table B. Various compounds of the inventionComp. ID Structure / '-oHB140kA' i_ i ki i n o Vx X B141 > z:i Hx / / h \ — Q ( / B1142 LL) — A Jxz: ' ™zz / o =r of o X > NZAI o HI A- B143o J-L< 4 HHN-JBl 44B145 AAA. HNH / '-NH VNo 1 1B146HOAK'Attorney Docket No.: INMD-216 / 01WO 315953-4442Table B. Various compounds of the inventionComp. ID Structureho 1!FBl 47O A„.- < 7 H\ H° LJ_ o h 1 II A V 1 B148 ^0o T 1= ■7 - O. AMV- b^ "' iH0 ”h / A y \=o O 1 1B149 ji i \HO pZ-HhB150, — 0HM' 7 HB151 rB152H J \=O Bl 53Attorney Docket No.: INMD-216 / 01WO 315953-4442Table B. Various compounds of the inventionComp. ID Structure1o 1 1Bl 54O JL,..- C,N / < 7 H\ r i || T V=o o 1B1551 1 JxH < N-77H_NH •V..-QB156 O LL ft — —F / / z K Q B157o= / || T ifiF __NHH 1 \CN.-kr 0 / Bl 58F _. NH.. N -Q B159Jr i fH__ NB160o i I _N KI T 'NTV / ’’Attorney Docket No.: INMD-216 / 01WO 315953-4442Table B. Various compounds of the inventionComp. ID StructureB161OrO 1B162HHO.. fl 0F fl TB163N— ON3 HN...(B164 "o hiT I "NF

[0738] In embodiments, provided herein is a compound selected from Compounds 1-49, or a pharmaceutically acceptable salt thereof, a deuterated form thereof, racemic form thereof, or stereoisomer thereof.

[0739] In embodiments, provided herein is a compound selected from Compounds 1-71, or a pharmaceutically acceptable salt thereof, a deuterated form thereof, racemic form thereof, or stereoisomer thereof.

[0740] In embodiments, provided herein is a compound in Table C, or a pharmaceutically acceptable salt thereof, deuterated form thereof, racemic form thereof, or stereoisomer thereof.Attorney Docket No.: INMD-216 / 01WO 315953-4442

[0741] In embodiments, provided herein is a compound in Table C, or a pharmaceutically acceptable salt thereof, or stereoisomer thereof.

[0742] In embodiments, provided herein is a compound in Table C, or a pharmaceutically acceptable salt thereof.

[0743] In one embodiment, provided herein is a compound set forth in Table C.

[0744] In some embodiments, provided herein is a pharmaceutically acceptable salt of a compound in Table CTable C. Various compounds of the inventionComp ID Structure1O o z1YFx / ^r 'N''' oF\_-NHHoS'o!2r K NH k.i 1 [| \=00 i3 [ J \rvV- HH / x,oS' 1 II | \=o0 i 14 [ J \k / ". Ho i5X / J I'iFV, NHHAttorney Docket No.: INMD-216 / 01WO 315953-4442Table C. Various compounds of the inventionComp ID StructureON 'Q^>=O O6F\Z> A<Nv L JC JXF>VJHN07 1 jTli \o Oo z. AN [ |To 1 i l c8 jT j \H | H\^--FQ_ / _ — / o N£YV° OO9 x A ■H'’V \ox>N \ || \=o o 3 i10 HO II [ J \L JHHh011 HQ ijHN-X^XVA'N'''L J'OHH12Attorney Docket No.: INMD-216 / 01WO 315953-4442Table C. Various compounds of the inventionComp ID Structurer t || 1 \z^o o 113 JI. L J] \C v0N H | \^O O IN O14 JL L 1 J< A^ X / ' HN-"7OHHH l — 00 1 I15 r J \( I / 'F HH ZIsi || | \=O0 116 [ J \( OTI / 'O HN--7iH1zv°N f| | \=O O I I17 HO H 1 1 U \ / J HV-N'7HISAttorney Docket No.: INMD-216 / 01WO 315953-4442Attorney Docket No.: INMD-216 / 01WO 315953-4442Table C. Various compounds of the inventionComp ID Structure\OS1 1 o 122A yj - A1 X Tz / vJH^ < O=r F X022B H?1r j \ 1 orNV^N- L J HQ i O Z - 1 HO'-'' XkZY--° si p n T v=o 23 HO O 1 o Z.k k - Y 6 o V-NHH^^O i- r r A=O HO 0 i23Ak X < LXJNHO^k / ' H'VKIHHr23B HO 0 1AJVV-NHbO i24" "r 1 "\ V 4 N' -L"k ^ HH124A*\JUxAttorney Docket No.: INMD-216 / 01WO 315953-4442Table C. Various compounds of the inventionComp ID Structureb 1 j| \^rO O0 124B JI ZI K 'N'"HMixture of di aster eomers, ON | || \=O o o o III24C* 11 ( Jf o A < A oV^ \\ fsb<x'N'''kNZHH Oo z.1Yo 125 o HO-Z'Y HV-NHr r 11 — o o 125A L J \HO„. / Y H ’V— NHr 1 IIo 1 lfzJS? XVzA-z^25B [ J \ / JL,H0.- / 7 NVKIHHro 125CHO,.. Z>' NVNHHO 125DHO^ / ~'VZ^N''’VJHHAttorney Docket No.: INMD-216 / 01WO 315953-4442Table C. Various compounds of the inventionComp ID Structurex^.,0N Ho o 11 zAXX'N26 fg\ 1 I 1 JxJJzHxHo ' —IZh H \=O o 127 HO U [1 1 \r Xc ^N''’IN7 HHh r if y=o o 127A* |l JI I \[ LTH_^y ■ xx^G1 |T V=° X ° x<:s5;X^ 27B* ZI <? i ji JJ \£!1 _o'TxSX_. O| || \ — O X-'=S55X^27C* JI JJ \028x o A • f J] \ y^yN^’L^NHHX=x_°N r ji \=o o II / ^x^Av 28A Jl l \l^NHHAttorney Docket No.: INMD-216 / 01WO 315953-4442Table C. Various compounds of the inventionComp ID Structure^5^0■4 H | \=O 29 H H!1 \ / A - < J H1 | || \=O o i 129AHII r j \< J Hh29B H?N«AN,.11\ f H'ZOHH029C ii1JJ \< cis / HT)H29D\ H'" OHX^r--0O30 F 1p V N'' LxF \_NHHNx^N^"”0 OH 0 131 jf Jj \HO JI 1T J^NTH HAttorney Docket No.: INMD-216 / 01WO 315953-4442Attorney Docket No.: INMD-216 / 01WO 315953-4442Table C. Various compounds of the invention Comp ID StructureN J==O o 138 HN-''X ANJ jf J \ / 1 HV / ^OHOHNo 138A HN-"\ X^ jf J \ / HOHN0 138C HN-\AN^ jf J \ / 1 HV / ^OHOH039 1 [Tjj \ / 1 HHC^ OHM H \z^O Or ji39E HN-^. ANv JJ \ / J HHO £)HM f| \=O O 1ji39F JJ \ / 1 HHC* OHAttorney Docket No.: INMD-216 / 01WO 315953-4442Table C. Various compounds of the invention Comp ID StructureN H T \zzrO o H pAAT 39G / 1 HHC7OHO 140 JJN h lo III41HN-^AN.-UU / J HN Ij ]O 111 N 41 A / j HN h i41BHN-XJ>.NVLV ' / J H.. ON h l A“° o l|l42 Z~^° K I 1 Uk / FHN-"7H1 [o 142A Z~“° JL I J( kr^N'''k / 'F HN—7HAttorney Docket No.: INMD-216 / 01WO 315953-4442Table C. Various compounds of the inventionComp ID StructureKz:O O 142B \ \ z' o z —[ kvN'’k / ^F HN- H o —U0)" EE Z EE Z — - fs0 1 z.43 HN— \ JI [ jj \ / o YxCU O O Z 'Z-,.°N f| | \z^: O O 1 U Y1 Y uboo 44 HN-KAN(.-UVVY o k H45o46 HN— x JU _c>47Attorney Docket No.: INMD-216 / 01WO 315953-4442Table C. Various compounds of the inventionComp ID StructureT10 I vvCiy048 x-o JL JI 1 \\ T._.F' f^K—NHIZ\ o 49O o \ c o 49-A O JIF-< Y H\ _ NHz V-£['- £X ioofic= O=I i I50N jf Y >° 0 1 151 r j \HN-XSV^NV'\£z'°HN r iiD o HI52DYL 0 I J \D^DH / NNF fH]O 11153Z£IHAttorney Docket No.: INMD-216 / 01WO 315953-4442Attorney Docket No.: INMD-216 / 01WO 315953-4442Attorney Docket No.: INMD-216 / 01WO 315953-4442Table C. Various compounds of the inventionComp ID StructureH OH / H66zw0^V / -N X^'N' H_-NO- / H67 / vy.\l y | 'NH / —NOH / > HDD68 r rf N V-D4 || 1 'N X-s^N' FH69I5N H i y=o O Wrx< XYX^^70 HN—K r jj \( JHX— OxX^oN [| | \=o 0!71 r j \^Represented stereochemistry s assumed.Attorney Docket No.: INMD-216 / 01WO 315953-4442

[0745] In embodiments, provided herein is a compound of Formula (B), (B-I), or (B-II), selected from Compounds Pl-Pl 1, or a pharmaceutically acceptable salt thereof, a deuterated form thereof, racemic form thereof, or stereoisomer thereof.

[0746] In embodiments, provided herein is a compound in Table D, or a pharm ceutically acceptable sal\t th ”eor=eof, deuterated form thereof, racemic form thereof, or stereoisomer othereof. O zl\a li— o- —

[0747] In embodiments, provided herein is a compound in Table D, or a pharmaceutically acceptable salt thereof, or stere / o TSisomer thereof.\ " H

[0748] In embodiments, provided herein is a compound in Table D, or a pharmaceutically acceptable salt thereof.

[0749] In one embodiment, provided herein is a compound set forth in Table D.

[0750] In some embodiments, provided herein is a o z, pharmaceutically acceptable salt of a compound in Table D. YooTable D. Various compounds of the inventionComp ID StructurePlAP2P3Attorney Docket No.: INMD-216 / 01WO 315953-4442Table D. Various compounds of the inventionComp ID Structurefls r 'HP4o6O=Aoo< o= ----- P5 ^ oo=T12 o / LL. / TZ ) T1( LL ) T)P6 ^ oo / === — j yoOoV' o o P7P8P9Attorney Docket No.: INMD-216 / 01WO 315953-4442

[0751] Compositions

[0752] The compounds of Formula (A'), (A), (I), (LA), (I-B), (LC), (LD), (LE), (LF), (LG), (II), (ILA), (ILB), (ILC), (II-D), (II-D-1), (ILD-2), (ILD-3), (ILD-4), (II-D-4'), (ILD-4"), (II-E), (ILF), (ILG), (ILH), (III), (B), (B-I), or (B-II), or Tables A-D, or pharmaceutically acceptable salts thereof, or deuterated versions of the foregoing, may be used on their own but will generally be administered in the form of a pharmaceutical composition in which the compounds of Formula (A'), (A), (1), (LA), (LB), (LC), (LD), (LE), (LF), (LG), (11), (ILA), (ILB), (ILC), (II-D), (ILD-1), (ILD-2), (II-D-3), (ILD-4), (ILD-4'), (ILD-4"), (II-E), (ILF), (ILG), (ILH), (III), (B), (B-I), or (B-II), or Tables A-D, or pharmaceutically acceptable salts thereof, or deuterated versions thereof (active ingredient) is in association with pharmaceutically acceptable adjuvant(s), diluent(s) or carrier(s). Conventional procedures for the selection and preparation of suitable pharmaceutical formulations are described in, for example, ‘‘Pharmaceuticals - The Science of Dosage Form Designs”, M. E. Aulton, Churchill Livingstone, 2ndEd. 2002.

[0753] Depending on the mode of administration, the pharmaceutical composition will preferably comprise from 0.05 to 99 %w (per cent by weight), more preferably from 0.05 to 80 %w, still more preferably from 0.10 to 70 %w, and even more preferably from 0.10 to 50 %w, of active ingredient, all percentages by weight being based on total composition.

[0754] In embodiments, the present disclosure provides pharmaceutical composition(s) comprising a compound of Formula (A'), (A), (I), (LA), (LB ), (LC), (I-D), (LE), (LF), (LG), (II), (ILA), (ILB), (ILC), (ILD), (II-D-1), (ILD-2), (II-D-3), (II-D-4), (ILD-4'), (ILD-4"), (II- E), (ILF), (ILG), (ILH), (III), (B), (B-I), or (B-II), or Tables A-D, or a pharmaceuticallyAttorney Docket No.: INM D-216 / 01 WO 315953-4442acceptable salt thereof, as hereinbefore defined in association with pharmaceutically acceptable adjuvant(s), diluent(s) or carrier(s),

[0755] The disclosure further provides a process for the preparation of a pharmaceutical composition of the disclosure which comprises mixing a compound of Formula (A'), (A), (I), (LA), (LB), (I-C), (LD), (I-E), (LF), (LG), (II), (ILA), (ILB), (ILC), (ILD), (ILD-1), (ILD-2), (ILD-3), (TLD-4), (ILD-4'), (ILD-4"), (TLE), (ILF), (ILG), (ILH), (III), (B), (B-I), or (B-II), or Tables A-D, or a pharmaceutically acceptable salt thereof, as hereinbefore defined with a pharmaceutically acceptable adjuvant(s), diluents(s) or carrier(s).

[0756] The pharmaceutical compositions may be administered topically (e.g., to the skin or to the lung and / or airways) in the form, e.g., of creams, solutions, suspensions, heptafluoroalkane (HFA) aerosols and dry powder formulations, for example, formulations in the inhaler device known as the Turbuhaler®; or systemically, e.g., by oral administration in the form of tablets, capsules, syrups, powders or granules; or by parenteral administration in the form of a sterile solution, suspension or emulsion for injection (including intravenous, subcutaneous, intramuscular, intravascular or infusion); or by rectal administration in the form of suppositories.

[0757] For oral administration the compound of the disclosure may be admixed with adjuvant(s), diluent(s) or carrier(s), for example, lactose, saccharose, sorbitol, mannitol; starch, for example, potato starch, com starch or amylopectin; cellulose derivative; binder, for example, gelatin or polyvinylpyrrolidone; disintegrant, for example cellulose derivative, and / or lubricant, for example, magnesium stearate, calcium stearate, polyethylene glycol, wax, paraffin, and the like, and then compressed into tablets. If coated tablets are required, the cores, prepared as described above, may be coated with a suitable polymer dissolved or dispersed in water or readily volatile organic solvent(s). Alternatively, the tablet may be coated with a concentrated sugar solution which may contain, for example, gum arabic, gelatin, talcum and titanium dioxide.

[0758] For the preparation of soft gelatin capsules, the compound of the disclosure may be admixed with, for example, a vegetable oil or polyethylene glycol. Hard gelatin capsules may contain granules of the compound using pharmaceutical excipients like the abovementioned excipients for tablets. Additionally, liquid or semisolid formulations of the compound of the disclosure may be filled into hard gelatin capsules.

[0759] Liquid preparations for oral application may be in the form of syrups, solutions or suspensions. Solutions, for example may contain the compound of the disclosure, the balance being sugar and a mixture of ethanol, water, glycerol and propylene glycol. Optionally suchAttorney Docket No.: INMD-216 / 01WO 315953-4442liquid preparations may contain coloring agents, flavoring agents, saccharine and / or carboxymethylcellulose as a thickening agent. Furthermore, other excipients known to those skilled in art may be used when making formulations for oral use.

[0760] Therapeutic Use

[0761] In embodiments, the compounds of Formula (A'), (A), (I), (I-A), (T-B), (I-C), (I-D), (I-E), (I-F), (I-G), (II), (II-A), (II-B), (II-C), (II-D), (II-D-1), (II-D-2), (II-D-3), (II-D-4), (II-D- 4'), (II-D-4"), (II-E), (II-F), (II-G), (II-H), (III), (B), (B-I), or (B-II), or Tables A-D, and their pharmaceutically acceptable salts or deuterated form thereof, are DPP1 inhibitors, and thus may be used in any disease area where DPP1 plays a role. As such, in one aspect of the disclosure, a method of treatment is provided. The method of treatment, in one embodiment, comprises, administering to a subject in need thereof, a composition comprising an effective amount of a compound of Formula (A'), (A), (I), (I-A), (I-B), (I-C), (I-D), (I-E), (I-F), (I-G), (II), (II-A), (II-B), (II-C), (II-D), (II-D-1), (II-D-2), (II-D-3), (II-D-4), (II-D-4'), (II-D-4"), (II-E), (II-F), (II-G), (II-H), (III), (B), (B-I), or (B-II), or Tables A-D, or a pharmaceutically acceptable salt thereof, a deuterated form thereof, a racemic form thereof, or a stereoisomer thereof. In embodiments, the method of treatment comprises administering to a subject in need thereof, an effective amount of Compound A3, A34, A35, A36, A39, B3, B3-A, B3-B, B34, B34-A, B34-B, B37, B41, B41-A, B41-B, B44, B44-A, B44-B, B162, or B163, or a pharmaceutically acceptable salt thereof, a deuterated form thereof, racemic form thereof, or stereoisomer thereof. In embodiments, the composition is administered to the patient for an administration period.

[0762] In embodiments, the compounds of Formula (A'), (A), (I), (I-A), (I-B), (I-C), (I-D), (I-E), (I-F), (I-G), (II), (II-A), (II-B), (II-C), (II-D), (II-E), (II-F), (II-G), (II-H), or (III), or Tables A-C, and their pharmaceutically acceptable salts or deuterated form thereof, are DPP I inhibitors, and thus may be used in any disease area where DPP1 plays a role. As such, in one aspect of the disclosure, a method of treatment is provided. The method of treatment, in one embodiment, comprises, administering to a subject in need thereof, a composition comprising an effective amount of a compound of Formula (A'), (A), (I), (I-A), (I-B), (I-C), (I-D), (I-E), (I-F), (I-G), (II), (II-A), (II-B), (II-C), (II-D), (I I-E), (II-F), (II-G), (Il-H), or (III), or Tables A- C, or a pharmaceutically acceptable salt thereof, a deuterated form thereof a racemic form thereof, or a stereoisomer thereof. In embodiments, the method of treatment comprises administering to a subject in need thereof, an effective amount of Compound A3, B3, B34, B37, B41, or B44, or a pharmaceutically acceptable salt thereof, a deuterated form thereof,Attorney Docket No.: INM D-216 / 01 WO 315953-4442racemic form thereof, or stereoisomer thereof. In embodiments, the composition is administered to the patient for an administration period.

[0763] In embodiments, a compound or composition of the present disclosure is administered to a patient in a method for treating a obstructive disease of the airway; chronic rhinosinusitis (CRS); hidradenitis suppurativa (HS); cancer (e.g., cancer metastasis), granulomatosis with polyangiitis (GPA); microscopic polyangiitis (MPA); giant cell arteritis; polyarteritis nodosa; anti-GBM disease (Goodpasture’s); rheumatoid arthritis; lupus nephritis; systemic lupus erythematosus; systemic scleroderma; inflammatory' bowel disease (IBD) (e.g., ulcerative colitis; Crohn’s disease); diabetic nephropathy; diabetic neuropathy; diabetic retinopathy, diabetic ulcers; Duchenne muscular dystrophy; bronchiolitis obliterans; long covid) - prophylaxis of ILD; atopic dermatitis; pyoderma gangrenosum; sweet’s syndrome; dermatomyositis / polymyositis; neutrophilic dermatoses; uveitis; Behcet’s disease; thrombosis including deep vein thrombosis (DVT); bronchopulmonary dysplasia, amyotrophic lateral sclerosis; sickle cell anemia, psoriasis; ventilator-induced lung injury. In embodiments, a compound or composition of the present disclosure is administered to a patient in a method for treating granulomatosis with polyangiitis (GPA).

[0764] In embodiments, a compound or composition of the present disclosure is administered to a patient in a method for treating thrombosis In embodiments, the thrombosis is deep vein thrombosis (DVT).

[0765] In embodiments, a compound or composition of the present disclosure is administered to a patient in a method for treating an obstructive disease of the airway. The obstructive disease of the airway, in one embodiment, is asthma (e.g., bronchial, allergic, intrinsic, extrinsic, exercise-induced, neutrophilic, drug-induced (including aspirin and NSAID-induced and dust- induced asthma, both intermittent and persistent and of all severities) airway hyperresponsiveness, chronic obstructive pulmonary disease (COPD), bronchitis (e.g., infectious bronchitis, eosinophilic bronchitis), emphysema, cystic fibrosis (CF), bronchiectasis (e.g., non-CF bronchiectasis (NCFBE) and bronchiectasis associated with CF), cystic fibrosis; sarcoidosis; alpha-1 antitrypsin (A1AT) deficiency, farmer’s lung and related diseases, hypersensitivity pneumonitis, interstitial lung disease, pulmonary' fibrosis (also known as lung fibrosis) including idiopathic pulmonary fibrosis, cryptogenic fibrosing alveolitis, idiopathic interstitial pneumonias, fibrosis complicating anti-neoplastic therapy and chronic infection, including tuberculosis and aspergillosis and other fungal infections), complications of lung transplantation, vasculitic and thrombotic disorders of the lung vasculature, pulmonary hypertension (e.g., pulmonary arterial hypertension), antitussive activity including treatmentAttorney Docket No.: INMD-216 / 01WO 315953-4442of chronic cough associated with inflammatory' and secretory conditions of the airways, iatrogenic cough, acute and chronic rhinitis including rhinitis medicamentosa, and vasomotor rhinitis; perennial and seasonal allergic rhinitis including rhinitis nervosa (hay fever), nasal polyposis; acute viral infection including the common cold, and infection due to a respiratory vims (e.g., respiratory syncytial virus, influenza, coronavirus (including SARS) and adenovirus), acute lung injury, acute respiratory distress syndrome (ARDS), as well as exacerbations of each of the foregoing respiratory tract disease states. In embodiments, asthma is neutrophilic asthma.

[0766] In embodiments, a compound or composition of the present disclosure is administered to a patient in a method for treating pulmonary' hypertension. In some embodiment, pulmonary hypertension is pulmonary arterial hypertension. In some embodiments, pulmonary' hypertension is pulmonary' hypertension due to left heart disease. In some embodiments, pulmonary' hypertension is pulmonary hypertension associated with chronic lung disease.

[0767] Cystic fibrosis (CF) is caused by abnormalities in the CF transmembrane conductance regulator protein, causing chronic lung infections (particularly with Pseudomonas aeruginosa) and excessive inflammation, and leading to bronchiectasis, declining lung function, respiratory' insufficiency and quality of life. The inflammatory process is dominated by neutrophils that produce NE, as well as other destructive NSPs including CatG and PR3, that directly act upon extracellular matrix proteins and play a role in the host response to inflammation and infection (Dittrich et al., Eur Respir J 2018;51(3)). The methods provided herein employ reversible inhibitors of DPP1. Without wishing to be bound by theory', it is thought that the compounds of formula (A'), (A), (I), (I-A), (I-B), (I-C), (I-D), (I-E), (I-F), (I-G), (II), (II-A), (II-B), (II-C), (II-D), (II-E), (II-F), (II-G), (II-H), or (III), or Tables A-C, or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, administered via the methods provided herein have beneficial effects via inhibiting the activation of NSPs and decreasing inflammation, which in turn leads to a decrease in pulmonary' exacerbations, a decrease in the rate of pulmonary exacerbations, and / or an improvement in lung function (e.g., forced expiratory volume in 1 second [FEVi ]) in CF patients.

[0768] In one embodiment, a method is provided for treating CF comprising administering to a CF patient in need of treatment, a composition comprising an effective amount of a compound of Formula (A'), (A), (I), (I-A), (I-B), (I-C), (I-D), (I-E), (I-F), (I-G), (II), (II- A), (II-B), (II-C), (II-D), (II-D-1), (II-D-2), (II-D-3), (II-D-4), (II-D-4'), (II-D-4"), (II-E), (II-F), (II-G), (II-H), (III), (B), (B-I), or (B-II), or Tables A-D, or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof.Attorney Docket No.: INM D-216 / 01 WO 315953-4442

[0769] In one CF treatment method, a composition comprising an effective amount of a compound of Formula (A'), (A), (I), (I-A), (I-B), (I-C), (I-D), (I-E), (I-F), (I-G), (II), (II- A), (11-B), (11-C), (11-D), (11-D-l), (Il-D-2), (ll-D-3), (Il-D-4), (ll-D-4'), (ll-D-4"), (Il-E), (11-F), (II-G), (II-H), (III), (B), (B-I), or (B-II), or Tables A-D, or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, is administered to a CF patient in need of treatment for an administration period. The method comprises improving the lung function of the patient during the administration period, as compared to the lung function of the patient prior to the administration period. The improvement in lung function in one embodiment, is measured by spirometry.

[0770] Improving the lung function of the patient, in one embodiment, comprises increasing the patient’s forced expiratory volume in 1 second (FEVi), increasing the patient’s forced vital capacity (FVC), increasing the patient’s peak expiratory flow rate (PEFR), or increasing the patient’s forced expiratory' flow between 25% and 75% of FVC (FEF (25-75%)), as compared to the respective value prior to the administration period. Increasing, in one embodiment, is by about 5%, by about 10%, by about 15%, by about 20%, by about 25%, by about 30%, by about 35%, by about 40%, by about 45% or by about 50% of the respective value. Increasing, in one embodiment, is by at least about 5%, by at least about 10%, by at least about 15%, by at least about 20%, by at least about 25%, by at. least about 30%, by at least about 35%, by at least about 40%, by at least about 45% or by at least about 50%. In yet another embodiment, the increasing is by about 5% to about 50%, by about 5% to about 40%, by about 5% to about 30% or by about 5% to about 20%. In even another embodiment, increasing is by about 10% to about 50%, by about 15% to about 50%, by about 20% to about 50%, or by about 25% to about 50%.

[0771] In one embodiment of a method provided herein, a composition comprising an effective amount of a compound of Formula (A'), (A), (I), (I-A), (I-B), (I-C), (I-D), (I-E), (I-F), (I-G), (II), (II-A), (II-B), (II-C), (II-D), (II-D-1), (II-D-2), (II-D-3), (II-D-4), (II-D-4'), (II-D-4"), (II-E), (II-F), (II-G), (II-H), (III), (B), (B-I), or (B-II), or Tables A-D, or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, is administered to a bronchiectasis patient in need of treatment for an administration period. Bronchiectasis is considered a pathological endpoint that results from many disease processes and is a persistent or progressive condition characterized by dilated thick-walled bronchi. The symptoms vary from intermittent episodes of expectoration and infection localized to the region of the lung that is affected to persistent daily expectoration often of large volumes of purulent sputum. Bronchiectasis may be associated with other non-specific respiratory symptoms. TheAttorney Docket No.: INMD-216 / 01WO 315953-4442underlying pathological process of bronchiectasis, without wishing to be bound by theory, has been reported as damage to the airways which results from an event or series of events where inflammation is central to the process (Guideline for non-CF Bronchiectasis, Thorax, July 2010, V. 65(Suppl 1), incorporated by reference herein in its entirety for all purposes).

[0772] Bronchiectasis is considered a pathological endpoint that results from many disease processes and is a persistent or progressive condition characterized by dilated thick-walled bronchi. The symptoms vary from intermittent episodes of expectoration and infection localized to the region of the lung that is affected to persistent daily expectoration often of large volumes of purulent sputum. Bronchiectasis may be associated with other non-specific respiratory symptoms. The underlying pathological process of bronchiectasis, without wishing to be bound by theory, has been reported as damage to the airways which results from an event or series of events where inflammation is central to the process (Guideline for non-CF Bronchiectasis, Thorax, July 2010, V. 65(Suppl 1), incorporated by reference herein in its entirety for ah purposes).

[0773] The methods provided herein employ reversible inhibitors of DPP1. Without wishing to be bound by theory, it is thought that the compounds of Formula (A'), (A), (I), (I- A), (I-B), (I-C), (I-D), (I-E), (I-F), (I-G), (II), (II- A), (II-B), (II-C), (II-D), (II-D-1), (II-D-2), (II-D-3), (II-D-4), (II-D-4'), (11-0-4"), (II-E), (II-F), (II-G), (II-H), (III), (B), (B-I), or (B-II), or Tables A-D, or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, administered via the methods provided herein have beneficial effects via decreasing inflammation and mucus hypersecretion, which in some embodiments, leads to a decrease in pulmonary exacerbations, a decrease in the rate of pulmonary' exacerbations, and / or an improvement in lung function (cough, sputum production, and forced expiratory' volume in 1 second [FEV r ] ) in bronchiectasis patients. Without wishing to be bound by theory, it is thought that the methods provided herein modify bronchiectasis progression by reducing the accelerated rate of lung function decline or lung tissue destruction.

[0774] In one embodiment, the bronchiectasis is non-CF bronchiectasis.

[0775] In one embodiment, the method for treating bronchiectasis comprises improving lung function of the patient during the administration period, as compared to the lung function of the patient prior to the administration period.

[0776] A pulmonary exacerbation, in one embodiment, is characterized by three or more of the following symptoms exhibited for at least 48 hours by the patient: (I) increased cough; (2) increased sputum volume or change in sputum consistency; (3) increased sputum purulence; (4) increased breathlessness and / or decreased exercise tolerance; (5) fatigue and / or malaise;Attorney Docket No.: INM D-216 / 01 WO 315953-4442(6) hemoptysis. In a further embodiment, the three or more symptoms result in a physician’s decision to prescribe an antibiotic(s) to the patient exhibiting the symptoms,

[0777] In one embodiment of a method for treating bronchiectasis, the method comprises decreasing the rate of pulmonary' exacerbation in the subject, compared to the rate of pulmonary exacerbation experienced by the subject prior to the administration period of the composition, or compared to a control subject with bronchiectasis that is not subject to the method of treatment. In a further embodiment, the bronchiectasis is non-CF bronchiectasis.

[0778] In another aspect, a method for treating chronic rhinosinusitis (CRS) in a subject in need thereof is provided. The method comprises in one embodiment, administering to the subject for an administration period, a pharmaceutical composition comprising an effective amount of a compound of Formula (A'), (A), (I), (I-A), (I-B), (I-C), (I-D), (I-E), (I-F), (1-G), (II), (II-A), (II-B), (II-C), (II-D), (II-D-I), (II-D-2), (IL-D-3), (II-D-4), (II-D-4'), (II-D-4"), (II- E), (II-F), (II-G), (II-H), (III), (B), (B-I), or (B-II), or Tables A-D, or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof.

[0779] The chronic rhinosinusitis is chronic rhinosinusitis without nasal polyps (CRSsNP), or chronic rhinosinusitis with nasal polyps (CRSwNP) In some embodiments, the chronic rhinosinusitis is chronic rhinosinusitis without nasal polyps (CRSsNP) In some embodiments, the chronic rhinosinusitis is chronic rhinosinusitis with nasal polyps (CRSwNP). In some embodiments, the chronic rhinosinusitis is refractory’ chronic rhinosinusitis. In some embodiments, the refractory chronic rhinosinusitis is refractory chronic rhinosinusitis without nasal polyps (CRSsNP). In some embodiments, the refractory chronic rhinosinusitis is refractory chronic rhinosinusitis with nasal polyps (CRSwNP).

[0780] In some embodiments, the subject exhibits one or more symptoms of CRS. In some embodiments, the one or more symptoms of CRS are: (a) nasal congestion; (b) nasal obstruction; (c) nasal discharge; (d) post-nasal drip; I facial pressure; (f) facial pain; (g) facial fullness; (h) reduced smell; (i) depression; (j) mucosal edema; (k) mucopurulent discharge; (1) obstruction of the middle meatus; (m) mucosal changes within the ostiomeatal complex and sinuses; (n) rhinorrhea; or (o) any combinations thereof. In some embodiments, obstruction of the middle meatus is mucosal obstruction, edematous obstruction, or a combination thereof.

[0781] In some embodiments, the administration of the pharmaceutical composition reduces, diminishes the severity of, delays the onset of, or eliminates one or more symptoms of CRS. In some embodiments, the one or more symptoms of CRS are: (a) nasal congestion; (b) nasal obstruction; (c) nasal discharge; (d) post-nasal drip; I facial pressure; (f) facial pain; (g) facial fullness; (h) reduced smell; (i) depression; (j) mucosal edema; (k) mucopurulent discharge; (1)Attorney Docket No.: INMD-216 / 01WO 315953-4442obstruction of the middle meatus; (m) mucosal changes within the ostiomeatal complex and sinuses, (n) rhinorrhea; (o) or any combinations thereof. In some embodiments, the administration of the pharmaceutical composition enhances sinus drainage.

[0782] In some embodiments, the methods comprise reducing a composite severity score of one or more symptoms of CRS. As used herein, the “composite severity score” is a quantitative measure of all the symptoms of CRS exhibited by the subject. In some embodiments, the composite severity score is a sum total of all the daily symptoms exhibited by the subject. In some embodiments, the composite severity score is reduced during or subsequent to the administration period, as compared to the composite severity score measured prior to the administration period. In some embodiments, the one or more symptoms of CRS exhibited by the subject may be any symptoms described herein or known in the art to be associated with CRS. In some embodiments, the one or more symptoms of CRS are: nasal congestion, reduced smell, rhinorrhea, or any combination thereof. In some embodiments, the rhinorrhea is anterior rhinorrhea. In some embodiments, the rhinorrhea is posterior rhinorrhea.

[0783] In some embodiments, the methods comprise decreasing the Sino-Nasal Outcome Test- 22 (SNOT-22) score of the subject during the administration period or subsequent to the administration period, compared to the SNOT-22 score of the subject prior to the administration period. As used herein, “SNOT-22” is a patient-reported measure of outcome developed for use in CRS with or without nasal polyps and contains 22 individual questions. The questions cover a broad range of health and health-related quality of life problems including physical problems, functional limitations and emotional consequences. The theoretical range of the SNOT-22 score is 0-110, with lower scores implying a better health- related quality of life. Further details of SNOT-22 are provided in Hopkins, et al., Clin. Otolaryngol. 2009, 34, 447-454, and Kennedy, et al., Ann Allergy Asthma Immunol. 2013 October; 111(4): 246-251, the contents of which are incorporated herein by reference in its entirety.

[0784] Hidradenitis suppurativa (HS) is a chronic relapsing inflammatory disorder. The symptoms include skin lesions that are often associated hair follicles, and may be painful, inflamed and / or swollen. In some cases, when the skin lesions heal, they can recur, and may lead to tunnels under the skin and progressive scarring. Since HS is a chronic condition, it can persist for many years and also, worsen over time, with serious effects on quality of life, psychological and emotional well-being. In fact, HS patients have increased rates of anxiety and depression with a risk of suicide two and a half times that of the general population.Attorney Docket No.: INMD-216 / 01WO 315953-4442

[0785] HS patients are categorized according to disease severity, termed Hurley staging, as mild (Stage I), moderate (Stage II), or severe (Stage III). Although more than 200,000 cases of HS are diagnosed in the U. S. per year, this disease can be difficult to diagnose and requires specialized care. HS may be mistaken for an infection, an ingrown hair or other conditions. Moreover, current treatment options are limited and lack efficacy.

[0786] In one aspect, a method of treating HS in a subject in need thereof is provided. The method comprises in one embodiment, administering to the subject for an administration period, a pharmaceutical composition comprising an effective amount of a compound of Formula (A'), (A), (I), (I-A), (1-B), (I-C), (I-D), (I-E), (I-F), (I-G), (II), (II-A), (Il-B), (II-C), (II-D), (II-D-1), (II-D-2), (II-D-3), (II-D-4), (II-D-4'), (II-D-4"), (II-E), (II-F), (II-G), (II-H), (III), (B), (B-I), or (B-II), or Tables A-D, or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof. In a further embodiment, the method of treating HS comprises reducing neutrophilic inflammation in the subject.

[0787] The HS in one embodiment, is Hurley Stage I HS, Hurley Stage II HS or Hurley Stage III HS. In some embodiments, the HS is Hurley Stage I HS. In some embodiments, the HS is Hurley Stage II HS. In some embodiments, the HS is Hurley Stage III HS.

[0788] The disclosure provides methods of treating cancer in a subject in need thereof, comprising, administering to the subject, a pharmaceutical composition comprising an effective amount of any one of the compounds disclosed herein. The disclosure provides methods of treating cancer-induced pain in a subject having cancer, comprising, administering to the subject for an administration period, a pharmaceutical composition comprising an effective amount of any one of the compounds disclosed herein. In some embodiments, the cancer-induced pain is cancer-induced bone pain. The disclosure also provides methods of treating cancer-induced bone pain in a subject having cancer, comprising, administering to the subject for an administration period, a pharmaceutical composition comprising an effective amount of any one of the compounds disclosed herein.

[0789] In some embodiments, the cancer comprises a primary solid tumor. In some embodiments, the cancer is bladder cancer, lung cancer, brain cancer, ovarian cancer, pancreatic cancer, colorectal cancer, prostate cancer, liver cancer, hepatocellular carcinoma, kidney cancer, stomach cancer, skin cancer, fibroid cancer, lymphoma, virus-induced cancer, oropharyngeal cancer, testicular cancer, thymus cancer, thyroid cancer, melanoma, or bone cancer.

[0790] In some embodiments, the cancer is bladder cancer. In some embodiments, the cancer is lung cancer. In some embodiments, the cancer is brain cancer. In some embodiments, theAttorney Docket No.: INMD-216 / 01WO 315953-4442cancer is ovarian cancer. In some embodiments, the cancer is pancreatic cancer. In some embodiments, the cancer is colorectal cancer. In some embodiments, the cancer is prostate cancer. In some embodiments, the cancer is liver cancer. In some embodiments, the cancer is hepatocellular carcinoma. In some embodiments, the cancer is kidney cancer. In some embodiments, the cancer is stomach cancer. In some embodiments, the cancer is skin cancer. In some embodiments, the cancer is fibroid cancer. In some embodiments, the cancer is lymphoma. In some embodiments, the cancer Is virus-induced cancer. In some embodiments, the cancer is oropharyngeal cancer. In some embodiments, the cancer is testicular cancer. In some embodiments, the cancer is thymus cancer. In some embodiments, the cancer is thyroid cancer. In some embodiments, the cancer is melanoma. In some embodiments, the cancer is bone cancer. In some embodiments, the fibroid cancer is leiomyosarcoma.

[0791] In some embodiments, the breast cancer comprises ductal carcinoma, lobular carcinoma, medullary' carcinoma, colloid carcinoma, tubular carcinoma, or inflammatory' breast cancer. In some embodiments, the breast cancer comprises ductal carcinoma. In some embodiments, the breast cancer comprises lobular carcinoma. In some embodiments, the breast cancer comprises medullary carcinoma. In some embodiments, the breast cancer comprises colloid carcinoma In some embodiments, the breast cancer comprises tubular carcinoma In some embodiments, the breast cancer comprises inflammatory breast cancer.

[0792] In some embodiments, the breast cancer is triple-negative breast cancer. In some embodiments, the breast cancer does not respond to hormonal therapy or therapeutics that target the HER2 protein receptors.

[0793] In some embodiments, the lymphoma is Hodgkin’s lymphoma, non-Hodgkin’s lymphoma, diffuse large B-cell lymphoma, B-cell immunoblastic lymphoma, Natural Killer cell lymphoma, T-cell lymphoma, Burkitt lymphoma or Kaposi’s Sarcoma. In some embodiments, the lymphoma is Hodgkin’s lymphoma. In some embodiments, the lymphoma is non-Hodgkin’s lymphoma. In some embodiments, the lymphoma is diffuse large B-cell lymphoma. In some embodiments, the lymphoma is B-cell immunoblastic lymphoma. In some embodiments, the lymphoma is Natural Killer cell lymphoma. In some embodiments, the lymphoma is T-cell lymphoma. In some embodiments, the lymphoma is Burkitt lymphoma. In some embodiments, the lymphoma is Kaposi’s Sarcoma.

[0794] In some embodiments, the brain cancer is astrocytoma, anaplastic astrocytoma, glioblastoma multiforme, oligodendroglioma, ependymoma, meningioma, schwannoma, or medulloblastoma. In some embodiments, the brain cancer is astrocytoma. In some embodiments, the brain cancer is anaplastic astrocytoma. In some embodiments, the brainAttorney Docket No.: INMD-216 / 01WO 315953-4442cancer is glioblastoma multiforme. In some embodiments, the brain cancer is oligodendroglioma. In some embodiments, the brain cancer is ependymoma. In some embodiments, the brain cancer is meningioma. In some embodiments, the brain cancer is schwannoma In some embodiments, the brain cancer is medulloblastoma.

[0795] In some embodiments, the cancer is liquid tumor. In some embodiments, the liquid tumor is acute myeloid leukemia (AML), acute lymphoblastic leukemia, acute lymphocytic leukemia, acute promyelocytic leukemia, chronic myeloid leukemia, hairy cell leukemia, a myeloproliferative disorder, Natural Killer cell leukemia, blastic plasmacytoid dendritic cell neoplasm, chronic myelogenous leukemia (CML), mastocytosis, chronic lymphocytic leukemia (CLL), multiple myeloma (MM), or myelodysplastic syndrome (MDS). In some embodiments, the liquid tumor is acute myeloid leukemia (AML). In some embodiments, the liquid tumor is acute lymphoblastic leukemia. In some embodiments, the liquid tumor is acute lymphocytic leukemia. In some embodiments, the liquid tumor is acute promyelocytic leukemia In some embodiments, the liquid tumor is chronic myeloid leukemia. In some embodiments, the liquid tumor is hairy cell leukemia. In some embodiments, the liquid tumor is a myeloproliferative disorder. In some embodiments, the liquid tumor is Natural Killer cell leukemia In some embodiments, the liquid tumor is blastic plasmacytoid dendritic cell neoplasm. In some embodiments, the liquid tumor is chronic myelogenous leukemia (CML). In some embodiments, the liquid tumor is mastocytosis. In some embodiments, the liquid tumor is chronic lymphocytic leukemia (CLL). In some embodiments, the liquid tumor is multiple myeloma (MM). In some embodiments, the liquid tumor is myelodysplastic syndrome (MDS).

[0796] In some embodiments, the cancer is a pediatric cancer. In some embodiments, the pediatric cancer is neuroblastoma, Wilms tumor, rhabdomyosarcoma, retinoblastoma, osteosarcoma or Ewing sarcoma. In some embodiments, the pediatric cancer is neuroblastoma. In some embodiments, the pediatric cancer is Wilms tumor. In some embodiments, the pediatric cancer is rhabdomyosarcoma. In some embodiments, the pediatric cancer is retinoblastoma In some embodiments, the pediatric cancer is osteosarcoma. In some embodiments, the pediatric cancer is Ewing sarcoma.

[0797] In some embodiments, the cancer is metastatic cancer. In some embodiments, the subject is at a risk for developing metastatic cancer. In some embodiments, the metastatic cancer comprises metastasis of breast cancer to the brain, bone, pancreas, lymph nodes, and / or liver. In some embodiments, the metastatic cancer comprises metastasis of bone cancer to the lung. In some embodiments, the metastatic cancer comprises metastasis of colorectal cancer to the peritoneum, the pancreas, the stomach, the lung, the liver, the kidney, and / or the spleen. InAttorney Docket No.: INMD-216 / 01WO 315953-4442some embodiments, the metastatic cancer comprises metastasis of stomach cancer to the mesentery, the spleen, the pancreas, the lung, the liver, the adrenal gland, and / or the ovary. In some embodiments, the metastatic cancer comprises metastasis of leukemia to the lymph nodes, the lung, the liver, the hind limb, the brain, the kidney, and / or the spleen. In some embodiments, the metastatic cancer comprises metastasis of liver cancer to the intestine, the spleen, the pancreas, the stomach, the lung, and / or the kidney. In some embodiments, the metastatic cancer comprises metastasis of lymphoma to the kidney, the ovary, the liver, the bladder, and / or the spleen.

[0798] In some embodiments, the metastatic cancer comprises metastasis of hematopoietic cancer to the intestine, the lung, the liver, the spleen, the kidney, and / or the stomach. In some embodiments, the metastatic cancer comprises metastasis of melanoma to lymph nodes and / or the lung. In some embodiments, the metastatic cancer comprises metastasis of pancreatic cancer to the mesentery, the ovary', the kidney, the spleen, the lymph nodes, the stomach, and / or the liver. In some embodiments, the metastatic cancer comprises metastasis of prostate cancer to the lung, the pancreas, the kidney, the spleen, the intestine, the liver, the bone, and / or the lymph nodes. In some embodiments, the metastatic cancer comprises metastasis of ovarian cancer to the diaphragm, the liver, the intestine, the stomach, the lung, the pancreas, the spleen, the kidney, the lymph nodes, and / or the uterus. In some embodiments, the metastatic cancer comprises metastasis of myeloma to the bone.

[0799] In some embodiments, the metastatic cancer comprises metastasis of lung cancer to the bone, the brain, the lymph nodes, the liver, the ovary, and / or the intestine. In some embodiments, the metastatic cancer comprises metastasis of kidney cancer to the liver, the lung, the pancreas, the stomach, the brain, and / or the spleen. In some embodiments, the metastatic cancer comprises metastasis of bladder cancer to the bone, the liver and / or the lung. In some embodiments, the metastatic cancer comprises metastasis of thyroid cancer to the bone, the liver and / or the lung.

[0800] In some embodiments, the methods disclosed herein comprise treating cancer-induced bone pain (CIBP) in a subject having metastasis of a cancer to the bone. In some embodiments, the subject has metastasis of prostate cancer, breast cancer, lung cancer, or myeloma to the bone. In some embodiments, the subject is identified as having metastasis to the bone by the use of any one of the following methods: plain film radiography, computed tomography, technetium 99m bone scan, magnetic resonance imaging, fluorodeoxy glucose positron emission tomography, fluorine positron emission tomography, and / or choline positron emission tomography, but is not yet feeling cancer-induced bone pain. In some embodiments,Attorney Docket No.: INMD-216 / 01WO 315953-4442the subject is suffering from cancer-induced bone pain, which is indicative of metastasis of a previously treated or untreated primary' tumor to the bone. In some embodiments, the cancer has metastasized to vertebrae, pelvis, long bones, or ribs.

[0801] In some embodiments, administration of the composition diminishes the severity of, delays the onset of, or eliminates a symptom of cancer. In some embodiments, the symptom of cancer is cancer-induced bone pain (CIBP). Tn some embodiments, the CIBP is neuropathic pain. In some embodiments, the CIBP is inflammatory pain. In some embodiments, the CIBP is spontaneous pain. In some embodiments, the symptom of cancer is nociceptive hypersensitivity. In some embodiments, the symptom of cancer is allodynia, In some embodiments, the allodynia is tactile allodynia. In some embodiments, the tactile allodynia is static mechanical allodynia. In some embodiments, the tactile allodynia is dynamic mechanical allodynia. In some embodiments, the subject has bone cancer or metastasis to the bone.

[0802] In yet another embodiment of the present disclosure, a method for treating lupus nephritis (LN) in a subject in need thereof is provided. The method comprises administering to the subject for an administration period, a pharmaceutical composition comprising an effective amount of a compound of Formula (A'), (A), (I), (I-A), (I-B), (I-C), (I-D), (I-E), (I-F), (I-G), (II), (II-A), (II-B), (II-C), (II-D), (II-D-1), (II-D-2), (II-D-3), (II-D-4), (II-D-4'), (II-D-4''), (II-E), (II-F), (II-G), (H-H), (III), (B), (B-I), or (B-II), or Tables A-D, or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof.

[0803] In embodiments of the present disclosure, a method for treating arthritis in a subject in need thereof is provided. The method comprises administering to the subject for an administration period, a pharmaceutical composition comprising an effective amount of a compound of Formula (A'), (A), (I), (I-A), (I-B), (I-C), (I-D), (I-E), (I-F), (I-G), (II), (II-A), (II-B), (II-C), (II-D), (II-D-1), (II-D-2), (II-D-3), (II-D-4), (II-D-4'), (II-D-4"), (II-E), (II-F), (II-G), (II-II), (III), (B), (B-I), or (B-II), or Tables A-D, or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof. In embodiments, arthritis is osteoarthritis. In embodiments, arthritis is rheumatoid arthritis.

[0804] Osteoarthritis (OA) is typically not autoimmune in origin and is typically a gradual, degenerative joint disease due to age-related chronic use or injury of the joints leading to cartilage breakdown, bone changes and local non-resolving synovial inflammation. In embodiments, the present disclosure provides a method for treating osteoarthritis (OA) in a patient in need thereof, comprising administering to the patient an effective amount of a compound disclosed herein (e.g., a compound of Formula (A'), (A), (I), (I-A), (I-B), (I-C), (I- D), (I-E), (I-F), (I-G), (II), (II-A), (II-B), (II-C), (II-D), (II-D-1), (II-D-2), (II-D-3), (II-D-4),Attorney Docket No.: INMD-216 / 01WO 315953-4442(ILD-4'), (ILD-4"), (ILE), (ILF), (ILG), (ILH), (III), (B), (B-I), or (B-II), or Tables A-D, or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof) In embodiments, the treating of osteoarthritis (OA) comprises improving weight loss and / or inflamed paw volume of the patient during the administration period, as compared to the weight loss and / or inflamed paw volume of the patient prior reducing weight loss and / or inflamed paw volume of the patient during the administration period, as compared to the weight loss and / or inflamed paw volume of the patient prior to the administration period.

[0805] Rheumatoid arthritis (RA) is characterized by inflammation and thickening of the joint capsule, together with an effect on the underlying bone and cartilage. Currently, the cause of RA is unknown and no satisfactory' cure for RA is available. While a number of therapeutic agents have been developed and utilized to alleviate pain and inflammation associated with the disease, such as disease-modifying antirheumatic drugs (DMARDs) and non-steroidal antiinflammatory' agents (NSAIDs), they often produce intolerable side effects. To addresses this and other needs, the present disclosure, in one embodiment, provides a method for treating RA using reversible inhibitors of DPP 1 of Formula (A'), (A), (I), (LA), (LB), (LC), (LD), (LE), (LF), (LG), (II), (ILA), (ILB), (ILC), (II-D), (II-D-1), (ILD-2), (ILD-3), (II-D-4), (II-D-4’), (ILD-4"), (ILE), (ILF), (ILG), (ILH), (III), (B), (B-I), or (B-II), or Tables A-D, or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof. In one embodiment, a method of for treating RA in a subject in need thereof is provided, and comprises administering to the subject for an administration period, a pharmaceutical composition comprising an effective amount of a compound of Formula (A'), (A), (I), (LA), (LB), (LC), (LD), (LE), (LF), (LG), (II), (ILA), (ILB), (ILC), (11-D), (11-D-l), (ILD-2), (11- D-3), (ILD-4), (ILD-4'), (ILD-4"), (ILE), (ILF), (ILG), (ILH), (III), (B), (B-I), or (B-II), or Tables A-D, or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof. In a further embodiment, the method comprises reducing neutrophilic inflammation in the subject.

[0806] Inflammatory bowel disease (IBD) is a group of inflammatory conditions that affect the colon and small intestine. The most common IBDs are Crohn’s disease and ulcerative colitis. The present disclosure, in one embodiment, addresses the need for novel IBD therapies. Specifically, in one embodiment, a method for treating an inflammatory bowel disease (IBD) in a subject in need thereof is provided. The method comprises administering to the subject for an administration period, a pharmaceutical composition comprising an effective amount of a compound of Formula (A'), (A), (I), (LA), (LB), (LC), (LD), (LE), (LF), (LG), (II), (ILA), (ILB), (ILC), (ILD), (ILD-1), (ILD-2), (ILD-3), (ILD-4), (ILD-4'), (ILD-4"), (ILE), (ILF),Attorney Docket No.: INMD-216 / 01 WO 315953-4442(II-G), (II-H), (III), (B), (B-I), or (B-II), or Tables A-D, or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof,

[0807] In a further embodiment, the 1BD is Crohn’s disease or ulcerative colitis. In even a further embodiment, the method comprises reducing neutrophilic inflammation in the subject.

[0808] In embodiments, a compound or composition of the present disclosure is administered to a patient in a method for treating heart failure. In some embodiments, heart failure is heart failure with reduced ejection fraction. In some embodiments, heart failure is heart failure with preserved ejection fraction.

[0809] In yet another embodiment of the disclosure, a method for treating i schemia / reperfusion (IR) injury is provided, comprising administering to a patient in need of treatment, a compound or composition of the present disclosure to the patient in need of treatment. The IR injury, in one embodiment, is due to Heart transplantation (HTX). As such, in one embodiment, the patient is a heart transplant recipient. In a further embodiment, the patient is administered a compound or composition of the present disclosure during heart transplantation or subsequent to heart transplantation. In one embodiment of this method, the patient is administered one of the compounds set forth in Tables A-C. In yet even a further embodiment, the compound is present in an oral composition and is administered once daily to the patient in need of treatment.

[0810] Treating the IR injury in one embodiment, comprises improving left-ventricular (LV) graft function. Graft function can be measured, in one embodiment, by measuring LV systolic function, e.g., by measuring left-ventricular systolic pressure (LVSP), developed pressure, maximal slope of systolic pressure increment (dP / dtmax), and / or rate pressure product (mmHg*bpm).

[0811] In one embodiment, treating IR injury comprises increasing the patient’s LVSP (mmHg) during or subsequent to the administration period, as compared to the patient’s LVSP (mmHg) prior to the administration period. In one embodiment, treating IR injury comprises increasing the patient’s developed pressure (mmHg) during or subsequent to the administration period, as compared to the patient’s developed pressure (mmHg) prior to the administration period. In yet another embodiment, treating IR injury in a patient in need of treatment comprises increasing the maximal slope of systolic pressure increment (dP / dtmax) for the patient during or subsequent to the administration period, as compared to the maximal slope of systolic pressure increment (dP / dtmax) for the patient prior to the administration period. In even yet another embodiment, treating IR injury in a patient in need of treatment comprises increasing the patient’s rate pressure product during or subsequent to the administration period, as compared to the patient’s rate pressure product prior to the administration period.Attorney Docket No.: INMD-216 / 01WO 315953-4442

[0812] In embodiments, a compound or composition of the present disclosure is administered to a patient in a method for treating liver injury. The method comprises administering to the subject for an administration period, a pharmaceutical composition comprising an effective amount of a compound of Formula (A / ), (A), (I), (I-A), (LB), (I-C), (I-D), (I E), (I-F), (LG), (II), (ILA), (II-B), (ILC), (II-D), (II-D-1 ), (II-D-2), (ILD-3), (1I-D-4), (ILD-4'), (Il-D-4"), (II-E), (ILF), (TI-G), (II-H), (III), (B), (B-T), or (B-IT), or Tables A-D, or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof. In embodiments, the liver injury is acute liver injury. In embodiments, the liver injury' is drug-induced acute liver injury. In one embodiment, the liver injury is acetaminophen (APAP)-induced acute liver injury. In one embodiment, the liver injury is caused by acetaminophen overdose. In embodiment, the liver injury is caused by nonsteroidal anti-inflammatory drugs (NSAIDs), such as ibuprofen, diclofenac, and naproxen. In one embodiment, the treatment of ALI is a prophylactic treatment

[0813] In embodiments, a compound or composition of the present disclosure is administered to a patient in a method for treating sepsis. The method comprises administering to the subject for an administration period, a pharmaceutical composition comprising an effective amount of a compound of Formula (A'), (A), (I), (I-A), (I-B), (I-C), (I-D), (I-E), (I-F), (I-G), (II), (ILA), (II-B), (ILC), (ILD), (ILD-1), (ILD-2), (ILD-3), (ILD-4), (ILD-4'), (ILD-4"), (ILE), (ILF), (II-G), (II-H), (III), (B), (B-I), or (B-II), or Tables A-D, or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof. In one embodiment, sepsis is a consequence of the patient’s response to overwhelming bacterial infection. In one embodiment, the treatment of sepsis prevents organ dysfunction and death of the patient.

[0814] The length of the administration period in any given case may depend on the nature and severity of the condition being treated and / or prevented and be determined by the physician. In one embodiment, the administration period starts at about the time of condition / disease diagnosis and continues for the lifetime of the patient.

[0815] In some embodiments, the administration period is about 30 days, about 35 days, about 40 days, about 45 days, about 50 days, about 1 month, about 2 months, about 3 months, about 4 months, about 5 months, about 6 months, about 7 months, about 8 months, about 9 months, about 10 months, about 11 months, about 12 months, about 13 months, about 14 months, about 15 months, about 16 months, about 17 months, about 18 months, about 19 months, about 20 months, about 21 months, about 22 months, about 23 months, about 24 months, about 30 months, about 36 months, about 4 years, about 5 years, about 10 years, about 15 years or about 20 years. In some embodiments, the compounds or compositions disclosed herein may be administered for a period of about 24 weeks. In some embodiments, the compounds orAttorney Docket No.: INMD-216 / 01WO 315953-4442compositions disclosed herein may be administered for a period of about 52 weeks. In yet another embodiment, the administration period is at least about 1 month, at least about 2 months, at least about 3 months, at least about 4 months, at least about 5 months, at least about 6 months, at least about 7 months, at least about 8 months, at least about 9 months, at least about 10 months, at least about 11 months, at least about 12 months, at least about 13 months, at least about 14 months, at least about 15 months, at least about 16 months, at least about 17 months, at least about 18 months, at least about 19 months, at least about 20 months, at least about 21 months, at least about 22 months, at least about 23 months, at least about 24 months, at least about 30 months, at least about 36 months, at least about 4 years, at least about 5 years, at least about 10 years, at least about 15 years or at least about 20 years.

[0816] In some embodiments, the administration period for the methods provided herein is at least about 30 days, at least about 35 days, at least about 40 days, at least about 45 days, at least about 50 days, at least about 2 months, at least about 3 months, at least about 4 months or at least about 6 months, at least about 7 months, at least about 8 months, at least about 9 months, at least about 10 months, at least about 11 months, at least about 1 year, at least about 2 years, at least about 3 years, at least about 4 years, at least about 5 years. The administration period for the methods provided herein, in another embodiment, is from about 30 days to about 180 days. In another embodiment, the administration period is from about 30 days to about 36 months, or from about 30 days to about 30 months, or from about 30 days to about 24 months, or from about 30 days to about 18 months, or from about 30 days to about 12 months, or from about 30 days to about 6 months, or from about 6 months to about 30 months, or from about 6 months to about 24 months, or from about 6 months to about 18 months, or from about 12 months to about 36 months, or from about 12 months to about 24 months.

[0817] In one embodiment, the administration period is from about 1 year to about 30 years. For example, the administration period, in one embodiment, is from about 1 year to about 25 years, 1 year to about 20 years, from about 1 year to about 15 years, from about I year to about 10 years, from about 1 year to about 5 years, from about 1 year to about 3 years, from about 1 year to about 2 years, from about 2 years to about 15 years, from about 2 year to about 10 years, from about 2 years to about 8 years, from about 2 year to about 5 years, from about 2 years to about 4 years, or from about 2 years to about 3 years.

[0818] In one embodiment of the method, the subject is administered the composition once daily during the administration period. In another embodiment, the patient is administered the composition twice daily, or every7other day, or once a week during the administration period.Attorney Docket No.: INMD-216 / 01WO 315953-4442In another embodiment, administration is every other day, every third day, 3 times per week or 4 times per week during the administration period.

[0819] In one embodiment, the oral dosage form is administered once daily during the administration period. In a further embodiment, the oral dosage form is administered at approximately the same time every day, e.g., prior to breakfast. In another embodiment, the composition comprising an effective amount of the compound of Formula (A'), (A), (I), (I-A), (LB), (LC), (I-D), (I-E), (LF), (LG), (II), (ILA), (ILB), (ILC), (ILD), (ILD-1), (ILD-2), (II- D-3), (ILD-4), (ILD-4'), (ILD-4"), (ILE), (ILF), (ILG), (ILH), (III), (B), (B-I), or (B-II), or Tables A-D, or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof is administered once a day or twice a day during the administration period. In yet another embodiment, the composition comprising an effective amount of the compound of Formula (A'), (A), (I), (LA), (LB), (LC), (I-D), (LE), (LF), (LG), (II), (ILA), (ILB), (ILC), (ILD), (II-D-l), (ILD-2), (ILD-3), (ILD-4), (ILD-4'), (ILD-4"), (ILE), (ILF), (ILG), (ILH), (III), (B), (B-I), or (B-II), or Tables A-D, or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof is administered once per week, every other day, every third day, twice per week, three times per week, four times per week, or five times per week during the administration period.

[0820] Administration, in one embodiment, is via the oral route. In a further embodiment, the composition is administered once daily.

[0821] The dosage administered will vary' with the compound of Formula (A'), (A), (I), (LA), (LB), (LC), (I-D), (LE), (LF), (LG), (II), (ILA), (ILB), (ILC), (II-D), (ILD-1), (ILD-2), (II- D-3), (ILD-4), (ll-D-4'), (ILD-4"), (ILE), (ILF), (11-G), (11-H), (III), (B), (B-I), or (B-II), or Tables A-D, or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof employed, the mode of administration, and the treatment outcome desired. For example, in one embodiment, the daily dosage of the compound of Formula (A'), (A), (I), (LA), (LB), (LC), (I-D), (LE), (LF), (LG), (II), (ILA), (ILB), (ILC), (ILD), (ILD-1), (ILD-2), (ILD-3), (ILD-4), (II-D-4'), (II-D-4"), (ILE), (ILF), (ILG), (ILH), (III), (B), (B-I), or (B-II), or Tables A-D, or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof if inhaled, may be in the range from 0.05 micrograms per kilogram body weight (pg / kg) to 100 micrograms per kilogram body weight (pg / kg). Alternatively, in one embodiment, if the compound of Formula (A'), (A), (I), (LA), (LB), (LC), (LD), (LE), (LF), (LG), (II), (ILA), (ILB), (ILC), (ILD), (ILD-1), (ILD-2), (ILD-3), (ILD-4), (ILD-4'), (II-D-4"), (ILE), (ILF), (ILG), (ILH), (III), (B), (B-I), or (B-II), or Tables A-D, or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof is administered orally, then the daily dosage of the compound ofAttorney Docket No.: INMD-216 / 01WO 315953-4442the disclosure may be in the range from 0.01 micrograms per kilogram body weight (pg / kg) to 100 milligrams per kilogram body weight (mg / kg).

[0822] The compounds of Formula (A'), (A), (1), (LA), (LB), (1-C), (LD), (LE), (1-F), (LG), (II), (ILA), (ILB), (II-C), (II-D), (ILD-1), (II-D-2), (ILD-3), (ILD-4), (ILD-4'), (ILD-4"), (II-E), (ILF), (ILG), (ILH), (III), (B), (B-I), or (B-II), or Tables A-D, or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof may be used on their own but will generally be administered in the form of a pharmaceutical composition in which the Formula (A'), (A), (I), (LA), (LB), (LC), (LD), (LE), (LF), (LG), (II), (ILA), (ILB), (ILC), (ILD), (II-D-1), (ILD-2), (II-D-3), (ILD-4), (ILD-4'), (ILD-4"), (ILE), (ILF), (ILG), (ILH), (III), (B), (B-I), or (B-II), or Tables A-D, or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof is in association with pharmaceutically acceptable adjuvant(s), diluents(s) or carrier(s). Conventional procedures for the selection and preparation of suitable pharmaceutical formulations are described in, for example, “Pharmaceuticals - The Science of Dosage Form Designs”, M. E Aulton, Churchill Livingstone, 2ndEd. 2002.

[0823] EXAMPLES

[0824] The present disclosure is further illustrated by reference to the following Examples. However, it should be noted that these Examples, like the embodiments described above, are illustrative and are not to be construed as restricting the scope of the disclosure in any way.

[0825] In embodiments, compounds of the present disclosure can be synthesized using the following methods. General reaction conditions are given, and reaction products can be purified by generally known methods including silica gel chromatography using various organic solvents such as hexane, dichloromethane, ethyl acetate, methanol and the like or preparative reverse phase high pressure liquid chromatography.

[0826] Example 1: Synthesis of Compounds of the DisclosureN'Acid-A CH3CN, BSA H, N Step 2 H Step 1 Amine Intermediate-1Intermediate-2Attorney Docket No.: INMD-216 / 01WO 315953-4442

[0827] Step 1: Starting Amine (25-30 mg, 1.00 equiv), CH3CN (2 mL) and N, O- bis(trimethylsilyl)acetamide (BSA) (1.20 equiv) were placed into a sealed 8-mL tube. The mixture was stirred for 4 h at 40 °C. After cooled to room temperature. The reaction was used in the next step directly.

[0828] Examples of the starting Amine includes:Attorney Docket No.: INMD-216 / 01WO 315953-4442

[0829] Step 2: Intermediate- 1 (25-30 mg, 1.00 equiv) in CH3CN, or the mixture of the preceding step were placed into a sealed 8-mL tube. Then DIEA (4.00 equiv), Acid-A (1.20 equiv), HATU (1.20 equiv) and CH3CN (2 mL) were added to the tube. The mixture was stirred for 1 h at room temperature. The reaction was quenched with MeOH (1 mL). The mixture was purified by Prep-HPLC to give Intermediate-2.

[0830] Examples of Acid-A includes:Attorney Docket No.: INMD-216 / 01WO 315953-4442HO

[0831] Step 3: Interm ediate-2 (15-25 mg, 1.00 equiv), BSA (1.20 equiv) in CH3CN (3 mL) was stirred at room temperature for 4 h. The reaction was quenched with MeOH (1 mL). The mixture was purified by Prep-HPLC to give the desired product.

[0832] Compounds prepared according to this Examples are listed in Table 1 below'.Table 1. Synthesized CompoundsComp. MW Yield PurityMass (ES, m / z)No. (g / mol) (mg, %) (%)”A4 477.56 5.1 mg, 18.91 % 98.278% [M+H]+ calcd 478.2, found 4782 A5 432.52 15 mg, 56.11 % 99.742% [M+H]+ calcd 433.2, found 433.2 A6 519.6 9.2 mg, 32.38 % 92.831% [M+H]+ calcd 520.3, found 520.3 A7 420.47 11.4 mg, 42.44 % 99.452% [M+H]+ calcd 421.2, found 421.2 A8 495.56 11.5 mg, 43.18 % 99.294% [M+H]+ calcd 496.2, found 496.2 A9 450.51 5.9 mg, 20.43 % 92.09% [M+H]+ calcd 451.2, found 451.2 A10 537.59 8.1 mg, 29.56 % 96.079% [M+H]+ calcd 538.2, found 538.2 All 438.46 5.9 mg, 21.64 % 97.704% [M+H]+ calcd 439.2, found 439.2 A12 539.61 9.2 mg, 34.89 % 99.803% [M+H]+ calcd 540.3, found 540.3 A26 469.49 10.8 mg, 32.19 % 97.956% [M+H]+ calcd 470.2, found 470.2 A27 420.44 17.1 mg, 58.11 % 100% [M+H]+ calcd 421.2, found 421.2 A28 466.47 2.8 mg, 8.58 % 98.314% [M+H]+ calcd 467.2, found 4672 A29 420.44 15.3 mg, 51.1 % 98.291% [M+H]+ calcd 421.2, found 421.2 A30 466.47 14.8 mg, 44.49 % 98.146% [M+H]+ calcd 467.2, found 4672 A40 417.51 13 mg, 48.56 % 99.843% [M+H]+ calcd 418.2, found 418.2 A41 486.62 2.4 mg, 8.36 % 92.192% [M+H]+ calcd 487.3, found 4873 A42 405.5 6.5 mg, 23,47 % 96.708% [M+H]+ calcd 406.2, found 406.2 A43 435.5 16.3 mg, 61.15 % 100% [M+H]+ calcd 436.2, found 436.2 A44 504.61 7.7 mg, 27,75 % 95.186% [M+H]+ calcd 505.3, found 505.3 A45 423.49 6 mg, 20.74 % 92,328% [M+H]-!- calcd 424.2, found 424.2Attorney Docket No.: INMD-216 / 01WO 315953-4442Table 1 Synthesized CompoundsComp. MW Yield PurityMass (ES, m / z) No. (g / mol) (mg, %) (%)A46 403.49 7 mg, 2609 % 99.85% [M+Hp calcd 404.2, found 404.2 A47 404.47 8 mg, 28.39 % 95.076% [M+Hp- calcd 405.2, found 405.2 A48 405.5 2.4 mg, 8.86 % 98.882% [M+Hp calcd 406.2, found 406.2 A49 421.48 3.9 mg, 14.44 % 98.913% [M+H]+ calcd 422.2, found 422.2 A50 422.46 4.9 mg, 18.31 % 99.829% [M+H]+ calcd 423.2, found 423.2 A51 423.49 6.2 mg, 22.77 % 98.054% [M+H]+ calcd 424.2, found 4242 A64 472.63 2.5 mg, 8.97 % 95.145% [M+H]+ calcd 473.3, found 473.3 A65 501.63 4.7 mg, 17.07 % 95.992% [M+H]+ calcd 502.3, found 5023 A66 460.53 7.6 mg, 24.57 % 85.856% [M+H]+ calcd 461.2, found 461.2 A67 474.56 6.4 mg, 23.85 % 98.772% [M+H]+ calcd 475.2, found 475 2 A68 516.64 10.1 mg, 37.47 % 97.879% [M+H]+ calcd 517.3, found 517.3 A69 490.62 2.2 mg, 8.04 % 96.742% [M+H]+ calcd 491.3, found 491 3 A70 519.62 12.7 mg, 48.08 % 99.848% [M+H]+ calcd 520.3, found 520.3 A71 478.52 6.6 mg, 24.17 % 97.045% [M+H]+ calcd 479.2, found 479.2 A72 492.55 11.7 mg, 43.79 % 99.007% [M+H]-r calcd 493.2, found 493.2 A73 534.63 7 mg, 24.94 % 93.807% [M+H]+ calcd 535.3, found 535.3 A84 461.61 5.9 mg, 21.89 % 98.522% [M+H]+ calcd 462.3, found 462.3 A85 479.6 6.1 mg, 22.9 % 99.44% [M+H]+ calcd 480.3, found 480.3 A86 468.57 12.8 mg, 47.15 % 97.735% [M+H]+ calcd 469.2, found 469.2 A87 486.56 10.3 mg, 38.48 % 98.884% [M+H]+ calcd 487.2, found 487.2 B2 519.6 2.3 mg, 7.36 % 92.31% [M+H]+ calcd 520.3, found 520.3 B3 474.56 0.9 mg, 2.99 % 97.094% [M+H]+ calcd 475.2, found 475.2 B4 561.64 2.1 mg, 7.06 % 95.884% [M+H]+ calcd 562.3, found 562.3 B6 537.59 1.3 mg, 3.9 % 86.031% [M+H]+ calcd 538.2, found 538.2 B7 492.55 2 mg, 6.01 % 87.398% [M+H]+ calcd 493.2, found 493 2 B8 579.63 0.8 mg, 2.7 % 95.893% [M+H]+ calcd 580.3, found 580.3 BIO 581.64 2.5 mg, 8.04 % 91.189% [M+H]+ calcd 582.3, found 582.3 Bll 505.62 4.1 mg, 7.24 % 85.015% [M+H]+ calcd 506.3, found 506.3Attorney Docket No.: INMD-216 / 01WO 315953-4442Table 1 Synthesized CompoundsComp. MW Yield PurityMass (ES, m / z) No. (g / mol) (mg, %) (%)B12 460.58 12.4 mg, 25.97 % 91.889% [M+H]+ calcd 461.3, found 461.3 B13 547.66 63 mg, 10.27 % 85.049% [M+H]+ calcd 548.3, found 548.3 B14 448.52 14.6 mg, 32.96 % 96.465% [M+H] + calcd 449.2, found 449.2 B15 523.61 1.2 mg, 2.23 % 92.808% [M+H]+ calcd 524.3, found 524.3 B16 478.57 9.2 mg, 18.53 % 91.846% [M+H]+ calcd 479.2, found 479.2 B17 565.65 1.3 mg, 2.38 % 98.777% [M+H]+ calcd 566.3, found 5663 B18 466.51 6.5 mg, 13.9 % 95.02% [M+H]+ calcd 467.2, found 467.2 B19 567.66 6.8 mg, 11.24 % 89.41% [M+H]+ calcd 568.3, found 5683 B21 462.48 15.2 mg, 45.37 % 96.616% [M+H]+ calcd 463.2, found 463.2 B22 508.51 15.9 mg, 41.48 % 92.846% [M+H]+ calcd 509.2, found 5092 B23 462.48 15.7 mg, 46.15 % 95.163% [M+H]+ calcd 463.2, found 463.2 B24 508.51 19.1 mg, 50.22 % 93.59% [M+H]+ calcd 509.2, found 509.2 B26 455.46 2.5 mg, 8.33 % 98.169% [M+H]+ calcd 456.2, found 456.2 B27 497.54 2.1 mg, 4.35 % 98.28% [M+H]+ calcd 498.2, found 498.2 B28 448.5 18.8 mg, 43.47 % 98.794% [M+H]+ calcd 449.2, found 449.2 B29 494.52 8.3 mg, 17.62 % 100% [M+H]- calcd 495.2, found 495.2 B30 448.5 9.8 mg, 22.63 % 98.653% [M+H]+ calcd 449.2, found 449.2 B31 494.52 17.1 mg, 36.01 % 99.226% [M+H]+ calcd 495.2, found 495.2 B33 441.48 3.7 mg, 8.16 % 92.765% [M+H]+ calcd 442.2, found 442.2 B34 459.55 5.6 mg, 17.75 % 93.248% [M+H]+ calcd 460.2, found 460.2 B35 528.66 1.5 mg, 4.5 % 86.225% [M+H]+ calcd 529.3, found 529.3 B37 477.54 4.2 mg, 13.65 % 95.007% [M+H]+ calcd 478.2, found 478.2 B38 546.65 2.2 mg, 6.96 % 90.474% [M+H]+ calcd 547.3, found 547.3 B40 445.52 7.9 mg, 26.02 % 97.446% [M+H]+ calcd 446.2, found 446.2 B41 446.51 5.6 mg, 17.76 % 93.804% [M+H]+ calcd 447.2, found 4472 B42 447 54 2.3 mg, 7.23 % 92.896% [M+H]+ calcd 448.2, found 448.2 B43 463.51 6.5 mg, 21.03 % 95.043% [M+H]+ calcd 464.2, found 464.2 B44 464.5 10.1 mg, 31.9 % 92.75.9% [M+H]+ calcd 465.2, found 465.2Attorney Docket No.: INMD-216 / 01WO 315953-4442Table 1 Synthesized CompoundsComp. MW Yield PurityMass (ES, m / z) No. (g / mol) (mg, %) (%)B45 465.53 1 mg, 3.28 % 96.393% [M+H]+ calcd 466.2, found 466.2 B46 445.57 65 mg, 14.37 % 93.815% [M+H]+ calcd 446.3, found 446.3 B47 514.67 3.7 mg, 6.6 % 87.484% [M+H] + calcd 515.3, found 515.3 B48 433.56 6.9 mg, 15.87 % 95.029% [M+H]+ calcd 434.3, found 434.3 B49 463.56 2.1 mg, 4.7 % 98.777% [M+H]+ calcd 464.2, found 464.2 B50 532.66 16.6 mg, 32.1 % 98.139% [M+H]+ calcd 533.3, found 533 3 B52 4 «? 1.54 9.2 mg, 20.31 % 90.753% [M+H]+ calcd 432.2, found 432.2 B53 432.53 3.4 mg, 7.41 % 89.827% [M+H]+ calcd 433.2, found 433 2 B54 433.56 5 mg, 10.69 % 88.291% [M+H]+ calcd 434.3, found 434.3 B55 449.53 11.9 mg, 24.8 % 89.253% [M+H]+ calcd 450.2, found 4502 B56 450.52 5.9 mg, 12.4 % 90.196% [M+H]+ calcd 451.2, found 451.2 B57 451.55 3.4 mg, 7.18 % 90.845% [M+H]+ calcd 452.2, found 4522 B58 514.67 2.4 mg, 8.09 % 97.326% [M+H]+ calcd 515.3, found 515.3 B59 543.67 2.4 mg, 7.7 % 91.899% [M+H]+ calcd 544.3, found 544.3 B60 502.57 1.5 mg, 4.62 % 89.175% [M+H]+ calcd 503.2, found 503.2 B61 516.6 3.6 mg, 11.23 % 90.019% [M+H]+ calcd 517.2, found 517.2 B62 558.68 5.4 mg, 18.01 % 95.127% [M+H]+ calcd 559.3, found 559.3 B63 532.66 1 mg, 3.17 % 91.121% [M+H]+ calcd 533.3, found 533.3 B65 520.56 12.8 mg, 42.3 % 95.257% [M+H]+ calcd 521.2, found 521.2 B66 534.59 1.5 mg, 4.77 % 91.295% [M+H]+ calcd 535.2, found 535.2 B67 576.67 2.5 mg, 8.48 % 96.359% [M+H]+ calcd 577.3, found 577.3 B68 500.69 2.2 mg, 4.54 % 98.35% [M+H]+ calcd 501.3, found 501.3 B70 488.59 2.1 mg, 4.2 % 93.044% [M+H]+ calcd 489.2, found 489.2 B71 502.62 7.2 mg, 14.68 % 97.598% [M+H]+ calcd 503.3, found 503.3 B72 544.7 1.7 mg, 2.89 % 88.347% [M+H]+ calcd 545.3, found 545 3 B73 518.68 1.9 mg, 3.27 % 85.172% [M+H]+ calcd 519.3, found 519.3 B74 547.67 7.8 mg, 12.96 % 86.702% [M+H]+ calcd 548.3, found 548.3 B76 520.61 14.2 mg, 28.36 % 99.043% [M+H]+ calcd 521.3, found 521.3Attorney Docket No.: INMD-216 / 01WO 315953-4442Table 1 Synthesized CompoundsComp. MW Yield PurityMass (ES, m / z)No. (g / mol) (mg, %) (%)B78 503.65 2.5 mg, 7.61 % 88.224% [M+H]+ calcd 504.3, found 504.3 B81 528.6 2 mg, 6.27 % 90.197% [M+H]+ calcd 529.2, found 529.2 B84 496.63 3.5 mg, 6.4 % 86.475% [M+H]+ calcd 497.2, found 497.2 B85 514.62 8.1 mg, 14.88 % 90.053% [M+H]+ calcd 515.2, found 515.2

[0833] Example 2: Synthesis of N-[(lS)-l-cyano-2-[4-(3-methyl-2-oxo-l,3-benzoxazol-5-yl)phenyl]ethyI]-3-ethoxyazetidine-3-carboxamide (Compound Al)

[0834] Step 1. Synthesis of l-(tert-butoxycarbonyl)-3-ethoxyazetidine-3 -carboxylic acid O O HNZ\<^OHBQC2O, TEA » Boc-N / \<^OH? DCM. rt. 3 h 9HCI I I

[0835] To a stirred solution of di-tert-butyl dicarbonate (721 mg, 3.30 mmol, 1.2 equiv) and 3- ethoxyazetidine-3 -carboxylic acid hydrochloride (500 mg, 2.75 mmol, 1.00 equiv) in DCM (10 mL)was added TEA (836 mg, 8.26 mmol, 3 equiv) dropwise at room temperature. The resulting mixture was stirred for 3 h at room temperature. The mixture was acidified to pH 4 with cone. HC1. The resulting mixture was extracted with EtOAc (3 x 30 mL). The combined organic layers were washed with brine (3 x 30 mL), dried over anhydrous NaiSCU. After filtration, the filtrate was concentrated under reduced pressure. This resulted in l-(tert-butoxycarbonyl)-3-ethoxyazetidine-3-carboxylic acid (600 mg, 88.86%) as a light-yellow oil. LCMS (ES, m / z) [M+H]L 246

[0836] Step 2. Synthesis of butyl 3-{[(l S)-l-cyano-2-[4-(3-methyl-2-oxo-l,3-benzoxazol-5-yl jphenyl ] ethyl ] carbarn oyl } -3 -ethoxy azeti dine- 1 -carboxyl ate

[0837] To a stirred mixture of l-(tert-butoxycarbonyl)-3-ethoxyazetidine-3-carboxylic acid (90 mg, 0.37 mmol, 1.2 equiv), (2S)-2-amino-3-[4-(3-methyl-2-oxo-l,3-benzoxazol-5-yl)phenyl]propanenitrile (90 mg, 031 mmol, 1.00 equiv) and DIE (119 mg, 0.92 mmol, 3Attorney Docket No.: INMD-216 / 01WO 315953-4442equiv) in DCM (5 mL) were added HATU (140 mg, 0.37 mmol, 1.2 equiv) in portions at 0 °C. The resulting mixture was stirred for additional 3 h at 0 °C. The residue was purified by silica gel column chromatography, eluted with PE / THF ( 1: 1 ) to afford tert-butyl 3 - { [ ( 1 S )- 1 -cy ano-2-[4-(3-methyl-2-oxo-l,3-benzoxazol-5-yl)phenyl]ethyl]carbamoyl}-3-ethoxyazetidine-1-carboxylate (120 mg, 75.13%) as a light yellow oil. LCMS (ES, m / z) [M+H]⁺: 521.

[0838] Step 3. Synthesis of N-[(lS)-l-cyano~2-[4-(3-methyl-2-oxo-l,3-benzoxazol-5- yl)phenyl]ethyl]-3-ethoxyazetidine-3-carboxamideN N O W TsOH, ACN. rt, 2 h o Boc—

[0839] Into a 50 mL round-bottom flask were added tert-butyl 3-{[(lS)-l-cyano-2-[4-(3-methyl-2-oxo-l,3-benzoxazol-5-yl)phenyl]ethyl]carbamoyl}-3-ethoxyazetidine-l -carboxylate (120 mg, 0.23 mmol, 1 equiv), TsOH·H₂O (132 mg, 0.69 mmol, 3 equiv) and ACN (3 mL) at room temperature. The resulting mixture was stirred for additional 3 h at room temperature. The residue was purified by reversed-phase flash chromatography with the following conditions: column, Cl 8 silica gel; mobile phase, MeCN in Water (0.1% NH₃·H₂O), 10% to 50% gradient in 10 min; detector, UV 254 nm. This resulted in N-[( lS)-l-cyano-2-[4-(3-methyl-2-oxo-l,3-benzoxazol-5-yl)phenyl]ethyl]-3-ethoxyazetidine-3-carboxamide (20 mg, 20.64%) as a white solid. LCMS (ES, m z) [M+H]⁺: 421.lH NMR (400 MHz, DMSO-ife) ’H NMR (300 MHz, DMSO-t / 6) 5 8.68 (d, J= 8.3 Hz, 1H), 7.66 (d, J= 8.2 Hz, 2H), 7.57 (t, J = 1.1 Hz, 1H), 7.45 - 7.36 (m, 4H), 5.09 (q, J = 8.2 Hz, 1H), 3.59 (d, J = 8.7 Hz, 1H), 3 50 (d, J = 8.7 Hz, 1H), 3.43 - 3.35 (m, 5H), 3.30 - 3.10 (m, ...

Claims

Attorney Docket No.: INMD-216 / 01 WO 315953-4442CLAIMSWhat is claimed is:

1. A compound of Formula (A)H „ NR3R2(RV (A),or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, wherein:ring A is a carbocyclyl, aryl, heterocyclyl, or heteroaryl ring,R1CIR2is a carbocycle, aryl, heterocycle, or heteroaryl ring, wherein each R2is optionally substituted with 1, 2, 3, or 4 R6;R3is H; or R3together with one of Rbcan form a tricyclic, tetracyclic, or pentacyclic ring optionally containing 1, 2, or 3 heteroatoms selected from N, S, or O, wherein the tricyclic, tetracyclic, or pentacyclic ring is optionally substituted with 1, 2, 3, or 4 R’;each R4is independently halogen, -Ci-Ce alkyl, -Ci-Ce haloalkyl, -S(Ci-Ce alkyl), -SO(Ci-Ce alkyl), -SO2(Ci-C6 alkyl), or -CN;R5and R6are each independently halogen, -OH, oxo, -CN, -Ci-Cr, alkyl, -C1-C6 alkyl-OH, -(Ci-Co alkylene)-O-(Ci-C6 alkyl), -(Ci-Ce alkylene)-O-(Ci-C6 alkyl)-OH, -(Ci-C6alkylene)-O-(Ci-C6 alkylene)-O-(Ci-Cfi alkyl), -(Ci-Ce alkylene)-O-(Ci-Ce alkylene)-O-(Ci-C6 alkyl)-OH, -Ci-Cio haloalkyl, -Ci-Cio haloalkyl-OH, -NR7R8, -Ci-Ce alkyl-NR7R8, -S(Ci-C6alkyl), -SO(Ci-C6alkyl), -SO2(Ci-Ce alkyl), -SO2NR7R8, -(Ci-Ce alkylene)-carbocycle, - (Ci-Ce alkylene)-heterocycle, carbocycle, or heterocycle, wherein each carbocycle and heterocycle is optionally substituted by 1 or 2 Rn;R7and R8are each independently H or -Ci-Ce alkyl; or R7and R8together with the nitrogen atom to which they are attached form a heterocyclyl;Attorney Docket No.: INMD-216 / 01WO 315953-4442R9and R9aare each independently deuterium, halogen, cyano, hydroxyl, -NH2, - NH(CI-C6 alkyl), -N(CI-C6 alkyl)2, -COOH, -C1-C6 alkyl, -C2-C6 alkenyl, -C2-C6 alkynyl, -Ci-Ce haloalkyl, -C2-C6 haloalkenyl, -C2-C6 haloalkynyl, -Ci-Ce alkyl-OH, -CONH2, -SH, -S(=O)NH2, -S(O)2NH2, -OCI-CO alkyl, -OCi-Cc, haloalkyl, -S(Ci-C6alkyl), -SO(CJ-C6alkyl), -SO2(Ci-C6 alkyl), -SO2NR7R8, -S(=NH)(O)(C1-C6alkyl), -(Ci-Ce alkylene)-carbocyclyl, or -(CJ -Ce alkylene)-heteroaryl;R10is H or -Ci-Ce alkyl;each Ruis independently halogen, -OH, oxo, -CN, -Ci-Ce alkyl, -Ci-Ce alkyl-OH, - C1-C10 haloalkyl, -C1-C10 haloalkyl-OH, -OCi-Ce alkyl, -NR7R8, -Ci-Ce alkyl-NR7R8, -S(Ci-C6alkyl), -SO(Ci-C6alkyl), -SO2(Ci-C6 alkyl), -SO2NR7R8, -(Ci-Ce alkylene)-carbocycle, - (Ci-Ce alkylene)-heterocycle, carbocycle, or heterocycle;m is 0, 1, 2, or 3; andn is 0, 1, 2, or 3;R1° R9a,, (R >,?if Twherein when Riszand R is H, R“ is not';dihydrobenzo[d]oxaz.ol-5-yl)phenyl)ethyl)-3-(difluoromethyl)azetidine-3 -carboxamide, (5)- A7-(l-cyano-2-(2-fluoro-4-(3-methyl-2-oxo-2,3-dihydrobenzo[d]oxazol-5-yl)phenyI)ethyl)-3-methoxyazetidine-3-carboxamide, (. S)-r-(l-cyano-2-(2-fluoro-4-(3-methyl-2-oxo-2,3-Attorney Docket No.: INMD-216 / 01WO 315953-4442dihydrobenzo[d]oxazol-5-yl)phenyl)ethyl)-3-methoxy-l-methylazetidine-3-carboxamide, ( )- ’-(l-cyano-2-(2-fluoro-4-(T-(oxetan-3-yl)-3H-spiro[isobenzofuran-l,4'-piperidin]-6-yl)phenyl)ethyl)-3-(difluoromethyl)azetidine-3 -carboxamide, or (A’)-yV-(l-cyano-2-(2-fluoro-4-H'-(oxetan-3-yl)-3H-spiro[isobenzofuran-l,4'-piperidin]-6-yl)phenyl)ethyl)-3-(difluoromethyl)-l-methylazetidine-3-carboxamide, or a stereoisomer thereof.The compound of claim 1 or a pharmaceutically acceptable salt, a stereoisomer, or adeuterated form thereof, wherein R1is3. The compound of claim 1 or 2 or a pharmaceutically acceptable salt, a stereoisomer,p10 p>9a HN-'A,w.. (R9)n or a deuterated form thereof, wherein R1is (R9)"4. The compound of any one of claims 1-3 or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, wherein R10is H or methyl.

5. The compound of any one of claims 1 -4 or a pharmaceuti cally acceptable salt, a stereoisomer, or a deuterated form thereof, wherein R9and R9aare each independently deuterium, halogen, hydroxyl, -Ci-Ce alkyl, -C2-C6 alkenyl, -C2-C6 alkynyl, -Ci-Ce haloalkyl, -C2-C6 haloalkenyl, -C2-C6 haloalkynyl, -OCi-Ce alkyl, or -OC1-C6 haloalkyl.Attorney Docket No.: INMD-216 / 01WO 315953-44426. The compound of any one of claims 1-5 or a pharmaceutically acceptable salt, a7. The compound of any one of claims 1-5 or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, wherein R1is8. The compound of claim 1 or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, wherein R1isAttorney Docket No.: INMD-216 / 01WO 315953-44429. The compound of claim 1 or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, wherein the compound has the structure of Formula (1):or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, wherein:ring A is a carbocycle, aryl, heterocycle, or heteroaryl ring;R2is a carbocycle, aryl, heterocycle, or heteroaryl ring, wherein each R2is optionally substituted with 1, 2, 3, or 4 R6;R3is H; or R3together with one of R6can form a tricyclic, tetracyclic, or pentacyclic ring optionally containing 1, 2, or 3 heteroatoms selected from N, S, or O, wherein the tricyclic, tetracyclic, or pentacyclic ring is optionally substituted with 1, 2, 3, or 4 R3;each R4is independently halogen, -Ci-Cs alkyl, -Ci-Ce haloalkyl, -S(Ci-Ce alkyl), -SO(Ci-Ce alkyl), -SO2(Ci-C6alkyl), or -CN;R5and R6are each independently halogen, -OH, oxo, -CN, -Ci-Ce alkyl, -Ci-Ce alkyl -OH, -(Ci-Ce alkylene)-O-(Ci-Ce alkyl), -(Ci-Ce alkylene)-O-(Ci-C6 alkyl)-OH, -(Ci-Cs alkylene)-O-(Ci-C6 alkylene)-O-(Ci-C6 alkyl), -(CJ-C6 alkylene)-O-(Ci-C6 alkylene)-O-(Ci-C6alkyl)-OH, -Ci-Cio haloalkyl, -Ci-Cio haloalkyl-OH, -NR7R8, -Ci-C6alkyl-NR7R8, -S(Ci- C6 alkyl), -SO(Ci-C6 alkyl), -SO2(Ci-C6 alkyl), - -SO2NR'R8, -(Cj-Ce alkylene)-carbocycle, -(Ci-Ce alkylene)-heterocycle, carbocycle, or heterocycle, wherein each carbocycle and heterocycle is optionally substituted by 1 or 2 R11;R' and R8are each independently H or -Ci-Ce alkyl; or R7and R8together with the nitrogen atom to which they are attached form a heterocyclyl;R9and R9aare each independently deuterium, halogen, cyano, hydroxyl, -NH2, -NH(C1-C6alkyl), -N(Ci-Ce alkyl)2, -COOH, -Ci-Ce alkyl, -C2-C6 alkenyl, -C2-C6 alkynyl, -C1-C6 haloalkyl, -C2-C6 haloalkenyl, -Ci-C haloalkynyl, -Ci-C6alkyl-OH, -CONH2, -SH, - S(=O)NH2, -S(O)2NH2, -OC1-C6 alkyl, -OCi-C6haloalkyl, -S(Ci-C6alkyl), -SO(Ci-C6 alkyl), -SO2(Ci-C6alkyl), -SO2NR7R8, -S(=NH)(O)(CI-C6alkyl), -(Ci-C6alkylene)-carbocyclyl, or -(C 1 -C& alkyl ene)-heteroaryl;R10is H or -C1-C6 alkyl;Attorney Docket No.: INMD-216 / 01WO 315953-4442each R11is independently halogen, -OH, oxo, -CN, -C1-C6 alkyl, -Ci-C, alkyl-OH, -C1-C10 haloalkyl, -C1-C10 haloalkyl-OH, -OCi-Ce alkyl, -NR7R8, -Ci-Ce alky1-NR7R8, -S(Ci-Cr, alkyl), -SO(Ci-C6 alkyl), -SO2(CJ-C6 alkyl), -SO2NR7R8, -(Ci-Ce alkylene)-carbocycle, - (Ci-Cb alkylene)-heterocycle, carbocycle, or heterocycle,m is 0, 1, 2, or 3; andn is 0, I, 2, or 3;wherein when R- is H, R is not;u L ■wherein R2is not°; andwherein the compound is not:(5’)-A-(l-cyano-2-(4-(3-methyl-2-oxo-2,3-dihydrobenzo[d]oxazol-5-yl)phenyl)ethyl)-3- (difluoromethyl)azetidine-3 -carboxamide, (5)-A'-(l-cyano-2-(2-fluoro-4-(3-methyl-2-oxo-2,3-dihydrobenzo[dJoxazol-5-yl)phenyl)ethyl)-3-methoxyazetidine-3-carboxamide, (5)-A-(l- cyano-2-(2-fluoro-4-(3-methyl-2-oxo-2,3-dihydrobenzo[d]oxazol-5-yl)phenyl)ethyl)-3- ni ethoxy- 1 -methylazetidine-3-carboxamide, S)-N-( 1 -cy ano-2-(2-fluoro-4-( 1 '-(oxetan-3 -yl)- 3H-spiro[isobenzofuran-l,4'-piperidin]-6-yl)phenyl)ethyl)-3-(difluoromethyl)azetidine-3-carboxami e, or (5)-Af-( 1 -cy ano-2-(2-fluoro-4-( 1 '-(oxetan-3 -yl)-3H-spiro[isobenzofuran- 1,4'-piperidin]-6-yl)phenyl)ethyl)-3-(difluoromethyl)-l-methylazetidine-3-carboxamide.

10. The compound of any one of claims 1-9 or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, wherein R2is a bicyclic ring, wherein at least one ring is aromatic, and wherein R2is optionally substituted with 1, 2, 3, or 4 Rb.

11. The compound of claim 10 or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, wherein R2is a fused bicyclic ring, optionally substituted with 1, 2, 3, or 4 R6.

12. The compound of claim 11 or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, wherein R2is a 5,5-, 5,6-, 6,5-, or 6,6-fused bicyclic ring, optionally substituted with 1, 2, 3, or 4 R6.Attorney Docket No.: INMD-216 / 01WO 315953-444213, The compound of any one of claims 1-12 or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, wherein:each X,ais independently -NRfja-, -O-, -CR12R13-, -C(O)-, -S-, -S(O) - or -S(O)2-; each R'‘ is independently halogen, -OH, oxo, -CN, -CI-CG alkyl, -CI-CG alkyl-OH, - (CI-CG alkylene)-O-(Ct-C6 alkyl), -(CI-CG alkylene)-O-(Ci-C6 alkyl)-OH, -(CI-CG alkylene)-0-(C1-C6alkylene)-O-(Ci-C6 alkyl), -(CI-CG alkylene)-O-(Ci-Cd alkylene)-O-(Ct-C6 alkyl)- OH, -C1-C10 haloalkyl, -C1-C10 haloalkyl-OH, -NR7R8, -Ci-C6alkyl-NR7R8, -S(CI-CG alkyl), -SO(Ci-C6 alkyl), -SO2(Ci-C6alkyl), - -SO2NR7R8, -(C1-C6alkylene)-carbocycle, -(CI-CG alkylene)-heterocycle, carbocycle, or heterocycle, wherein each carbocycle and heterocycle is optionally substituted by 1 or 2 R1’;each R6ais independently H, -Ci-Ce alkyl, -CI-CG alkyl-OH, -C1-C10 haloalkyl, -Ci-C10 haloalkyl-OH, -CI-CG alkyl-NR7R8, -(CI-CG alkyl ene)-O-(Ci-C6 alkyl), -(CI-CG alkylene)-O-(CI-CG alkyl)-OH, -(C1-C0 alkylene)-O-(Ci-C6 alkyl)-COOH, -(CI-CG alkylene)-O-(Ci-C6 alkvlene)-O-(Ci-C6 alkyl), -(CI-CG alkylene)-O-(Ci-CG alkylene)-NR7R8, -(CI-CG alkylene)-0-(CJ-C6alkylene)-C(O)NR7R8, -(CI-CG alkylene)-O-(Ci-C6alkylene)-NR7C(O)-(Ci-C6 alkyl), -(CI-CG alkylene)-O-(Ci-C6 alkylene)-C(O)NR7-(Ci-C6 alkylene)-O-(Ci-C6 alkyl), -(CI-CG alkylene)-O-(Ci-C6alkylene)-NR7C(O)-(Ci-C alkylene)-O-(Ci-C6alkyl), -(CI-CG alkylene)-O-(Ci-C6 alkylene)-C(O)NR'-(Ci-C6 alkylene)-O-(Ci-C6 alkylene)-NR7-aryl, -(CI- CG alkylene)-O-(Ci-C6 alkylene)-NR'C(O)-(Ci-C6 alkylene)-O-(Ci-C6 alkylene)-NR7-aryl, - (C1-C0 alkylene)-NR7R8, -(Ci-C6alkylene)-NR7-(Ci-C6 alkyl)-OH, -(Ci-Ce alkylene)-NR7- (Ci-Cr, alkyl)-O-(Ci-C6 alkyl), -(CI-C alkylene)-NR7-(Ci-C6 alkylene)-NR7R8, -(Ci-Ce alkylene)-heterocycle, or -(Cj-Ce alkyl ene)-heteroaryl;R' and R8are each independently H or -Ci-Ce alkyl; or R7and R8together with the nitrogen atom to which they are attached form a heterocyclyl;each R11is independently halogen, -OH, oxo, -CN, -CI-CG alkyl, -CI-CG alkyl-OH, - C1-C10 haloalkyl, -Ci-Cw haloalkyl-OH, -OCI-CG alkyl, -NR7R8, -Ci-C6alkyl-NR7R8, -S(Ci-CG alkyl), -SO(Ci-C6alkyl), -SO2(Ci-C6alkyl), -SO2NR7R8, -(C1-C6alkylene)-carbocycle, -(CI-CG alkylene)-heterocycle, carbocycle, or heterocycle;Attorney Docket No.: INMD-216 / 01WO 315953-4442R12and R13are each independently selected from H, deuterium, halogen, or -Ci-Ce alkyl; andp is 0, 1, 2, or 3.

14. The compound of any one of claims 1 -9 or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, wherein R2is a tricyclic ring, wherein at least one ring is aromatic, and wherein R2is optionally substituted with 1, 2, 3, or 4 R6.

15. The compound of claim 14 or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, wherein R is a tricyclic ring containing at least one phenyl ring and wherein R2is optionally substituted with 1, 2, 3, or 4 R6.

16. The compound of any one of claims 1-15 or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, wherein A is phenylene.

17. The compound of any one of claims 1-16 or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, wherein R3together with one of R° can form a tricyclic, tetracyclic, or pentacyclic ring optionally containing 1, 2, or 3 heteroato s selected from N, S, or O, wherein the tricyclic, tetracyclic, or pentacyclic ring is optionally substituted with 1, 2, 3, or 4 R;.

18. The compound of claim 1 or 9 or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, wherein the compound has the structure of Formula (I-A)(R4)m(LA),or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, wherein:ring A is a carbocycle, aryl, heterocycle, or heteroaryl ring;Attorney Docket No.: INMD-216 / 01WO 315953-4442each Xlais independently -NR6a-, -0-, -CR!2R13-, -C(0)-, -S-, -S(0) - or -S(O)2-; R1is H; or R3together with one of Rhcan form a tricyclic, tetracyclic, or pentacyclic ring optionally containing 1, 2, or 3 heteroatoms selected from N, S, or O, wherein the tricyclic, tetracyclic, or pentacyclic ring is optionally substituted with 1, 2, 3, or 4 R:';each R4is independently halogen, -Ci-Co alkyl, -Ci-Ce haloalkyl, -S(Ci-C6 alkyl), -SO(C1-C6alkyl), -SO2(Ci-C6 alkyl), or -CN;I and R6are each independently halogen, -OH, oxo, -CN, -Ci-Cb alkyl, -Ci-Co alkyl-OH, -(Ci-C6alkylene)-O-(Ci-C6 alkyl), -(Ci-C6 alkylene)-O-(Ci-C6 alkyl)-OH, -(Ci-Cs alkylene)-O-(Ci-C6 alkylene)-O-(Ci-Co alkyl), -(Ci-Ce alkylene)-O-(Ci-C6 alkylene)-O-(Ci-C6alkyl)-OH, -Ci-Cio haloalkyl, -Ci-Cio haloalkyl-OH, -NR7R8, -Ci-C6alkyl-NR7R8, -S(Ci-Ce alkyl), -SO(Ci-C6 alkyl), -SO2(Ci-C6 alkyl), -SO2NR7R8, -(Ci-Ce alkylene)-ca bocycle, -(Ci-Cs alkylene)-heterocycle, carbocycle, or heterocycle, wherein each carbocycle and heterocycle is optionally substituted by 1 or 2 R11;each R6ais independently H, -Ci-Ce alkyl, -Ci-Ce alkyl-OH, -Ci-Cio haloalkyl, -Ci- Cio haloalkyl-OH, -Ci-Ce alkyl-NR7R8, -(Ci-Ce alkylene)-O-(Ci-C6 alkyl), -(Ci-Cb alkylene)-O-(Ci-Ce alkyl)-OH, -(Ci-Cs alkylene)-O-(Ci-Ce alkyl)-COOH, -(Ci-Ce alkylene)-O-(Ci-C6 alkylene)-O-(Ci-Ce alkyl), -(Ci-Ce alkylene)-O-(Ci-C6 alkylene)-NR7R8, -(Ci-Cc alkylene)-O-(Ci-Ce alkylene)-C(O)NR7R8, -(Ci-Ce alkylene)-O-(Ci-C6 alkylene)-NR7C(O)-(Ci-Cs alkyl), -(Ci-Ce alkylene)-O-(Ci-C6 alkylene)-C(O)NR7-(Cj-C6 alkylene)-O-(Ci-Ce alkyl), - (Ci-Ce alkylene)-O-(Ci-C6 alk lene)-NR7C(O)-(Ci-Ce alkylene)-O-(Ci-C6 alkyl), -(Ci-Ce alkylene)-O-(Ci-C6 alkylene)-C(O)NR'-(Ci-C6 alkylene)-O-(Ci-C6 alkylene)-NR7-aryl, -(Ci- Ce alkylene)-O-(Ci-Ce alkylene)-NR7C(O)-(Ci-C6 alkylene)-O-(Ct-C6 alkylene)-NR / -aryl, - (Ci-Ce alkylene)-NR7R8, -(Ci-Ce alkylene)-NR7-(Ci-Ce alkyl)-OH, -(Ci-C<5 alkylene)-NlV- (Ci-C6alkyl)-O-(Ci-Ce alkyl), -(Ci-Ce alkylene)-NR7-(Ci-Ce alkylene)-NR7R8, -(Ci-C6a1kylene)-heterocycle, or -(Ci-Ce alkylene)-heteroaryl;R7and R8are each independently H or -Ci-Ce alkyl; or R7and R8together with the nitrogen atom to which they are attached form a heterocyclyl;R9and R9aare each independently deuterium, halogen, cyano, hydroxyl, -NH2, - NH(Ci-C6alkyl), -N(Ci-C6alkyl, -COOH, -Ci-C6alkyl, -C2-C6alkenyl, -C2-C6alkynyl, -Ci-Ce haloalkyl, -C2-C6 haloalkenyl, -C2-C6 haloalkynyl, -Ci-Ce alkyl-OH, -CONH2, -SH, - S(=O)NH2, -S(O)2NH2, -OC1-C6 alkyl, -OCi-C6haloalkyl, -S(CJ-C6alkyl), -SO(Cj-C6alkyl), -SO2(Ci-C6 alkyl), -SO2NR7R8, -S(=NH)(0)(CI-C6 alkyl), -(Ci-Ck alkylene)-carbocyclyl, or — ( C ] -C6 alkylene)-heteroaryl;R10is H or -Ci-Ce alkyl,Attorney Docket No.: INMD-216 / 01WO 315953-4442each R11is independently halogen, -OH, oxo, -CN, -C1-C6 alkyl, -Ci-C, alkyl-OH, -C1-C10 haloalkyl, -C1-C10 haloalkyl-OH, -OCi-Ce alkyl, -NR7R8, -Ci-Ce alky1-NR7R8, -S(Ci-Cr, alkyl), -SO(Ci-C6 alkyl), -SO2(CJ-C6 alkyl), -SO2NR7R8, -(Ci-Ce alkylene)-carbocycle, - (Ci-Cb alkylene)-heterocycle, carbocycle, or heterocycle,R12and R13are each independently selected from H, deuterium, halogen, or -Ci-Ce alkyl:m is 0, 1, 2, or 3;n is 0, 1, 2, or 3; andp is 0, 1, 2, or 3;^. Nwherein when R3is H, R2is not;wherein R2is not°; andwherein the compound is not:(5)-A^l-cyano-2-(4-(3-methyl-2-oxo-2,3-dihydrobenzo[d]oxazol-5-yl)phenyl)ethyl)-3- (difluoromethyl)azetidine-3-carboxamide, (b')- / A-(l-cyano-2-(2-fluoro-4-(3-methyl-2-oxo-2,3-dihydrobenzo[d]oxazol-5-yl)phenyl)ethyl)-3-methoxyazetidine-3-carboxamide, (5)-. V-(l-cyano-2-(2-fluoro-4-(3-methyl-2-oxo-2,3-dihydrobenzo[d]oxazol-5-yl)phenyl)ethyl)~3-raethoxy-l-methylazetidine-3-carboxamide, (5)- / V-(l-cyano-2-(2-fluoro-4-(l'-(oxetan-3-yl)-3H-spiro[isobeiizofuran-l,4'-piperidin]-6-yl)phenyl)ethyl)-3-(difluoromethyl)azetidine-3-carboxamide, or (S)-2V-( 1 -cyano-2-(2-fl uoro-4-( 1 '-(ox etan- -yl)-3H-spiro[isobenzofuran- 1,4'-piperidin]-6-yl)phenyl)ethyl)-3-(difluoromethyl)-l-methylazetidine-3-carboxamide.

19. The compound of any one of claims 1-18 or a pharmaceutically acceptable salt, astereoisomer, or a deuterated form thereof, wherein A isOr20, The compound of claim 1 or 9 or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, wherein the compound has the structure of Formula (I-B)Attorney Docket No.: INMD-216 / 01WO 315953-4442or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, wherein:each Xlais independently -NRba-, -O-, -CR12R13-, -C(O)-, -S-, -S(O) - or -S(O)2-; each R4is independently halogen, -Ci-Ce alkyl, -Ci-Ce haloalkyl, -SfCi-Cs alkyl), -SO(C1-C6alkyl), -SO2(Ci-C6 alkyl), or -CN;each R6is independently halogen, -OH, oxo, -CN, -Ci-Cs alkyl, -Ci-C6alkyl-OH, -(Ci-C6alkylene)-O-(Ci-C6 alkyl), -(C1-C6alkylene)-O-(C1-C6alkyl)-OH, -(Ci-Cs alkylene)-O-(Ci-Ce alkylene)-O-(Ci-C6 alkyl), -(Ci-Ce alkylene)-O-(Ci-C6 alkylene)-O-(Ci-C6 alkyl)-OH, -C1-C10 haloalkyl, -C1-C10 haloalkyl-OH, -NR7R8, -Ci-Ce alkyl-NR7R8, -S(Ci-Ce alkyl), -SO(C1-C6alkyl), -SO2(Ci-C6alkyl), -SO2NR7R8, -(Ci-Co alkylene)-carbocycle, -(Ci-C6alkylene)-heterocycle, carbocycle, or heterocycle, wherein each carbocycle and heterocycle is optionally substituted by 1 or 2 R11;each R6ais independently H, -Ci-Ce alkyl, -Ci-Ce. alkyl-OH, -C1-C10 haloalkyl, -Ci-Cio haloalkyl-OH, -Ci-Ce alkyl-NR7R8, -(Ci-Ce alkylene)-O-(Ci-C6 alkyl), -(Ci-Ce alkylene)-O-(C1-C6alkyl)-OH, -(Ci-C6al ylene)-O-(Ci-C6alkyl)-COOH, -(Ci-C alkylene)-O-(Ci-C6alkylene)-O-(Ci-C6 alkyl), -(Ci-Ce alkylene)-O-(Ci-C6 alkylene)-NR7R8, -(Ci-Ce alkylene)-O-(Ci-Ce alkylene)-C(O)NR7R8, -(Ci-Ce alkylene)-O-(Ci-C6 alkylene)-NR7C(O)-(Ci-C6 alkyl), -(Ci-Ce alkylene)-O-(Ci-C6 alkylene)-C(O)NR7-(Ci-C6 alkylene)-O-(Ci-Cg alkyl), -(CJ-C6 alkylene)-O-(Ci-C6 alkylene)-NR7C(O)-(Ci-C6 alkylene)-O-(Ci-C6 alkyl), -(Ci-C alkvlene)-O-(Ci-C6 alkylene)-C(O)NR'-(Ci-C6 alkylene)-O-(Ci-C6 alkylene)-NR7-aryl, -(Ci-Ce alkylene)-O-(Ci-C6 alkylene)-NR'C(O)-(Ct-C6 alkylene)-O-(Ci-Ce alkylene)-NR7-aryl, -(Ci-Co alkylene)-NR7R8, -(Ci-Ce alkylene)-NR7-(Ci-C6 alkyl)-OH, -(Ci-C’6 alkylene)-NR7-(C1-C6 alkyl)-O-(Ci-Ce alkyl), -(Ci-Ce alkylene)-NR7-(Ci-C6 alkylene)-NR7R8, -(Ct-Cc, alkylene)-heterocycle, or -(Ci-Ce alkyl ene)-heteroaryl;R7and R8are each independently H or -Ci-Ce alkyl; or R7and R8together with the nitrogen atom to which they are attached form a heterocyclyl;Attorney Docket No.: INMD-216 / 01WO 315953-4442R9and R9aare each independently deuterium, halogen, cyano, hydroxyl, -NH2, - NH(CI-C6 alkyl), -N(CI-C6 alkyl)2, -COOH, -C1-C6 alkyl, -C2-C6 alkenyl, -C2-C6 alkynyl, -Ci-Ce haloalkyl, -C2-C6 haloalkenyl, -C2-C6 haloalkynyl, -Ci-Ce alkyl-OH, -CONH2, -SH, - S(=O)NH2, -S(O)2NH2, -OCI-CO alkyl, -OCi-Cc, haloalkyl, -S(Ci-C6alkyl), -SO(CJ-C6alkyl), -SO2(Ci-C6 alkyl), -SO2NR7R8, -S(=NH)(O)(C1-C6alkyl), -(Ci-Ce alkylene)-carbocyclyl, or -(CJ -Ce alkylene)-heteroaryl;R10is H or -Ci-Ce alkyl;each Ruis independently halogen, -OH, oxo, -CN, -Ci-Ce alkyl, -Ci-Ce alkyl-OH, - C1-C10 haloalkyl, -C1-C10 haloalkyl-OH, -OCi-Ce alkyl, -NR7R8, -Ci-Ce alkyl-NR7R8, -S(Ci-C6alkyl), -SO(Ci-C6alkyl), -SO2(Ci-C6 alkyl), -SO2NR7R8, -(Ci-Ce alkylene)-carbocycle, - (Ci-Ce alkylene)-heterocycle, carbocycle, or heterocycle;R12and R13are each independently selected from H, deuterium, halogen, or -Ci-Ce alkyl,m is 0, 1, 2, or 3;n is 0, 1, 2, or 3; andp is 0, 1, 2, or 3;wherein the compound is not:(5’)-7V-(l-cyano-2-(4-(3-methyl-2-oxo-2,3-dihydrobenzo[d]oxazol-5-yl)phenyl)ethyl)-3-(difluoroniethyl)azetidine-3 -carboxamide, ( )-A’-(l-cyano-2-(2-fluoro-4-(3-methyl-2-oxo-2,3-dihydrobenzo[d]oxazol-5-yl)phenyl)ethyl)-3-methoxyazetidine-3-carboxamide, or (, S')-iV-(l-cyano-2-(2-fluoro-4-(3-methyl-2-oxo-2,3-dihydrobenzo[d]oxazol-5-yl)phenyl)ethyl)-3-methoxy- 1 -methylazetidine-3-carboxamide.

21. The compound of claim 20 or a pharmaceutically acceptable salt, a stereoisomer, or adeuterated form thereof, wherein R2isAttorney Docket No.: INMD-216 / 01WO 315953-444222. The compound of claim 20 or 21, or a pharmaceutically acceptable salt, astereoisomer, or a deuterated form thereof, wherein R2is23. The compound of claim 1 or 9, or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, wherein the compound has the structure of Formula (I-C):or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, wherein:ring B is 5-8 membered ring optionally containing 1, 2, or 3 heteroatoms selected from N, S, or O;ring C is monocyclic, bicyclic, or tricyclic ring containing at least one aromatic ring; each R4is independently halogen, -Ci-Ce alkyl, -Ci-Ce haloalkyl, -S(Ci-C6 alkyl), -SO(C1-C6alkyl), -SO2(C]-C6 alkyl), or -CN:R5and R6are each independently halogen, -OH, oxo, -CN, -Ci-Ce alkyl, -Ci-Ce alkyl- OH, -(Ci-C6alkylene)-O-(Ci-C6 alkyl), -(Ci-Ce alkyl ene)-O-(Ci-Ce alkyl)-OH, -(Ci-Ce alkylene)-O-(Ci-Co alkylene)-O-(Ci-C6 alkyl), -(Ci-Ce alkylene)-O-(Ci-Ce alkyl ene)-O-(Ci-Ce alkyl)-OH, -Ci-Cio haloalkyl, -Ci-Cio haloalkyl-OH, -NR7R8, -Ci-Ce alkyl-NR7R8, -S(Ci- C6alkyl), -SO(Ci-C6alkyl), -SO2(Ct-C6alkyl), -SO2NR7R8, -(Ci-C6alkylene)-carbocycle, - (Ci-Ce alkylene)-heterocycle, carbocycle, or heterocycle, wherein each carbocycle and heterocycle is optionally substituted by 1 or 2 R11;Attorney Docket No.: INMD-216 / 01WO 315953-4442R7and R8are each independently H or -CI-CG alkyl; or R7and R8together with the nitrogen atom to which they are attached form a heterocyclyl;R9and R9aare each independently halogen, cyano, hydroxyl, -NH2, -NH(CI-CG alkyl), -N(CJ-CG alkyl)2, -COOH, -CI-CG alkyl, -C2-C6 alkenyl, -C2-C6 alkynyl, -CI-CG haloalkyl, -C2-C6 haloalkenyl, -C2-C6 haloalkynyl, -CI-CG alkyl-OH, -CONH2, -SH, -S(=0)NH2, - S(O)2NH2, -OCI-CG alkyl, -OCi-C6haloalkyl, -S(Ci-C6alkyl), -SO(Ci-C6alkyl), -SO2(Ci-C6alkyl), -SO2NR7R8, -S(=NH)(O)(CI-C6alkyl ), -(Ci-Ce alkylene)-carbocyclyl, or -(CI-CG alkylene)-heteroaryl;R10is H or -CI-CG alkyl;each R11is independently halogen, -OH, oxo, -CN, -CI-CG alkyl, -CI-CG alkyl-OH, -C1-C10 haloalkyl, -C1-C10 haloalkyl-OH, -OCI-CG alkyl, -NR7R8, -CI-CG alkyl-NR7R8, -S(Ci-C6alkyl), -SO(Ci-C6alkyl), -SO2(CI-CG alkyl), -SO2NR7R8, -(C1-C6alkylene)-carbocycle, - (CI-CG alkylene)-heterocycle, carbocycle, or heterocycle;m is 0, 1, 2, or 3;n is 0, 1, 2, or 3;p is 0, 1, 2, or 3; andq is 0, 1, 2, or 3.

24. The compound of claim 23 or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, wherein ring C is phenyl.

25. The compound of claim 24 or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, wherein:the multicyclic ring containing ring B and ring C isXlais -NR6a-, -O-, -CR!2R13-, -C(O)-, -S-, -S(O) - or -S(O)2-; andAttorney Docket No.: INMD-216 / 01WO 315953-4442R12and R13are each independently selected from H, deuterium, halogen, or Ci-6 alkyl.

26. The compound of claim 25 or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, wherein Xlais -NH-, -NCH3-, -O-, or -CH2-27. The compound of any one of claims 23-26 or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, wherein the multicyclic ring containing ring B and ring C isor 1 and p is 0, 1, or 2.

28. The compound of any one of claims 23-27 or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, wherein each R4is independently halogen, -C1-C3 alkyl, or -CN.

29. The compound of claim 28 or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, wherein R4is F.

30. The compound of any one of claims 23-29 or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, wherein each R6is independently halogen, -OH, - CN -C1-C3 alkyl, -CJ-CS haloalkyl, -S(Ci-C alkyl), -SO(Ci-C alkyl), -SO (Ci-C3 alkyl), - SO2N(CI-C3alkyl), -SOiNR7R8, or 4-6 membered heterocycle.Attorney Docket No.: INMD-216 / 01WO 315953-444231, The compound of any one of claims 23-29 or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, wherein each R6is independently halogen, -CN,32. The compound of any one of claims 23-26 and 28-31 or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, wherein q is 0.

33. The compound of any one of claims 23-32 or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, wherein the multicyclic ring containing ring B and ring C is34. The compound of claim 23 or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, wherein ring C is a bicyclic ring wherein one ring is a phenyl ring.

35. The compound of claim 34 or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, wherein ring C is a fused bicyclic ring,36. The compound of claim 34 or 35, or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, wherein:the multicyclic ring containing ring B and ring C hast the structure:Attorney Docket No.: INMD-216 / 01WO 315953-4442from N, S, or O.37, The compound of any one of claims 34-36 or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof wherein each R6is independently halogen, -OH, - CN -C1-C3 alkyl, -C1-C3 haloalkyl, -S(Ci-C3alkyl), -SO(Ci-C3alkyl), -SO2(Ci-C3alkyl), -SO2N(CI-C3alkyl), -SO2NR7R8, or 4-6 membered heterocycle.

38. The compound of any one of claims 34-37 or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, wherein each R6is independently halogen, -C1-C3alkyl, -CN,, or39. The compound of any one of claims 34-38, or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, wherein the multicyclic ring containing ring B and ring C isAttorney Docket No.: INMD-216 / 01WO 315953-4442o40. The compound of any one of claims 34-39 or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, wherein each R4is independently halogen, -C1-C3 alkyl, or -CN.

41. The compound of claim 40 or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, wherein R4is F.

42. The compound of any one of claims 34-41, or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, wherein the multicyclic ring containing ring B and oring Cis43. The compound of claim 23 or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, wherein ring C is a tricyclic ring wherein one ring is a phenyl ring.

44. The compound of claim 23, or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, wherein:the multicyclic ring containing ring B and ring C has the structure:Attorney Docket No.: INMD-216 / 01WO 315953-4442(R6)Pring D is a 7-12 membered bicyclic ring wherein at least one ring is a heterocyclic ring containing 1, 2, or 3 heteroatoms selected from N, S, or O.

45. The compound of claim 44, or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, wherein ring D is a spiro bicyclic ring.

46. The compound of any one of claims 43-45 or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, wherein each R6is independently halogen, -OH, - CN -C1-C3 alkyl, -C1-C3 haloalkyl, -S(Ci-C3 alkyl), -SO(Ci-C3 alkyl), -SO2(Ci-C3 alkyl), - SO2N(CI-C3 alkyl), -SO2NR7R8, or 4-6 membered heterocycle.

47. The compound of any one of claims 43-46 or a pharmaceutically acceptabl e salt, a stereoisomer, or a deuterated form thereof, wherein each R6is independently halogen or -Ci-C alkyl.

48. The compound of any one of claims 43-47, or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, wherein the multicyclic ring containing ring B andN'ring C i s HN' N N'H \ HAttorney Docket No.: INMD-216 / 01WO 315953-444249. The compound of any one of claims 43-48 or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, wherein each R4is independently halogen, -C1-C3 alkyl, or -CN.

50. The compound of claim 49 or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, wherein R4is F.

51. The compound of any one of claims 44-50, or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, wherein the pentacyclic ring containing ring Band ringC is52. The compound of claim 1 or 9 or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, wherein the compound has the structure of Formula (T-D)or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, wherein:ring A is a carbocycle, aryl, heterocycle, or heteroaryl ring;Attorney Docket No.: INMD-216 / 01WO 315953-4442R3is H; or R3together with one of R6can form a tricyclic, tetracyclic, or pentacyclic ring optionally containing 1, 2, or 3 heteroatoms selected from N, S, or O, wherein the tricyclic, tetracyclic, or pentacyclic ring is optionally substituted with 1, 2, 3, or 4 R5;each R'1is independently halogen, -Ci-Ce alkyl, -Ci-Ce haloalkyl, -S(Ci-C6 alkyl), - SO(Ci-C6 alkyl), -SChfCi-Ce alkyl), or -CN;each R' is independently hydrogen, halogen, -OH, -CN, -Cj-Ce alkyl, -Ci-Ce alkyl- OH, -O-(Ci-C6 alkyl), -(Ci-Ck alkylene)-O-(Ci-C6 alkyl), -(Ci-Ce alkylene)-O-(Ci-C6 alkyl)-OH, -(Ci-Ce alkylene)-O-(Ci-C6 alkylene)-O-(Ci-C6 alkyl), -(Ci-Ce alkylene)-O-(Ci-C6 alkylene)-O-(Ci-C6 alkyl)-OH, -Ci-Cio haloalkyl, -Ci-Cio haloalkyl-OH, -NR7R8, -CONR7R8, -Ci-C6alkyl-NR7R8, -SF5, -S(Ci-C6alkyl), -SO(Ci-C6alkyl), -SO2(Ci-C6alkyl), - - SO2NR7R8, -(Ci-Ce alkylenej-carbocycle, -(Ci-Ce alky1ene)-heterocyc1e, carbocycle, or heterocycle, wherein each carbocycle and heterocycle is optionally substituted by 1 or 2 R15;each R6is independently halogen, -OH, oxo, -CN, -Ci-Ca alkyl, -Cj-Cs alkyl-OH, -O-(Ci-C6 alkyl), -(Ci-Ce alkylene)-O-(Ci-C6 alkyl), -(Ci-Ce alkylene)-O-(Ci-C6 alkyl)-OH, -(Ci-Ce alkylene)-O-(Ci-C6 alkylene)-O-(Ci-C6 alkyl), -(Ci-Ce alkyl ene)-O-(Ci-Ce alkylene)-O-(Ci-Ce alkyl)-OH, -Ci-Cio haloalkyl, -Ci-Cio haloalkyl-OH, -NR7R8, -Ci-Ce alkyl-NR7R8, -SI x -S(Ci-C6 alkyl), -SO(Ci-C6alkyl), -SO2(Cj-C6 alkyl), -SO2NR7R8, -(Ci- Ce alkyl ene)-carbocycle, -(Ci-Ce alkylene)-heterocycle, carbocycle, or heterocycle, wherein each carbocycle and heterocycle is optionally substituted by 1 or 2 R11;Attorney Docket No.: INMD-216 / 01WO 315953-4442R7and R8are each independently H or -CI-CG alkyl; or R7and R8together with the nitrogen atom to which they are attached form a heterocyclyl;R9and R9aare each independently halogen, cyano, hydroxyl, -NH2, -NH(CI-CG alkyl), -N(CJ-CG alkyl)2, -COOH, -CI-CG alkyl, -C2-C6 alkenyl, -C2-C6 alkynyl, -CI-CG haloalkyl, -C2-C6 haloalkenyl, -C2-C6 haloalkynyl, -CI-CG alkyl-OH, -CONH2, -SH, -S(=0)NH2, - S(O)2NH2, -OCI-CG alkyl, -OCi-C6haloalkyl, -S(Ci-C6alkyl), -SO(Ci-C6alkyl), -SO2(Ci-C6alkyl), -SO2NR7R8, -S(=NH)(O)(CI-C6alkyl ), -(Ci-Ce alkylene)-carbocyclyl, or -(CI-CG alkylene)-heteroaryl;R10is H or -CI-CG alkyl;each R11is independently halogen, -OH, oxo, -CN, -CI-CG alkyl, -CI-CG alkyl-OH, -C1-C10 haloalkyl, -C1-C10 haloalkyl-OH, -OCI-CG alkyl, -NR7R8, -CI-CG alkyl-NR7R8, -S(Ci-C6alkyl), -SO(Ci-C6alkyl), -SO2(CI-CG alkyl), -SO2NR7R8, -(C1-C6alkylene)-carbocycle, - (CI-CG alkylene)-heterocycle, carbocycle, or heterocycle;Z1is CH2, NR5, S, S(O), or S(O)2;g is 0, 1, 2, or 3;m is 0, 1, 2, or 3;n is 0, 1, 2, or 3; andp is 0, I, 2, or 3,53. The compound of claim 52 or a pharmaceutically acceptable salt, a stereoisomer, or a R5deuterated form thereof, wherein R2is54. The compound of claim 52 or 53 or a pharmaceutically acceptable salt, astereoisomer, or a deuterated form thereof, wherein R2isAttorney Docket No.: INMD-216 / 01WO 315953-444255. The compound of any one of claims 52-54 or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, wherein each R6is independently halogen, -OH, - Ci-C6alkyl, -O-(CJ-C6alkyl), -Ci-Cio haloalkyl, -NR7R8, -S(Ci-C6alkyl), -SO(Ci-C6alkyl), - SO2(Ci-C6 alkyl), carbocycle, or heterocycle, wherein each carbocycle and heterocycle is optionally substituted by 1 or 2 R11.

56. The compound of any one of claims 52-55 or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, wherein each R11is independently halogen, -OH, -Ci-C6alkyl, -NR~R8, -S(Ci-C6alkyl), -SO(Ci-C6alkyl), or-SO2(Ci-C6 alkyl).

57. The compound of any one of claims 52-56 or a pharmaceutically acceptable salt, astereoisomer, or a deuterated form thereof, wherein R2is58. The compound of claim 1 or 9 or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, wherein the compound has the structure of Formula (I-E)Attorney Docket No.: INMD-216 / 01WO 315953-4442(R4> (RE),or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, wherein:ring A is a carbocycle, aryl, heterocycle, or heteroaryl ring;R6;each R4is independently halogen, -Ci-Ce alkyl, -Ci-Ce haloalkyl, -S(Cj-Ce alkyl), - SO(C1-C6 alkyl), -SO2(Ci-C6 alkyl), or -CN;each R3is independently hydrogen, halogen, -OH, -CN, -Ci-Ce alkyl, -Ci-Ce alkyl- OH, -O-(Ci-Ce alkyl), -(Ci-Ce alkylene)-O-(Ci-Ce alkyl), -(Ci-Ce alkylene)-O-(Ci-C’6 alkyl)- OH, -(Ci-G, alkylene)-O-(Ci-Ce alkylene)-O-(Ci-Ce alkyl), -(Ci-Ce alkylene)-O-(Ci-C6 alkylene)-O-(Ci-Ce alkyl)-OH, -C1-C10 haloalkyl, -C1-C10 haloalkyl-OH, -NR7R8, -CONR7R8, -Ci-Cc alkyl-NR7R8, -SF5, -S(Ci-Ce alkyl), -SO(Ci-Ce alkyl), -SO2(Ci-Ce alkyl), -SO2NR7R8, -(Ci-Ce alkylene)-carbocycle, -(Ci-Ce alkylene)-heterocycle, carbocycle, or heterocycle, wherein each carbocycle and heterocycle is optionally substituted by 1 or 2 R!!;Attorney Docket No.: INMD-216 / 01WO 315953-4442each R6is independently halogen, -OH, oxo, -CN, -Ci-Cc, alkyl, -Ci-Cc, alkyl- OH, -O-(Ci-C6 alkyl), -(C1-C6 alkylene)-O-(Ci-C6 alkyl), -(Ci-Ct. alkylene)-O-(Ci-C6 alkyl)-OH, -(C1-C6 alkylene)-O-(Ci-C6 alkylene)-O-(Ci-C6 alkyl), -(Ci-Ce alkylene)-O-(Ci-C6 alkylene)-O-(Ci-Co alkyl)-OH, -C1-C10 haloalkyl, -CJ-CIO haloalkyl-OH, -NR7R8, -CJ-CG alkyi-NR7R8, -Si x -S(Ci-C6alkyl), -SO(Ci-C6alkyl), -SO2(Ci-C6 alkyl), -SO2NR7R8, -(Ci- C6 alkylene)-carbocycle, -(Ci-Ce al ylene)-heterocycle, carbocycle, or heterocycle, wherein each carbocycle and heterocycle is optionally substituted by 1 or 2 R11;R7and R8are each independently H or -C1-C6 alkyl; or R7and R8together with the nitrogen atom to which they are attached form a heterocyclyl;R9and R9aare each independently halogen, cyano, hydroxyl, -NH2, -NH(Ci-Ce alkyl), -N(CI-C6 alkyl)2, -COOH, -Ci-Ce alkyl, -C2-C6 alkenyl, -C2-C6 alk yl, -Ci-Ce haloalkyl, -C2-Ce haloalkenyl, -C2-C6 haloalkynyl, -Ci-Ce alkyl-OH, -CONH2, -SH, -S(=O)NH2, -S(O)2NH2, -OC1-C6 alkyl, -OCi-C6haloalkyl, -S(CJ-C6alkyl), -S0(CJ-C6alkyl), -SO2(Ci-C6alkyl), -SO2NR'R8, -S(=NH)(O)(C1-C6alkyl), -(Ci-Ce alkylene)-carbocyclyl, or --(Ci-Ce alkylene)-heteroaryl;R10is H or -Ci-Ce alkyl,each Ruis independently halogen, -OH, oxo, -CN, -Ci-Ce alkyl, -Ci-Ce alkyl-OH, - C1-C10 haloalkyl, -C1-C10 haloalkyl-OH, -OCi-Ce alkyl, -NR7R8, -Ci-Ce alkyl-NR7R8, -S(Ci-Ce alkyl), -SO(Ci-C6 alkyl), -SO2(Ci-C6 alkyl), -SO2NR7R8, -(C1-C6 alkylene)-carbocycle, - (Ci-Ce alkylene)-heterocycle, carbocycle, or heterocycle;m is 0, 1, 2, or 3;n is 0, 1, 2, or 3; andp is 0, 1, 2, or 3.

59. The compound of claim 58 or a pharmaceutically acceptable salt, a stereoisomer, or aR2is optionally substituted with 1 or 2 R°.Attorney Docket No.: INMD-216 / 01WO 315953-444260, The compound of claim 58 or 59 or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, wherein each R3is independently hydrogen, -Ci- CG alkyl, -(Ci-Cr, alkylene)-carbocycle, -(Ci-Cc alkylene)-heterocycle, carbocycle, or heterocycle.

61. The compound of any one of claims 58-60 or a pharmaceutically acceptable salt, astereoisomer, or a deuterated form thereof, wherein R2is62. The compound of any one of claims 58-61 or a pharmaceutically acceptable salt, aAttorney Docket No.: INMD-216 / 01WO 315953-444263, The compound of any one of claims 52-62 or a pharmaceutically acceptable salt, astereoisomer, or a deuterated form thereof wherein A is64. The compound of any one of claims 52-63 or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, Rf0is H or methyl.

65. The compound of claim 1 or 9 or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, wherein the compound has the structure of Formula (I-F)or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, wherein:each R4is independently halogen, -Ci-Cr, alkyl, -Ci-Ce haloalkyl, -S(Ci-C6 alkyl), -SO(Ci-Ce alkyl), -SChfCi-Ce alkyl), or -CN;R6is -NR7R8, -CI-C6alkyl-NR7R8, -S(Ci-C6 alkyl), -SO / G-Ce alkyl), -SO2(CJ-C6 alkyl), -SO2NR7R8, -(Ci-Ce alkylenel-carbocycle, -(Ci-Cs alkylene)-heterocycle, carbocycle, or heterocycle, wherein each carbocycle and heterocycle is optionally substituted by 1 or 2 R11,Attorney Docket No.: INMD-216 / 01WO 315953-4442R7and R8are each is independently H or -Ci -CG alkyl; or R7and R8together with the nitrogen atom to which they are attached form a heterocyclyl;R9and R9aare each independently halogen, cyano, hydroxyl, -NH2, -NH(CI-CG alkyl), -N(CJ-CG alkyl)2, -COOH, -CI-CG alkyl, -C2-C6 alkenyl, -C2-C6 alkynyl, -CI-CG haloalkyl, -C2-C6 haloalkenyl, -C2-C6 haloalkynyl, -CI-CG alkyl-OH, -CONH2, -SH, -S(=0)NH2, - S(O)2NH2, -OCI-CG alkyl, -OCi-C6haloalkyl, -S(Ci-C6alkyl), -SO(Ci-C6alkyl), -SO2(Ci-C6alkyl), -SO2NR7R8, -S(=NH)(O)(CI-C6alkyl ), -(Ci-Ce alkylene)-carbocyclyl, or -(CI-CG alkylene)-heteroaryl;R10is H or -CI-CG alkyl;each R11is independently halogen, -OH, oxo, -CN, -CI-CG alkyl, -CI-CG alkyl-OH, -C1-C10 haloalkyl, -C1-C10 haloalkyl-OH, -OCI-CG alkyl, -NR7R8, -CI-CG alkyl-NR7R8, -S(Ci-C6alkyl), -SO(Ci-C6alkyl), -SO2(CI-CG alkyl), -SO2NR7R8, -(C1-C6alkylene)-carbocycle, - (CI-CG alkylene)-heterocycle, carbocycle, or heterocycle;m is 0, 1, 2, or 3; andn is 0, 1, 2, or 3.

66. The compound of claim 65 or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, wherein R6is at the para position,67. The compound of claim 65 or 66 or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, wherein R6is -SO2NR7R8or -(CI-CG alkylene)-heterocycle, wherein the heterocycle is optionally substituted by 1 or 2 R11.

68. The compound of claim 67 or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, wherein:R6is -SO2NR7R8or (C1-C3 alkylene)-(6-membered heterocycle), wherein the heterocycle is optionally substituted by 1 or 2 R11;R7and R8together with the nitrogen atom to which they are attached form a 3- to 6-membered heterocyclyl, andeach R11is independently halogen or -C1-C3 alkyl.Attorney Docket No.: INMD-216 / 01WO 315953-444269. The compound of any one of claims 65-68 or a pharmaceutically acceptable salt, a O 0' L N stereoisomer, or a deuterated form thereof, wherein R6is'-"'sorXs^z’.

70. The compound of claim 1 or 9 or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, wherein the compound has the structure of Formula (I-G)(R>(i-G),or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof wherein:ring A is a fused bicyclic heteroaryl ring,Atorney Docket No.: 1NMD-216 / 01 WO 315953-4442each Xlais independently -NR6il-, -0-, -CR12R13-, -C(0)-, -S-, -S(0) - or -S(O)2-, each Z1is independently -CH2-, -NR3-, -S-, -S(O) -, or -S(O)2-;R3is H;each R4is independently halogen, -C1-C0 alkyl, -Ci-Ce haloalkyl, -S(Ci-C6 alkyl), - SO(C1-C6alkyl), -SO2(C]-C6 alkyl), or -CN;each R'' is independently hydrogen, -OH, -CN, -Ci-Ce alkyl, -Ci-Ce alkyl-OH, -O-(Ci-C6 alkyl), -(Ci-Cs alkylene)-O-(Ci-Cs alkyl), -(Ci-Ce alkylene)-O-(Ci-C6 alkyl)-OH, -(Ci-Ce alkylene)-O-(Ci-Co alkylene)-O-(Ci-C6 alkyl), -(Ci-Ce alkylene)-O-(Ci-Ce alkyl ene)-O-(Ci- Ce alkyl)-OH, -C1-C10 haloalkyl, -C1-C10 haloalkyl-OH, -NR7R8, -CONR7R8, -Ci-C6alkyl-NR7R8, -SF5, -S(C1-C6alkyl), -SO(Ci-C6alkyl), -SO2(Ci-C6alkyl), - -SO2NR7R8, -(Ci-C6alkylene)-carbocycle, -(Ci-Ce alkylene)-heterocycle, carbocycle, or heterocycle, wherein each carbocycle and heterocycle is optionally substituted by 1 or 2 Rn;each R6is independently halogen, -OH, oxo, -CN, -Ci-Ce alkyl, -Ci-Ce alkyl-OH, -O-(C1-C6 alkyl), -(Ci-C, alkylene)-O-(C1-C6 alkyl), -(C1-C6 alkylene)-O-(Ci-C6 alkyl)-OH, -(Ci-Ce alkylene)-O-(Ci-Ce alkylene)-O-(Ci-C6 alkyl), -(Ci-Ce alkylene)-O-(Ci-C6 alkylene)-O-(Ci-C6 alkyl)-OH, -C1-C10 haloalkyl, -C1-C10 haloalkyl-OH, -NR7R8, -Ci-Ck alkyl-NR7R8, -SF5, -S(Ci-C6alkyl), -SO(Ci-C6alkyl), -SO2(CJ-C6alkyl), -SO2NR7R8, -(Ci- Ce alkylene )-carbocycle, -(Ci-Ce alkylene)-heterocycle, carbocycle, or heterocycle, wherein each carbocycle and heterocycle is optionally substituted by 1 or 2 R11;each R6ais independently H, -Ci-CN alkyl, -Ci-CN alkyl-OH, -C1-C10 haloalkyl, -Ci-C10 haloalkyl-OH, -C1-C6 alkyl-NR7R8, -(C1-C6 alkyl ene)-O-(Cj-C6 alkyl), -(Ci-Cr, alkylene)-O-(Ci-C6 alkyl)-OH, -(Ci-Ce alkylene)-O-(Ci-C6 alkyl)-COOH, -(Ci-Ce alkylene)-O-(Ci-Cb alkylene)-O-(Ci-C6 alkyl), -(C1-C6 alkylene)-O-(Cj-C6 alkylene)-NR7R8, -(C1-C6 alkylene)-O-(Ci-Ce alkylene)-C(O)NR7R8, -(Ci-Ce alkylene)-O-(Ci-Ce alkylene)-NR7C(O)-(Ci-C6 alkyl), -(Ci-Cb alkylene)-O-(Ci-C6 alkylene)-C(O)NR7-(Ci-C6 alkylene)-O-(Ci-C6 alkyl), -(Ct-C6alkylene)-O-(Ct-C6alkylene)-NR7C(O)-(Ci-C6alkylene)-O-(Ci-C6alkyl), -(Ci-C6Attorney Docket No.: INMD-216 / 01WO 315953-4442alkylene)-0-(Ci-C6 alkylene)-C(O)N7-(Ci-C6 alkylene)-O-(Ci-Ce alkylene)-NR'-aryl, -(Ct-C6 alkylene)-0-(Ci-C6 alkylene)-NR'C(0)-(Ci-C6 a1kylene)-0-(Ci-C6 alkylene)-NR7-aryl, -(Ci-C6alkylene)-NR7R8, -(Cj-Ce alkylene)-NR7-(Ct-C6 alkyl)-OH, -(Ci-C alkylene)-NR7-(Ci-C6alkyl)-0-(Ci-C6 alkyl), -(Ci-Cc alkylene)-NR7-(Ci-C6 alkylene)-NR7R8, -(Ci-Cc alkylene)-heterocycle, or -(Ci-Ce alkylene)-heteroaryl;R7and R8are each independently H or -Ci-Ce alkyl; or R7and R8together with the nitrogen atom to which they are attached form a heterocyclyl;R9and R9aare each independently halogen, cyano, hydroxyl, -NH2, -NH(C1-C6alkyl), -N(Ci-Ce alkyl)2, -COOH, -Ci-Cs alkyl, -C2-C6alkenyl, -C2-C6 alkynyl, -Ci-C6haloalkyl, -C -C6 haloalkenyl, -C -C6 haloalkynyl, -C1-C0 alkyl-OH, -CONH2, -SH, -S(=O)NH2, -S(O)2NH2, -OC1-C6 alkyl, -OCi-C6haloalkyl, -S(Ci-C6alkyl), -SO(Ci-C6alkyl), -SO2(Ci-C6alkyl), -SO2NR7R8, -S(=NH)(O)(C1-C6alkyl), -(Ci-Ce alkylene)-carbocyclyl, or -(Ci-Cs alkylene)-heteroaryl;R10is H or -C1-C.6 alkyl;each Rnis independently halogen, -OH, oxo, -CN, -Ci-Cs alkyl, -Ci-Ce alkyl-OH, - C1-C10 haloalkyl, -C1-C10 haloalkyl-OH, -OCi-C6alkyl, -NR7R8, -Ci-Ce alkyl-NR7R8, -S(Ci-C6alkyl), -SO(Ci-C6alkyl), -SO2(Ci-C6alkyl), -SO2NR7R8, -(Ci-C6alkylene)-carbocycle, - (Ci-Cb alkylene)-heterocycle, carbocycle, or heterocycle;R12and R13are each independently selected from H, deuterium, halogen, or -Ci-Ce alkyl;g is 0, 1, 2, or 3;m is 0, 1, 2, or 3;n is 0, 1, 2, or 3; andp is 0, 1, 2, or 3.

71. The compound of claim 70 or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, wherein A is a 5,6-fused heteroaryl, 6,5-fused heteroaryl, or 6,6-fused heteroaryl.Attorney Docket No.: INMD-216 / 01WO 315953-444272. The compound of claim 70 or 71 or a pharmaceutically acceptable salt, a73. The compound of any one of claims 70-72 or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, wherein each R4is independently halogen or -Ci-C-6 alkyl.

74. The compound of any one of claims 70-73 or a pharmaceutically acceptable salt, astereoisomer, or a deuterated form thereof, wherein A isF75. The compound of any one of claims 70-74 or a pharmaceutically acceptable salt, astereoisomer, or a deuterated form thereof, wherein R2isAttorney Docket No.: INMD-216 / 01WO 315953-444276. The compound of any one of claims 70-75 or a pharmaceutically acceptable salt, astereoisomer, or a deuterated form thereof, wherein R2is77. The compound of any one of claims 70-76 or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, wherein R5is halogen or -Ci-Co alkyl.

78. The compound of any one of claims 70-77 or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof wherein:R6ais H, -C1-C3 alkyl, -C1-C3 alkyl-NR7R8, -(C1-C3 alkylene)-NR7-(Ci-C3 alkyl)-O- (C1-C3 alkyl), or -(C1-C3 alkylene)-heterocycle; andR7and R8are each independently H or -Ci-Ce alkyl.

79. The compound of any one of claims 70-78 or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, wherein:each R6is independently halogen, -Ci-Ce alkyl, or heterocycle, wherein each heterocycle is optionally substituted by 1 or 2 R11; andeach R11is independently halogen or -C1-C3 alkyl.80, The compound of any one of claims 70-79 or a pharmaceutically acceptable salt, astereoisomer, or a deuterated form thereof, R2isAttorney Docket No.: INMD-216 / 01WO 315953-444281. The compound of any one of claims 9-80 or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, wherein R9ais halogen, hydroxyl, -NH2, -NH(Ci-Ce alkyl), -NtCi-Cs alkyl)2, -C1-C6 alkyl, -Ci-Ce haloalkyl, -C1-C6 alkyl-OH, -OCi-Ce alkyl, -OC1-C haloalkyl, -S(Ci-C6alkyl), -SO(Ci-C6alkyl), or -SO2(Ci-C6 alkyl).

82. The compound of any one of claims 9-81 or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof wherein R9ais halogen, hydroxyl, -Ci-Ce alkyl, -C1-C6 haloalkyl, -OC1-C6 alkyl, or -OC1-C6 haloalkyl.

83. The compound of any one of claims 9-82 or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, wherein n is 0.

84. The compound of any one of claims 9-82 or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, R10is H or methyl.

85. The compound of claim 1 or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, wherein the compound has the structure of Formula (11):or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, wherein:ring A is a carbocycle, aryl, heterocycle, or heteroaryl ring;Attorney Docket No.: INMD-216 / 01WO 315953-4442R2is a carbocycle, aryl, heterocycle, or heteroaryl ring, wherein each R2is optionally substituted with 1, 2, 3, or 4 R6;R3is H; or R3together with one of R6can form a tricyclic, tetracyclic, or pentacyclic ring optionally containing 1, 2, or 3 heteroatoms selected from N, S, or O, wherein the tricyclic, tetracyclic, or pentacyclic ring is optionally substituted with 1, 2, 3, or 4 R3;each R'1is independently halogen, -Ci-Ce alkyl, -Ci-Co haloalkyl, -S(Ci-C6 alkyl), - SO(C1-C6alkyl), -SO2(Ci-C6alkyl), or -CN;R3and R6are each independently halogen, -OH, oxo, -CN, -Ci-Ce alkyl, -Ci-Ce alkyl-OH, -(Ci-C6alkylene)-O-(Ci-C6 alkyl), -(Ci-C6alkylene)-O-(Ci-C6 alkyl)-OH, -(Ci-C alkylene)-O-(Ci-C6 alkylene)-O-(Ci-C6 alkyl), -(Ci-Ce alkylene)-O-(Ci-C6 alkylene)-O-(Ci-Cs alkyl)-OH, -Ci-Cio haloalkyl, -Ci-Cio haloalkyl-OH, -NR7R8, -Ci-C6alkyl-NR7R8, -S(Ci- Ce alkyl), -SO(Ci-C6 alkyl), -SO2(Ci-C6 alkyl), -SO2NR7R8, -(C1-C6 alkylene)-carbocycle, - (Ci-Ce alkylene)-heterocycle, carbocycle, or heterocycle, wherein each carbocycle and heterocycle is optionally substituted by 1 or 2 R11;R7and R8are each independently H or -Cj-Ce alkyl; or R7and R8together with the nitrogen atom to which they are attached form a heterocyclyl;R9is halogen, cyano, hydroxyl, -NH2, -NH(C1-C6alkyl), -N(CI-CG alkyl)2, -COOH, -Ci-Ce alkyl, -C2-C6 alkenyl, -C2-C6 alkynyl, -Ci-Ce haloalkyl, -C2-Ce haloalkenyl, -C2-C6 haloalkynyl, -Ci-C6alkyl-OH, -CONH2, -SH, -S(=O)NH2, -S(O)2NH2, -OCi-Cs alkyl, -OCi- Ce haloalkyl, -S(Ci-Ce alkyl), -SO(Ci-Cs alkyl), -SO2(Ci-C6alkyl), -SO2NR7R8, -S(=NH)(O)(C1-C6alkyl), -(C1-C6 alkylene)-carbocyclyl, or -(Ci-Ce alkylene)-heteroaryl; each R11is independently halogen, -OH, oxo, -CN, -Ci-C6alkyl, -Ci-Ce alkyl-OH, - C1-C10 haloalkyl, -C1-C10 haloalkyl-OH, -OCi-Ce alkyl, -NR7R8, -Ci-Ce alkyl-NR7R8, -S(Ci-Ce alkyl), -SO(Ci-C6 alkyl), -SO2(Cj-Ce alkyl), -SO2NR''R8, -(Ci-Ce alkylene)-carbocycle, - (Ci-Ce alkylene)-heterocycle, carbocycle, or heterocycle;R10is H or -Ci-Ce alkyl,m is 0, 1, 2, or 3; andn is 0, 1, 2, or 3;Attorney Docket No.: INMD-216 / 01WO 315953-444286. The compound of claim 85 or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, wherein R2is a bicyclic ring, wherein at least one ring is aromatic, and wherein R2is optionally substituted with 1, 2, 3, or 4 R6.

87. The compound of claim 86 or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, wherein R2is a fused bicyclic ring, optionally substituted with 1, 2, 3, or 4 R6.

88. The compound of claim 87 or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, wherein R2is a 5,5-, 5,6-, 6,5-, or 6,6-fused bicyclic ring, optionally substituted with I, 2, 3, or 4 R6.

89. The compound of any one of claims 85-88 or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, wherein:each Xlais independently -NR6a~, -O-, -CR12R13-, -C(O)-, -S-, -S(O) - or -S(O)2-; each R'1is independently halogen, -OH, oxo, -CN, -Ci-C<5 alkyl, -C1-C6alkyl-OH, - (Ci-Ce alkylene)-O-(Ct-C6 alkyl), -(Ci-Ce alkylene)-O-(Ci-C6 alkyl)-OH, -(C1-C6 alkylene)-O-(Ci-Ce alkylene)-O-(Ci-Ce alkyl), -(Ci-Ce alkylene)-O-(Ci-C6 alkyl ene)-O-(Ci-C6 alkyl)-OH, -Ci-Cio haloalkyl, -Ci-Cio haloalkyl-OH, -NR7R8, -Ci-C6alkyl-NR7R8, -S(Ci-C6alkyl),Attorney Docket No.: INMD-216 / 01WO 315953-4442-S0(Ci-C6 alkyl), -SCh(Ci-C6 alkyl), -SO2NR7R8, -(Ci-Ce alkylene)-carbocycle, -(Ci-Ce alkylene)-heterocycle, carbocycle, or heterocycle, wherein each carbocycle and heterocycle is optionally substituted by 1 or 2 R11;each R6ais independently H, -Ci-Ce alkyl, -Cj-Cr, alkyl-OH, -Ci-Cio haloalkyl, -Ci-Cio haloalkyl-OH, -Ci-C6alkyl-NR7R8, -(Ci-C6alkylene)-O-(Ci-C6 alkyl), -(Ci-Ce alkylene)-O-(Ci-C6 alkyl)-OH, -(Ci-C6alkylene)-O-(Ci-C6alkyl)-COOH, -(Ci-C6alkyl ene)-O-(Ci-C6alkylene)-O-(Ci-Cs alkyl), -(Ci-Ce alkyl ene)-O-(Ci-C6 alkylene)-NR7R8, -(Ci-Ck alkylene)-O-(C]-C6alkylene)-C(O)NR7R8, -(Ci-Ce alkylene)-O-(Ci-C6alkylene)-NR7C(O)-(Ci-C6 alkyl), -(Ci-C6alkylene)-O-(Ci-C6 alkylene)-C(O)NR7-(Ci-C6alkylene)-O-(Ci-C6alkyl), -(Ci-Cr, alkylene)-O-(Ci-Cb alkylene)-NR7C(O)-(Ci-Ce alkylene)-O-(Ci-C6 alkyl), -(Ci-Ce alkylene)-O-(Ci-Ce alkylene)-C(O)NR7-(Ci-C6 alkylene)-O-(Ci-C6 alkylene)-NR7-aryl, -(Ci-Ce alkylene)-O-(Ci-Cb alkylene)-NR'C(O)-(Ci-C6 alkylene)-O-(Ci-C6 alkylene)-NR7-aryl, -(Ci-Cs alkylene)-NR7R8, -(Ci-C6alkylene)-NR7-(Ci-C6alkyl)-OH, -(Ci-C6alkylene)-NR7-(Ci-C6alkyl)-O-(Ci-C6 alkyl), -(Ci-Ce alkylene)-NR7-(Ci-C6 alkylene)-NR7Rs, -(Ci-Ce alkylene)-heterocycle, or -(Cj-Ce alkylene)-heteroaryl;R7and R8are each independently H or -Ci-Ce alkyl; or R7and R8together with the nitrogen atom to which they are attached form a heterocyclyl;each R11is independently halogen, -OH, oxo, -CN, -Ci-Ce alkyl, -Ci-Ce alkyl-OH, - Ci-Cio haloalkyl, -Ci-Cw haloalkyl-OH, -OCi-C6alkyl, -NR7R8, -Ci-C6alkyl-NR7R8, -S(Cr-C6alkyl), -SO(Ci-Cb alkyl), -SO2(Ci-C6alkyl), -SO2NR7R8, -(Ci-Cs alkylene)-carbocycle, -(Ci-Ce alkylene)-heterocycle, carbocycle, or heterocycle;R12and R13are each independently selected from H, deuterium, halogen, or -C1-C6 alkyl; andp is 0, 1, 2, or 3.

90. The compound of any one of claims 85-89 or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, wherein R2is a tricyclic ring, wherein at least one ring is aromatic, and wherein R2is optionally substituted with 1, 2, 3, or 4 R691. The compound of claim 90 or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, wherein R2is a tricyclic ring containing at least one phenyl ring and wherein R2is optionally substituted with 1, 2, 3, or 4 R6.Attorney Docket No.: INMD-216 / 01WO 315953-444292. The compound of any one of claims 85-91 or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, wherein A is phenylene.

93. The compound of any one of claims 85-92 or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, wherein R3together with one of R6can form a tricyclic, tetracyclic, or pentacyclic ring optionally containing 1, 2, or 3 heteroatoms selected from N, S, or O, wherein the tricyclic, tetracyclic, or pentacyclic ring is optionally substituted with 1, 2, 3, or 4 R3.

94. The compound of claim 1 or 85 or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, wherein the compound has the structure of Formula (II-A)H. NR1NIf XXvR3T A i(R4)m(II-A),or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, wherein:ring A is a carbocycle, aryl, heterocycle, or heteroaryl ring;each X1ais independently -NRGa-, -O-, -CR1R13-, -C(O)-, -S-, -S(O) - or -S(O)2-; R3is H; or R3together with one of R6can form a tricyclic, tetracyclic, or pentacyclic ring optionally containing 1, 2, or 3 heteroatoms selected from N, S, or O, wherein the tricyclic, tetracyclic, or pentacyclic ring is optionally substituted with 1, 2, 3, or 4 R5;each R4is independently halogen, -Ci-Ce alkyl, -Ci-Ce haloalkyl, -S(Ci-C6 alkyl), - SO(Ci-Ce alkyl), -SO2(Ci-C6 alkyl), or -CN;R5and R6are each independently halogen, -OH, oxo, -CN, -Ci-Ce alkyl, -Ci-Ce alkyl-OH, -(Ci-Ce alkylene)-O-(Ci-Co alkyl), -(Ci-Ce aJkylene)-O-(Ci-Ce alkyl)-OH, -(Ci-Ce alkylene)-O-(Ci-C6 alkylene)-O-(Ci-Cs alkyl), -(Ci-Gs alkylene)-O-(Ci-C6 alkylene)-O-(Ci-Attorney Docket No.: INMD-216 / 01WO 315953-4442Ce alkyl)-OH, -C1-C10 haloalkyl, -Ci-Cio haloalkyl-OH, -NR7R8, -Ci-Ce alkyl-NR7R8, -S(C i-Ce alkyl), -SO(Ci-C6 alkyl), -SO2(Ci-Ce alkyl), -SO2NR7R8, -(Ci-Ce alkylene)-carbocycle, -(Ci-Ce alkylene)-heterocycle, carbocycle, or heterocycle, wherein each carbocycle and heterocycle is optionally substituted by 1 or 2 R11;each R6ais independently H, -Ci-Ce alkyl, -Ci-Ce alkyl-OH, -Ci-Cio haloalkyl, -Ci- Cio haloalkyl-OH, -Ci-C6alkyl-NR7R8, -(Ci-C6alkylene)-O-(Ci-C6alkyl), -(Ci-Ce alkylene)-O-(Ci-Ce alkyl)-OH, -(Ci-Ce alkylene)-O-(Ci-C’6 alkyl)-COOH, -(Ci-Ce alkylene)-O-(Ci-Ce alkylene)-O-(Ci-Ce alkyl), -(Ci-Ce alkylene)-O-(Ci-Ce alkylene)-NR7R8, -(Ci-Ce alkylene)-O-(Ci-Ce alkylene)-C(O)NR7R8, -(Ci-Ce alkylene)-O-(Ci-Ce alkylene)-NR7C(O)-(Ci-Ce alkyl), -(Ci-Ce alkylene)-O-(Ci-Ce alkylene)-C(O)NR7-(Ci-Ce alkylene)-O-(Ci-Ce alkyl), - (Ci-Ce alkylene)-O-(Ci-C6 alkylene)-NR7C(O)-(Ci-C6 alkylene)-O-(Ci-C6 alkyl), -(Ci-Ce alkylene)-O-(Ci-Ce alkylene)-C(O)NR'-(Ci-Ce alkylene)-O-(Ci-Ce alkylene)-NR7-aryl, -(Ci- Ce alkylene)-O-(Ci-Ce alkylene)-NR'C(O)-(Ci-Ce alkylene)-O-(Ci-Ce alkylene)-NR / -aryl, -(Ci-Ce alkylene)-NR7R8, -(Ci-Ce alkylene)-NR7-(Ci-C6 alkyl)-OH, -(Ci-Ce alkylene)-NR'- (Ci-C6alkyl)-O-(Ci-C6 alkyl), -(Ci-Ce alkylene)-NR7-(Ci-Ce alkylene)-NR7R8, -(Ci-Ce alkylene)-heterocycle, or -(Ci-Ce. alkylene)-heteroaryl;R7and R8are each independently H or -Ci-Ce alkyl; or R7and R8together with the nitrogen atom to which they are attached form a heterocyclyl;R9is halogen, cyano, hydroxyl, -NHz, -NH(Ci-Ce alkyl), -N(Ci-Ce alkyl)2, -COOH, - Ci-Ce alkyl, -C2-C6 alkenyl, -Cz-Ce alkynyl, -Ci-Ce haloalkyl, -C2-C6 haloalkenyl, -C2-C6 haloalkynyl, -C1-C0 alkyl-OH, -CONH2, -SH, -S(=O)NH2, -S(O)2NH2, -OCi-Co alkyl, -OCi- Ce haloalkyl, -S(Ci-Ce alkyl), -SO(Ci-Ce alkyl), -SO2(Ci-C6 alkyl), -SO2NR7R8, - S(=NH)(O)(CI-C6 alkyl), -(Ci-Ce alkylene)-carbocyclyl, or --(Ci-Ce alkylene)-heteroaryl;R10is H or -Ci-Ce alkyl,each R11is independently halogen, -OH, oxo, -CN, -Ci-Ce alkyl, -Ci-Ce alkyl-OH, - Ci-Cio haloalkyl, -C1-C10 haloalkyl-OH, -OCi-Ce alkyl, -NR7R8, -Ci-Ce alkyl-NR7R8, -S(C 1-Ce alkyl), -SO(Ci-Ce alkyl), -SO2(Ci-Ce alkyl), -SO2NR7R8, -(Ci-Ce alkylene)-carbocycle, -(Ci-Ce alkylene)-heterocycle, carbocycle, or heterocycle;R12and R13are each independently selected from H, deuterium, halogen, or -C1-C0 alkyl;m is 0, 1, 2, or 3;n is 0, I, 2, or 3; andp is 0, 1, 2, or 3.Attorney Docket No.: INMD-216 / 01WO 315953-444295. The compound of any one of claims 85-94 or a pharmaceutically acceptable salt, astereoisomer, or a deuterated form thereof, wherein A is96. The compound of claim 1 or 85 or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, wherein the compound has the structure of Formula (II-B)HR2(SV (n-B),or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, wherein:each X,ais independently -NR6a~, -O-, -CR12R13-, -C(O)-, -S-, -S(O) - or -S(O)2-; each R4is independently halogen, -Ci-Ce alkyl, -Ci-Ce haloalkyl, -S(Ci-C6 alkyl), - SO(Ci-Ce alkyl), -SO2(Ci-C6 alkyl), or -CN;each R6is independently halogen, -OH, oxo, -CN, -Ci-Cs alkyl, -Ci-Ce alkyl-OH, - (Ci-C6alkylene)-O-(Ci-Cb alkyl), -(Ci-Cs alkylene)-O-(Ci-Ce alkyl)-OH, -(Ci-Ce alkylene)-O-(Ci-C6 alkylene)-O-(Ci-Ce alkyl), -(Ci-Cs alkylene)-O-(Ci-C6 alkylene)-O-(Ci-C6 alkyl)-OH, -Ci-Cio haloalkyl, -Ci-Cw haloalkyl-OH, -NR7R8, -Ci-Ce alkyl-NR7R8, -S(Ci-C6alkyl), -SO(Ci-C6 alkyl), -SO2(Ci-C6 alkyl), -SO2NR7R8, -(Ci-Ce a1kylene)-carbocycle, -(Ci-Cs alkylene)-heterocycle, carbocycle, or heterocycle, wherein each carbocycle and heterocycle is optionally substituted by 1 or 2 R11,each R6ais independently H, -Ci-Co alkyl, -Ci-Ce alkyl-OH, -Ci-Cio haloalkyl, -Ci-Cio haloalkyl-OH, -Ci-C6alkyl-NR7R8, -(Ci-C6alkylene)-O-(Cj-C6alkyl), -(Ci-Ce alkylene)- O-(Ci-C6 alkyl)-OH, -(Ci-Ce alkylene)-O-(Ci-C6 alkyl)-COOH, -(Ci-Cs alkylene)-O-(Ci-C6 alkylene)-O-(Ci-C6 alkyl), -(Ci-C6 alkylene)-O-(C]-C6 alkylene)-NR7R8, -(Ci-C6 alkylene)-Attorney Docket No.: INMD-216 / 01WO 315953-44420-(Ci-C6 alkylene)-C(O)NR7R8, -(Ci-Ce alkylene)-0-(Ci-C6 alkylene)-NR7C(O)-(Ct-C6 alkyl), -(Ci-C’6 alkyl ene)-0-(Ci-C6 alkylene)-C(0)NR'-(Ci-C6 alkylene)-0-(Ci-C6 alkyl), -(Ci-Ce alkylene)-0-(Ci-C6 alkylene)-NR7C(O)-(Ci-C6 alkylene)-0-(Ci-C6 alkyl), -(Ci-Cb alkylene)-O-(Ci-Co dkylene)-C(0)NR'-(Ci-C6 alkylene)-O-(Ci-Ce alkylene)-NR7-aryl, -(Ci-Ce alkylene )-0-(Ci-C6 alkylene)-NR7C(O)-(Ci-C6 alkylene)-0-(Ci-C6 alkylene)-NR7-aryl, - (C1-C6 alkylene)-NR7R8, -(Ci-Cs alkylene)-NR7-(Ci-C6 alkyl)-OH, -(Ci-Ce alkylene)-NR7- (Ci-Ce alkyl)-0-(Ci-C6 alkyl), -(Ci-Ce alkylene)-NR7-(Ci-C6 alkylene)-NR7R8, -(Ci-Cs alkylene)-heterocycle, or -(Ci-Ce alkyl ene)-heteroaryl;R7and R8are each independently H or -Ci-Ce alkyl; or R7and R8together with the nitrogen atom to which they are attached form a heterocyclyl;R9is halogen, cyano, hydroxyl, -NH2, -NH(Ci-Ce alkyl), -N(Ci-Cb alkyl)2, -COOH, -Ci-Ce alkyl, -C2-C6 alkenyl, -C2-C6 alkynyl, -Ci-Cs haloalkyl, -C2-C6 haloalkenyl, -C2-C6 haloalkynyl, -Ci-C6alkyl-OH, -CONH2, -SH, -S(=O)NH2, -S(O)2NH2, -OCi-Co alkyl, -OCi-Ce haloalkyl, -S(Ci-C6 alkyl), -SO(Ci-C6 alkyl), -SO2(Ci-C6 alkyl), -SO2NR R8, - S(=NH)(O)(CI-C6 alkyl), -(Ci-Ce alkylene)-carbocyclyl, or-(Ci-C6 alkylene)-heteroaryl;R10is H or -Ci-Ce alkyl,each Ruis independently halogen, -OH, oxo, -CN, -Ci-Ce alkyl, -Ci-Ce alkyl-OH, - C1-C10 haloalkyl, -C1-C10 haloalkyl-OH, -OCi-Ce alkyl, -NR7R8, -Ci-Ce alkyl-NR7R8, -S(Ci-Ce alkyl), -SO(Ci-C6 alkyl), -SO2(Ci-C6 alkyl), -SO2NR7R8, -(C1-C6 alkylene)-carbocycle, - (Ci-Ce alkylene)-heterocycle, carbocycle, or heterocycle;R12and R13are each independently selected from H, deuterium, halogen, or -Ci-Cb alkyl;m is 0, 1, 2, or 3;n is 0, 1, 2, or 3, andp is 0, 1, 2, or 3.

97. The compound of claim 96 or a pharmaceutically acceptable salt, a stereoisomer, or adeuterated form thereof, wherein R2is; and p is 0 or 1.Attorney Docket No.: INMD-216 / 01WO 315953-444298, The compound of claim 96 or 97, or a pharmaceutically acceptable salt, astereoisomer, or a deuterated form thereof wherein R2is99, The compound of claim 1 or 85, or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, wherein the compound has the structure of Formula (II-C):or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, wherein:ring B is 5-8 membered ring optionally containing 1, 2, or 3 heteroatoms selected from N, S, or O;ring C is monocyclic, bicyclic, or tricyclic ring containing at least one aromatic ring;each R4is independently halogen, -Ci- alkyl, -Ci-Ce haloalkyl, -S(Cj-Ce alkyl), - SO(C1-C6alkyl), -SO2(Ci-C6alkyl), or -CN;R5and R6are each independently halogen, -OH, oxo, -CN, -Ci-Cf, alkyl, -C1-C6 alkyl- OH, -(Ci-C6alkylene)-O-(Ci-C6alkyl), -(Ci-C6alkylene)-O-(C]-C6alkyl)-OH, -(Ci-Cs alkylene)-O-(Ci-C6 alkylene)-O-(Ci-C6 alkyl), -(Ci-Ce alkylene)-O-(Ci-C<5 alkvlene)-O-(Ci-C6alkyl)-OH, -Ci-Cio haloalkyl, -Ci-Cio haloalkyl-OH, -NR7R8, -Ci-Ce alkyl-NR7R8, -S(C i-Attorney Docket No.: INMD-216 / 01WO 315953-4442C6alkyl), -S0(Ci-C6 alkyl), -SO2(Ct-C6alkyl), -SO2NR7R8, -(Ci-C6alkylene)-carbocycle, - (Ci-Cc. alkylene)-heterocycle, carbocycle, or heterocycle, wherein each carbocycle and heterocycle is optionally substituted by 1 or 2 R11;R7and R8are each independently H or -Ci-Cr, alkyl, or R7and R8together with the nitrogen atom to which they are attached form a heterocyclyl,R9is halogen, cyano, hydroxyl, -NH2, -NH(Ci-Cfi alkyl), -N(Ci-Ca alkyl)2, -COOH, - Ci-Ce alkyl, -C2-C<5 alkenyl, -C2-C6 alkynyl, -Ci-Co haloalkyl, -C2-C6 haloalkenyl, -C2-C6 haloalkynyl, -Ci-C6alkyl-OH, -CONH2, -SH, -S(=O)NH2, -S(O)2NH2, -OCi-Cs alkyl, -OCi-Ce haloalkyl, -S(Ci-Ce alkyl), -SO(Ci-Ce alkyl), -SO2(Ci-Ce alkyl), -SO2NR'R8, -S(=NH)(0)(CI-C6 alkyl), -(Cs-Ce alkylene)-carbocyclyl, or -(Ci-Ce alkylene)-heteroaryl;R10is H or -Ci-Ce alkyl,each Ruis independently halogen, -OH, oxo, -CN, -Ci-Ce alkyl, -Ci-Ce alkyl-OH, -Ci-Cio haloalkyl, -C1-C10 haloalkyl-OH, -OCi-Ce alkyl, -NR7R8, -Ci-Ce alkyl-NR7R8, -S(CJ- Ce alkyl), -SO(Ci-Ce alkyl), -SO2(Ci-Ce alkyl), -SO2NR7R8, - Ci-Ce alkylene)-carbocycle, -(Ci-Ce alkylene)-heterocycle, carbocycle, or heterocycle;m is 0, 1, 2, or 3;n is 0, 1, 2, or 3;p is 0, 1, 2, or 3; andq is 0, I, 2, or 3.

100. The compound of claim 99 or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, wherein ring C is phenyl.

101. The compound of claim 100 or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, wherein:the tricyclic ring containing ring B and ring C isAttorney Docket No.: INMD-216 / 01WO 315953-4442X]ais -NR6a-, -O-, -CR’2R13-, -C(O)-, -S-, -S(O) - or -S(O)2-; andR12and R13are each independently selected from H, deuterium, halogen, or C1-6 alkyl.

102. The compound of claim 101 or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, wherein Xlais -NH-, -NCH3-, -O-, or -CH2-.

103. The compound of any one of claims 99-102 or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof wherein the tricyclic ring containing ring B and ring C isAttorney Docket No.: INMD-216 / 01WO 315953-4442104. The compound of any one of claims 99-103 or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, wherein each R4is independently halogen, -C1-C3 alkyl, or -CN.

105. The compound of claim 104 or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, wherein R4is F.

106. The compound of any one of claims 99-105 or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof wherein each R° is independently halogen, -OH, - CN -C1-C3 alkyl, -C1-C3 haloalkyl, -S(Ci-C3 alkyl), -SO(Ci-C3 alkyl), -SO2(Ci-C,3 alkyl), - SO2MC1-C3 alkyl), -SO2NR7R8, or 4-6 membered heterocycle.

107. The compound of any one of claims 99-105 or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof wherein each R6is independently halogen, -CN,108. The compound of any one of claims 99-102 and 104-107 or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, wherein q is 0.

109. The compound of any one of claims 99-108 or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, wherein the tricyclic ring containing ring B and ring C isAttorney Docket No.: INMD-216 / 01WO 315953-4442110. The compound of claim 99 or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, wherein ring C is a bicyclic ring wherein one ring is a phenyl ring.

111. The compound of claim 110 or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, wherein ring C is a feud bicyclic ring.

112. The compound of claim 110 or 111, or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, wherein:the tetracyclic ring containing ring B and ring C hast the structure:ring D is a 5-7 membered heterocyclic ring containing 1, 2, or 3 heteroatoms selected from N, S„ or O.

113. The compound of any one of claims 110-112 or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, wherein each R6is independently halogen, -OH, - CN -C1-C3 alkyl, -C1-C3 haloalkyl, -S(Ci-C3alkyl), -SO(Ci-C3alkyl), -SChfCi-Cs alkyl), -SO2N(CI-C3alkyl), -SChNR7!^, or 4-6 membered heterocycle.

114. The compound of any one of claims 110-113 or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, wherein each R° is independently halogen, -Ci-C?alkyl, -CN,Attorney Docket No.: INMD-216 / 01WO 315953-4442115. The compound of any one of claims 110-114, or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, wherein the tetracyclic ring containing ring B and ring C is116. The compound of any one of claims 110-115 or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, wherein each R is independently halogen, -C1-C3 alkyl, or -CN.

117. The compound of claim 116 or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, wherein R4is F.

118. The compound of any one of claims 110-117, or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, wherein the tetracyclic ring containing ring B and ring C is119. The compound of claim 99 or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, wherein ring C is a tricyclic ring wherein one ring is a phenyl ring.Attorney Docket No.: INMD-216 / 01WO 315953-4442120. The compound of claim 99, or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, wherein:the pentacyclic ring containing ring B and ring C has the structure:ring containing 1, 2, or 3 heteroatoms selected from N, S, or O.

121. The compound of claim 120, or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, wherein ring D is a spiro bicyclic ring.

122. The compound of any one of claims 119-121 or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, wherein each R6is independently halogen, -OH, -CN -C1-C3 alkyl, -G-C3 haloalkyl, -S(Ci-C3alkyl), -SO(Ci-C.3 alkyl), -SO2(Ci-C.3 alkyl), - SO2N(CI-C3alkyl), -SOiNR’R8, or 4-6 membered heterocycle,123. The compound of any one of claims 119-122 or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, wherein each R6is independently halogen or -Ci-C3 alkyl.

124. The compound of any one of claims 119-123, or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, wherein the pentacyclic ring containing ring BAttorney Docket No.: INMD-216 / 01WO 315953-4442125. The compound of any one of claims 119-124 or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, wherein each R4is independently halogen, -C1-C3 alkyl, or -CN.

126. The compound of claim 125 or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, wherein R4is F.

127. The compound of any one of claims 119-126, or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, wherein the pentacyclic ring containing ring B128. The compound of claim 1 or 85 or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, wherein the compound has the structure of Formula (II-D)or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, wherein:ring A is a carbocycle, aryl, heterocycle, or heteroaryl ring;Attorney Docket No.: INMD-216 / 01 WO 315953-4442R3is H; or R3together with one of R° can form a tricyclic, tetracyclic, or pentacyclic ring optionally containing 1, 2, or 3 heteroatoms selected from N, S, or O, wherein the tricyclic, tetracyclic, or pentacyclic ring is optionally substituted with 1, 2, 3, or 4 R';each R4is independently halogen, -Ci-Cs alkyl, -Ci-Ce haloalkyl, -S(CJ-CS alkyl), - SO(C1-C6 alkyl), -SO2(Ci-C6 alkyl), or -CN;each R5is independently hydrogen, halogen, -OH, -CN, -Ct-Ce alkyl, -Ci-Ce alkyl-OH, -O-(Ci-Ce alkyl), -(Ci-Ce alkylene)-O-(Ci-C6 alkyl), -(Ci-Ce alkylene)-O-(Ci-C6 alkyl)-Attorney Docket No.: INMD-216 / 01WO 315953-4442OH, -(Ci-Co alkylene)-O-(Ci-C6 alkylene)-O-(Ci-C6 alkyl), -(Ci-Ce alkylene)-O-(Ci-C6 alkylene)-O-(Ci-C6 alkyl)-OH, -C1-C10 haloalkyl, -C1-C10 haloalkyl-OH, -NR7R8, -CONR7R8, -Ci-C6alkyl-NR7R8, -SF5, -S(Ci-C6alkyl), -SO(Ci-C6alkyl), -SO2(Ci-C6alkyl), -SO2NR7R8, -(Ci-Ce alkylene)-carbocycle, -(C1-C0 alkylene)-heterocycle, carbocycle, or heterocycle, wherein each carbocycle and heterocycle is optionally substituted by 1 or 2 Rn;each R6is independently halogen, -OH, oxo, -CN, -Ci-Cs alkyl, -Ci-Ce alkyl- OH, -O-(Ci-C6 alkvl), -(Ci-Cs alkylene)-O-(Ci-Ce alkyl), -(Ci-Ce alkylene)-O-(Ci-C6 alkyl)- OH, -(Ci-Cr, alkylene)-O-(Ci-C6 alkylene)-O-(Ci-C6 alkyl), -(C1-C6 alkylene)-O-(Ci-C6 alkylene)-O-(Ci-C6 alkyl)-OH, -C1-C10 haloalkyl, -C1-C10 haloalkyl-OH, -NR7R8, -Ci-Ce alkyl-NR7R8, -SF5, -S(Ci-C6alkyl), -SO(Ci-C6alkyl), -SO2(Ci-C6alkyl), -SO2NR7R8, -(Ci-Ce alkylene)-carbocycle, -(Ci-Ce alkylene)-heterocycle, carbocycle, or heterocycle, wherein each carbocycle and heterocycle is optionally substituted by 1 or 2 R11;R7and R8are each independently H or -C1-C6 alkyl; or R7and R8together with the nitrogen atom to which they are attached form a heterocyclyl;R9is halogen, cyano, hydroxyl, -NH2, -NH(Ci-Ce alkyl), -N(CI-CG alkyl)2, -COOH, - Ci-Ce alkyl, -C2-C6 alkenyl, -C2-C6 alkynyl, -Ci-Ce haloalkyl, -C2-C6 haloalkenyl, -C2-C6 haloalkynyl, -CI-CA alkyl-OH, -CONH2, -SH, -S(=O)NH2, -S(O)2NH2, -OCi-Ce alkyl, -OCi-Ce haloalkyl, -S(Ci-Ce alkyl), -SO(Ci-Cs alkyl), -SO2(Ci-Ce alkyl), -SO2NR'R8, -S(=NH)(O)(C1-C6alkyl), -(Ci-Ce alkylene)-carbocyclyl, or -(Ci-Ce alkylene)-heteroaryl;R10isH or -Ci-C6alkyl,each R11is independently halogen, -OH, oxo, -CN, -Ci-Ce alkyl, -Ci-Ce alkyl-OH, -C1-C10 haloalkyl, -C1-C10 haloalkyl-OH, -OCi-Ce alkyl, -NR7R8, -Ci-Ce alkyl-NR7R8, -S(Ci-Ce alkyl), -SO(Ci-Ce alkyl), -SO2(Ci-C6alkyl), -SO2NR7R8, -(Ci-Ce alkylene)-carbocycle, -(Cj-Ce alkylene)-heterocycle, carbocycle, or heterocycle;Z1is CH2, NR5, S, S(O), or S(O)2;g is 0, 1, 2, or 3;m is 0, 1, 2, or 3;n is 0, 1, 2, or 3; andp is 0, 1, 2, or 3.Attorney Docket No.: INMD-216 / 01WO 315953-4442129. The compound of claim 128 or a pharmaceutically acceptable salt, a stereoisomer, orR5(R )P130. The compound of claim 128 or 129 or a pharmaceutically acceptable salt a131. The compound of any one of claims 128-130 or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, wherein each R° is independently halogen, -OH, - Ci-C6alkyl, -O-(Ci-Ce alkyl), -Ci-Cio haloalkyl, -NR7R8, -S(Ci-C6alkyl), -SO(Ci-C6alkyl), -SO2(Ci-C6alkyl), carbocycle, or heterocycle, wherein each carbocycle and heterocycle is optionally substituted by 1 or 2 R11.

132. The compound of any one of claims 128-131 or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, wherein each R11is independently halogen, -OH, -Ci-Ce alkyl, -NR7R8, -S(Ci-Cb alkyl), -SO(Ci-Cb alkyl), or -SO2(Ci-Ce alkyl).

133. The compound of any one of claims 128-132 or a pharmaceutically acceptable salt, astereoisomer, or a deuterated form thereof, wherein R2isAttorney Docket No.: INMD-216 / 01WO 315953-4442134 The compound of claim 1 or 85 or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, wherein the compound has the structure of Formula (II-E)or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, wherein:ring A is a carbocycle, aryl, heterocycle, or heteroaryl ring;Attorney Docket No.: INMD-216 / 01WO 315953-4442, wherein each R2is optionally substituted with 1 or 2 R6;each R4is independently halogen, -Ci-Ce alkyl, -Ci-Ce haloalkyl, -S(Ci-C6 alkyl), - SO(Ci-Ce alkyl), -SO2(Ci-C6alkyl), or -CN;each R5is independently hydrogen, halogen, -OH, -CN, -Ci-Co alkyl, -Ci-Ce alkyl-OH, -O-(Ci-C6 alkyl), -(Ci-Cr, alkylene)-O-(Ci-C6 alkyl), -(C1-C6 alkylene)-O-(Ci-C6 alkyl)-OH, -(Ci-Cs alkylene)-O-(Ci-Ce alkylene)-O-(Ci-C6 alkyl), -(Ci-Ce alkylene)-O-(Ci-C6 alkylene)-O-(Ci-C6 alkyl)-OH, -C1-C10 haloalkyl, -Ci-Cio haloalkyl-OH, -NR7R8, -CONR7R8, -Ct-C6alkyl-NR7R8, -SF5, -S(Ci-C6alkyl), -SO(Ci-C6alkyl), -SO2(Ci-C6alkyl), -SO2NR7R8, -(Ci-Ce alkylene)-carbocycle, -(Ci-Cs alkylene)-heterocycle, carbocycle, or heterocycle, wherein each carbocycle and heterocycle is optionally substituted by 1 or 2 R11,each R6is independently halogen, -OH, oxo, -CN, -Ci-Ce alkyl, -Ci-Ce alkyl- OH, -O-(Ci-C<5 alkyl), -(C1-C0 alkylene)-O-(Ct-C6 alkyl), -(Ci-Ce alkylene)-O-(Ci-C6 alkyl)-OH, -(Ci-Co alkylene)-O-(Ci-C6 alkylene)-O-(Ci-C6 alkyl), -(Ci-Ce. alkyl ene)-O-(Ci-C6 alkylene)-O-(Ci-C6 alkyl)-OH, -Ci-Cio haloalkyl, -Ci-Cio haloalkyl-OH, -NR7R8, -Ci-Ce alkyl-NR7R8, -SF5, -S(Ci-C6alkyl), -SO(Ci-C6alkyl), -SO2(Ci-C6alkyl), -SO2NR7R8, -(Ci- Ce alkylene)-carbocycle, -(Ci-Ce alkylene)-heterocycle, carbocycle, or heterocycle, wherein each carbocycle and heterocycle is optionally substituted by 1 or 2 R11;R7and R8are each independently H or -Ci-Ce alkyl, or R7and R8together with the nitrogen atom to which they are attached form a heterocyclyl;R9is halogen, cyano, hydroxyl, -NH2, -NH(Ci-Ce alkyl), -N(Ci-Ce alkyl)2, -COOH, -Ci-Ce alkyl, -C2-Ce alkenyl, -C2-C6 alkynyl, -Ci-Ce haloalkyl, -C2-C6 haloalkenyl, -C2-C6 haloalkynyl, -Ci-Ce alkyl-OH, -CONH2, -SH, -S(=O)NH2, -S(O)2NH2, -OCi-Ce alkyl, -OCi-C6haloalkyl, -S(Ci-C6alkyl), -SO(Ci-C6alkyl), -SO2(Ci-C6alkyl), -SO2NR7R8, - S(=NH)(O)(CI-C6 alkyl), -(Ci-Ce alkylene)-carbocyclyl, or-(Ci-C6 alkylene)-heteroaryl;R10is H or -C1-C6 alkyl,each R11is independently halogen, -OH, oxo, -CN, -C1-C alkyl, -Ci-Ce alkyl-OH, - C1-C10 haloalkyl, -C1-C10 haloalkyl-OH, -OCi-C6alkyl, -NR7R8, -Ci-Ce alkyl-NR7R8, -S(Ci-C6 alkyl), -SO(Ci-C6alkyl), -SO2(Ci-C6alkyl), -SO2NR7R8, -(Ci-C6alkylene)-carbocycle, -(Ci-Ce alkylene)-heterocycle, carbocycle, or heterocycle;m is 0, 1, 2, or 3;Attorney Docket No.: INMD-216 / 01WO 315953-4442n is 0, 1, 2, or 3; andp is 0, 1, 2, or 3.

135. The compound of claim 134 or a pharm ceutically acceptable salt, a stereoisomer, ora deuterated form thereof, wherein R2isR2is optionally substituted with 1 or 2 R6.

136. The compound of claim 134 or 135 or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, wherein each R5is independently hydrogen, -Ci-Ce alkyl, -(Ci-Ce alkylene)-carbocycle, -(Ci-Ce alkylene)-heterocycle, carbocycle, or heterocycle.137 The compound of any one of claims 1 4-136 or a pharmaceutically acceptable salt, astereoisomer, or a deuterated form thereof, wherein R2isAttorney Docket No.: INMD-216 / 01WO 315953-4442138. The compound of any one of claims 134-137 or a pharmaceutically acceptable salt, a139. The compound of any one of claims 134-138 or a pharmaceutically acceptable salt, astereoisomer, or a deuterated form thereof, wherein A is140 The compound of claim 1 or 85 or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, wherein the compound has the structure of Formula (II-F)or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, wherein:Attorney Docket No.: INMD-216 / 01WO 315953-4442each R4is independently halogen, -Ci-Ce alkyl, -Ci-Ce haloalkyl, -S(Ci-C6 alkyl), - SO(Ci-Ce alkyl), -SChfCi-Ce alkyl), or -CN;R6is -NR7R8, -CI-C6alkyl-NR7R8, -S(Ci-C6 alkyl), -SO(Ci-C6alkyl), -SO2(CJ-C6 alkyl), -SO2NR7R8, -(Ci-Ce. alkylene)-carbocycle, -(Ci-Ce alkylene)-heterocycle, carbocycle, or heterocycle, wherein each carbocycle and heterocycle is optionally substituted by 1 or 2 R31;R7and R8are each independently H or -Ci-Ce alkyl; or R7and R8together with the nitrogen atom to which they are attached form a heterocyclyl;R9is halogen, cyano, hydroxyl, -NH2, -NH(C1-C6alkyl), -N(CI-C6 alkyl)2, -COOH, -Ci-Ce alkyl, -C2-C6 alkenyl, -C -C6 alkynvl, -CJ-C6 haloalkyl, -C2-C6 haloalkenyl, -C2-C6 haloalkynyl, -Ci-Ce alkyl-OH, -CONH2, -SH, --S(=O)NH2, -S(O)2NH2, -OCi-C6alkyl, -OCi- C6haloalkyl, -S(Ci-C6 alkyl), -SO(Ci-C6 alkyl), -SO2(Ci-C6 alkyl), -SO2NR7R8, - S(:::NH)(O)(CI-C6 alkyl), -(Ci-Ce alkylene)-carbocyclyl, or -(Ci-Ce alkylene)-heteroaryl;R’° is H or -Ci-Ce alkyl,each R11is independently halogen, -OH, oxo, -CN, -C1-C6 alkyl, -Ci-Ce alkyl-OH, -C1-C10 haloalkyl, -C1-C10 haloalkyl-OH, -OCi-C6alkyl, -NR7R8, -Ci-C6alkyl-NR7R8, -S(Ci-Co alkyl), -SO(Ci-C alkyl), -SO2(Ci-C6 alkyl), -SO2NR7R8, -(Ci-C6alkylene)-carbocycle, -(Ci-Cs alkylene)-heterocycle, carbocycle, or heterocycle;m is 0, 1, 2, or 3; andn is 0, I, 2, or 3,141. The compound of claim 140 or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, wherein R6is at the para position.

142. The compound of claim 140 or 141 or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, wherein R6is -SO2NR7R8or -(CJ-CS alkylene)- heterocycle, wherein the heterocycle is optionally substituted by 1 or 2 R11.

143. The compound of any one of claims 140-142 or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, wherein:Attorney Docket No.: INMD-216 / 01WO 315953-4442R6is -SChNR7R8or-(Ci-C3 alkylene)-(6-membered heterocycle), wherein the heterocycle is optionally substituted by 1 or 2 R";R7and R8together with the nitrogen atom to which they are attached form a 3- to 6-membered heterocyclyl; andeach Rnis independently halogen or -C1-C3 alkyl.

144. The compound of any one of claims 140-143 or a pharmaceutically acceptable salt, astereoisomer, or a deuterated form thereof, wherein R6is145. The compound of claim 1 or 85 or a pharmaceutically acceptable salt, a stereoisomer. or a deuterated form thereof, wherein the compound has the structure of Formula (II-G):or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof wherein:ring A is a fused bicyclic heteroaryl ring;Attorney Docket No.: INMD-216 / 01WO 315953-4442each X,ais independently -NR6a-, -O-, -CR12R13-, -C(O)-, -S-, -S(O) - or -S(O)2-; each Z1is independently -CH2-, -NR5-, -S-, -S(O) -, or -S(O)2-;R3is H;each R4is independently halogen, -Ci-Ce alkyl, -Ci-Ce haloalkyl, -S(Ci-Ce alkyl), -SO(Cj- Ce alkyl), -SO2(Ci-C6alkyl), or -CN;each R- is independently hydrogen, -OH, -CN, -Ci-Ce alkyl, -C1-C6alkyl-OH, -O-(Ci-Ce alkyl), -(Ci-C6alkyl ene)-O-(Ci-C6alkyl), -(Ci-C6alkylene)-O-(Ci-C6 alkyl)-OH, -(Ci-C6alkylene)-O-(Ci-C6 alkylene)-O-(Ci-Ce alkyl), -(Ci-Ce alkylene)-O-(Ci-Ce alkylene)-O-(Cj- Ce alkyl)-OH, -Ci-Cio haloalkyl, -Ci-Cio haloalkyl-OH, -NR7R8, -CONR7R8, -Ci-C6alkyl- NR7R8, -SF, -S(CI-C6 alkyl), -SO(Ci-C6 alkyl), -SO2(Ci-C6 alkyl), -SO2NR7R8, -(Ci-Ce alkylene)-carbocycle, -(Ci-Ce alkylene)-heterocycle, carbocycle, or heterocycle, wherein each carbocycle and heterocycle is optionally substituted by 1 or 2 Rn;each R6is independently halogen, -OH, oxo, -CN, -Ci-Ca alkyl, -Ci-Ce alkyl-OH, -O-(CJ- Ce alkyl), -(Ci-Ce alkylene)-O-(Ci-C6 alkyl), -(Ci-C6alkylene)-O-(Ci-C6alkyl)-OH, -(Ci-Ce alkylene)-O-(Ci-Ce alkylene)-O-(Ci-C6 alkyl), -(Ci-Ce alkylene)-O-(Ci-C6 alkylene)-O-(Ct- C6alkyl)-OH, -C1-C10 haloalkyl, -C1-C10 haloalkyl-OH, -NR7R8, -Ci-Ce alkyl-NR7R8, -SF5, - S(C1-C6 alkyl), -SOCC1-C6 alkyl), -SO2(Ci-C6 alkyl), -SO2NR7R8, -(C]-C6alkylene)-carbocycle, -(Ci-Ce alkylene)-heterocycle, carbocycle, or heterocycle, wherein each carbocycle and heterocycle is optionally substituted by 1 or 2 R11;each R6ais independently H, -Ci-Cs alkyl, -Ci-Ce alkyl-OH, -Ci-Cio haloalkyl, -Ci-Cio haloalkyl-OH, -Ci-Ce alkyl-NR7R8, -(Ci-Ce alkylene)-O-(Ci-C6 alkyl), -(Ci-Ce alkylene)-O-(Ci-Co alkyl)-OH, -(Ci-Ce alkylene)-O-(Ci-Ce alkyl)-COOH, -(Ci-Ce alkylene)-O-(Ci-C6 alkylene)-O-(Ci-C6 alkyl), -(Ci-Ce alkylene)-O-(Ci-C6 alkyl ene)-NR7R8, -(Ci-Ce alkylene)-O-Attorney Docket No.: INMD-216 / 01WO 315953-4442(Cl -C6 alkylene)-C(O)NR7R8, -(Ci-C6alkylene)-O-(Ci-C6alkylene)-NR7C(O)-(Ci-C6alkyl), - (Ci-Cc. alkylene)-O-(Ci-C6alkylene)-C(O)NR7-(Ci-C6 alkylene)-0-(Ci-C6 alkyl), -(Ci-C6alkylene)-0-(Ci-C6 alkylene)-NR7C(O)-(Ci-C6 alkylene)-0-(Ci-C6 alkyl), -(Ci-Ce alkylene)- 0-(CJ-C6 alkylene)-C(O)NR7-(Ct-C6 alkylene)-0-(Ci-C6 alkylene)-NR'-aryl, -(Ci-Cr alkylene)-0-(Ci-C6 alkylene)-NR7C(O)-(Ci-C6 alkylene)-0-(Ci-C6 alkylene)-NR7-aryl, -(Ci-C6alkylene)-NR7R8, -(Ci-C6alkylene)-NR7-(Ci-C6alkyl)-OH, -(Ci-C6alkylene)-NR7-(Ci-C6 alkyl )-O-(Ci-C6alkyl), -(Ci-C6alkylene)-NR7-(Ci-C6alkylene)-NR7R8, -(Ci-Ce alkylene)- heterocycle, or -(Ci-Ce alkylene)-heteroaryl;R7and R8are each independently H or -Ci-Cs alkyl; or R7and R8together with the nitrogen atom to which they are attached form a heterocyclyl;R9is halogen, cyano, hydroxyl, -NH2, -NH(C1-C6alkyl), -N(CI-C6 alkyl )2, -COOH, -Ci-Ce alkyl, -C2-C6 alkenyl, -C2-C6 alkynyl, -Ci-Ce haloalkyl, -C2-C6 haloalkenyl, -C2-C6 haloalkynyl, -Ci-C6alkyl-OH, -CONH2, -SH, -S(=O)NH2, -S(O)2NH2, -OCj-Cr alkyl, -OCi-Ce haloalkyl, -S(Ci-C6alkyl), -SO(Ci-Ce alkyl), -SO2(Ci-C6 alkyl), -SO2NR7R8, - S(=NH)(0)(CI-C6 alkyl), -(Ci-Ce alkylene)-carbocyclyl, or-(Ci-C6 alkylene)-heteroaryl;R10is H or -C1-C6 alkyl;each R11is independently halogen, -OH, oxo, -CN, -Ci-Ce alkyl, -C1-C6 alkyl-OH, -CI-CJO haloalkyl, -C1-C10 haloalkyl-OH, -OCi-C6alkyl, -NR7R8, -Ci-Ce alkyl-NR7R8, -S(Ci-C6alkyl), -SO(Ci-C6 alkyl), -SO2(CJ-C6 alkyl), -SO2NR7R8, -(Ci-Ce alkylene)-carbocycle, -(Ci-Ce alkylene)-heterocycle, carbocycle, or heterocycle;Ri2and R17are each independently selected from H, deuterium, halogen, or -Ci-Ce alkyl, g is 0, 1, 2, or 3;m is 0, 1, 2, or 3;n is 0, 1, 2, or 3; andp is 0, 1, 2, or 3146. The compound of claim 145 or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, wherein A is a 5,6-fused heteroaryl, 6,5-fused heteroaryl, or 6,6-fused heteroaryl.Attorney Docket No.: INMD-216 / 01WO 315953-4442147. The compound of claim 145 or 146 or a pharmaceutically acceptable salt, a148. The compound of any one of claims 145-147 or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, wherein each R4is independently halogen or -Ci- C-6 alkyl.

149. The compound of any one of claims 145-148 or a pharmaceutically acceptable salt, a150. The compound of any one of claims 145-149 or a pharmaceutically acceptable salt, astereoisomer, or a deuterated form thereof, wherein R2isAttorney Docket No.: INMD-216 / 01WO 315953-4442151. The compound of any one of claims 145-150 or a pharmaceutically acceptable salt, astereoisomer, or a deuterated form thereof, wherein R2is152. The compound of any one of claims 145-151 or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, wherein R5is halogen or -Ci-Co alkyl.

153. The compound of any one of claims 145-152 or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof wherein:R6ais H, -C1-C3 alkyl, -C1-C3 alkyl-NR7R8, -(C1-C3 alkylene)-NR7-(Ci-C3 alkyl)-O-(C1-C3 alkyl), or -(C1-C3 alkylene)-heterocycle; andR7and R8are each independently H or -Ci-Ce alkyl.

154. The compound of any one of claims 145-153 or a pharmaceutic ally acceptable salt, a stereoisomer, or a deuterated form thereof, wherein:each R6is independently halogen, -Ci-Ce alkyl, or heterocycle, wherein each heterocycle is optionally substituted by 1 or 2 R11; andeach R11is independently halogen or -C1-C3 alkyl.

155. The compound of any one of claims 145-154 or a pharmaceutically acceptable salt, astereoisomer, or a deuterated form thereof, R2isAttorney Docket No.: INMD-216 / 01WO 315953-4442156 The compound of any one of claims 85-155 or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, wherein R1is157. The compound of claim 1 or 85 or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, wherein the compound has the structure of Formula (II -H) / oh(R)m(II-H),or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, wherein:each R4is independently halogen, -Ci-Ce alkyl, -Ci-Ce haloalkyl, -S(Ci-C6 alkyl), - SO(C1-C6alkyl), -SO2(Ci-C6alkyl), or -CN:R5is H, -Ci-Ce alkyl, -Ci-Cio haloalkyl, or -Ci-Ce alkyl-NR7R8;Attorney Docket No.: INMD-216 / 01WO 315953-4442each R6is independently halogen, -OH, -CN, -Ci-Cc, alkyl, -Ci-Ce alkyl-OH, -O-(Ci-C6 alkyl), -C1-C10 haloalkyl, -C1-C10 haloalkyl-OH, -NR7R8, -Ci-Ce alkyl-NR7Rs, -S(Ci-C6alkyl), -SO(Ci-C6alkyl), -SO2(Ci-C6alkyl), or -SO2NR7R8;R6ais H, -C1-C6 alkyl, -CJ-CIO haloalkyl, or -Ci-C6alkyl-NR7R8;R7and R8are each independently H or -Ci-Ce al yl; or R7and R8together with the nitrogen atom to which they are attached form a heterocyclyl;R9is halogen, cyano, hydroxyl, -NH2, -NH(Ci-Cs alkyl), -N(Ci-Ce alkyl)2, -COOH, - Ci-C6alkyl, -Ci-C6haloalkyl, -Cj-Ce alkyl-OH, -CONH2, -SH, -S(=O)NH2, -S(O)2NH2, -OCi-Ce alkyl, -OCi-C6haloalkyl, -S(Ci-C6alkyl), -SO(Ci-Cs alkyl), -SO2(Ci-C6alkyl), -SO2NH2, -SO2NH(CJ-C6 alkyl), -SO2N(CI-C6alkyl)2, or -S(=NH)(O)(Ci-Ce alkyl);R10is H or -Ci-Ce alkyl,tn is 0, 1 or 2;n is 0 or 1; andp is 0, 1, 2, or 3.

158. The compound of claim 157 or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, wherein each R6is independently H or methyl159. The compound of claim 157 or 158 or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, wherein R:and R6aare each independently H, methyl, or ethyl.

160. The compound of any one of claims 1 7-159 or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, wherein each R4is halogen.

161. The compound of any one of claims 157-159 or a pharmaceutically acceptable salt, astereoisomer, or a deuterated form thereof, wherein R1isH162. The compound of any one of claims 85-160 or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, R10is H or methyl.Attorney Docket No.: INMD-216 / 01WO 315953-4442163. The compound of any one of claims 85-160 and 162 or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, wherein R9is halogen, hydroxyl, -Ci-Cs alkyl, -CJ-C6 haloalkyl, -OCi-Ce alkyl, or -OCi-Ce haloalkyl.

164. The compound of any one of claims 85-160, 162, and 163 or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, wherein n is 0.

165. The compound of claim 1 or 9 or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, wherein the compound is:Attorney Docket No.: INMD-216 / 01 WO 315953-4442Attorney Docket No.: INMD-216 / 01WO 315953-4442Attorney Docket No.: INMD-216 / 01WO 315953-4442Attorney Docket No.: INMD-216 / 01WO 315953-4442Attorney Docket No.: INMD-216 / 01WO 315953-4442Attorney Docket No.: INMD-216 / 01WO 315953-4442Attorney Docket No.: INMD-216 / 01WO 315953-4442Attorney Docket No.: INMD-216 / 01WO 315953-4442or a pharmaceutically acceptable salt, stereoisomer, or deuterated form thereof.

166. The compound of claim 1 or 9 or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, wherein the compound is:Attorney Docket No.: INMD-216 / 01WO 315953-4442Attorney Docket No.: INMD-216 / 01 WO 315953-4442Attorney Docket No.: INMD-216 / 01WO 315953-4442Attorney Docket No.: INMD-216 / 01WO 315953-4442Attorney Docket No.: INMD-216 / 01WO 315953-4442Attorney Docket No.: INMD-216 / 01WO 315953-4442Attorney Docket No.: INMD-216 / 01WO 315953-4442Attorney Docket No.: INMD-216 / 01WO 315953-4442Attorney Docket No.: INMD-216 / 01WO 315953-4442or a pharmaceutically acceptable salt or deuterated form thereof.

167. The compound of claim 1 or 85 or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, wherein the compound is:Attorney Docket No.: INMD-216 / 01WO 315953-4442Attorney Docket No.: INMD-216 / 01WO 315953-4442Attorney Docket No.: INMD-216 / 01WO 315953-4442Attorney Docket No.: INMD-216 / 01WO 315953-4442ZIAttorney Docket No.: INMD-216 / 01WO 315953-4442Attorney Docket No.: INMD-216 / 01WO 315953-4442Attorney Docket No.: INMD-216 / 01WO 315953-4442Attorney Docket No.: INMD-216 / 01WO 315953-4442Attorney Docket No.: INMD-216 / 01WO 315953-4442Attorney Docket No.: INMD-216 / 01WO 315953-4442Attorney Docket No.: INMD-216 / 01WO 315953-4442Attorney Docket No.: INMD-216 / 01WO 315953-4442Attorney Docket No.: INMD-216 / 01WO 315953-4442Attorney Docket No.: INMD-216 / 01WO 315953-4442Attorney Docket No.: INMD-216 / 01WO 315953-4442Attorney Docket No.: INMD-216 / 01WO 315953-4442Attorney Docket No.: INMD-216 / 01WO 315953-4442Attorney Docket No.: INMD-216 / 01WO 315953-4442or a pharmaceutically acceptable salt, stereoisomer, or deuterated form thereof.Attorney Docket No.: INMD-216 / 01WO 315953-4442168. The compound of claim 1 or 85 or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, wherein the compound is:Attorney Docket No.: INMD-216 / 01WO 315953-4442Attorney Docket No.: INMD-216 / 01WO 315953-4442Attorney Docket No.: INMD-216 / 01WO 315953-4442ZIAttorney Docket No.: INMD-216 / 01WO 315953-4442Attorney Docket No.: INMD-216 / 01WO 315953-4442Attorney Docket No.: INMD-216 / 01WO 315953-4442Attorney Docket No.: INMD-216 / 01WO 315953-4442Attorney Docket No.: INMD-216 / 01WO 315953-4442Attorney Docket No.: INMD-216 / 01WO 315953-4442Attorney Docket No.: INMD-216 / 01WO 315953-4442Attorney Docket No.: INMD-216 / 01WO 315953-4442Attorney Docket No.: INMD-216 / 01WO 315953-4442Attorney Docket No.: INMD-216 / 01WO 315953-4442Attorney Docket No.: INMD-216 / 01WO 315953-4442Attorney Docket No.: INMD-216 / 01WO 315953-4442Attorney Docket No.: INMD-216 / 01WO 315953-4442Attorney Docket No.: INMD-216 / 01WO 315953-4442Attorney Docket No.: INMD-216 / 01WO 315953-4442or a pharmaceutically acceptable salt or deuterated form thereof.

169. A compound selected from:Attorney Docket No.: INMD-216 / 01WO 315953-4442Attorney Docket No.: INMD-216 / 01WO 315953-4442Attorney Docket No.: INMD-216 / 01WO 315953-4442Attorney Docket No.: INMD-216 / 01WO 315953-4442170. The compound of claim 169 or a pharmaceutically acceptable salt or deuterated form thereof, wherein the compound is selected from:Attorney Docket No.: INMD-216 / 01WO 315953-4442Attorney Docket No.: INMD-216 / 01WO 315953-4442Attorney Docket No.: INMD-216 / 01WO 315953-4442Attorney Docket No.: INMD-216 / 01WO 315953-4442Attorney Docket No.: INMD-216 / 01WO 315953-4442Attorney Docket No.: INMD-216 / 01WO 315953-4442Attorney Docket No.: INMD-216 / 01WO 315953-4442Attorney Docket No.: INMD-216 / 01WO 315953-4442or a pharmaceutically acceptable salt or deuterated form thereof.171 A. compound of Formula (B )R15VRor a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, wherein:ring A is a carbocyclyl, aryl, heterocyclyl, or heteroaryl ring,R2is a carbocycle, aryl, heterocycle, or heteroaryl ring, wherein each R2is optionally substituted with 1, 2, 3, or 4 Rb;R3is H; or R3together with one of R” can form a tricyclic, tetracyclic, or pentacyclic ring optionally containing 1, 2, or 3 heteroatoms selected from N, S, or O, wherein the tricyclic, tetracyclic, or pentacyclic ring is optionally substituted with 1, 2, 3, or 4 R3;each R4is independently halogen, -Ci-Co alkyl, -CI-C haloalkyl, -S(Ci-C6 alkyl), - SO(Ci-Ce alkyl), -SO2(Ci-C6 alkyl), or -CN;R5and R6are each independently halogen, -OH, oxo, -CN, -Ci-Cr, alkyl, -C1-C6 alkyl-OH, -(Ci-Co alkylene)-O-(Ci-C6 alkyl), -(Ci-C6alkylene)-O-(Ci-C6 alkyl)-OH, -(Ci-C6alkylene)-O-(Ci-C6 alkylene)-O-(Ci-Cs alkyl), -(Ci-Ce alkylene)-O-(Ci-C6 alkvlene)-O-(Ci-Co alkyl)-OH, -Ct-Cio haloalkyl, -Ci-Cto haloalkyl-OH, -NR7R8, -Ci-C6alkyl-NR7R8, -S(C i- C6alkyl), -SO(Ci-C6alkyl), -SO2(Ci-C6 alkyl), -SO2NR7R8, -(Ci-Ce alkylene)-carbocycle, -Attorney Docket No.: INMD-216 / 01WO 315953-4442(Ci-Cfi alkylene)-heterocycle, carbocycle, or heterocycle, wherein each carbocycle and heterocycle is optionally substituted by 1 or 2 R";R7and R8are each independently H or -C1-C6 alkyl; or R7and R8together with the nitrogen atom to which they are attached form a heterocyclyl;each R11is independently halogen, -OH, oxo, -CN, -Ci-Ce alkyl, -Ci-Ce alkyl-OH, - C1-C10 haloalkyl, -Ci-Cio haloalkyl-OH, -OCi-Cs alkyl, -NR7R8, -Ci-C6alkyl-NR7R8, -S(Ci- C'e alkyl), -SO(Ci-C6 alkyl), -SO2(Ci-C’6 alkyl), -SOzNR7!!8, -(Ci-Ce alkylene)-carbocycle, -(Ci-Ce alkylene)-heterocycle, carbocycle, or heterocycle;R14is optionally substituted -C1-C30 alkyl, optionally substituted -C2-C30 alkenyl, or optionally substituted C2-C30 alkynyl;R17and R16are each independently H or -Ci-Co alkyl; or R15and Rlbtogether with the nitrogen atom to which they are attached form a heterocyclyl; andm is 0, 1, 2, or 3.172 The compound of claim 171 or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, wherein the compound has the structure of Formula (B-l)or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, wherein:each X,ais independently -NR6a-, -O-, -CR12R13-, -C(O)-, -S-, -S(O) - or -S(O)2-; each R4is independently halogen, -Ci-Ce alkyl, -Ci-Ce haloalkyl, -S(Cj-Ce alkyl), -SO(C1-C6 alkyl), -SO2(Ci-C6 alkyl), or -CN;each R6is independently halogen, -OH, oxo, -CN, -C 1 -Cf, alkyl, -C1-C6alkyl-OH, -(Ci-Cb alkylene)-O-(Ci-C6 alkyl), -(Ci-Cs alkyl ene)-O-(Ci-Ce alkyl)-OH, -(Ci-Ce alkylene)-O-(Ci-Ce alkylene)-O-(Ci-C6 alkyl), -(C1-C6 alkylene)-O-(Ci-C6 alkylene)-O-(Ci-C6 alkyl)-OH, -C1-C10 haloalkyl, -C1-C10 haloalkyl-OH, -NR7R8, -Ci-Ce alkyl-NR7R8, -S(Ci-C6alkyl),Attorney Docket No.: INMD-216 / 01WO 315953-4442-S0(Ci-C6 alkyl), -SCh(Ci-C6 alkyl), -SO2NR7R8, -(Ci-Ce alkylene)-carbocycle, -(Ci-Ce alkylene)-heterocycle, carbocycle, or heterocycle, wherein each carbocycle and heterocycle is optionally substituted by 1 or 2 R11;each R6ais independently H, -Ci-Ce alkyl, -Cj-Cr, alkyl-OH, -Ci-Cio haloalkyl, -Ci-Cio haloalkyl-OH, -Ci-C6alkyl-NR7R8, -(Ci-C6alkylene)-O-(Ci-C6 alkyl), -(Ci-Ce alkylene)-O-(Ci-C6 alkyl)-OH, -(Ci-C6alkylene)-O-(Ci-C6alkyl)-COOH, -(Ci-Ce alkyl ene)-O-(Ci-C6alkylene)-O-(Ci-Cs alkyl), -(Ci-Ce alkyl ene)-O-(Ci-C6 alkylene)-NR7R8, -(Ci-Ck alkylene)-O-(C]-C6alkylene)-C(O)NR7R8, -(Ci-Ce alkylene)-O-(Ci-C6alkylene)-NR7C(O)-(Ci-C6 alkyl), -(Ci-C6alkylene)-O-(Ci-C6 alkylene)-C(O)NR7-(Ci-C6alkylene)-O-(Ci-C6alkyl), -(Ci-Cr, alkylene)-O-(Ci-Cb alkylene)-NR7C(O)-(Ci-Ce alkylene)-O-(Ci-C6 alkyl), -(Ci-Ce alkylene)-O-(Ci-Ce alkylene)-C(O)NR7-(Ci-C6 alkylene)-O-(Ci-C6 alkylene)-NR7-aryl, -(Ci-Ce alkylene)-O-(Ci-Cb alkylene)-NR'C(O)-(Ci-C6 alkylene)-O-(Ci-C6 alkylene)-NR7-aryl, -(Ci-Cs alkylene)-NR7R8, -(Ci-Ce alkylene)-NR7-(Ci-C6alkyl)-OH, -(Ci-C6alkylene)-NR7-(Ci-C6alkyl)-O-(Ci-C6 alkyl), -(Ci-Ce alkylene)-NR7-(Ci-C6 alkylene)-NR7Rs, -(Ci-Ce alkylene)-heterocycle, or -(Cj-Ce alkylene)-heteroaryl;R7and R8are each independently H or -Ci-Ce alkyl; or R7and R8together with the nitrogen atom to which they are attached form a heterocyclyl;each R11is independently halogen, -OH, oxo, -CN, -Ci-Ce alkyl, -Ci-Ce alkyl-OH, - Ci-Cio haloalkyl, -Ci-Cw haloalkyl-OH, -OCi-C6alkyl, -NR7R8, -Ci-C6alkyl-NR7R8, -S(Cr-C6alkyl), -SO(Ci-Cb alkyl), -SO2(Ci-C6alkyl), -SO2NR7R8, -(Ci-Cs alkylene)-carbocycle, -(Ci-Ce alkylene)-heterocycle, carbocycle, or heterocycle;R12and R13are each independently selected from H, deuterium, halogen, or -C1-C6 alkyl;Rl4is optionally substituted -C1-C30 alkyl, optionally substituted -C2-C30 alkenyl, or optionally substituted C2-C30 alkynyl;R13and Rl° are each independently H or -Ci-Ce alkyl; or R15and R16together with the nitrogen atom to which they are attached form a heterocyclyl;m is 0, 1, 2, or 3; andp is 0, 1, 2, or 3.

173. The compound of claim 172, having a structure of Formula (B-II)Attorney Docket No.: INMD-216 / 01WO 315953-4442R15\ R!6H NR14R2(B-II),or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, wherein:each R4is independently halogen, -Ci-Ce alkyl, or -Ci-Ce haloalkyl; andm is 0 or 1.174 The compound of claim 172 or 173 or a pharmaceutically acceptable salt, astereoi somer, or a deuterated form thereof, wherein175. The compound of claim 172 or 173 or a pharmaceutically acceptable salt, astereoisomer, or a deuterated form thereof, wherein176. The compound of any one of claims 171-175 or a pharmaceutically acceptable salt, astereoisomer, or a deuterated form thereof, wherein R2isAttorney Docket No.: INMD-216 / 01WO 315953-4442177. The compound of any one of claims 171-175 or a pharmaceutically acceptable salt, a Ob6a stereoisomer, or a deuterated form thereof, wherein R2is; and p is 0 or 1.

178. The compound of any one of claims 171-177 or a pharmaceutically acceptable salt, astereoisomer, or a deuterated form thereof, wherein R2is179. The compound of any one of claims 171-178 or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, wherein R14is optionally substituted -C1-C20 alkyl, optionally substituted -C2-C20 alkenyl, or optionally substituted C2-C20 alkynyl.

180. The compound of any one of claims 171-179 or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, wherein R14is optionally substituted -C1-C16 alkyl.

181. The compound of any one of claims 171-180 or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, wherein R14is -CH3, -CH2CH3, -CH(CH3)2, - C(CH3)3, -(CH2)2CH3, -(CH2 CH3, -(CH2)4CH3, -(CH2)5CH3, -(CH2)6CH3, -(CH2)7CH3, -(CH 2 CH3, -(CH2)9CH3, -(CH2)IOCH3, -(CH2)HCH3, -(CH2)I2CH3, -(CH2)I3CH3, -(CH2)i4CH3, or -(CH2)I5CH3.

182. The compound of any one of claims 171-180 or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, wherein R14is -CH3, -CH(CH3)2, - C(CH3)3, -(CH2)2CH3, -(CH2)3CH3, -(CH2)4CH3, -(CH2)6CH3, -(CH2)SCH3, -(CH2)IOCH3, -(C H2)12CH3, or -(CH2)14CH3.

183. The compound of any one of claims 171-182 or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, wherein R15and R16are each -CI-CG alkyl.

184. The compound of any one of claims 171-183 or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, wherein R15and R16are -CH3.Attorney Docket No.: INMD-216 / 01WO 315953-4442185. The compound of claim 171 or 172 or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, wherein the compound is:Attorney Docket No.: INMD-216 / 01WO 315953-4442or a pharmaceutically acceptable salt, stereoisomer, or deuterated form thereof.

186. The compound of claim 171 or 172 or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, wherein the compound is:Attorney Docket No.: INMD-216 / 01WO 315953-4442Attorney Docket No.: INMD-216 / 01WO 315953-4442or a pharmaceutically acceptable salt or deuterated form thereof.

187. A pharmaceutical composition comprising an effective amount of a compound of any one of claims 1-186, or a pharmaceutically acceptable salt or deuterated form thereof and a pharmaceutically acceptable adjuvant, diluent or carrier.188 A method for treating an obstructive disease of the airway in a patient in need thereof, comprising, administering to the patient an effective amount of a compound of any one of claims 1-186 or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, or the composition of claim 187.

189. The method of claim 188, wherein the obstructive disease of the airway is asthma, chronic obstructive pulmonary disease (COPD), bronchitis, emphysema, cystic fibrosis (CF),Attorney Docket No.: INMD-216 / 01WO 315953-4442bronchiectasis, sarcoidosis, alpha- 1 antitrypsin (A1AT) deficiency, farmer’s lung and related diseases, hypersensitivity pneumonitis, pulmonary fibrosis, complications of lung transplantation, vasculitic and thrombotic disorders of the lung vasculature, pulmonary hypertension, antitussive activity including treatment of chronic cough associated with inflammatory and secretory conditions of the airways, iatrogenic cough, acute and chronic rhinitis including rhinitis edica entosa, and vasomotor rhinitis; perennial and seasonal allergic rhinitis including rhinitis nervosa (hay fever), nasal polyposis; acute viral infection including the common cold, and infection due to a respiratory virus, acute lung injury, or acute respiratory distress syndrome (ARDS).

190. The method of claim 189, wherein the obstructive disease of the airway is asthma.

191. The method of claim 189, wherein the obstructive disease of the airway is acute respiratory distress syndrome (ARDS)192. The method of claim 189, wherein the obstructive disease of the airway is bronchitis.

193. The method of claim 189, wherein the obstructive disease of the airway is pulmonary fibrosis.

194. The method of claim 189, wherein the obstructive disease of the airway is emphysema.

195. The method of claim 189, wherein the obstructive disease of the airway is cystic fibrosis (CF).

196. The method of claim 189, wherein the obstructive disease of the airway is bronchiectasis.197 The method of claim 189, wherein the obstructive disease of the airway is sarcoidosis.

198. The method of claim 189, wherein the obstructive disease of the airway is alpha-1 antitrypsin (Al AT) deficiency.Attorney Docket No.: INMD-216 / 01WO 315953-4442199. The method of claim 189, wherein the obstructive disease of the airway is farmer’s lung.

200. The method of claim 189, wherein the obstructive disease of the airway is hypersensitivity pneumonitis.

201. The method of claim 189, wherein the obstructive disease of the airway is a complication of lung transplantation.

202. The method of claim 189, wherein the obstructive disease of the airway is a vasculitic or thrombotic disorder of the lung vasculature.

203. The method of claim 189, wherein the obstructive disease of the airway is pulmonary hypertension.

204. The method of claim 189, wherein the obstructive disease of the airway is iatrogenic cough.

205. The method of claim 189, wherein the obstructive disease of the airway is acute rhinitis.

206. The method of claim 189, wherein the obstructive disease of the airway is chronic rhinitis.

207. The method of claim 189, wherein the obstructive disease of the airway is rhinitis medicamentosa or vasomotor rhinitis.

208. The method of claim 189, wherein the obstructive disease of the airway is nasal polyposis.

209. The method of claim 189, wherein the obstructive disease of the airway is COPD.

210. The method of claim 190, wherein the asthma is bronchial, allergic, intrinsic, extrinsic, neutrophilic, exercise-induced, or drug-induced asthma.Attorney Docket No.: INMD-216 / 01WO 315953-4442211. The method of claim 210, wherein the bronchitis is infectious bronchitis or eosinophilic bronchitis.

212. The method of claim 193, wherein the pulmonary fibrosis is idiopathic pulmonary fibrosis, cryptogenic fibrosing alveolitis, idiopathic interstitial pneumonia, or fibrosis complicating anti-neoplastic therapy or chronic infection.

213. The method of claim 1 6, wherein the bronchiectasis is non-cystic fibrosis bronchiectasis (NCFBE).

214. The method of claim 196, wherein the bronchiectasis is associated with cystic fibrosis.215 The method of claim 203, wherein the pulmonary hypertension is pulmonary' arterial hypertension216. The method of claim 203, wherein the pulmonary hypertension is pulmonary hypertension due to left heart disease.

217. The method of claim 203, wherein the pulmonary hypertension is pulmonary hypertension associated with chronic lung disease.

218. A method for treating cystic fibrosis in a patient in need thereof, comprising, administering to the patient an effective amount of a compound of any one of claims 1-186 or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, or the composition of claim 187.

219. The method of claim 218, wherein the treating comprises improving the lung function of the patient, as compared to the lung function of the patient prior to treatment.

220. The method of claim 219, wherein improving lung function of the patient comprises increasing the patient’s forced expiratory volume in 1 second (FEV i), increasing the patient’s forced vital capacity (FVC), increasing the patient’s peak expiratory flow rate (PEFR), orAttorney Docket No.: INMD-216 / 01WO 315953-4442increasing the patient’s forced expiratory flow between 25% and 75% of FVC (FEF(25-?5%)), as compared to the respective value for the patient prior treatment221. The method of claim 219 or 220, wherein the lung function is measured by spirometry.

222. A method for treating bronchiectasis in a patient in need thereof, comprising, administering to the patient, an effective amount of a compound of any one of claims 1-186 or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, or the composition of claim 187.

223. The method of claim 222, wherein the bronchiectasis is non-cystic fibrosis bronchiectasis (NCFBE).224 The method of claim 222, wherein the bronchiectasis is associated with cystic fibrosis.

225. The method of any one of claims 222-224, wherein the treating comprises improving the lung function of the patient, as compared to the lung function of the patient prior to treatment.

226. The method of claim 225, wherein improving lung function of the patient comprises increasing the patient’s forced expiratory volume in 1 second (FEVi), increasing the patient’s forced vital capacity (FVC), increasing the patient’s peak expiratory flow rate (PEFR), or increasing the patient’s forced expiratory flow between 25% and 75% of FVC (FEF(25-75%)), as compared to the respective value for the patient prior to treatment.

227. The method of claim 225 or 226, wherein the lung function is measured by spirometry.

228. The method of any one of claims 222-227, wherein the treating comprises decreasing the rate of pulmonary exacerbation, as compared to the rate of pulmonary exacerbation of the patient prior to treatment.Attorney Docket No.: INMD-216 / 01WO 315953-4442229. The method of any one of claims 222-228, wherein treating comprises increasing the time to first pulmonary exacerbation, as compared to an untreated patient230. The method of claim 228 or 229, wherein the pulmonary' exacerbation is characterized by three or more of the following symptoms exhibited for at least 48 hours by the patient: (1) increased cough; (2) increased sputum volume or change in sputum consistency; (3) increased sputum purulence; (4) increased breathlessness and / or decreased exercise tolerance; (5) fatigue and / or malaise, (6) hemoptysis.

231. A method for treating chronic rhinosinusitis (CRS) in a patient in need thereof, comprising, administering to the patient, an effective amount of a compound of any one of claims 1-186 or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, or the composition of claim 187.232 The method of claim 231, wherein the chronic rhinosinusitis is chronic rhinosinusitis without nasal polyps (CRSsNP).

233. The method of claim 231, wherein the chronic rhinosinusitis is chronic rhinosinusitis with nasal polyps (CRSw'NP).

234. The method of any one of claims 231-233, wherein the chronic rhinosinusitis is refractory chronic rhinosinusitis.

235. The method of any one of claims 231-234, wherein treating comprises reducing, diminishing the severity of, delaying the onset of, or eliminating one or more symptoms of CRS.

236. The method of claim 235, wherein the one or more symptoms of CRS is nasal congestion; nasal obstruction, nasal discharge; post-nasal drip, facial pressure; facial pain, facial fullness; reduced smell; depression; mucosal edema; mucopurulent discharge; obstruction of the middle meatus; mucosal changes within the ostiomeatal complex and sinuses; or rhinorrhea.Attorney Docket No.: INMD-216 / 01WO 315953-4442237. A method for treating hidradenitis suppurativa (HS) in a patient in need thereof, comprising, administering to the patient, an effective amount of a compound of any one of claims 1-186 or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, or the composition of claim 187238 The method of claim 237, wherein the hidradenitis suppurativa (HS) is Hurley stage I.

239. The method of claim 237, wherein the hidradenitis suppurativa (HS) is Hurley stage II240. The method of claim 237, wherein the hidradenitis suppurativa (HS) is Hurley stage III241. A method for treating cancer in a patient in need thereof, comprising, administering to the patient, an effective amount of a compound of any one of claims 1-186 or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, or the composition of claim 187.

242. The method of claim 241, wherein the cancer is a metastatic cancer.

243. The method of claim 242, wherein the metastatic cancer is breast to lung metastatic cancer.

244. The method of claim 242, wherein the metastatic cancer comprises metastasis of breast cancer to the brain, bone, pancreas, lymph nodes or liver.

245. The method of clai m 242, wherein the metastatic cancer compri ses metastasis of bone cancer to the lung.246 The method of claim 242, wherein the metastatic cancer comprises metastasis of colorectal cancer to the peritoneum, the pancreas, the stomach, the lung, the liver, the kidney, or the spleen.Attorney Docket No.: INMD-216 / 01WO 315953-4442247. The method of claim 242, wherein the metastatic cancer comprises metastasis of stomach cancer to the mesentery, the spleen, the pancreas, the lung, the liver, the adrenal gland, or the ovary.

248. The method of claim 242, wherein the metastatic cancer comprises metastasis of liver cancer to the intestine, spleen, pancreas, stomach, lung, or the kidney.

249. The method of claim 242, wherein the metastatic cancer comprises metastasis of lymphoma to the kidney, ovary, liver, bladder, or the spleen250. A method for treating lupus nephritis in a patient in need thereof, comprising, administering to the patient, an effective amount of a compound of any one of claims 1-186 or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, or the composition of claim 187.

251. A method for treating arthritis in a patient in need thereof, comprising, administering to the patient, an effective amount of a compound of any one of claims 1-186 or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, or the composition of claim 187.

252. The method of claim 251, wherein the arthritis is rheumatoid arthritis or osteoarthritis.

253. A method for treating inflammatory bowel disease (IBD) in a patient in need thereof, comprising, administering to the patient, an effective amount of a compound of any one of claims 1-186 or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, or the composition of claim 187.

254. The method of claim 253, wherein the inflammatory bowel disease (IBD) is Crohn’s disease.

255. The method of claim 253, wherein the inflammatory bowel disease (IBD) is ulcerative colitis.Attorney Docket No.: INMD-216 / 01WO 315953-4442256. A method for treating an anti-neutrophil cytoplasmic antibody (ANCA) associated vasculitis in a patient in need thereof, comprising, administering to the patient, an effective amount of a compound of any one of claims 1-186 or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, or the composition of claim 187.257 The method of claim 256, wherein the ANCA associated disease is granulo atosis with poly angiitis (GPA).

258. The method of claim 256, wherein the ANCA associated disease is microscopic poly angiitis (MPA).

259. A method for treating a disease in a patient in need thereof comprising, administering to the patient, an effective amount of a compound of any one of claims 1-186 or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, or the composition of claim 187, wherein the disease is giant cell arteritis, polyarteritis nodosa, anti- GBM disease (Goodpasture’s), systemic scleroderma, diabetic nephropathy, diabetic neuropathy, diabetic retinopathy, diabetic ulcers, Duchenne muscular dystrophy, bronchiolitis obliterans, atopic dermatitis, pyoderma gangrenosum, sweet’s syndrome, dermatomyositis / polymyositis, neutrophilic dermatoses, thrombosis, bronchopulmonary dysplasia, amyotrophic lateral sclerosis, sickle cell anemia, psoriasis, or a ventilator-induced lung injury.

260. A method for treating a heart failure in a patient in need thereof, comprising administering to the patient, an effective amount of a compound of any one of claims 1-186 or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, or the composition of claim 187.

261. The method of claim 260, wherein the heart failure is heart failure with reduced ejection fraction.

262. The method of claim 260, wherein the heart failure is heart failure with preserved ejection fraction.Attorney Docket No.: INMD-216 / 01WO 315953-4442263. A method for treating ischemia / reperfusion (IR) injury' in a patient in need thereof comprising, administering to the patient, an effective amount of a compound of any one of claims 1-186 or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, or the composition of claim 187264 The method of claim 263, wherein the patient is a heart transplant recipient.

265. The method of claim 263 or 264, wherein the IR injury is due to heart transplantation.

266. The method of any one of claims 263-265, wherein the treating comprises improving left- ventricular (LV) graft function of the patient.

267. The method of claim 266, wherein improving left-ventricular (LV) graft function comprises improving LV systolic function of the patient.

268. The method of claim 267, wherein improving left-ventricular (LV) systolic function of the patient comprises improving LV systolic pressure (LVSP), developed pressure, maximal slope of systolic pressure increment (dP / dtmax), the rate pressure product (mmHg*bpm) of the patient, or a combination thereof.

269. A method for treating liver injury in a patient in need thereof comprising, administering to the patient, an effective amount of the compound of any one of claims 1-186 or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, or the composition of claim 187.

270. The method of claim 269, w'herein the liver injury is acute liver injury.

271. The method of claim 269, wherein the liver injury' is drug-induced acute liver injury.272 The method of any one of claims 188-271, wherein the effective amount of the compound or composition is administered once daily during an administration period.

273. The method of any one of claims 188-272, wherein the effective amount of the compound or composition is administered orally.

Images